imipenem, anhydrous profile

Imipenem is a broad-spectrum antibiotic of the carbapenem class. It is a synthetic derivative of thienamycin, a naturally occurring antibiotic produced by the bacterium Streptomyces cattleya. Imipenem is effective against a wide range of gram-positive and gram-negative bacteria, including penicillin-resistant strains. Imipenem is administered intravenously or intramuscularly. It is often given in combination with cilastatin, an inhibitor of renal dehydropeptidase I, which prevents the breakdown of imipenem in the kidneys. Imipenem is used to treat a variety of serious bacterial infections, including pneumonia, urinary tract infections, skin infections, and intra-abdominal infections. It is also used to treat infections caused by bacteria that are resistant to other antibiotics. The synthesis of imipenem involves a multi-step process that starts with the preparation of a key intermediate, 6-aminopenicillanic acid (6-APA). 6-APA is then reacted with a variety of reagents to produce the final product. The synthesis of imipenem is a complex process that requires specialized equipment and expertise. Imipenem is an important antibiotic because it is effective against a wide range of bacteria, including those that are resistant to other antibiotics. It is also relatively well-tolerated. The study of imipenem is important for a number of reasons. First, it is important to understand the mechanisms by which imipenem exerts its antimicrobial effects. Second, it is important to identify the factors that contribute to the development of resistance to imipenem. Third, it is important to develop new antibiotics that are effective against bacteria that are resistant to imipenem.'

Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	104838
CHEMBL ID	148
CHEBI ID	471744
SCHEMBL ID	1649260
SCHEMBL ID	8781920
MeSH ID	M0329530

Synonym
BIDD:GT0686
bdbm50049708
mk-0787
(5r,6s)-6-[(1r)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
PRESTWICK2_000519
PRESTWICK_844
imipenem (inn)
D04515
[5r-[5.alpha.,6.alpha.(r*)]]-6-(1-hydroxyethyl)-3-[[2- [(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid monohydrate
tienamycin
imipenem, n-formimidoyl thienamycin
mk 0787
n-formimidoylthienamycin
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1r)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-, (5r,6s)-
(5r,6s)-6-[(1r)-1-hydroxyethyl]-3-(2-methanimidamidoethylsulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
imipemide
BSPBIO_000477
BPBIO1_000525
(5r,6s)-6-((r)-1-hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure
mk-787
imipenem, anhydrous
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))-
einecs 264-734-5
imipenemum [latin]
imipenem
imipenem anhydrous
64221-86-9
C06665
DB01598
(5r,6s)-3-((2-(formimidoylamino)ethyl)thio)-6-((r)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
n-formimidoyl thienamycin
(5r,6s)-3-(2-formimidoylamino-ethylsulfanyl)-6-((r)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
nsc-717864
nsc717864
PRESTWICK3_000519
mk0787
PRESTWICK1_000519
SPBIO_002398
PRESTWICK0_000519
NCGC00167958-02
NCGC00167958-01
HMS2090A15
NCGC00167958-03
CHEMBL148 ,
sr-05000000294
CHEBI:471744 ,
HMS1569H19
(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
HMS2096H19
HMS3260H20
anhydrous imipenem
nsc759901
pharmakon1600-01506001
tox21_110689
dtxcid903143
dtxsid2023143 ,
cas-64221-86-9
AKOS016010844
imipenen
q20im7he75 ,
unii-q20im7he75
imipenem [inn]
imipenemum
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r,6s)-
LP00279
imipenem [mi]
1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5.alpha.,6.alpha.(r*)))-
imipenem [who-dd]
imipenem anhydrate
EPITOPE ID:120384
CCG-221583
CCG-220519
ZSKVGTPCRGIANV-ZXFLCMHBSA-N
tox21_110689_1
NCGC00167958-05
SCHEMBL1649260
tox21_500279
NCGC00260964-01
SCHEMBL8781920
AB01563339_01
(5r,6s)-3-({2-[(e)-(aminomethylidene)amino]ethyl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
SR-05000000294-5
SR-05000000294-2
AS-75130
(5r,6s)-6-[(1r)-1-hydroxyethyl]-3-[(2-methanimidamidoethyl)sulfanyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
HMS3713H19
(5r,6s)-3-((2-formimidamidoethyl)thio)-6-((r)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5r,6s)-3-(2-formimidamidoethylthio)-6-((r)-1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Q425152
imipen
bdbm50213266
BCP13012
SDCCGSBI-0633697.P001
NCGC00167958-09
primaxin (imipenem + cilastatin)
recarbrio (imipenem + cilastatin + relebactam).
gtpl10821
D96091
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1r)-1-hydroxyethyl]-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-,(5r,6s)-
EN300-19766283
thienamycin p-nitrobenzylester hydrochloride(n-methylpyrrolidinonesolvate)
HY-B1369A
CS-0077844

Excerpt	Reference	Relevance
" The recently released thienamycin antibiotic, imipenem, like the toxic cephalosporins, produces acute proximal tubular necrosis which can be prevented completely by prior administration of probenecid."	( Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Fravert, D; Hsu, CY; Tune, BM, 1989)	0.28
" Adverse effects were generally mild and reversible and included diarrhea alone or with vomiting (5."	( Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United States. Ahonkhai, VI; Brown, KR; Cyhan, GM; Wilson, SE, 1989)	0.28
" In the remaining two patients treatment had to be prematurely discontinued due to adverse effects."	( Efficacy and safety of imipenem/cilastatin in the empirical treatment of septicemia. Del Valle, J; Noriega, AR; Otero, JR; Revilla, AP; Sanz, F, 1987)	0.27
" The most common clinical adverse experiences were local ones related to the site of intravenous infusion."	( The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. Aziz, M; Brown, KR; Calandra, GB; Wang, C, 1986)	0.27
" No patients experienced drug-related clinical adverse effects."	( Safety and efficacy of imipenem/cilastatin in treatment of complicated urinary tract infections. Corrado, ML; Cox, CE, 1985)	0.27
" Twenty-one patients had no adverse reaction; of the remaining 10 patients, 4 had nausea, 1 had urticaria, and 6 had mild abnormalities in hepatic function; three episodes of diarrhea included two with Clostridium difficile toxin in stool and one with pseudomembranous colitis, as determined by sigmoidoscopy."	( Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. Fisher, MA; Gibson, GA; MacGregor, RR; Zajac, BA, 1985)	0.27
"To test the toxic action of two antibiotics, imipenem and aztreonam, on the functional and morphologic integrity of the albino rabbit retina."	( Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Lazar, M; Loewenstein, A; Perlman, I; Zemel, E, 1993)	0.29
" Azactam is highly toxic at high levels (more than 10 mg injected into the vitreous)."	( Drug-induced retinal toxicity in albino rabbits: the effects of imipenem and aztreonam. Lazar, M; Loewenstein, A; Perlman, I; Zemel, E, 1993)	0.29
" Because VCM has the adverse reaction of nephrotoxicity, we are apprehensive about using VCM with other antibiotics, which might increase this problem."	( [Nephrotoxicity and drug interaction of vancomycin (2)]. Nakagawa, Y; Toyoguchi, T, 1996)	0.29
" Both VCM and IPM have the adverse reaction of nephrotoxicity, whereas CS restrains the nephrotoxicity of IPM."	( [Nephrotoxicity and drug interaction of vancomycin]. Nakagawa, Y; Toyoguchi, T; Watanabe, H, 1996)	0.29
" The possibility of administering meropenem in intravenous infusion or bolus injection with lower volumes of fluid, without increasing the incidence of these adverse reactions, may have practical advantages in special situations."	( [Tolerance and safety of carbapenems: the use of meropenem]. Lizasoaín, M; Noriega, AR, 1997)	0.3
" Meropenem-related adverse events most frequently reported were diarrhoea (2."	( Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Gildon, KM; Norrby, SR, 1999)	0.3
" Comparable incidences of adverse events, mainly mild or moderate in intensity, were experienced in each treatment group."	( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. Luke, DR; Peterson, J, )	0.13
" The incidence, severity and type of adverse events were similar in both treatment groups."	( An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Briggs, A; Feldman, C; Flitcroft, A; O'Grady, J; Richards, G; White, H, 2001)	0.31
"719]) were the most frequently reported adverse events."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Babinchak, T; Dartois, N; Ellis-Grosse, E; Loh, E; Rose, GM, 2005)	0.33
"435]) were the most frequently reported adverse events."	( A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. Babinchak, T; Campos, M; Ellis-Grosse, EJ; Loh, E; Oliva, ME; Pasternak, J; Rekha, A; Rose, GM; Yellin, A, 2005)	0.33
" Most commonly reported treatment emergent adverse events for tigecycline and imipenem/cilastatin were nausea (14."	( The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience. Babinchak, T; Castaing, N; Cooper, A; Dartois, N; De Vane, N; Fomin, P; Koalov, S; Tellado, J, 2008)	0.35
" Drug-induced seizures are a rare but serious adverse effect, with carbapenems being one of the most common classes of antibiotics associated with seizures."	( Safety of imipenem/cilastatin in neurocritical care patients. Brophy, GM; Hoffman, J; Trimble, J, 2009)	0.35
" The overall incidence of treatment-emergent adverse events was 80."	( Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. Bi, J; Chen, X; Chen, Z; Cooper, A; Leng, X; Li, R; Liu, D; Ma, X; Maroko, R; Quan, Z; Wei, J; Wu, J; Wu, Z; Yan, L; Yu, Y; Zhang, Y, 2010)	0.36
" Adverse events were observed in 67."	( Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Duttaroy, DD; González Patzán, LD; Kreidly, Z; Lipka, J; Sable, C; Stricklin, D; Vazquez, JA, 2012)	0.38
" We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin."	( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)	0.39
" Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness."	( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)	0.39
"In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin."	( Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Benjamin, DK; Capparelli, EV; Clark, RH; Cohen-Wolkowiez, M; Herring, AH; Hornik, CP; Kearns, GL; Smith, PB; van den Anker, J, 2013)	0.39
" Although the combination was safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload."	( Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Carratalà, J; Cuquet, J; del Río, A; Garcia de la Mària, C; Gasch, O; Gatell, JM; Gudiol, F; Marco, F; Mestres, CA; Miró, JM; Moreno, A; Pare, JC; Peña, C; Soy, D; Suárez, C; Tubau, F, 2014)	0.4
"Fosfomycin plus imipenem was an effective and safe combination when used as rescue therapy for complicated MRSA bloodstream infections and deserves further clinical evaluation as initial therapy in these infections."	( Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Carratalà, J; Cuquet, J; del Río, A; Garcia de la Mària, C; Gasch, O; Gatell, JM; Gudiol, F; Marco, F; Mestres, CA; Miró, JM; Moreno, A; Pare, JC; Peña, C; Soy, D; Suárez, C; Tubau, F, 2014)	0.4
" Azithromycin was not associated with excess serious adverse events (SAEs)."	( Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Butler-Laporte, G; Menzies, D; Winters, N, 2015)	0.42
" While no adverse events were reported for IC, 2 minor side effects, only, were attributed to linezolid (17%); in both cases the drug was re-started without further problems."	( Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. Arbex, MA; Bonini, EH; Centis, R; D'Ambrosio, L; Kawakame Pirolla, G; Migliori, GB, )	0.13
"To detect signals of adverse drug events after imipenem treatment using the Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database (KIDS-KD)."	( Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database. Jin, XM; Kim, J; Kwon, KE; Lee, J; Park, BJ; Park, K; Soukavong, M; Yang, BR, 2017)	0.46
"We performed data mining using KIDS-KD, which was constructed using spontaneously reported adverse event (AE) reports between December 1988 and June 2014."	( Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database. Jin, XM; Kim, J; Kwon, KE; Lee, J; Park, BJ; Park, K; Soukavong, M; Yang, BR, 2017)	0.46
"0% of patients, respectively, had treatment-emergent adverse events."	( Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Akers, W; Brown, ML; Du, J; Kartsonis, NA; Lee, YC; Mariyanovski, V; McLeroth, P; Paschke, A; Pedley, A; Sims, M, 2017)	0.46
" Fifteen (5%) patients experienced an adverse event considered at least possibly related to imipenem."	( Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study. Bricheux, A; Hughes, S; Huttner, A; Karmime, A; Lenggenhager, L; Lescuyer, P, 2019)	0.51
" Patients were followed up for sputum smear and culture conversion and adverse events during the treatment."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
" 29 adverse events (AE) were reported among 17 patients and there were 11 deaths."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
"BDQ and DLM given together in a salvage regimen is efficacious with low rate of adverse events."	( Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis. Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V, 2019)	0.51
" Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = ."	( RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Aggrey, A; Boucher, HW; Brown, ML; Butterton, JR; Du, J; File, TM; Joeng, HK; Kartsonis, NA; Kaye, KS; Khan, I; Köksal, I; Lyulko, O; Motsch, J; Murta de Oliveira, C; Paschke, A; Stus, V; Tipping, RW; Young, K, 2020)	0.56
" However, renal adverse effects limit its clinical application."	( Targeting renal OATs to develop renal protective agent from traditional Chinese medicines: Protective effect of Apigenin against Imipenem-induced nephrotoxicity. Huo, X; Liu, K; Ma, X; Meng, Q; Sun, H; Sun, P; Wang, C; Wu, J; Zhu, Y, 2020)	0.56
" Serious adverse events (AEs) occurred in 26."	( A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Boucher, HW; Brown, ML; Butterton, JR; Chen, LF; David-Wang, A; Du, J; Kartsonis, NA; Kaye, KS; Losada, MC; Paschke, A; Patel, M; Rizk, ML; Rodríguez Gonzalez, D; Roquilly, A; Tipping, R; Titov, I; Wunderink, RG; Young, K, 2021)	0.62
" Adverse events (AEs) were reported in 74."	( The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. Aoyama, N; Bando, H; Brown, M; Kawahara, K; Kikukawa, H; Kohno, S; Paschke, A; Shirakawa, M; Takase, A; Yoneyama, F, 2021)	0.62
" Relebactam/imipenem/cilastatin was well tolerated; mild adverse events occurred during single dosing, and one participant experienced serious adverse events after multiple doses."	( A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. Boundy, KE; Colon-Gonzalez, F; Li, H; Liu, N; Patel, M; Wang, H; Wang, X; Wei, Y; Yan, B; Zang, Y; Zhang, S; Zhao, X, 2021)	0.62
" The primary outcome was treatment success without modification; the secondary outcomes were adverse events (AEs), all-cause mortality, and new infections."	( Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis. Chen, X; Guo, S; Li, Y; Liang, X; Su, H; Tan, X; Xi, J, 2021)	0.62
"Many antibiotics are well known for being associated with adverse events (AEs) of central nervous system, ceftazidime/avibactam (CAZ/AVI) is a novel β-lactam/β-lactamase inhibitor combinations."	( Central nervous system adverse events of ceftazidime/avibactam: A retrospective study using Food and Drug Administration Adverse Event Reporting System. Cui, X; Guo, M; Guo, X; Li, J, 2022)	0.72
" No severe or life-threatening adverse events were encountered."	( Effectiveness and Safety of Intra-arterial Imipenem/Cilastatin Sodium Infusion for Patients with Hand Osteoarthritis-Related Interphalangeal Joint Pain. Huang, HH; Liang, KW; Tsao, TF; Tyan, YS; Wang, B; Wang, PH, 2023)	0.91

Excerpt	Reference	Relevance
" In this thesis pharmacodynamic parameters have been studied after brief exposure of gram-positive bacteria to daptomycin, imipenem or vancomycin and after short exposure of gram-negative bacteria to amikacin, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, imipenem, mecillinam, or piperacillin."	( Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Hanberger, H, 1992)	0.28
"The pharmacokinetic profiles of imipenem after intramuscular (i."	( Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. File, TM; Salstrom, SJ; Signs, SA; Tan, JS, 1992)	0.28
" To circumvent the problem of short elimination time in small animals, imipenem was administered in fractionized, decreasing doses such that the pharmacokinetic profiles as observed in humans after intravenous and intramuscular injections were approximated in mice."	( Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Flückiger, U; Gerber, AU; Segessenmann, C, 1991)	0.28
" The mean peak serum concentration was 26 mg/l, the mean half-life 55 min and the AUC 40 mg/l/h-1."	( Pharmacokinetics of imipenem in patients undergoing major colon surgery. Erttmann, M; Krausse, R; Ullmann, U, )	0.13
" Following an intravenous infusion of imipenem 500 mg, the main pharmacokinetic values for the antibiotic are: area under the plasma concentration curve 43."	( [Clinical pharmacokinetics of an imipenem-cilastatin combination]. Singlas, E, 1990)	0.28
" Intravenously administered FCE 22101 at a dose of 250 mg gave peak plasma concentrations of about 12 mg/l and the plasma half-life was about 60 min."	( Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. Burman, LA; Cassinelli, G; Corigli, R; Dornbusch, K; Franceschi, G; Norrby, SR; Sassella, D, 1990)	0.28
"96 mg/l), plasma half-life (60 min), volume of distribution (0."	( Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. Farrell, I; Janmohamed, RM; Kelly, J; Leyland, MJ, 1990)	0.28
" A linear relationship was observed between dose and Cmax following subcutaneous injection of drug in mice."	( Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester. Campbell, B; Foulds, G; Girard, D; Gootz, T; Jasys, J; Kelbaugh, P; Kellogg, M; Schelkley, W; Stam, J; Tensfeldt, T, 1990)	0.28
"76 hours, and the half-life of CS tended to be longer than that of IPM."	( [Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants]. Fujimoto, T; Kawakami, A; Koga, T; Motohiro, T; Oda, K; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, S, 1989)	0.28
" The blood half-life of CS tended to be longer than that of IPM."	( [Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group]. Fujii, R; Fujita, K; Hashira, S; Inyaku, F; Maruyama, S; Nakazawa, S; Sakata, H; Sato, H; Tajima, T; Yoshioka, H, 1989)	0.28
" Pharmacokinetic studies were performed in the 11 children and in 10 of the neonates."	( [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]. Baron, S; Bégué, P; Challier, P; Fontaine, JL; Lasfargues, G; Quinet, B, 1989)	0.28
" Drug levels in plasma and the peritoneal dialysis fluid were analyzed at frequent intervals, and various pharmacokinetic variables were calculated for a one-compartment open model."	( Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Freimer, EH; Gross, ML; Higgins, JT; Somani, P, 1988)	0.27
" The mean serum half-life was 82."	( Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections. Bland, JA; Gibson, GA; MacGregor, RR, 1986)	0.27
" Our data suggest that a minimum dosage, greater than 10 mg/kg, of cilastatin may be required to prolong the half-life of imipenem to adult values."	( Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. Engelhard, D; Greenwood, R; Griffis, J; Marks, MI; Shalit, I; Stutman, HR, 1986)	0.27
" Pharmacokinetic studies were done in 7 patients whose ages ranged from 3 years 2 months to 13 years 1 month."	( [Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children]. Fujita, K; Inyaku, F; Kakehashi, H; Maruyama, S; Murono, K; Ohmi, H; Sakata, H; Sanae, N; Yoshioka, H, 1986)	0.27
" Pharmacokinetic studies Peak plasma concentrations of MK-0787/MK-0791 were 27."	( [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. Arimasu, O; Fujii, R; Fujita, K; Inyaku, F; Maruyama, S; Meguro, H; Nagamatsu, I; Takase, A; Wagatsuma, Y; Yoshioka, H, 1986)	0.27
" Pharmacokinetic parameters were calculated from the results."	( Pharmacokinetic studies of imipenem/cilastatin in elderly patients. Craddock, C; Deaney, NB; Finch, RG; Kelly, J, 1986)	0.27
" The half-life was similar in plasma, muscle and fat (approximately 1 h)."	( Imipenem pharmacokinetics in elective colorectal surgery. Eardley, I; Gartell, PC; Porte, M; Sutton, GL; Taylor, EA, 1986)	0.27
" Pharmacokinetic studies were performed in the 11 children and in 10 of the neonates."	( Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. Baron, S; Bégué, PC; Challier, P; Fontaine, JL; Lasfargues, G, 1987)	0.27
" Although probenecid causes only a minor effect on imipenem pharmacology, it increases the area under the curve and half-life of imipenem and decreases the renal clearance of cilastatin significantly."	( Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Drusano, GL; Standiford, HC, 1985)	0.27
" Pharmacokinetic evaluation after the first dose and again under steady-state conditions revealed biodisposition characteristics which were similar and independent of the daily dose administered."	( Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Blumer, JL; Myers, CM; O'Brien, CA; Reed, MD; Stern, RC; Yamashita, TS, 1985)	0.27
" Kinetics of imipenem in plasma are less variable, and the half-life of imipenem in plasma is 1 hr."	( Pharmacokinetics of imipenem and cilastatin in volunteers. Bland, JA; Calandra, GB; Demetriades, JL; Ferber, F; Meisinger, MA; Rogers, JD, )	0.13
" The plasma half-life of N-formimidoyl thienamycin was slightly less than 1 h and did not increase significantly with the coadministration of probenecid."	( Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Alestig, K; Ferber, F; Huber, JL; Jones, KH; Kahan, FM; Meisinger, MA; Norrby, SR; Rogers, JD, 1983)	0.27
" Co-administration of imipenem with probenecid resulted in a slight but significant increase of the plasma half life and a corresponding increase of the area under the plasma concentration curve (AUC)."	( Pharmacokinetics of imipenem in healthy volunteers. Björnegård, B; Ferber, F; Jones, KH; Norrby, SR, 1983)	0.27
" The mean plasma half-life of imipenem varied from 52 min in subjects with normal renal function to 173 min in subjects with end-stage renal failure studied while off-dialysis."	( The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Buntinx, AP; De Broe, ME; Entwistle, LA; Jones, KH; Verbist, L; Verpooten, GA, 1984)	0.27
" The terminal excretion half-life was short (1."	( The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Bustamante, CI; Drusano, GL; Forrest, A; Rivera, G; Schimpff, SC; Standiford, HC; Tatem, B, 1984)	0.27
" Comparison of imipenem plasma pharmacokinetic data derived from these children with data reported from adult subjects revealed disparities for both the apparent volume of distribution and plasma clearance."	( Single-dose pharmacokinetics of imipenem in children. Brown, AL; Jacobs, RF; Kearns, GL; Kluza, RB; Marmer, B; McIntosh, JC; Trang, JM; Underwood, FL, 1984)	0.27
"We characterized the pharmacokinetic profile of imipenem-cilastatin administered intravenously to six normal volunteers in a dose of 1,000 mg of each drug every 6 h for 40 doses."	( Multiple-dose pharmacokinetics of imipenem-cilastatin. Bustamante, C; Delaportas, D; Drusano, GL; Forrest, A; Leslie, J; MacGregor, RR; Rivera, G; Schimpff, SC; Standiford, HC; Tatem, B, 1984)	0.27
"To determine the appropriate compartmental and noncompartmental pharmacokinetic parameters for intravenous piperacillin and tazobactam."	( Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Burm, JP; Gill, MA; Jhee, SS; Kern, JW; Yellin, AE, )	0.13
"The estimated noncompartmental pharmacokinetic parameters (mean +/- SD) for piperacillin and tazobactam, respectively, were as follows: maximum concentration in plasma 218."	( Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections. Burm, JP; Gill, MA; Jhee, SS; Kern, JW; Yellin, AE, )	0.13
" Therefore, knowledge of the impact of continuous haemofiltration on drug elimination and the pharmacokinetic profile of drugs is essential to good clinical management."	( Clinical pharmacokinetics during continuous haemofiltration. Bressolle, F; de la Coussaye, JE; Eledjam, JJ; Galtier, M; Kinowski, JM; Wynn, N, 1994)	0.29
"The pharmacodynamic effects of extended imipenem dosing intervals were studied against two strains of Pseudomonas aeruginosa (ATCC 27853 and an imipenem-resistant mutant, 27853R) in an in vitro model of infection."	( Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Lamp, KC; McGrath, BJ; Rybak, MJ, 1993)	0.29
" Imipenem pharmacokinetic parameters were determined in 10 anuric patients with renal failure managed by continuous venovenous hemofiltration (CVVH)."	( Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Macias, WL; Mueller, BA; Scarim, SK, 1993)	0.29
" Pharmacokinetic parameters were based on an open two-compartment model and a noncompartmental technique."	( Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Borner, K; Dreetz, M; Eller, J; Hamacher, J; Koeppe, P; Lode, H; Schaberg, T, 1996)	0.29
" Pharmacodynamic parameters were compared by using the Wilcoxon signed-rank test."	( Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Bosso, J; Burgess, D; Friedrich, L; Warkentin, D; White, R, 1996)	0.29
"h/ml in the chimpanzee) and a longer half-life at beta phase (1."	( Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus. Cama, L; Kropp, H; Sasor, MW; Sundelof, JG; Thompson, R; White, KM, 1996)	0.29
"To evaluate the pharmacokinetic profiles of aztreonam and imipenem in critically ill trauma patients with pneumonia."	( Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Boucher, BA; Croce, MA; Fabian, TC; Hess, MM; McKindley, DS, )	0.13
"The pharmacodynamic effects of amikacin, imipenem, ofloxacin, rifampin, and vancomycin were studied on the slime-producing, oxacillin-resistant strain Staphylococcus epidermidis ATCC 35984 growing in Mueller Hinton broth or, in order to inhibit growth, incubated in phosphate-buffered saline."	( Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Hanberger, H; Nilsson, LE; Svensson, E, 1997)	0.3
" The pharmacokinetic parameters for meropenem are similar to those for imipenem/cilastatin, with the exception of meropenem's smaller volume of distribution."	( Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Chung, KC; Gill, MA; Moon, YS, 1997)	0.3
" The assay was applied to pharmacokinetic studies in patients."	( Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. Arroyo, C; Bonal, J; Garcia-Capdevila, L; López-Calull, C; Mangues, MA; Moral, MA, 1997)	0.3
" Pharmacokinetic variables were calculated by a first-order, two-compartment pharmacokinetic model for both substances."	( Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Bremer, F; Brune, K; Geisslinger, G; Oelkers, R; Schobel, H; Schüttler, J; Tegeder, I, 1997)	0.3
" A one-compartment in vitro pharmacodynamic model was used to simulate bacteremic infection."	( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, )	0.13
"L-749,345 is a new parenteral carbapenem with a very long half-life similar to that of ceftriaxone."	( In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. Cars, O; Löwdin, E; Odenholt, I, 1998)	0.3
" Based on pharmacodynamic data, cefepime is an appropriate empiric choice for treatment of nosocomial infections."	( Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Kays, MB, 1999)	0.3
"Efficacy and pharmacokinetic parameters of imipenem/cilastatin (I/C) were investigated in a retrospective evaluation in 104 premature and newborn infants."	( Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. Böswald, M; Döbig, C; Guggenbichler, JP; Kändler, C; Krüger, C; Scharf, J; Soergel, F; Zink, S, 1999)	0.3
" The half-life of meropenem (approximately 1 hour in healthy volunteers) is prolonged up to 13."	( Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Hörl, WH; Thalhammer, F, 2000)	0.31
" response, when normalized by the MIC and corrected for drug degradation, these agents displayed similar pharmacodynamic parameter-response relationships."	( Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis. Bosso, JA; Friedrich, LV; Manduru, M; Mihm, LB; White, RL, 2001)	0.31
" Results previously obtained with healthy rats were used to estimate the dose of imipenem required to induce an observable but nonlethal EEG effect on the assumption that only the pharmacokinetic parameters of the model would be affected by renal failure."	( Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure. Bouquet, S; Couet, W; Dupuis, A; Limosin, A; Mimoz, O; Paquereau, J, 2001)	0.31
"To investigate the pharmacokinetic characteristics of Imipenem/cilastatin in burn patients during the acute phase."	( [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. Peng, Y; Wang, H; Xiao, G, 2000)	0.31
"Compared to those in control group, pharmacokinetic parameters of Imipenem exhibited evident difference, such as prolonged half-life [(1."	( [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase]. Peng, Y; Wang, H; Xiao, G, 2000)	0.31
"The probability of attaining lower pharmacodynamic targets for most gram-negative bacteria is similar for these carbapenems; however, differences become apparent as the pharmacodynamic requirement increases."	( Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Florea, NR; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)	0.32
"The common usage of extended spectrum beta-lactams co-administered with amikacin in everyday clinical practice for infections by multidrug-resistant isolates has created the need to search for pharmacokinetic interaction."	( Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Adamis, G; Gargalianos, P; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kosmidis, J; Papaioannou, MG, 2004)	0.32
"The interindividual variability of imipenem pharmacokinetic parameters in burn patients suggest that these parameters have to be estimated with a large number of patients."	( Population pharmacokinetics of imipenem in burn patients. Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Pannier, M, 2003)	0.32
" The pharmacokinetic-pharmacodynamic model with an effect compartment previously developed in healthy rats described the data adequately and pharmacodynamic parameters in hypovolaemic and endotoxaemic rats were not significantly different from corresponding values estimated in the control group."	( Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. Couet, W; Dupuis, A; Lamarche, I; Limosin, A; Mimoz, O; Paquereau, J, 2004)	0.32
" Monte Carlo simulation was used to construct pharmacodynamic models for imipenem, meropenem, ertapenem, levofloxacin, gatifloxacin, and ciprofloxacin."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.32
" In the pharmacodynamic models, imipenem and meropenem had an equal likelihood of achieving a free T>MIC > or =40% against bacteria that produced ESBLs (> or =97%) and bacteria that did not produce ESBLs (> or =98%)."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.32
" Pharmacodynamic modeling based on local ESBL-producing isolates and pharmacokinetic data from healthy humans indicated that imipenem and meropenem may have a greater likelihood of achieving pharmacodynamic targets against bacteria that produce ESBLs than ertapenem or fluoroquinolones."	( Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Burgess, DS; Frei, CR; Moczygemba, LR, 2004)	0.32
"A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of Acinetobacter baumannii was developed to assess the in-vitro and in-vivo activities of imipenem, alone or in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters."	( Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Bernabeu-Wittel, M; García-Curiel, A; Ibáñez-Martínez, J; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C, 2005)	0.33
"To evaluate and compare the pharmacokinetic profiles of imipenem and meropenem in a population of critically ill patients with sepsis to find possible differences that may help in selecting the most appropriate drug and/or dosage in order to optimise empiric antimicrobial therapy."	( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)	0.33
" Pharmacokinetic analysis was carried out through computerised programs using the least-square regression method and a two-compartment open model."	( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)	0.33
"The following pharmacokinetic differences between the two drugs were observed: the imipenem mean peak serum concentration was significantly higher than for meropenem (90."	( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)	0.33
"The more favourable pharmacokinetic profile of imipenem compared with meropenem in critically ill patients with sepsis might balance the possibly greater potency demonstrated in vitro for meropenem against Gram-negative strains."	( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)	0.33
"Carbapenem antibiotics cause pharmacokinetic interaction with valproic acid (VPA) in clinical pharmacotherapy."	( Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. Kiribayashi, Y; Maeda, Y; Murakami, T; Nagai, J; Omoda, K; Takano, M; Yumoto, R, 2005)	0.33
" Pharmacokinetic parameters, obtained from previously published studies in healthy volunteers were used to simulate the %T > MIC for 10,000 patients receiving imipenem-cilastatin, meropenem, and piperacillin/tazobactam."	( Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Kotapati, S; Kuti, JL; Nicolau, DP, 2005)	0.33
"To compare the probability of achieving specific pharmacodynamic exposures of commonly used intravenous antibiotics for the empirical treatment of nosocomial pneumonia against those pathogens most commonly implicated in the disease."	( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Kuti, JL; Nicolau, DP; Sun, HK, 2005)	0.33
" The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were calculated."	( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Kuti, JL; Nicolau, DP; Sun, HK, 2005)	0.33
"The bactericidal exposures necessary for positive clinical outcomes among skin and soft tissue infections are largely dependent on interpatient pharmacokinetic variability and pathogen drug susceptibility."	( Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Kuti, JL; Nicolau, DP; Ong, CT, 2005)	0.33
"The pharmacodynamic potency of imipenem, meropenem and ertapenem against extended-spectrum beta-lactamase (ESBL)-producing isolates was investigated."	( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)	0.33
"Owing to increasing resistance rates in Europe, pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Pseudomonas aeruginosa isolated in Hungary."	( Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP, 2006)	0.33
"Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime."	( Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J, 2007)	0.34
" A two-compartment open model was employed for population pharmacokinetic modeling."	( Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Bulitta, JB; Drusano, GL; Glauner, AK; Kinzig-Schippers, M; Pfister, W; Sakka, SG; Sörgel, F, 2007)	0.34
"In this study we investigated the interplay of antibiotic pharmacokinetic profiles and the development of mutation-mediated resistance in wild-type and hypermutable Pseudomonas aeruginosa strains."	( Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Henrichfreise, B; Luhmer-Becker, I; Wiedemann, B; Wiegand, I, 2007)	0.34
"A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to simulate in vivo bactericidal effects for three carbapenem antibiotics, doripenem (DRPM), meropenem (MEPM)/cilastatin (CS), and imipenem (IPM)/CS, against a Pseudomonas aeruginosa (P."	( Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. Katsube, T; Yamano, Y; Yano, Y, 2008)	0.35
"5, 1, 2, 3, 4, 6, and 8 h after drug injection, and the main pharmacokinetic parameters determined were C(max), T(max), elimination half-life (t(1/2)), area under the concentration-versus-time curve (AUC), total serum clearance (CL/F), and volume of distribution (V/F)."	( Chronopharmacokinetics of imipenem in the rat. Besnard, T; Boulamery, A; Bruguerolle, B; Kadra, G; Simon, N, 2007)	0.34
" The total drug concentrations in plasma and intraperitoneal fluid were analyzed noncompartmentally and 3-compartmentally (population pharmacokinetic analysis), and used for a Monte Carlo simulation with minimum inhibitory concentration data."	( Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sakamoto, K; Sueda, T; Takesue, Y, 2008)	0.35
" The pharmacodynamic exposures in the intraperitoneal fluid were higher than in the plasma."	( Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sakamoto, K; Sueda, T; Takesue, Y, 2008)	0.35
"Microdialysis studies of antibacterial tissue distribution in critically ill patients have sometimes led to results that were spectacular but inconsistent with basic pharmacokinetic concepts."	( Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Bodin, M; Couet, W; Dahyot, C; Debeane, B; Marchand, S; Mimoz, O, 2008)	0.35
" Unbound imipenem concentrations were determined by high-performance liquid chromatography in plasma ultrafiltrates and muscle dialysates, and submitted to noncompartmental pharmacokinetic analysis."	( Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Bodin, M; Couet, W; Dahyot, C; Debeane, B; Marchand, S; Mimoz, O, 2008)	0.35
"These new results are not consistent with previously published data obtained in similar conditions by another group, but they are in agreement with results previously obtained in rats, as well as being consistent with basic pharmacokinetic concepts."	( Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Bodin, M; Couet, W; Dahyot, C; Debeane, B; Marchand, S; Mimoz, O, 2008)	0.35
"A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)."	( A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. Dowzicky, M; Kuti, JL; Nicolau, DP, 2008)	0.35
" For pharmacokinetic evaluation, antibiotics were subcutaneously administered at 3 hours after the pancreatitis induction."	( Pharmacokinetic and pharmacodynamic properties of biapenem, a carbapenem antibiotic, in rat experimental model of severe acute pancreatitis. Hikida, M; Ito, F; Kataoka, H; Kijima, K; Maebashi, K; Mikami, Y; Muto, Y; Niida, M; Sakakibara, S; Shimizu, A; Suzuki, K; Takata, T; Takeda, K; Unno, M, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Monte Carlo simulations were conducted for conventional and prolonged infusion regimens of doripenem, imipenem and meropenem using pharmacokinetic data from adult patients with conserved renal function."	( Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Gomersall, C; Kuti, JL; Kwa, A; Montakantikul, P; Nicolau, DP; Roberts, JA, 2011)	0.37
" Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers."	( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Gonçalves-Pereira, J; Póvoa, P, 2011)	0.37
" Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function."	( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Gonçalves-Pereira, J; Póvoa, P, 2011)	0.37
"To compare the antipseudomonal efficacy of doripenem and imipenem as well as their abilities to restrict the enrichment of resistant Pseudomonas aeruginosa, multiple-dosing regimens of each drug were simulated at comparable values of the cumulative percentages of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (T(>MIC)) and ratios of the 24-hour area under the curve (AUC(24)) to the MIC."	( Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH, 2012)	0.38
"This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity."	( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )	0.13
" In this study, pharmacodynamic profiles of doripenem, imipenem and meropenem were evaluated against Gram-negative bacteria isolated from hospitalised patients."	( Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Keel, RA; Kiratisin, P; Nicolau, DP, 2013)	0.39
"Population pharmacokinetic (PK)-pharmacodynamic target attainment analysis of imipenem was performed to elucidate the PK properties in neonates and children and to rationalize and optimize dosing regimens."	( Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Yoshizawa, K, 2013)	0.39
" The newly developed models were then used to estimate the probability of attaining the pharmacodynamic target (40% of the time above the minimum inhibitory concentration) against clinical isolates of common bacteria in pediatric patients."	( Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Yoshizawa, K, 2013)	0.39
"The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates."	( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013)	0.39
"Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance."	( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013)	0.39
" The pharmacodynamic target was defined as the probability of achieving a fractional time above the minimal inhibitory concentration (MIC) of >40%."	( Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Armand-Lefevre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M, 2014)	0.4
" The objectives of this study were to compare the pharmacokinetic parameters of imipenem administered by standard short infusion (1g imipenem/1g cilastatin over 30min three times daily) and by extended infusion with a reduced total dose (0."	( Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Balík, M; Lipš, M; Siller, M; Strojil, J; Suchánková, H; Urbánek, K, 2014)	0.4
" Significant differences in PK parameters (medians), such as biological half-life (2."	( Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment. da Silva, JM; Gemperli, R; Gomez, DS; Oliveira, AM; Sanches-Giraud, C; Santos, SR; Silva, CV, 2015)	0.42
" We assessed the impact of imipenem and amikacin pharmacokinetic and pharmacodynamic parameters on microbiological outcome in these patients."	( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015)	0.42
" Blood samples for pharmacokinetic analysis were collected after empirical administration of a combination of imipenem three times daily and one single dose of amikacin."	( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015)	0.42
" No imipenem pharmacodynamic parameter was significantly associated with the microbiological success."	( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015)	0.42
"In ICU patients with VAP, classic imipenem pharmacodynamic targets are easily reached with usual dosing regimens."	( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015)	0.42
" Patient-specific data were used in conjunction with published population pharmacokinetic models to construct concentration-time profiles for each patient."	( Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence. Aubry, A; Chastre, J; Crandon, JL; Luyt, CE; Nicolau, DP, 2016)	0.43
" Cmax of imipenem in the fetlock joint using the cephalic and the saphenous vein was 87 and 60μg⁄mL, respectively."	( Evaluation of the pharmacokinetics of imipenem following regional limb perfusion using the saphenous and the cephalic veins in standing horses. Britzi, M; Kdoshim, E; Kelmer, G; Segev, G; Tatz, AJ, 2017)	0.46
"This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem."	( Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. Bi, S; Butterton, JR; Chavez-Eng, CM; Gotfried, MH; Jumes, PA; Mangin, E; Rhee, EG; Rizk, ML; Zhang, Z; Zhao, T, 2018)	0.48
" The volume of distribution, total clearance, elimination half-life and the area under the concentration-time curve between 0 and 6 h were 33."	( Pharmacokinetics of Imipenem in Critically Ill Patients with Life-threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation. Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M; Sriwiriyajan, S; Vattanavanit, V, 2019)	0.51
"Pathophysiological changes in critically ill patients with severe infections during support with ECMO had a greater impact on altered pharmacokinetic patterns of imipenem than those that occur in critically ill patients without ECMO support."	( Pharmacokinetics of Imipenem in Critically Ill Patients with Life-threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation. Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M; Sriwiriyajan, S; Vattanavanit, V, 2019)	0.51
"Simulations demonstrated that the ratio of the area under the concentration-time curve for free drug to the minimum inhibitory concentration (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC=7."	( A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. Bhagunde, P; Carr, D; Racine, F; Rizk, ML; Wu, J; Young, K; Zhang, Z, 2019)	0.51
"Population pharmacokinetic (popPK) models for antibiotics are used to improve dosing strategies and individualize dosing by therapeutic drug monitoring."	( Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. de Velde, F; de Winter, BCM; Harbarth, S; Huttner, A; Koch, BCP; Mouton, JW; Neely, MN; van Gelder, T; von Dach, E; Yamada, WM, 2020)	0.56
" Pharmacokinetic parameters were calculated according to a noncompartment model."	( Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study. Guo, F; Huang, Y; Liu, L; Liu, S; Qiu, H; Xie, J; Yang, J; Yang, Y, 2020)	0.56
"The aim of this study was to build and verify a preliminary physiologically based pharmacokinetic (PBPK) model of Chinese pregnant women."	( Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Li, X; Liu, D; Liu, X; Song, L; Xu, Y; Yu, Z; Zhou, T, 2020)	0.56
" A population pharmacokinetic model was developed using a nonlinear mixed-effects modeling method."	( Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem. Bai, J; Duan, M; Li, X; Li, Z; Shen, S; Wen, A, 2020)	0.56
"Extracorporeal membrane oxygenation (ECMO), a cardiopulmonary bypass device, has been found to increase the profound pathophysiological changes associated with life-threatening severe infections in patients with multiple comorbidities, which results in alterations of pharmacokinetic patterns for antibiotics."	( Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation. Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M; Vattanavanit, V; Wongpoowarak, W, 2020)	0.56
"A high dosage regimen such as 1 g every 6 h of imipenem may be required to achieve pharmacodynamic targets against less susceptible pathogens in this patient population."	( Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation. Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M; Vattanavanit, V; Wongpoowarak, W, 2020)	0.56
"The objectives of this study were (i) to determine the population pharmacokinetic (PK) of imipenem in critically ill patients with life-threatening severe infections, (ii) to investigate the impact of extracorporeal membrane oxygenation (ECMO) on the population PK of imipenem during support with ECMO compared to those without ECMO support, and (iii) to assess the probability of target attainment (PTA) for finding the optimal dosage regimens of imipenem in critically ill patients with life-threatening severe infections."	( NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit. Boonpeng, A; Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M, 2021)	0.62
" However, the effect of Seraph 100 on achieving pharmacodynamic (PD) targets is not well described."	( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach. Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)	0.91
" For vancomycin and gentamicin, published pharmacokinetic models were used to explore the effect of Seraph 100 on ability to achieve probability of target attainment (PTA)."	( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach. Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)	0.91
" Population pharmacokinetic models with and without covariates were fit using the non-parametric adaptive grid algorithm in Pmetrics."	( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022)	0.72
" A base population pharmacokinetic model with two-compartments fitted the data best."	( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022)	0.72
" Although alterations of antibiotic pharmacokinetic parameters have been reported in such patients, little data is available on imipenem."	( Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients. Berçot, B; Burdet, C; Fourmont, M; Goldwirt, L; Hammas, K; Houze, P; Lafaurie, M; Mentré, F; Molina, JM; Sauvageon, H, 2023)	0.91
"Prospective, single-center, non-interventional pharmacokinetic cohort study in adults with chemotherapy-induced febrile neutropenia."	( Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients. Berçot, B; Burdet, C; Fourmont, M; Goldwirt, L; Hammas, K; Houze, P; Lafaurie, M; Mentré, F; Molina, JM; Sauvageon, H, 2023)	0.91

Excerpt	Reference	Relevance
"The in-vitro activity of imipenem combined with beta-lactam antibiotics was studied for 25 strains of methicillin and imipenem-resistant Staphylococcus aureus (MRSA) in comparison with that of fosfomycin combined with cefmetazole."	( In-vitro activity of imipenem combined with beta-lactam antibiotics for methicillin-resistant Staphylococcus aureus. Asahi, Y; Inoue, M; Matsuda, K; Nakagawa, S; Sanada, M; Tanaka, N, 1991)	0.28
"We compared the "in vitro" activity of imipenem with 14 beta-lactams, both alone and in combination with clavulanic acid, and sulbactam against 110 beta-lactamase-producing strains of Bacteroides fragilis."	( Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis. Alados, JC; Castillo, AM; Liébana, J; Marín, A; Martín, MA; Piédrola, G, 1991)	0.28
"IPM in combination with ABPC produced synergistic effects against MRSA."	( [Antibacterial activity of imipenem in combination with ampicillin against methicillin-resistant strains of Staphylococcus aureus]. Inoue, K; Kobayashi, I; Miyake, N; Saionji, K; Shitara, M, 1990)	0.28
" Imipenem in combination with vancomycin or teicoplanin exerted a synergistic or additive effect against a majority of Staphylococcus aureus and Staphylococcus epidermidis isolates tested by the checkerboard method."	( In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Barr, JG; Hogg, GM; Smyth, ET, 1990)	0.28
" (2) Electron microscopic observation showed that IPM in combination with FOM caused lysis of the cells."	( [Antibacterial activities and electron microscopic studies of imipenem in combination with fosfomycin against methicillin and fosfomycin resistant strains of Staphylococcus aureus]. Kobayashi, I; Saionji, K; Shitara, S, 1990)	0.28
" MICs and MBCs of netilmicin alone and combined with azlocillin, mezlocillin and imipenem were studied."	( In vitro activity of netilmicin alone and in combination with azlocillin, mezlocillin and imipenem against 149 coagulase-negative staphylococci. Allocati, N; Cellini, L; D'Antonio, D; D'Eletto, MR; Di Girolamo, A; Piccolomini, R; Ravagnan, G, 1989)	0.28
"In a randomised and coordinated multicentre study, 143 patients with severe infections received treatment with either imipenem/cilastatin (72; I/C group) or cefotaxime combined with metronidazole and optional cloxacillin (71; CX/M/CL group)."	( Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Report from a Norwegian Study Group. , 1987)	0.27
"Imipenem was evaluated for its in vitro and in vivo activities alone and in combination with gentamicin against a clinical isolate of Listeria monocytogenes, and the results were compared with the activities of ampicillin with and without gentamicin."	( In vitro and in vivo studies of imipenem-cilastatin alone and in combination with gentamicin against Listeria monocytogenes. Kim, KS, 1986)	0.27
"The antibacterial activity of ciprofloxacin, either alone or in combination with azlocillin, imipenem, mezlocillin or tobramycin, was tested against enterococcus and pseudomonas species."	( [Ciprofloxacin in combination with other antimicrobial substances]. Mellinghoff, D; Shah, PM; Stille, W, 1988)	0.27
"The antibacterial activity of imipenem combined with norfloxacin, ciprofloxacin, or ofloxacin against 43 gram-positive cocci and 53 aerobic gram-negative rods compared to results obtained with the combination of imipenem with amikacin."	( In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives. Gulden, H; Kern, W; Kurrle, E; Vanek, E, 1988)	0.27
"Imipenem combined with vancomycin resulted in a marked additive effect in vitro against 9 clinical isolates of multiple-drug resistant (MDR), coagulase-negative staphylococci, including strains resistant against imipenem."	( In vitro additive effect of imipenem combined with vancomycin against multiple-drug resistant, coagulase-negative Staphylococci. Bauer, D; Spohr, M; Traub, WH, 1986)	0.27
"Nine severe Gram-negative septicaemias in neutropenic (less than 500 neutrophils/mm3) children with neoplastic diseases were treated with imipenem/cilastatin (75 mg/kg/day) in combination with an aminoglycoside."	( Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside. Andremont, A; Baruchel, A; Hartmann, O; Tancrède, C, 1986)	0.27
"The in vitro activity of fosfomycin alone and in combination with rifampin, pefloxacin and imipenem was studied by the time-kill method against staphylococci."	( In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method. Bebear, C; Lafferriere, C; Noury, P; Quentin, C; Saivin, S, 1987)	0.27
" Fosfomycin combined with pefloxacin was found to be additive or moderately synergistic."	( [In vitro action of fosfomycin combined with rifampicin, pefloxacin and imipenem on staphylococci (checkerboard method in a liquid medium)]. Bebear, C; Laurent, C; Noury, P; Quentin, C; Saivin, S, 1987)	0.27
"The in vitro activities of imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) and amikacin in combination with cefotaxime, trimethoprim-sulfamethoxazole, and each other were tested against 26 Nocardia asteroides strains."	( Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia asteroides. Aulicino, TM; Gombert, ME, 1983)	0.27
"The activities of ticarcillin, cefsulodin, ceftazidime, aztreonam, and imipenem, formerly known as N-formimidoyl thienamycin, were evaluated alone and in combination with aminoglycosides against 56 clinical isolates of Pseudomonas aeruginosa, which were characterized by aminoglycoside susceptibility and content of aminoglycoside-modifying enzymatic activities."	( Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Berndt, KD; Boisvert, WE; Dudek, EJ; Lerner, SA, )	0.13
" These results indicate that IPM/CS alone produces of good response in moderate to severe respiratory infections while IPM/CS combined with AMK is useful in intractable respiratory infections."	( [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections]. Ichikawa, Y; Ishibashi, T; Oizumi, K; Takamoto, M; Tamaru, N; Tanaka, H; Tokunaga, N; Toyoshima, H; Watanabe, K; Yoshida, M, 1994)	0.29
" Imipenem was administered as monotherapy (simulated 1-g bolus every 8 or every 12 h) and in combination with amikacin (7."	( Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Lamp, KC; McGrath, BJ; Rybak, MJ, 1993)	0.29
"The efficacy of hyperbaric oxygen (HBO) alone and in combination with several antimicrobial agents was evaluated in a lethal model of gas gangrene in mice."	( Evaluation of antimicrobials combined with hyperbaric oxygen in a mouse model of clostridial myonecrosis. Anderson, LH; Mehm, WJ; Muhvich, KH, 1994)	0.29
"The synergic activity of imipenem/cilastatin combined with cefotiam was studied in a mouse bacteraemia model."	( Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus. Asahi, Y; Goto, M; Inoue, M; Kaji, Y; Kimura, S; Matsuda, K; Nakagawa, S; Oka, S; Sanada, M; Shimada, K, 1993)	0.29
"The in-vitro activities of various antibiotics, either alone or in combination with amikacin were assessed in clinical isolates of Pseudomonas aeruginosa."	( In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker, AA; Gürler, B, 1995)	0.29
" Therefore, the nephrotoxic effects and pharmacokinetics of VCM were examined in rabbits and compared with those in rabbits administered with VCM and other antibiotics."	( [Nephrotoxicity and drug interaction of vancomycin (2)]. Nakagawa, Y; Toyoguchi, T, 1996)	0.29
"Against gram-positive sepsis, vancomycin (VCM) was administered in combination with imipenem or cilastatin (IPM/CS)."	( [Two cases of gram-positive sepsis successfully treated with vancomycin in combination with imipenem or cilastatin]. Maezawa, H; Nakazawa, Y; Saitoh, A; Sakai, O; Sakamoto, M; Saruta, K; Shiba, K; Shindo, N; Yoshida, M; Yoshikawa, K, 1996)	0.29
"The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients."	( Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Abi-Said, D; Bodey, G; Raad, I; Rolston, K; Whimbey, E, 1996)	0.29
" The main objective of this work was the study of the initial control of infection comparing two glycopeptidic antibiotics: vancomycin and teicoplanin combined with imipenem in first line of empiric therapy."	( [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes]. Arranz, R; Cámara, R; del Rey, MC; Fernández-Rañada, JM; Figuera, A; Hernández, L; Jiménez, ML; López-Lorenzo, JL; Peñarrubia, MJ; Tomás, JF, 1996)	0.29
"The in vitro activity of fosfomycin in combination with ceftazidime, imipenem, amikacin, or ciprofloxacin was studied by an agar plate checkerboard method against 40 clinical isolates of Pseudomonas aeruginosa with various antibiotic resistance profiles."	( In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Quentin, C; Tessier, F, 1997)	0.3
"The activity of piperacillin/tazobactam, ampicillin/sulbactam, imipenem and nafcillin alone and in combination with vancomycin was compared with vancomycin monotherapy against MRSA in test-tube time-kill studies and in infected fibrin clots."	( An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin Palmer, SM; Rybak, MJ, 1997)	0.3
"The purpose of this study was to compare once daily (To24) and thrice daily (To8) tobramycin dosing regimens alone and in combination with ceftazidime, ciprofloxacin and imipenem against a clinical and ATCC strain of Pseudomonas aeruginosa."	( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, )	0.13
"The antibacterial activities of human regimens of cefepime, ceftazidime, and imipenem alone or in combination with amikacin against an isogenic pair of Enterobacter cloacae strains (wild type and its corresponding derepressed cephalosporinase mutant) were compared by using our nonlethal model of pneumonia with 180 immunocompetent rats."	( Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains. Hidri, N; Jacolot, A; Leotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K, 1998)	0.3
" The combination beta-lactam-ciprofloxacin-tobramycin was the combination with the most consistently synergistic effect."	( Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999)	0.3
"The aim of this in vitro study was to compare the elution characteristics of vancomycin alone and in combination with imipenem-cilastatin from 3 acrylic bone-cements (CMW1 [DePuy International, Blackpool, UK], Palacos R [Schering-Plough, Wehrheim, Germany], and Simplex P [Howmedica International, London, UK])."	( The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: a pharmacokinetic study. Bocchi, L; Ceffa, R; Cerretani, D; Fornara, P; Ghisellini, F; Giorgi, G; Neri, L; Ritter, MA, 2002)	0.31
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."	( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. Fukuda, H; Kawamura, Y, 2002)	0.31
"The efficacy of cationic peptides combined with betalactams was investigated in a peritonitis rat model."	( Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. Cirioni, O; Ghiselli, R; Giacometti, A; Mocchegiani, F; Saba, V; Scalise, G; Viticchi, C, 2002)	0.31
"To investigate the characteristics of bacteriology and the drug resistance in the patients with chronic obstructive disease (COPD) combined with pneumonia at our respiratory intensive care unit(RICU) in 2001."	( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003)	0.32
"The sputum of 543 patients with COPD combined with pneumonia was collected with a regular method, the bacteria were cultured, and then the drug sensitivity was analyzed with K-B method."	( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003)	0.32
"The bacteria in the patients with COPD combined with pneumonia at RICU of the hospital in 2001 are mainly made up of G- bacillus and secondarily of G+ bacteria which are sensitive to imipenem, amikacin, and ceftazidime."	( [Characteristics of bacteriology and drug sensitivity in patients with COPD combined with pneumonia]. Xiang, XD; Yang, H; Yi, ZM, 2003)	0.32
"Indifference or moderate antagonism of linezolid combined with other antibiotics in vitro and in vivo have mainly been reported in the literature."	( In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Batard, E; Bugnon, D; Caillon, J; Jacqueline, C; Kergueris, MF; Le Mabecque, V; Miegeville, AF; Navas, D; Potel, G, 2005)	0.33
"To investigate the efficacy of pexiganan, a 22-residue magainin analog, alone and combined with betalactmas antibiotics in three experimental rat models of Gram-negative septic shock."	( Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Kamysz, W; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C; Łukasiak, J, 2005)	0.33
"A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of Acinetobacter baumannii was developed to assess the in-vitro and in-vivo activities of imipenem, alone or in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters."	( Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Bernabeu-Wittel, M; García-Curiel, A; Ibáñez-Martínez, J; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C, 2005)	0.33
" Also, mouse models of staphylococcal sepsis were used to evaluate the efficacy of temporin A alone and in combination with imipenem."	( Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, W; Licci, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C; Łukasiak, J, 2005)	0.33
"This randomized, double-blind, multicenter study compared the efficacy and safety of piperacillin/tazobactam (P/T) and imipenem/cilastatin (IMP), both in combination with an aminoglycoside, in hospitalized patients with acute nosocomial pneumonia (NP)."	( Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S, 2006)	0.33
" In-vitro studies have reported that polymyxins combined with carbapenems, rifampicin or azithromycin are synergistic against these strains despite in-vitro resistance to these agents alone."	( In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Bean, DC; Wareham, DW, 2006)	0.33
" Marked synergy was not seen with polymyxin in combination with imipenem, rifampicin or azithromycin against any of the strains."	( In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Bean, DC; Wareham, DW, 2006)	0.33
"In-vitro synergy with polymxyin in combination with imipenem, rifampicin or azithromycin is highly strain and method dependent."	( In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Bean, DC; Wareham, DW, 2006)	0.33
" These data suggest that colistin, in combination with rifampin and imipenem, is safe and effective, in promoting healing in DFI due to MDR P aeruginosa and suggest the need for controlled clinical studies."	( Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Gemignani, G; Leonildi, A; Menichetti, F; Palumbo, F; Piaggesi, A; Tascini, C; Tedeschi, A, 2006)	0.33
" A positive interaction was shown when the lipopeptides were combined with beta-lactams and vancomycin."	( In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. Cirioni, O; Della Vittoria, A; Giacometti, A; Kamysz, W; Licci, A; Okroj, M; Scalise, G; Silvestri, C, 2007)	0.34
"2 was combined with clarithromycin and minocycline."	( In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. Cirioni, O; Della Vittoria, A; Giacometti, A; Kamysz, W; Nadolski, P; Riva, A; Scalise, G; Silvestri, C; Łukasiak, J, 2007)	0.34
"The activities of tigecycline alone and in combination with other antimicrobials are not well defined for carbapenem-intermediate or -resistant Acinetobacter baumannii (CIRA)."	( In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Noskin, GA; Obias, A; Postelnick, MJ; Qi, C; Scheetz, MH; Warren, JR; Zembower, T, 2007)	0.34
" abscessus strains recovered from infections in Japan, the in vitro activity of imipenem in combination with clarithromycin, levofloxacin, moxifloxacin, minocycline, amikacin or tobramycin was investigated by the checkerboard method and compared with the combination amikacin and cefoxitin."	( In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. Kaku, M; Kanemitsu, K; Komatsu, M; Kunishima, H; Mitsutake, K; Miyasaka, T; Ohisa, Y; Tamai, K; Yanagisawa, H, 2007)	0.34
"Bridged monobactam beta-lactamase inhibitors were prepared and evaluated as potential partners for combination with imipenem to overcome class C beta-lactamase mediated resistance."	( Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Blizzard, TA; Chen, H; Felcetto, T; Fitzgerald, P; Ha, S; Hairston, N; Hammond, ML; Hermes, J; Hickey, E; Kim, S; Lee, SH; Lu, J; Misura, A; Ogawa, A; Painter, RE; Park, YW; Raghoobar, S; Sharma, N; Wu, J; Young, K, 2010)	0.36
" In vitro, fosfomycin showed a synergistic effect when combined with the other antimicrobials tested."	( Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Ariza, J; Cabellos, C; Domínguez, MA; Fernández, R; Gudiol, F; Pachón-Ibáñez, ME; Ribes, S; Tubau, F, 2011)	0.37
"ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes."	( Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa. Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA, 2011)	0.37
"This study evaluated the activity of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli co-producing extended-spectrum β-lactamases and acquired AmpC β-lactamases."	( Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Hur, J; Kim, HS; Lee, KM; Park, MJ; Park, MS; Song, W; Woo, H; Yim, H, 2011)	0.37
"Biapenem is a carbapenem being developed in combination with RPX7009, a new inhibitor of serine β-lactamases."	( In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, KL, 2013)	0.39
" Due to structural and mechanistic similarities between vancomycin and telavancin, we investigated the activity of telavancin combined with nafcillin and imipenem compared to the known synergistic combination of telavancin and gentamicin."	( Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Gandhi, RG; Leonard, SN; Patel, MD; Supple, ME, 2013)	0.39
" The purpose of this study was to investigate the clinical outcomes of patients with healthcare-associated infections (HAIs) caused by MDRAB who were treated with imipenem/cilastatin and sulbactam, and TG alone or in combination with other antibiotics."	( Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Hsueh, PR; Lee, YT; Tsao, SM, 2013)	0.39
"β-Lactamase inhibitors with a bicyclic urea core and a variety of heterocyclic side chains were prepared and evaluated as potential partners for combination with imipenem to overcome class A and C β-lactamase mediated antibiotic resistance."	( Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Blizzard, TA; Bodner, R; Chen, H; Fitzgerald, P; Gude, C; Ha, S; Hairston, N; Hammond, ML; Hermes, J; Imbriglio, J; Kim, S; Lu, J; Ogawa, A; Painter, RE; Park, YW; Raghoobar, S; Scapin, G; Sharma, N; Wisniewski, D; Wu, J; Young, K, 2014)	0.4
" Synergy was demonstrated when IB-367 was combined with colistin or imipenem."	( In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria. Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Mazzocato, S; Offidani, A; Orlando, F; Provinciali, M; Silvestri, C; Simonetti, O, 2014)	0.4
" They were treated with IMP/C alone (every 2 hours [q2h], various doses) or in combination with MK7655 in either a dose fractionation study or q2h for 24 h and sacrificed for CFU determinations."	( Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. Mangin, E; Mavridou, E; Melchers, RJ; Motyl, MR; Mouton, JW; van Mil, AC, 2015)	0.42
" In this study, we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline, or imipenem in experimental murine models of peritoneal sepsis and pneumonia."	( Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models. Ayerbe Algaba, R; Díaz, C; Gutiérrez Valencia, A; Jiménez Mejías, ME; López Cortés, LF; Pachón Ibáñez, ME; Pachón, J; Parra Millán, R; Pérez Del Palacio, J; Sánchez Encinales, V; Smani, Y, 2016)	0.43
" Imipenem, meropenem and doripenem were significantly more effective (reduced fold-change of MICs) when combined with rifampicin in bla VIM-negative isolates, especially in isolates with porin frameshift mutation."	( In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Hu, YF; Liu, CP; Shih, SC; Wang, NY, 2016)	0.43
" The SBPI analysis showed that CAZ-AVI in combination with imipenem achieved higher SBPI values than other CAZ-AVI-based combinations."	( In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Ambretti, S; Campoli, C; Gaibani, P; Giannella, M; Landini, MP; Lewis, RE; Re, MC; Viale, P; Volpe, SL, 2017)	0.46
" In this study, the activity of colistin (COL) as monotherapy and in combination with other antibiotics against Acinetobacter baumannii in vitro was investigated."	( In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli. Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z, 2020)	0.56
"Imipenem/relebactam is a carbapenem/β-lactamase inhibitor combination with in vitro activity against Pseudomonas aeruginosa and Enterobacterales, including KPC producers."	( In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. Abdelraouf, K; Nicolau, DP; Reyes, S, 2020)	0.56
"In the present study, the in vitro and in vivo activities of imipenem combined with BLI-489 against CRAb producing carbapenem-hydrolysing class D β-lactamases (CHDLs), namely OXA-23, OXA-24, OXA-51 and OXA-58, were determined."	( In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. Chen, TL; Chiang, MH; Chiu, CH; Huang, SW; Kuo, SC; Lee, IM; Lee, YT; Su, YS; Wang, FD; Wang, YC; Yang, YS, 2021)	0.62
"Imipenem combined with BLI-489 has synergistic effects against CHDL-producing CRAb isolates."	( In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. Chen, TL; Chiang, MH; Chiu, CH; Huang, SW; Kuo, SC; Lee, IM; Lee, YT; Su, YS; Wang, FD; Wang, YC; Yang, YS, 2021)	0.62
" The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method."	( Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Kasimati, A; Magkafouraki, E; Maraki, S; Mavromanolaki, VE; Moraitis, P; Scoulica, E; Stafylaki, D, 2021)	0.62
"A total of 29 MRSA, including 6 VISA, 14 hVISA, and 9 VSSA isolates, were subjected to a microbroth dilu- tion-minimum inhibitory concentration (MIC) checkerboard using vancomycin combined with cefotaxime, imipenem, or meropenem."	( Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin Booncharoen, S; Chaiyapoke, C; Chanawong, A; Lulitanond, A; Srisrattakarn, A; Tavichakorntrakool, R; Tippayawat, P; Wongthong, S, 2021)	0.62
" Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained only in the VISA isolates."	( Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin Booncharoen, S; Chaiyapoke, C; Chanawong, A; Lulitanond, A; Srisrattakarn, A; Tavichakorntrakool, R; Tippayawat, P; Wongthong, S, 2021)	0.62
"To investigate the antibacterial activity of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) in vivo and in vitro."	( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)	0.72
"Twenty-five CRE strains, including Klebsiella pneumoniae (n = 10), Escherichia coli (n = 6) and Enterobacter cloacae (n = 9), were used in chequerboard assays to evaluate the synergistic effect of BLI-489 combined with imipenem or meropenem."	( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)	0.72
"The novel β-lactamase inhibitor BLI-489 possesses a synergistic effect against diverse carbapenemase-producing CRE combined with imipenem or meropenem."	( Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Liu, Q; Shi, S; Xu, M; Yao, Z; Ye, J; Zhang, X; Zhang, Y; Zhou, B; Zhou, C; Zhou, T, 2022)	0.72
"The aim of this study was to explore the efficacy of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China using meta-analysis."	( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis. He, C; Jin, LR; Zhou, S, 2022)	0.72
"We searched China National Knowledge Network, Wanfang Medical Network, Chinese Science Citation Database, PubMed, and Embase Databases for publications of imipenem combined with glutamine in the treatment of severe acute pancreatitis abdominal infection."	( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis. He, C; Jin, LR; Zhou, S, 2022)	0.72
" Meta-analysis results showed that the efficacy of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection was significantly better than that of imipenem alone (odds ratio=0."	( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis. He, C; Jin, LR; Zhou, S, 2022)	0.72
"Imipenem combined with glutamine can significantly improve the efficacy in the treatment of severe acute pancreatitis with abdominal cavity infection."	( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis. He, C; Jin, LR; Zhou, S, 2022)	0.72
"The aim of this study was to investigate in vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant Gram-negative pathogens."	( In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens. Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T, 2022)	0.72
"This study aimed to investigate the synergistic activity of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii collected from China."	( Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Cui, L; Li, Y; Wang, Q; Xue, F; Zheng, B, 2022)	0.72
" Imipenem, ceftazidime, cefoperazone-sulbactam, ciprofloxacin, amikacin, and polymyxin B were selected to investigate their efficacy in combination with eravacycline against 60 carbapenem-resistant strains."	( Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Cui, L; Li, Y; Wang, Q; Xue, F; Zheng, B, 2022)	0.72
"Eravacycline combined with β-lactams or polymyxin B can lead to synergistic effects against clinically common carbapenem-resistant Gram-negative bacteria."	( Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Cui, L; Li, Y; Wang, Q; Xue, F; Zheng, B, 2022)	0.72
" RPE in combination with CEFO, IMI, and ERTA was evaluated on the formation or eradication of biofilm."	( Brazilian red propolis in combination with β-lactams exerts an efficient antibacterial action over methicillin-resistant Staphylococcus aureus (MRSA) strains. Aldana-Mejía, JA; Bastos, JK; Júnior, AF; Pereira, AFM; Rall, VLM; Ripari, N; Sforcin, JM, 2023)	0.91
" The results showed additivity when the substance was combined with ciprofloxacin and cefepime, indifference when associated with ceftazidime and synergistic effect when combined with meropenem and imipenem."	( Effect of 2-chloro-N-(4-fluoro-3-nitrophenyl)acetamide in combination with antibacterial drugs against Klebsiella pneumoniae. Andrade Júnior, FP; Athayde Filho, PF; Cordeiro, LV; Figueiredo, PTR; Lima, EO; Oliveira, RF; Oliveira-Filho, AA; Sousa, AP; Souza, HDS, 2023)	0.91
" In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A."	( In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii. Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M, 2023)	0.91

Excerpt	Reference	Relevance
" Excellent tissue pharmacokinetics and oral bioavailability suggest usefulness in the treatment of complicated intra-abdominal infections."	( Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Bur, F; Donahue, PE; Luke, DR; Mintz, SJ; Smith, DL; Yellin, AE, 1998)	0.3
" Linezolid is a new antibiotic with high bioavailability and an outstanding safety profile, synergistic with imipenem, which may deserve a place in the armamentarium for severe pneumonia in children."	( Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports. Caillon, J; Christophe Roze, J; Denizot, S; Godon, N; Gras-Le Guen, C; Podevin, G; Potel, G, 2006)	0.33
"99 microg ml(-1) and the systemic bioavailability was 65."	( Pharmacokinetics of imipenem in sheep with special reference to its hepato-renal effects. Abo EL-Sooud, K; Kadri, MN; Khammas, W, 2007)	0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Bioavailability was 93."	( Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. Albarellos, GA; Denamiel, GA; Landoni, MF; Lupi, MP; Montoya, L; Quaine, PC, 2013)	0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" One day during treatment days 2-8, multiple blood and urine samples were collected from each individual over a six hour dosing interval."	( Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis. Claesson, G; Eriksson, M; Rogers, JD, 1992)	0.28
" Both these antimicrobials seem appropriate for the treatment of meningitis caused by penicillin G-resistant pneumococci provided their dosage is adjusted to achieve adequate drug levels in the cerebrospinal fluid."	( [Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci]. Barakett, V; Burghoffer, B; Delisle, F; Guidet, B; Lesage, D; Offenstadt, G; Petit, JC; Richard, G; Vergez, P, 1992)	0.28
" Microbes which appeared after its dosing amounted to 6 classes of 17 strains, 6 NFB strains of which were identified."	( [Clinical studies of efficacy of imipenem/cilastatin sodium against urinary tract infections with ureterocutaneostomy]. Ikeuchi, T; Kai, Y; Yogi, S; Yoshikawa, H, 1992)	0.28
" This was offset, however, by greater costs in the C+A group for dosage preparation, material and labor, and need for therapeutic drug monitoring of the aminoglycoside."	( Cost-analysis of imipenem-cilastatin monotherapy compared with clindamycin+aminoglycoside combination therapy for treatment of serious lower respiratory, intra-abdominal, gynecologic, and urinary tract infections. Kreter, B, )	0.13
"To report a case of Pseudomonas aeruginosa endocarditis that was successfully treated with high-dose imipenem/cilastatin and to discuss dosage modification based on individual pharmacokinetic parameters."	( Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. Hrdy, DB; Kailath, EJ; King, JH, 1992)	0.28
" Dosage may need to be adjusted to body size in order to obtain optimal serum concentrations and activity."	( Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. Hrdy, DB; Kailath, EJ; King, JH, 1992)	0.28
" Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents."	( Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems. Hopkins, JA; Lami, JL; Wilson, SE, 1991)	0.28
" (22) and other dosages (a change in dosing regimen, 2)."	( [Clinical study of intramuscular imipenem/cilastatin sodium in the field of obstetrics and gynecology]. Banzai, M; Chimura, T; Kanasugi, H; Kihara, K; Matsuo, M; Miyata, R; Oda, T; Takahashi, H; Yamazaki, K; Yokoyama, Y, 1991)	0.28
" Mean imipenem AUCss (area under the concentration-time curve over a dosage interval at steady state) values were 38."	( Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. Bland, JA; Graziani, AL; Lawson, LA; MacGregor, RR; Pietroski, NA; Rogers, JD, 1991)	0.28
" In summary, a once-daily dosing regimen of amikacin 15 mg/kg is practical and probably efficacious and safe in severely infected patients."	( Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O, 1991)	0.28
" Dosing regimens in evaluable patients were 500 mg every 12 h (45."	( Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience. Calandra, GB; Garau, J, 1991)	0.28
"Imipenem is the broadest-spectrum antibiotic currently available but requires frequent intravenous dosing for efficacy."	( Overall clinical utility of the intramuscular preparation of imipenem/cilastatin. MacGregor, RR, 1991)	0.28
" Seizures ceased upon reduction in dosage or discontinuation of the suspected offending agents."	( Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. Allen, N; Semel, JD, 1991)	0.28
" Pharmacists evaluated I/C dosage based upon culture/sensitivity results and indicators of renal function."	( Evaluation of an imipenem/cilastatin target drug program. Abel, SR; Guba, EA, 1991)	0.28
" Microtiter checkerboard technique was compared with standard killing curve method and with killing curves obtained in kinetic in vitro models mimicking single or multiple dosing regimens according to human pharmacokinetics."	( Interactions of antimicrobial combinations in vitro: the relativity of synergism. Blaser, J, 1990)	0.28
" This makes it difficult to determine a mean dosage for therapeutic uses."	( [Clinical pharmacokinetics of an imipenem-cilastatin combination]. Singlas, E, 1990)	0.28
" The mean dosage and duration of treatment were 29."	( [An imipenem-cilastatin combination in the treatment of infection at general intensive care units]. Gouin, F, 1990)	0.28
" This dose should be the starting dose for a period of 12-h dosing intervals until the next IHF procedure."	( Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. Alarabi, AA; Cars, O; Danielson, BG; Salmonson, T; Wikström, B, 1990)	0.28
" Clinical trials are needed to assess the efficacy and cost-benefit ratio of a 12 h dosing regimen of ceftizoxime in combination with metronidazole for treating mixed aerobic/anaerobic infections."	( Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria. Echols, RM; Kowalsky, SF; McCormick, EM, 1990)	0.28
" Up to six hours after dosing the concentrations in prostatic secretions ranged between 1 and 2 mg/l."	( [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections]. Adam, D; Bauernfeind, A; Hönig, E; Naber, KG, 1986)	0.27
" We compared the relative efficacy and potency of three beta-lactams and two aminoglycosides in lung and thigh-infection models in neutropenic mice by defining the maximum attainable antimicrobial effect at 24 h (Emax) and the total dose required to reach 50% of maximum effect (P50) at several dosing intervals."	( Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. Calame, W; Craig, WA; Ebert, S; Fantin, B; Leggett, JE; Mattie, H; Totsuka, K; Vogelman, B, 1989)	0.28
"In 43 ICU patients undergoing continuous volume constant hemofiltration (CVHF), the pharmacokinetics of 12 drugs were investigated to ensure correct dosage adjustments."	( [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study]. Dehne, M; el Abed, K; Hofmann, W; Kroh, U; Lennartz, H, 1989)	0.28
" The concentration of IPM in plasma showed a dose-response to the 10 mg/10 mg/kg and 20 mg/20 mg/kg dosages."	( [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates]. Iwai, N; Kasai, K; Miyazu, M; Nakamura, H; Taneda, Y, 1989)	0.28
" maltophilia, although expression levels were gene dosage dependent for beta-lactamase synthesis."	( Molecular cloning and expression of the imipenem-hydrolyzing beta-lactamase gene from Pseudomonas maltophilia in Escherichia coli. Dufresne, J; Levesque, RC; Vézina, G, )	0.13
" Our work indicates that with serum concentration of 100 mg/l, superior to those obtained in therapeutic, neither imipenem nor cilastatin interact on the creatinine dosage using either the Jaffé reaction of the enzymatic technic."	( [Do imipenem and cilastatin interfere with the determination of serum creatinine?]. Dauchy, F, 1988)	0.27
" aerogenes septicemia required pefloxacin because blood cultures remained positive (d5) despite an increased dosage (90 mg/kg/d)."	( [Use of imipenem-cilastatin in neonatal septicemias caused by gram-negative bacilli multiresistant to beta-lactam antibiotics]. Aufrant, C; Bompard, Y; Chastel, A; Gantzer, A; Lambert, T; Voinnesson, A, 1988)	0.27
" With early treatment the dose-response relationship between the drug concentration and the diminution in bacterial counts in the vitreous humor was linear with all three drugs."	( Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections. Barza, M; Davey, PG; Stuart, M, 1987)	0.27
" In theory, a prolonged PAE could influence the dosage regimentation of selective antibiotics."	( Post-antibiotic effect in Bacteroides fragilis group. Clausz, JC; Edmiston, CE; Goheen, MP; Siverhus, DJ, )	0.13
" There was an association with Pseudomonas aeruginosa infection that remained statistically significant even after controlling for imipenem/cilastatin dosage as well as for the other factors indicated."	( Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Calandra, G; Carrigan, J; Guess, H; Lydick, E; Weiss, L, 1988)	0.27
" Plasma concentrations, half-lives, and areas under the curve of both imipenem and cilastatin was significantly greater at the 25 mg/kg dosage but the half-lives and clearances of the two drugs were similar to each other only at the larger dose."	( Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. Engelhard, D; Greenwood, R; Griffis, J; Marks, MI; Shalit, I; Stutman, HR, 1986)	0.27
" Clinically, MK-0787/MK-0791 was used for the treatment of obstetrical and gynecological infections at a dosage of 500 mg/500 mg twice daily by intravenous drip infusion."	( [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology]. Akagi, T; Fujiwara, A; Hara, T; Iwasaki, K; Kudo, Y; Masaoka, T; Matsuo, M; Naito, H; Urabe, T, 1986)	0.27
" In 112 patients the daily dosage ranged from 30/30 mg/kg to 59/59 mg/kg, and in 138 patients it ranged from 60/60 mg/kg to 99/99 mg/kg."	( [Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium]. Arimasu, O; Fujii, R; Fujita, K; Inyaku, F; Maruyama, S; Meguro, H; Nagamatsu, I; Takase, A; Wagatsuma, Y; Yoshioka, H, 1986)	0.27
" The average duration of treatment was 10 days with a dosage 3 X 500 mg imipenem daily."	( Effectiveness of imipenem in the treatment of chronic post-traumatic osteitis. Beckurts, T; Claudi, B; Ketterl, R; Stübinger, B, 1987)	0.27
"The chemistry, antimicrobial spectrum, mechanism of action, pharmacology and pharmacokinetics, clinical use, adverse effects, dosage and administration, place in therapy, cost-effectiveness, and formulary considerations of imipenem-cilastatin sodium are reviewed."	( Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination. Pastel, DA, 1986)	0.27
" Imipenem and cilastatin sodium in a dosage of 100 mg/kg/d was used for children 3 years of age or younger, while older ones received 60 mg/kg/d intravenously, divided in four equal doses."	( Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children. Freij, BJ; Kusmiesz, H; Nelson, JD; Shelton, S, 1987)	0.27
" These results suggest the possibility of future clinical studies with new experimental dosage schedules for imipenem."	( Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms. Baquero, F; Culebras, E; Medrano, JC; Patrón, C; Pérez-Díaz, JC; Vicente, MF, 1986)	0.27
" Therefore, dose adjustments will be required in patients with markedly reduced renal function and supplemental dosing will be required after hemodialysis."	( Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Bland, JA; Demetriades, JL; Gibson, TP, 1985)	0.27
" Pure tone audiograms were performed before and after dosing in 11 of 12 subjects; no changes were noted."	( Safety and tolerability of multiple doses of imipenem/cilastatin. Bustamante, CI; Delaportas, D; Drusano, GL; Forrest, A; Leslie, J; Rivera, G; Schimpff, SC; Standiford, HC; Tatem, B, 1985)	0.27
" In view of the important increase in half-life of cilastatin as a function of increasing renal failure, a dosage reduction is proposed in patients with severe renal failure."	( The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Buntinx, AP; De Broe, ME; Entwistle, LA; Jones, KH; Verbist, L; Verpooten, GA, 1984)	0.27
"5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively."	( Multiple-dose pharmacokinetics of imipenem-cilastatin. Bustamante, C; Delaportas, D; Drusano, GL; Forrest, A; Leslie, J; MacGregor, RR; Rivera, G; Schimpff, SC; Standiford, HC; Tatem, B, 1984)	0.27
", significantly lowered the convulsive threshold of pentylenetetrazol (PTZ) in mice and shifted the dose-response curve of PTZ."	( Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Day, IP; Goudie, J; Nishiki, K; Williams, PD, 1995)	0.29
"3% of the total dosage (20 mg/kg) within 8 hours."	( Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis. Munakata, K; Satoh, M; Takeuchi, H; Yoshida, O, 1994)	0.29
" Because patients undergoing continuous haemofiltration have impaired renal function, dosage reduction is often recommended so that adverse drug reactions are avoided."	( Clinical pharmacokinetics during continuous haemofiltration. Bressolle, F; de la Coussaye, JE; Eledjam, JJ; Galtier, M; Kinowski, JM; Wynn, N, 1994)	0.29
"The pharmacodynamic effects of extended imipenem dosing intervals were studied against two strains of Pseudomonas aeruginosa (ATCC 27853 and an imipenem-resistant mutant, 27853R) in an in vitro model of infection."	( Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Lamp, KC; McGrath, BJ; Rybak, MJ, 1993)	0.29
" The recommended dosage was 30 mg/kg/day and could be increased up to 50 mg/kg/day, without exceeding four grams per day, administered by four infusions per day."	( [Efficacy and tolerance of imipenem/cilastatin in the adjuvant treatment of surgery for peritonitis in patients over the age of 70 years]. Carles, J; Janvier, G, 1993)	0.29
" At the dosage used piperacillin/tazobactam was as safe as, and statistically more effective than, imipenem/cilastatin in the treatment of intra-abdominal infections caused by sensitive organisms."	( A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. Eklund, AE; Nord, CE, 1993)	0.29
" Current dosing recommendations for the administration of imipenem to patients with acute or chronic renal failure are based on this reduced clearance rate."	( Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Macias, WL; Mueller, BA; Scarim, SK, 1993)	0.29
"To develop computerized methods to monitor and recommend dosage changes for patients treated with excessive dosages of imipenem/cilastatin (I/C) and to determine the incidence of I/C-associated seizures in our patient population."	( Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Burke, JP; Classen, DC; Evans, RS; Pestotnik, SL; Stevens, LE, 1993)	0.29
" Additional computer-generated alerts identified patients who were receiving anticonvulsants concomitantly with I/C or whose therapy reflected dosage changes in the previous 24 hours."	( Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Burke, JP; Classen, DC; Evans, RS; Pestotnik, SL; Stevens, LE, 1993)	0.29
" We believe that appropriate dosing of I/C results in a low rate of associated seizures."	( Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Burke, JP; Classen, DC; Evans, RS; Pestotnik, SL; Stevens, LE, 1993)	0.29
" These results indicate that the timing of dosing of each antibiotic influences synergy, and administration of cefotiam 2 h after imipenem is more effective than the other regimens."	( Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus. Asahi, Y; Goto, M; Inoue, M; Kaji, Y; Kimura, S; Matsuda, K; Nakagawa, S; Oka, S; Sanada, M; Shimada, K, 1993)	0.29
" The convenience of use of the kit and the time required for the preparation of the dosing solution were evaluated by nurses and pharmacists at the Kitasato University East Hospital."	( [Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: convenience of use and preparation]. Hirayama, T; Kuroyama, M; Shimda, S, 1996)	0.29
" The amount of imipenem/cilastatin remaining in the newly developed kit should be negligible, because the kit serves as both a vial and a dosing package."	( [Study of the usefulness of a kit containing imipenem/cilastatin powder with diluent for injection: accuracy of reconstitution]. Hirayama, T; Kuroyama, M; Shimada, S, 1996)	0.29
" If the manufacturer's dosage recommendations are followed, the risk of seizures in patients receiving this combination is minimal."	( Neurotoxicity of carbapenem antibacterials. Norrby, SR, 1996)	0.29
"In a nonblind, randomised, parallel-group study, initial empirical monotherapy with meropenem 1 g intravenously every 8 h was compared to an identical dosage of imipenem/cilastatin for the treatment of 66 febrile episodes in 61 adult neutropenic patients."	( Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Böhme, A; Fuhr, HG; Halir, S; Heller, A; Jung, B; Köhler, A; Lips-Schulte, C; Schaumann, R; Shah, PM; Stille, W; Walther, F, )	0.13
" Approximately 70% of meropenem is excreted via the kidneys, thus dosage adjustments are required for patients with renal impairment."	( Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Chung, KC; Gill, MA; Moon, YS, 1997)	0.3
" Dosage reduction is required in patients with reduced renal function; no dosage adjustment is required for patients with hepatic impairment."	( The pharmacology of meropenem, a new carbapenem antibiotic. Craig, WA, 1997)	0.3
" Dosage was reduced in patients with renal impairment."	( [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]. Tonelli, F, 1997)	0.3
" The dosage of prednisolone was increased, and amikacin was injected to treat pneumonia that had developed in the right lung."	( [Legionella pneumonia successfully treated despite late diagnosis]. Takazakura, E; Tsuji, H, 1997)	0.3
" Plasma and hemofiltrate samples were taken at specified times during one dosing interval, and the concentrations of imipenem and cilastatin were determined by high-performance liquid chromatography."	( Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Bremer, F; Brune, K; Geisslinger, G; Oelkers, R; Schobel, H; Schüttler, J; Tegeder, I, 1997)	0.3
"The purpose of this study was to compare once daily (To24) and thrice daily (To8) tobramycin dosing regimens alone and in combination with ceftazidime, ciprofloxacin and imipenem against a clinical and ATCC strain of Pseudomonas aeruginosa."	( Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model. Hoban, DJ; Kabani, A; Karlowsky, JA; Zelenitsky, SA; Zhanel, GG, )	0.13
" The most frequent micro-organisms were Gram-negative, documented in 22% of the febrile episodes in the lower dosage group vs."	( Prospective randomized study to compare imipenem 1.5 grams per day vs. 3.0 grams per day in infections of granulocytopenic patients. Böhme, A; Hoelzer, D; Shah, PM; Stille, W, 1998)	0.3
" Cost-avoidance with meropenem is, therefore, mainly the result of less frequent dosing and the ability to administer meropenem by rapid intravenous injection."	( Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Ambrose, PG; Nightingale, CH; Quintiliani, R; Richerson, MA, 1998)	0.3
" The same dosage regimen resulted in complete bacterial eradication in 88% of the kidneys."	( Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998)	0.3
" Under base-case conditions, our pharmacoeconomic analysis showed that I/C was a cost-effective alternative to P/T at the dosage regimens studied."	( Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective. Bryce, EA; Frighetto, LO; Jewesson, PJ; Marra, CA; Marra, FO; Reynolds, RP; Sleigh, KM; Stiver, HG, 1999)	0.3
"All courses of IC administered to patients over age 60 during a four-month period were retrospectively assessed for appropriateness based on both dosing interval and dosage."	( Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight. Bailey, TC; Canaday, KL; Reichley, RM; Ritchie, DJ, )	0.13
" The projected annual cost savings that could have been realized by appropriately adjusting IC dosage based on estimated Cl cr and body weight was $11,500."	( Evaluation and financial impact of imipenem/cilastatin dosing in elderly patients based on renal function and body weight. Bailey, TC; Canaday, KL; Reichley, RM; Ritchie, DJ, )	0.13
" Drug-induced seizures have occurred and will continue to occur as healthcare professionals exceed recommended dosing guidelines to treat critically ill patients."	( Imipenem-induced seizure: a case of inappropriate, excessive, and prolonged surgical prophylaxis. Hunter, WJ, 1993)	0.29
" In patients with normal renal function, the recommended dosing interval is every 8 hours."	( Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Brewer, NS; Hellinger, WC, 1999)	0.3
" Thus, the dosing of imipenem-cilastatin 750 mg intramuscularly every 12 hours is a more cost effective method of drug delivery with equal efficacy and safety when compared to imipenem-cilastatin 500 mg given intravenously every 6 hours."	( A cost comparison of intramuscular versus intravenous imipenem. Appleman, MD; Berne, TV; Chin, A; Gill, MA; Heseltine, PN; Ito, MK; Yellin, AE, 1989)	0.28
" Adult Thai patients with suspected acute, severe melioidosis were randomized to receive either imipenem, at a dosage of 50 mg/(kg x d), or ceftazidime, at a dosage of 120 mg/(kg x d), for a minimum of 10 days."	( Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Angus, BJ; Chaowagul, W; Howe, PA; Rajanuwong, A; Simpson, AJ; Smith, MD; Suputtamongkol, Y; Walsh, AL; White, NJ; Wuthiekanun, V, 1999)	0.3
" In the mouse pentylenetetrazole (PTZ) convulsive model, intravenous pretreatment with cefazolin (800 mg/kg) or imipenem (200 mg/kg) shifted the dose-response curve of PTZ (i."	( Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners. Cho, JH; Jin, C; Jung, I; Kim, DH; Kim, M; Ku, HJ; Oh, CH; Yook, J, 1999)	0.3
" The T>MIC was calculated as percentage of the dosing interval in which free concentrations exceeded the weighted geometric mean MIC90."	( Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Kays, MB, 1999)	0.3
" Cost saving may be achieved with trovafloxacin due to the lack of any need to monitor creatinine levels and the once-daily dosing regimen that allows a switch to the same orally administered drug."	( Treatment of complicated intra-abdominal infections: comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. Luke, DR; Peterson, J, )	0.13
" Meropenem is predominately excreted unchanged in the urine, and thus dosage adjustments are necessary in patients with renal insufficiency and those undergoing intermittent haemodialysis (IHD) or various forms of continuous renal replacement therapy (CRRT), such as continuous venovenous haemodialysis, continuous venovenous haemodiafiltration (CVVHDF), continuous venovenous haemofiltration (CVVHF) or continuous ambulatory peritoneal dialysis (CAPD)."	( Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Hörl, WH; Thalhammer, F, 2000)	0.31
"Tazobactam/piperacillin (total daily dosage of 13."	( Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection. Daschner, F; Dietrich, ES; Ebner, W; Schubert, B, 2001)	0.31
"Charts of all patients in a 450-bed municipal hospital who received imipenem in a 6-month period, as determined by pharmacy records, were reviewed for dosage and duration of imipenem use, occurrence of seizures."	( Seizures in the critically ill: the role of imipenem. Daras, M; Hauser, WA; Koppel, BS; Politis, C; van Duin, D, 2001)	0.31
" The dose-response curves were bell shaped, indicating toxic effects for the sensor strain at high concentrations of beta-lactams."	( A luminescent Escherichia coli biosensor for the high throughput detection of beta-lactams. Karp, MT; Kurittu, JS; Valtonen, SJ, 2002)	0.31
"2%, without significant differences according to the type of pathogen or dosage schedule; however one of the two observed failures was due to a resistant Pseudomonas aeruginosa."	( Imipenem/cilastatin as empirical treatment of severe infections in compromised patients. Biglino, A; Bonasso, M; Gioannini, P, 1991)	0.28
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."	( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. Fukuda, H; Kawamura, Y, 2002)	0.31
" Animals were treated for 3 days with daily dosing regimens of 384 to 1,536 mg/kg of body weight that took into account the short half-life of this antibiotic in mice."	( Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. Buijk, SL; Gyssens, IC; Mouton, JW; Stearne, LE, 2002)	0.31
" For the free drug concentrations, the percentage of the dosing interval that the drug concentrations remain above the MIC (%T>MIC) for each carbapenem-bacteria combination was calculated for 10,000 iterations, substituting a different ClT, Vdbeta, fraction of unbound drug, and MIC into the equation each time based on the probability distribution for each parameter."	( Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Florea, NR; Kuti, JL; Nicolau, DP; Nightingale, CH, 2004)	0.32
" There is a very weak correlation between dosage and serum concentrations."	( Imipenem levels are not predictable in the critically ill patient. Belzberg, H; Cornwell, EE; Gill, MA; Murray, JA; Salim, A; Sava, J; Velmahos, GC; Zhu, J, 2004)	0.32
" This tendency inverse correlated to decreasing dosage of PCs."	( [The trend and susceptibility to antibacterial agents of enterococcus species from urinary tract infections]. Hoshinaga, K; Ishikawa, K; Miyakawa, S; Naide, Y; Shiroki, R; Tanaka, T, 2004)	0.32
"To evaluate and compare the pharmacokinetic profiles of imipenem and meropenem in a population of critically ill patients with sepsis to find possible differences that may help in selecting the most appropriate drug and/or dosage in order to optimise empiric antimicrobial therapy."	( Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Adembri, C; De Gaudio, AR; Fallani, S; Livi, P; Mazzei, T; Novelli, A, 2005)	0.33
" Pre- and postmembrane blood (plasma) and corresponding ultrafiltrate or dialysate samples were collected 1, 2, 4, and 8 or 12 h (depending on dosing interval) after completion of the drug infusion."	( Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Abraham, E; Fish, DN; Teitelbaum, I, 2005)	0.33
"Randomized controlled trials of adult patients with severe infections treated with meropenem or imipenem plus cilastatin at an equal dose, on a gram-for-gram basis, and with the same dosing regimen."	( Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Campbell, HE; Edwards, SJ; Emmas, CE, 2005)	0.33
") infusion at an imipenem dosage of 10 mg/kg (study 1) and 20 mg/kg (study 2)."	( Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses. Benson, CE; Boston, RC; Engiles, J; Moate, PJ; Norman, T; Orsini, JA; Poppenga, R, 2005)	0.33
" The probabilities of each drug and dosing regimen in achieving pharmacodynamic targets were calculated."	( Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Kuti, JL; Nicolau, DP; Sun, HK, 2005)	0.33
" For meaningful dosage recommendations to be made, further studies are required using larger populations and with more detail regarding liver dysfunction and duration of renal failure."	( Using imipenem and cilastatin during continuous renal replacement therapy. Brett, S; Cotton, A; Franklin, BD; Holmes, A, 2005)	0.33
" Pharmacodynamic exposure, measured as percent of the dosing interval during which free drug was above the MIC (% fT>MIC), was modelled via a 5000-subject Monte Carlo simulation."	( Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Eagye, KJ; Kiffer, CR; Kuti, JL; Mendes, C; Nicolau, DP, 2006)	0.33
" Appropriate antibiotic regimens must cover all likely pathogens, be administered promptly at the correct dosage and dosing interval, be well tolerated and prevent the emergence of resistance."	( Two decades of imipenem therapy. Goldstein, EJ; Rodloff, AC; Torres, A, 2006)	0.33
" A 5000-subject Monte Carlo simulation was performed to calculate the bactericidal cumulative fraction of response (CFR) for standard dosing regimens of cefepime, ceftazidime, ciprofloxacin, imipenem, meropenem and piperacillin/tazobactam."	( Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP, 2006)	0.33
" Whilst in-vivo imipenem activity appeared reduced against in-vitro susceptible VIM-1 producers compared with a VIM-1-negative control, an increased drug dosage could moderate this reduction."	( Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Daikos, GL; Loli, A; Miriagou, V; Panagiotakopoulou, A; Tzelepi, E; Tzouvelekis, LS, 2007)	0.34
" The percentage of the dosing interval during which free drug concentrations exceed the MIC (fT(>MIC)) is the measure of drug exposure that best correlates with clinical outcome for beta-lactams."	( Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Bulitta, JB; Drusano, GL; Glauner, AK; Kinzig-Schippers, M; Pfister, W; Sakka, SG; Sörgel, F, 2007)	0.34
" These results suggest that our simple and rapid HPLC method for the determination of the serum concentrations of carbapenems is useful for pharmacokinetic/pharmacodynamic (PK/PD)-based determination of carbapenem dosage regimens."	( Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography. Hori, S; Kizu, J; Kurihara, Y, 2008)	0.35
"These results may help us to understand the intraperitoneal penetration of imipenem and to determine the dosing regimen for intra-abdominal infections."	( Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sakamoto, K; Sueda, T; Takesue, Y, 2008)	0.35
"4 and (ii) sigmoidal dose-response curves with cloxacillin (0."	( Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics. Appelbaum, PC; Glupczynski, Y; Lemaire, S; Olivier, A; Tulkens, PM; Van Bambeke, F, 2008)	0.35
" The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients."	( Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Buclin, T; Calandra, T; Csajka, C; Lamoth, F; Marchetti, O; Pascual, A, 2009)	0.35
"When dosed appropriately, imipenem/cilastatin may be used to treat serious infections in critically ill patients with central nervous system (CNS) disorders or injury with minimal seizure risk."	( Safety of imipenem/cilastatin in neurocritical care patients. Brophy, GM; Hoffman, J; Trimble, J, 2009)	0.35
" Sixty-four patients underwent the imipenem-cilastatin intramuscular test dosing and none of them had a clinical reaction."	( Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams. Altomonte, G; Buonomo, A; Decinti, M; Lombardo, C; Nucera, E; Pascolini, L; Patriarca, G; Schiavino, D, 2009)	0.35
" Thus, antibiotic treatment should be adapted to the suspected bacterium and administered as early as possible at high dosage with - if necessary - a loading dose and continuous perfusion."	( [Presumptive bacterial meningitis in adults: initial antimicrobial therapy]. Chavanet, P, )	0.13
" So more attention should be paid to reducing the frequency, times and dosage of antimicrobials, especially third or fourth cephalosporins."	( Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae. Qin, JP; Shi, WF; Zhou, J, 2009)	0.35
"To compare clinical outcomes of patients receiving an alternative dosage of meropenem with those of patients receiving imipenem-cilastatin or the traditional dosage of meropenem after failure of or intolerance to cefepime for treatment of febrile neutropenia."	( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)	0.35
"Of the 127 patients, 40 received imipenem-cilastatin 500 mg every 6 hours between September 1, 2005, and August 31, 2006; 87 patients received meropenem between September 1, 2006, and August 31, 2007: 29 received a traditional dosage of meropenem 1 g every 8 hours, and 58 received an alternative dosage of meropenem 500 mg every 6 hours."	( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)	0.35
"The alternative meropenem dosage of 500 mg every 6 hours yielded similar patient outcomes, including time to defervescence, need for additional antibiotics, duration of therapy, and mortality, when compared with the traditional meropenem dosage and imipenem-cilastatin in adults with febrile neutropenia."	( Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Arnold, HM; Augustin, KM; Casabar, E; Dubberke, ER; Hladnik, LM; McKinnon, PS; Reichley, RM; Ritchie, DJ; Westervelt, P, 2009)	0.35
"A model that considered elimination from a peripheral compartment described the data and was used to simulate steady-state concentration profiles in plasma and peritoneal fluid during various dosing regimens."	( Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Couet, W; Dahyot-Fizelier, C; Laksiri, L; Lefeuvre, S; Marchand, S; Mimoz, O; Sawchuk, RJ, 2010)	0.36
" maltophilia did not exhibit a gene dosage effect on beta-lactamase expression."	( AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. Chung, TC; Hu, RM; Huang, YW; Lin, CW; Lin, YT; Yang, TC, 2010)	0.36
"019) than those with the genes chromosomally encoded, which is most likely due to increased gene dosage provided by the higher copy number of associated plasmids."	( Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan. Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK, 2010)	0.36
" Monte Carlo simulations using various dosage regimens at steady-state and 30-min and 3-h infusion rates were performed to evaluate the probabilities of attaining 20% (bacteriostatic), 30%, and 40% (maximum kill) time above the MIC."	( Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Bertino, JS; Drusano, GL; Jones, RN; Kinzig-Schippers, M; Lee, LS; Ma, L; Nafziger, AN; Sörgel, F, 2010)	0.36
" Evidence of in vivo synergy could lead to a reduction of the standard VAN dosage or treatment time."	( Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Araújo, MT; Nunes, AP; Santos, KR; Silva, LV, 2011)	0.37
"The time course of activity of colistin and imipenem against mucoid and nonmucoid Pseudomonas aeruginosa growing in a biofilm showed that compared with those for planktonic bacteria, the kinetics of colistin and imipenem retained the concentration- and time-dependent killing, respectively, but higher doses of antibiotics and longer dosing periods were required for biofilm eradication."	( Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Ciofu, O; Hengzhuang, W; Høiby, N; Song, Z; Wu, H, 2011)	0.37
" Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring."	( Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Gonçalves-Pereira, J; Póvoa, P, 2011)	0.37
"This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity."	( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )	0.13
" A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets were defined as free drug concentrations above the MIC for at least 40% of the dosing interval."	( Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Briceno, DF; Furtado, GH; Nicolau, DP; Ruiz, SJ; Villegas, MV, )	0.13
" However, there are few guidelines for the optimal dosing of inhibitors."	( Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. Bhagunde, P; Chang, KT; Hirsch, EB; Ledesma, KR; Nikolaou, M; Tam, VH, 2012)	0.38
" Mathematical model assessments were evaluated experimentally using clinically relevant dosing regimens of imipenem, with or without MK-7655, in a hollow-fiber infection model (HFIM)."	( In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Chang, KT; Hirsch, EB; Ledesma, KR; Motyl, MR; Schwartz, MS; Tam, VH, 2012)	0.38
" These results indicate that a shorter dosing interval is beneficial in patients with impaired renal function as it results in greater PK-PD breakpoints and a reduction in excessive maximum plasma concentrations."	( Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. Ikawa, K; Ikeda, K; Kumon, H; Morikawa, N; Ohge, H; Yoshizawa, K, 2012)	0.38
" Imipenem would be predicted to be effective for the treatment of antimicrobial resistant bacterial infections in cats at a dosage of 5 mg/kg every 6-8 h (IV, IM), or longer for the SC route."	( Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats. Albarellos, GA; Denamiel, GA; Landoni, MF; Lupi, MP; Montoya, L; Quaine, PC, 2013)	0.39
"Population pharmacokinetic (PK)-pharmacodynamic target attainment analysis of imipenem was performed to elucidate the PK properties in neonates and children and to rationalize and optimize dosing regimens."	( Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Yoshizawa, K, 2013)	0.39
"These results explain the changes in imipenem PK properties during the human growth process and provide guidance for tailoring dosing regimens in each pediatric age group."	( Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Yoshizawa, K, 2013)	0.39
"The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates."	( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013)	0.39
" Cefepime dosing was increased from 2 g q12h SI to 2 g q8h PI, a 52% increase in drug acquisition cost."	( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013)	0.39
"Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance."	( When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Goff, DA; Nicolau, DP, 2013)	0.39
" Exposure to imipenem especially in high dosage impaired the motor coordination in male and female rats."	( Hippocampus and cerebellum function following imipenem treatment in male and female rats: evaluation of sex differences during developmental stage. Golchin, L; Shabani, M; Vahidi, AA, 2013)	0.39
" We describe PK parameters of imipenem in intensive care unit (ICU) patients with suspected ventilator-associated pneumonia and evaluate several dosage regimens."	( Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Armand-Lefevre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M, 2014)	0.4
" A Monte Carlo simulation was performed to evaluate the following six dosage regimens: 500, 750 or 1000 mg with administration every 6 or 8 h."	( Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Armand-Lefevre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M, 2014)	0.4
" The simulation showed that for these patients, the best dosage regimen of imipenem is 750 mg every 6 h and not 1000 mg every 8 h."	( Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Armand-Lefevre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M, 2014)	0.4
" Data including the dosage and duration of the drug use, occurrence of seizures and mortality outcome was collected from the electronic pharmacy records."	( A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem. Chen, K; Shi, Z; Wang, Q; Wu, Y, 2014)	0.4
" There was not further risk for patients with pre-existing seizures or creatinine clearance abnormalities when dosed appropriate."	( A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem. Chen, K; Shi, Z; Wang, Q; Wu, Y, 2014)	0.4
" We examined the compliance of the empirical antimicrobial treatment with the programme recommendations and the treatment optimisation achieved by reducing the antibiotic spectrum and adjusting the dose, dosing interval and duration of treatment."	( The impact of an antimicrobial stewardship programme on the use of antimicrobials and the evolution of drug resistance. de la Torre, J; Del Arco, A; Faus, V; Fernández, F; García-Alegría, J; Montiel, N; Olalla, J; Prada, JL; Rivas, F; Tortajada, B, 2015)	0.42
" Nevertheless, few data are available on the impact of ECMO on pharmacokinetics, and no data on imipenem dosing during ECMO."	( Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation. Allou, N; Allyn, J; Augustin, P; Massias, L; Montravers, P; Welsch, C, 2015)	0.42
"In ICU patients with VAP, classic imipenem pharmacodynamic targets are easily reached with usual dosing regimens."	( Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M, 2015)	0.42
" Therapeutic drug monitoring (TDM) may aid antibiotic prescription and implementation of initial empirical antimicrobial dosage recommendations."	( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)	0.42
"Imipenem/cilastatin and meropenem use and daily empirical dosage at a five-bed burn ICU were analyzed retrospectively."	( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)	0.42
"Real-time carbapenem TDM availability significantly altered the empirical daily dosage of imipenem/cilastatin at our burn ICU."	( Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Decosterd, LA; Eggimann, P; Fournier, A; Marchetti, O; Pagani, JL; Pannatier, A; Que, YA; Revelly, JP; Voirol, P, 2015)	0.42
" In conclusion, the results indicate that a higher than manufacturer's dosage recommendation is required to maximize the activity of imipenem."	( Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia. Jaruratanasirikul, S; Jullangkoon, M; Samaeng, M; Wongpoowarak, W, 2015)	0.42
" In 6 hours interval dosage regimen, the percentages of the time > 4× minimum inhibitory concentration (MIC) at specific 4×MIC of 2, 4, 6, and 8 μg/mL of imipenem were more than 40% of the dosing interval."	( [Effect of continuous renal replacement therapy on the plasma concentration of imipenem in severe infection patients with acute renal injury]. Hu, Z; Liu, L; Xing, D; Yu, B; Zhao, C, 2015)	0.42
"48) mL×kg⁻¹×h⁻¹ in severe infective patients with severe sepsis complicating AKI, affecting the level of plasma drug concentration, need to adjust the dosage regimen."	( [Effect of continuous renal replacement therapy on the plasma concentration of imipenem in severe infection patients with acute renal injury]. Hu, Z; Liu, L; Xing, D; Yu, B; Zhao, C, 2015)	0.42
" Efficacy factors (EF) were calculated and the stability of the antibiotic solutions were evaluated to optimize the dosing regimen."	( Theoretical approach to local infusion of antibiotics for infected pancreatic necrosis. Domínguez-Muñoz, JE; González-López, J; Lariño-Noia, J; Macías-García, F, )	0.13
"Monte Carlo simulations allow prediction and comparison of concentration-time profiles arising from different dosing regimens in a defined population, provided a population pharmacokinetic model has been established."	( Is continuous infusion of imipenem always the best choice? Lipš, M; Neely, MN; Strojil, J; Suchánková, H; Urbánek, K, 2017)	0.46
" Various dosing strategies were used for the administration of imipenem, which has broad-spectrum coverage of enteric bacteria."	( Why Antibiotic Treatment Is Not Enough for Sepsis Resolution: an Evaluation in an Experimental Animal Model. Bickler, SW; Cauvi, DM; Coimbra, R; De Maio, A; Escobedo, O; Halbach, JL; Hawisher, D; Lizardo, RE; Reyes, T; Rosas, J; Wang, AW, 2017)	0.46
" Since the achievement and maintenance of optimum therapeutic levels of β-lactam antibiotics is critical for the resolution of many infectious clinical situations, and to avoid antibiotic resistance generation, the design of new non-aqueous dosage forms is urgent."	( A Natural Deep Eutectic Solvent Formulated to Stabilize β-Lactam Antibiotics. Calderón, C; M Munita, J; Martínez, F; Olivares, B; R Campodonico, P; Rivas, L, 2018)	0.48
"In patients with renal insufficiency, dose adjustments based on creatinine clearance and body weight have been a component of imipenem dosage instructions."	( Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments. Brown, M; Kantesaria, B; Lala, M; Paschke, A; Rizk, ML; Walker, B, 2019)	0.51
" The aim of this study was to describe the population PK of imipenem in patients receiving CRRT, and utilize this model to inform optimal dosing regimens using pharmacokinetics/pharmacodynamics (PK/PD) target as a surrogate marker for treatment efficacy."	( Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy. Li, S; Xie, F, 2019)	0.51
"We assessed the antibacterial effect of human simulations of dosing with imipenem/relebactam (with or without amikacin) on Enterobacteriaceae or Pseudomonas aeruginosa over 7 or 14 day antibiotic exposures."	( Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures. Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2019)	0.51
"4% and 0% were susceptible standard dosing regimen (S), 55."	( Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli. Antonelli, A; Camarlinghi, G; Coppi, M; Giani, T; Mattei, R; Nardone, M; Parisio, EM; Riccobono, E; Rossolini, GM, 2019)	0.51
" These dosing regimens provide sufficient antibacterial coverage (MIC ≤ 4 μg/mL) for all renal groups."	( Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections. Bhagunde, P; Copalu, W; Kulkarni, P; Lala, M; Patel, P; Rizk, ML; Watson, K; Xu, M; Young, K, 2019)	0.51
" Study PN019 evaluated the PK of REL (250 mg) and imipenem (500 mg; dosed as IMI) with/without probenecid (1 g; OAT inhibitor) in healthy adults."	( Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. Bhagunde, P; Boundy, K; Butterton, JR; Colon-Gonzalez, F; Garrett, G; Jumes, P; Lala, M; Lasseter, K; Liu, Y; Marbury, T; Rhee, EG; Rizk, ML; Wu, J; Xu, SS, 2020)	0.56
"Population pharmacokinetic (popPK) models for antibiotics are used to improve dosing strategies and individualize dosing by therapeutic drug monitoring."	( Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. de Velde, F; de Winter, BCM; Harbarth, S; Huttner, A; Koch, BCP; Mouton, JW; Neely, MN; van Gelder, T; von Dach, E; Yamada, WM, 2020)	0.56
" This may have consequences for estimated exposure during dosing simulations and should be further investigated in simulation studies."	( Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. de Velde, F; de Winter, BCM; Harbarth, S; Huttner, A; Koch, BCP; Mouton, JW; Neely, MN; van Gelder, T; von Dach, E; Yamada, WM, 2020)	0.56
" Hence, there is a strong rationale to individualize anti-infective dosing in these patients by using therapeutic drug monitoring (TDM)."	( Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients. Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L, 2020)	0.56
" Available clinical and pharmacokinetic data support the approved dosage of a 30-minute infusion of imipenem 500 mg-cilastatin 500 mg-relebactam 250 mg every 6 hours, along with dosage adjustments based on renal function."	( Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Claeys, KC; Rybak, JM; Smith, JR, 2020)	0.56
"This study explores factors that affect behavior in critically ill patients receiving continuous renal replacement therapy (CRRT) with imipenem and provides dosing regimens for these patients."	( Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem. Bai, J; Duan, M; Li, X; Li, Z; Shen, S; Wen, A, 2020)	0.56
" A population pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulations was performed to explore the effects of empirically used dosing regimens (0."	( Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem. Bai, J; Duan, M; Li, X; Li, Z; Shen, S; Wen, A, 2020)	0.56
"A high dosage regimen such as 1 g every 6 h of imipenem may be required to achieve pharmacodynamic targets against less susceptible pathogens in this patient population."	( Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation. Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M; Vattanavanit, V; Wongpoowarak, W, 2020)	0.56
"This phase 3, multicenter, open-label, noncomparative study (NCT03293485) evaluated relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days in Japanese patients with complicated intra-abdominal infections (cIAIs) or complicated urinary tract infections (cUTIs), including those with secondary sepsis."	( The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. Aoyama, N; Bando, H; Brown, M; Kawahara, K; Kikukawa, H; Kohno, S; Paschke, A; Shirakawa, M; Takase, A; Yoneyama, F, 2021)	0.62
"The objectives of this study were (i) to determine the population pharmacokinetic (PK) of imipenem in critically ill patients with life-threatening severe infections, (ii) to investigate the impact of extracorporeal membrane oxygenation (ECMO) on the population PK of imipenem during support with ECMO compared to those without ECMO support, and (iii) to assess the probability of target attainment (PTA) for finding the optimal dosage regimens of imipenem in critically ill patients with life-threatening severe infections."	( NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit. Boonpeng, A; Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M, 2021)	0.62
" A high dosage of imipenem may be required for achieving the PK/pharmacodynamic targets against less susceptible pathogens, however, the dosage regimens in patients with renal impairment may not need to be as high as those required in patients with normal renal function."	( NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit. Boonpeng, A; Jaruratanasirikul, S; Nawakitrangsan, M; Samaeng, M, 2021)	0.62
" At the recommended IMI/REL dosing regimens across renal categories, greater than 90% of patients in all renal function groups were predicted to achieve joint pharmacokinetic/pharmacodynamic targets at a minimum inhibitory concentration breakpoint of ≤2 μg/ml, regardless of ventilation status."	( Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia. Bellanti, F; Copalu, W; Daryani, NM; Gheyas, F; Hilbert, DW; Kulkarni, P; Noormohamed, N; Patel, M; Rizk, ML; Young, K, 2022)	0.72
" The objectives of our study were: (i) to characterize imipenem population pharmacokinetics (PK) in a cohort of neonates; and (ii) to conduct model-based simulations to evaluate the performance of six different dosing regimens aiming at optimizing PK target attainment."	( Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. André, P; Asner, SA; Buclin, T; Csajka, C; Dao, K; Decosterd, LA; Fuchs, A; Giannoni, E; Guidi, M; Marchetti, O; Pfister, M; Widmer, N, 2022)	0.72
"β-Lactam antibiotics are most commonly used in the critically ill, but their effective dosing is challenging and may result in sub-therapeutic concentrations that can lead to therapy failure and even promote antimicrobial resistance."	( Quantitative Determination of Unbound Piperacillin and Imipenem in Biological Material from Critically Ill Using Thin-Film Microextraction-Liquid Chromatography-Mass Spectrometry. Filipiak, W; Włodarski, R; Żuchowska, K, 2022)	0.72
" IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min."	( New evidence in severe pneumonia: imipenem/ cilastatin/relebactam. Alarcón, T; Girón, RM; Gómez-Punter, RM; Ibáñez, A, 2022)	0.72
" For aminoglycosides, we recommend extended interval dosing and initiating Seraph 100 at least 30 min to 1 h after completion of infusion to avoid the possibility of interference with maximum concentrations."	( Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach. Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023)	0.91
"Despite enhanced clearance of both imipenem and relebactam, the currently approved dosing regimen for normal renal function was predicted to achieve optimal exposure in critically-ill patients with ARC sufficient to treat most susceptible pathogens."	( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022)	0.72
" Therefore, conventional or standard dosing regimens do not achieve satisfactory anti-infective effects."	( A UPLC-MS/MS method for simultaneous determination of eight special-grade antimicrobials in human plasma and application in TDM. Liu, G; Qi, Y, 2022)	0.72
"Antibiotic dosing in critically ill patients is complicated by variations in the pharmacokinetics of antibiotics in this group."	( Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients. Becker, P; Chausse, J; Gous, A; Milne, M; Mitton, B; Paruk, F; Said, M, 2022)	0.72
" Owing to the variability of antibiotic pharmacokinetics in critically ill patients, this task becomes almost impossible when relying on conventional dosing guidelines."	( Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients. Becker, P; Chausse, J; Gous, A; Milne, M; Mitton, B; Paruk, F; Said, M, 2022)	0.72
"There is a paucity of published data to evaluate the efficacy and safety of imipenem, cefepime and piperacillin/tazobactam dosing regimens against bloodstream infections caused by Klebsiella aerogenes (BSIs-Kae) and Enterobacter cloacae complex (BSIs-Ecc) in patients with various degrees of renal function."	( Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis. Chen, W; Huang, C; Ji, J; Shi, Q; Wu, H; Wu, S; Xiao, Y; Ying, C, 2023)	0.91
" The dosing regimens of imipenem, cefepime and piperacillin were simulated with intermittent infusion and extended infusion."	( Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis. Chen, W; Huang, C; Ji, J; Shi, Q; Wu, H; Wu, S; Xiao, Y; Ying, C, 2023)	0.91
" aeruginosa to develop tolerance which may result in therapeutic failures if inappropriate dosing regimens are used to treat keratitis."	( Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. Khan, M; Ma, K; Wan, I; Willcox, MD, 2023)	0.91

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
zwitterion	A neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
carbapenems	The class of beta-lactam antibiotics that whose members have a carbapenem skeleton which is variously substituted at positions 3, 4, and 6.
beta-lactam antibiotic allergen	Any beta-lactam antibiotic which causes the onset of an allergic reaction.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
peptidoglycan biosynthesis V (u03B2-lactam resistance)	1	38
peptidoglycan maturation (meso-diaminopimelate containing)	16	41

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLS protein	Homo sapiens (human)	Potency	7.0795	0.3548	7.9355	39.8107	AID624146
GLI family zinc finger 3	Homo sapiens (human)	Potency	29.8493	0.0007	14.5928	83.7951	AID1259369
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	1.6181	0.0002	29.3054	16,493.5996	AID743069
arylsulfatase A	Homo sapiens (human)	Potency	0.9528	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	31.6228	0.0355	20.9770	89.1251	AID504332
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	5.6234	0.0178	9.6374	44.6684	AID588834
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	37.9330	0.4256	12.0591	28.1838	AID504536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Citrobacter freundii	Ki	0.0600	0.0600	0.6000	2.0000	AID405083
Beta-lactamase	Pseudomonas aeruginosa	IC50 (µMol)	0.1500	0.0600	0.1700	0.3700	AID511293
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.1100	7.1903	10.0000	AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Citrobacter gillenii	Km	2,977.0000	10.0000	10.0000	10.0000	AID285442
Beta-lactamase	Aeromonas caviae	Km	100.0000	7.0000	7.0000	7.0000	AID374363
Beta-lactamase	Shouchella clausii	Km	35.0000	0.0100	3.0050	6.0000	AID373209
Beta-lactamase	Acinetobacter baumannii	Km	5.0000	3.0000	5.6667	9.0000	AID567279
Beta-lactamase	Burkholderia cenocepacia	Km	60.0000	10.0000	10.0000	10.0000	AID541022
Metallo-beta-lactamase type 2	Klebsiella pneumoniae	Km	94.0000	8.0000	9.3333	10.0000	AID563972
Metallo-beta-lactamase VIM-11	Pseudomonas aeruginosa	Km	9.4000	4.5000	7.0000	9.4000	AID520385
Metallo-beta-lactamase VIM-2	Pseudomonas aeruginosa	Km	9.9000	5.5000	7.8750	9.9000	AID520386
Beta-lactamase	Aeromonas allosaccharophila	Km	1.5000	1.5000	6.3000	10.0000	AID584846
Metallo-beta-lactamase	Stutzerimonas stutzeri	Km	80.0000	3.5000	4.7500	6.0000	AID518728
Beta-lactamase	Acinetobacter baumannii	Km	6.0000	6.0000	7.6667	10.0000	AID567280
Beta-lactamase	Enterobacter cloacae	Km	24.0000	2.9000	6.4364	9.8000	AID495693
Beta-lactamase SHV-1	Klebsiella pneumoniae	Km	23.0000	4.2000	4.2500	4.3000	AID495687
Beta-lactamase	Pseudomonas aeruginosa PAO1	Km	10.8000	0.5000	4.2444	8.0000	AID495747; AID546426
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	Km	2,977.0000	10.0000	10.0000	10.0000	AID285442
Beta-lactamase TEM	Escherichia coli	Km	7.2000	5.4000	6.3000	7.2000	AID495686
B2 metallo-beta-lactamase	Chryseobacterium indologenes	Km	13.0000	3.0000	3.0000	3.0000	AID562337
Beta-lactamase	Acinetobacter pittii	Km	2.2900	0.0200	2.1814	6.7300	AID555223
Beta-lactamase	Acinetobacter pittii	Km	2.5600	0.1800	1.3683	3.8500	AID555225
Beta-lactamase	Acinetobacter pittii	Km	2.5100	0.1300	1.5250	4.5400	AID555227
Metallo-beta-lactamase VIM-2	Klebsiella pneumoniae	Km	10.0000	5.0000	7.5000	10.0000	AID563976
Beta-lactamase	Escherichia coli	Km	0.3100	0.0046	1.4149	4.5000	AID495746
Metallo-beta-lactamase	Escherichia coli	Km	11.5000	2.0000	6.8571	10.0000	AID583083; AID583084; AID583085; AID583094
Beta-lactamase	Serratia marcescens	Km	150.0000	2.2000	4.6000	8.2000	AID495696
Beta-lactamase	Klebsiella pneumoniae	Km	7.9000	1.0000	4.4500	7.9000	AID1320835
Beta-lactamase IMP-1	Pseudomonas aeruginosa	Km	33.0000	6.5000	6.5000	6.5000	AID495698
BlaVIM-1	Escherichia coli	Km	1.5000	1.5000	1.5000	1.5000	AID495914
Beta-lactamase	Pseudomonas aeruginosa	Km	15.0000	0.5000	2.7500	5.0000	AID546429
Beta-lactamase	Escherichia coli	Km	120.0000	7.1000	8.1667	8.7000	AID495688
Carbapenem-hydrolyzing beta-lactamase KPC	Klebsiella pneumoniae	Km	63.3333	1.6000	3.8000	6.0000	AID374025; AID495695; AID548044
Beta-lactamase class B VIM-2	Pseudomonas aeruginosa	Km	34.3750	2.0000	6.6500	9.4000	AID495697; AID529659; AID531315; AID575015
Beta-lactamase	Acinetobacter baumannii	Km	41.6500	1.3000	3.8000	9.6000	AID495699; AID495700
Beta-lactamase VIM-1	Pseudomonas aeruginosa	Km	4.0000	4.0000	4.0000	4.0000	AID530340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5307)

Assay ID	Title	Year	Journal	Article
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID523715	Antibacterial activity against Acinetobacter baumannii A897 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573358	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID535369	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1826213	Antibacterial activity against NDM-1 producing Serratia marcescens T2352 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID524105	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A849	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562736	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID533119	Antimicrobial activity against Staphylococcus aureus 10*3d1-10 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID576536	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008138 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584505	Antimicrobial activity against wild type Pseudomonas aeruginosa PA14 by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID532910	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID533413	Antimicrobial activity against Peptoniphilus asaccharolyticus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID555215	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 14 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID564946	Antimicrobial activity against Acinetobacter baumannii isolate Ab168 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID289890	Antibacterial activity against Bacillus megaterium	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID573400	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID162790	In vivo antibacterial activity against Pseudomonas aeruginosa 1771M	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID424319	Antimicrobial activity against Dialister pneumosintes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID565289	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID373050	Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID433151	Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID295799	Antibacterial activity against Staphylococcus aureus 209P after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID373772	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID560834	Antimicrobial activity against Acinetobacter baumannii isolate Ab5 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID433165	Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID574981	Antimicrobial activity against Actinomyces naeslundii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID323254	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID1124629	Stability of the compound in amorphous form in 1 M PO4 assessed as time at which 90% of initial UV-absorbance remains at 60 mg/ml at pH 7 at 23 degC	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID573138	Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID517958	Antimicrobial activity against Serratia marcescens by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID565535	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID565670	Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID557488	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID585177	Activity of Beta-lactamase GES-2 E104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID576528	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14474 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID574991	Antimicrobial activity against Bifidobacterium adolescentis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425995	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID532907	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID520385	Activity at Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID523720	Antibacterial activity against Acinetobacter baumannii A894 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546052	Antimicrobial activity against Proteus stuartii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1318933	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 79199	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID495509	Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID541501	Antimicrobial activity against Pseudomonas aeruginosa clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID574999	Antimicrobial activity against Eubacterium lentum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1056836	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 235 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID585183	Ratio of Kcat to Km for Beta-lactamase GES-2 E104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1528453	Antibacterial activity against Acinetobacter baumannii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID532212	Antibacterial activity against nonreplicate Klebsiella pneumoniae clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID565513	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID524118	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A894	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID560490	Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID532218	Antibacterial activity against nonreplicate Burkholderia cepacia complex clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID205977	In vitro antibacterial activity against Sa(II) Staphylococcus aureus ATCC 25923	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID511101	Cmax in New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID545555	Antibacterial activity against Escherichia coli ERR8a selected at 8 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID569262	Antimicrobial activity against Escherichia coli DH5alpha	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID535128	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495911	Antimicrobial activity in Escherichia coli J53 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID584730	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4069 harboring mutation in putative dTDP-4-rhamnose reductase-related protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545332	Antibacterial activity against Escherichia coli NIHJ by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545836	Antimicrobial activity against macrolide-resistant Streptococcus pyogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID425325	Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID544678	Antimicrobial activity against AmpC beta-lactamase-producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID582965	Antimicrobial activity against Yersinia enterocolitica Biovar 1B 8081 after 20 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID523499	Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID436879	Antibacterial activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene after 18 hrs by twofold serial broth dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID425075	Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID584747	Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring beta-lactamase OXA-164 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID522004	Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495802	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID531525	Antibacterial activity against Bacteroides ovatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID534600	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID511159	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 15 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID534609	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584733	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4393 harboring mutation in putative permease by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534409	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID68079	In vitro antibacterial activity against MDREFm.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID573152	Antibacterial activity against vancomycin-resistant Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID422690	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 30 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID573824	Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID368747	Antimicrobial activity against Escherichia coli Ec10 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID517947	Antimicrobial activity against Enterobacter aerogenes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535130	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID517953	Antimicrobial activity against Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID574774	Antimicrobial activity against Clostridium perfringens assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID576311	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID534879	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID533530	Antimicrobial activity against Pseudomonas aeruginosa PA552 expressing IMP-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID425330	Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533538	Antimicrobial activity against Pseudomonas aeruginosa PA553 expressing SPM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID535143	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID558594	Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID295792	Antibacterial activity against Klebsiella pneumoniae 523 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495741	Kcat/Km ratio of Serratia marcescens SME-3 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID565546	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID520880	Antibacterial activity against Achromobacter xylosoxidans TB1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID543415	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID285326	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 43300	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID573367	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID433351	Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533135	Antimicrobial activity against Bacteroides ovatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573593	Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID544906	Antimicrobial activity against Morganella morganii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID587532	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID206746	In vitro antibacterial activity against Staphylococcus aureus SG 511 by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID523755	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E418	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534650	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID511132	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 6	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID545837	Antimicrobial activity against macrolide-susceptible Streptococcus pyogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1373286	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID534642	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID404968	Activity of OXA58 from Acinetobacter baumannii T186 isolate carrying three bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID433364	Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID571920	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID588128	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID520977	Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID295823	Antibacterial activity against Enterobacter cloacae after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID556671	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 26 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID508731	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3D2 GM2 harboring acquired beta-lactamase BEL-3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID545825	Antimicrobial activity against Enterococcus faecalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565537	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID530330	Antimicrobial activity against Escherichia coli XL1-Blue by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID557491	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID531681	Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID584699	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5005 harboring mutation in putative carbamoyltransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1373311	Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID531334	Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID285678	Antimicrobial activity against Pseudomonas aeruginosa 29G6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID206744	In vitro antibacterial activity against Staphylococcus aureus SG 285 by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID495914	Hydrolytic activity of beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID584514	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1553 harboring mutation in putative cytochrome c oxidase, cbb3 type, subunit II by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520727	Activity of Escherichia coli TOP10 beta-lactamase OXA-97 assessed as specific activity per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID495796	Antimicrobial activity against Escherichia coli DH10B by Etest in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID68378	In vivo antibacterial activity against Enterobacter cloacae 1321E	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID574506	Antimicrobial activity against Bacteroides distasonis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574955	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID531684	Antimicrobial activity against Acinetobacter baumannii ATCC 15151T containing plasmid harboring OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID425077	Antimicrobial activity against beta lactamase-positive Bacteroides ovatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534408	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID541796	Antimicrobial activity against Clostridium perfringens clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID546177	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-17 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID285511	Antibacterial activity against Enterobacter sp.	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID546428	Activity at Pseudomonas aeruginosa PDC-3 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573531	Antibacterial activity against Klebsiella pneumoniae Kp1239 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID574050	Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534880	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425093	Antimicrobial activity against Fusobacterium varium isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495732	Kcat/Km ratio of Klebsiella pneumoniae SHV-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1373325	Chemical stability in pH 7.4 potassium phosphate buffer assessed as half life for compound hydrolysis at 37 degC by UPLC and mass spectrometry	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID544685	Antimicrobial activity against Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID433361	Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533529	Antimicrobial activity against Pseudomonas aeruginosa PA431 expressing IMP-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524095	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P326	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531315	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID584719	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2963 harboring mutation in putative aminodeoxychorismate lyase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID544684	Antimicrobial activity against Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID423064	Antibacterial activity against 31_C9 allele containing Pseudomonas aeruginosa PAO1 H1104 mutant strain with lon::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID559767	Antimycobacterial activity against Mycobacterium smegmatis harboring PknG Msm gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID285606	Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285661	Antimicrobial activity against Pseudomonas aeruginosa 19F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID557467	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae 3243 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID544930	Antimicrobial activity against Acinetobacter johnsonii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID289910	Antibacterial activity against Serratia marcescens 14273	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID534867	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID340728	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-9 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID533376	Antimicrobial activity against Bacteroides eggerthii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID544512	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID264473	Antibacterial activity against Staphylococcus epidermidis	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID533560	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA395	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID495838	Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID534899	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584717	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2128 harboring cupA1 mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID574728	Antimicrobial activity against Prevotella oralis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID563972	Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID561934	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 harboring plasmid ABVA01 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID545611	Antimicrobial activity against Pseudomonas aeruginosa PS31 with PFGE phenotype 11B obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID332075	Antibacterial activity against Pseudomonas aeruginosa by agar dilution method	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Antibacterial activity in serum of the 3,5-diamino-piperidine translation inhibitors.
AID544953	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID545840	Antimicrobial activity against ESBL-negative Enterobacter cloacae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID582976	Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID576331	Antibacterial activity against plasmid-mediated AmpC beta-Lactamase DHA-1 and ESBL-producing Klebsiella pneumoniae by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID517921	Antibacterial activity against Acinetobacter baumannii A929 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518463	Antimicrobial activity against Klebsiella pneumoniae 1338665 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535366	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID544679	Antimicrobial activity against AmpC beta-lactamase-producing Citrobacter freundii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID532390	Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID519821	Induction of morphological changes in Pseudomonas aeruginosa 27853 assessed as induction of sphere formation at antimicrobial MIC after 240 mins by microscopy	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533420	Antimicrobial activity against Micromonas micros assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID283218	Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
AID322782	Antimicrobial activity against Bacteroides merdae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID567279	Activity of Acinetobacter baumannii ADC-33 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID565536	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID422494	Antimicrobial activity against Escherichia coli BL21 (DE3) by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID425095	Antimicrobial activity against Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID520874	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU90 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID584720	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2970 harboring rpmF mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID573117	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524287	Antibacterial activity against Pseudomonas aeruginosa P356 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573391	Antibacterial activity against ceftazidime-susceptible Providencia sp. by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID532418	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID495813	Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID573116	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546180	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-20 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573333	Antibacterial activity against Enterobacter cloacae isolate El3280 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID561098	Antibacterial activity against Prevotella sp. by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID368739	Antimicrobial activity against Escherichia coli Ec2-a containing pEc1-C plasmid expressing CTX-M-15 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID56116	Dehydropeptidase-1 susceptibility.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID395736	Antimicrobial activity against Haemophilus influenzae ATCC 10211 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID295785	Antibacterial activity against coagulase negative Staphylococcus after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID433015	Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID518824	Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID279259	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID428292	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID405080	Antimicrobial activity against Citrobacter freundii 33587 isolate by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID373041	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ36 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID545446	Antimicrobial activity against extended-spectrum beta-lactamase-negative Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID572126	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID574510	Antimicrobial activity against Bacteroides vulgatus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID533561	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA734 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573783	Antibacterial activity against Prevotella buccae by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID575271	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID1546206	Half life in rat	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID496008	Antimicrobial activity against piperacillin-tazobactam resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID557948	Antimicrobial activity in Propionibacterium acnes by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID573785	Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID322788	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID517975	Antimicrobial activity against Klebsiella pneumoniae CRE harboring beta-lactamase KPC-2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID549332	Antimicrobial activity against Escherichia coli isolate 86 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID557483	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID433019	Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524268	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524451	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E418 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544675	Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID433157	Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID555228	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 195 ADC-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID576953	Antimicrobial activity against Shewanella putrefaciens Sp95 harboring intI1,sul1,sul2 and beta-lactamase OXA-48 like genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID289893	Antibacterial activity against Pseudomonas aeruginosa 880/2	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID545569	Antibacterial activity against Pseudomonas aeruginosa PRR4a selected at 4 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID524086	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P353	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID567281	Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1373291	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID495816	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID520330	Activity of Acinetobacter baumannii isolate TZ42/166 VIM-1 assessed as compound hydrolysis in presence of EDTA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID524075	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P335	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547789	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237M mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID544921	Antimicrobial activity against Acinetobacter calcoaceticus clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID1826216	Antibacterial activity against VIM-1 producing Enterobacter cloacae T2353 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID564948	Antimicrobial activity against Acinetobacter baumannii isolate Ab30 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID544952	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX and SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID285681	Antimicrobial activity against Pseudomonas aeruginosa 29H1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID509867	Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID285675	Antimicrobial activity against Pseudomonas aeruginosa 24F4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID517976	Antimicrobial activity against Klebsiella pneumoniae YC harboring beta-lactamase KPC-2,TEM-1and SHV-2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID561090	Antibacterial activity against Bacteroides fragilis by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID264471	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID395742	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 184 by Etest in presence of 0.781 uM efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID518729	Ratio of Kcat to Km for Pseudomonas stutzeri beta-lactamase DIM-1by UV-spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID556681	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 8 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID564016	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID283320	Antimicrobial activity against Klebsiella pneumoniae KPN15-NL	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID575007	Antimicrobial activity against Eubacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID545406	Antimicrobial activity against Pseudomonas aeruginosa PS13 with PFGE phenotype 11E obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID285603	Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373753	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID524467	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285601	Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID584700	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5038 harboring aroB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498811	Antimicrobial activity against Escherichia coli ZJ86T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID532211	Antibacterial activity against nonreplicate Pseudomonas aeruginosa clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID541498	Antimicrobial activity against Stenotrophomonas maltophilia clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573375	Antibacterial activity against multidrug-resistant Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID68375	In vitro synergistic activity against Enterobacter cloacae SC12629 (AmpC inducible)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID557505	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID285261	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-36 and IRT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID517964	Antimicrobial activity against Escherichia coli HB101 harboring beta-lactamase TEM-5 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523744	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E460	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557524	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID285596	Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID518520	Antimicrobial activity against Escherichia coli TOP10(pNOR-1) expressing CSP-1 gene after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID541513	Antimicrobial activity against Moraxella catarrhalis clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID545828	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID285265	Antimicrobial activity against Escherichia coli DH5-alpha isolate expressing pBK-CMV by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID323040	Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID425102	Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID556695	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID373029	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID582887	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 3.8 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID583092	Activity of Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID533361	Antimicrobial activity against Bacteroides thetaiotaomicron by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID531526	Antibacterial activity against Bacteroides distasonis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559534	Antibacterial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID517957	Antimicrobial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID546431	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-2 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID496006	Antimicrobial activity against imipenem resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID498841	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SX67 deficient in SHV-2, CTX-M-14, DHA-1, qnrB6/S1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID1373306	Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID533397	Antimicrobial activity against Clostridium paraputrificum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID245121	Minimum inhibitory concentration against Escherichia coli 1507 E strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID283118	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM5	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID283137	Antibacterial activity against Pseudomonas aeruginosa PAO1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID433016	Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573346	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285632	Antimicrobial activity against Pseudomonas aeruginosa 10A9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534105	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by Etest MBL strip method in presence of EDTA	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID559765	Antimycobacterial activity against PknGMsm-deficient Mycobacterium smegmatis harboring PknG K181M mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID554987	Antibacterial activity against Acinetobacter genomosp. 3 isolate 52 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1373289	Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1824299	Antimicrobial activity against Pseudomonas aeruginosa T2217 expressing VIM-2 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID278571	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID496590	Antimicrobial activity against Klebsiella pneumoniae 1534 harboring beta lactamase KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID545350	Displacement of [14C]benzylpenicillin from PBP 5 in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID558582	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID523749	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E358	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562756	Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID524824	Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID532405	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID556684	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 11 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID575275	Antimicrobial activity against Clostridium difficile by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID766248	Ratio of Kcat to Km for recombinant SPM-1 (unknown origin)	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID245177	Minimum inhibitory concentration against Enterobacter cloacae 1321E strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID523513	Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID535170	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433186	Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID575016	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamaseVIM-2 by UV spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID530339	Activity of Pseudomonas aeruginosa VIM-13 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID285635	Antimicrobial activity against Pseudomonas aeruginosa 12A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534294	Antimicrobial activity against Stenotrophomonas maltophilia KJ by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID575273	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID206631	Compound was evaluated for the anti-MRSA activity as MIC50	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID278570	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID582925	Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID576532	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008143 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID520384	Antimicrobial activity Escherichia coli DH5alpha expressing beta lactamase VIM-2 by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID564228	Activity of Escherichia coli TOP10 beta-lactamase OXA-143	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID609151	Antibacterial activity against Enterococcus faecium ATCC 19434	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID1201605	Antibacterial activity against Staphylococcus aureus after 24 hrs	2015	European journal of medicinal chemistry, May-05, Volume: 95	Pentacyclic triterpene derivatives possessing polyhydroxyl ring A inhibit gram-positive bacteria growth by regulating metabolism and virulence genes expression.
AID545413	Antimicrobial activity against Pseudomonas aeruginosa PS21 with PFGE phenotype 11F obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID433007	Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534622	Antimicrobial activity against Non-ESBL Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID554986	Antibacterial activity against Acinetobacter genomosp. 3 isolate 21 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID559271	Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID559764	Antimycobacterial activity against PknGMsm-deficient Mycobacterium smegmatis by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID295798	Antibacterial activity against Staphylococcus aureus giorgio after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID516142	Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID544493	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID573502	Antibacterial activity against Klebsiella pneumoniae isolate Kp38045 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID545573	Antibacterial activity against Pseudomonas aeruginosa PMR2a selected at 2 times MIC of meropenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID283129	Antibacterial activity against Pseudomonas aeruginosa 22029 expressing metallo beta lactamase	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID523936	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID207123	In vitro synergistic activity against Stenotrophomonas maltophilia 1712(L1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID533385	Antimicrobial activity against Clostridium difficile by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID534602	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID575084	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID511388	Antibacterial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID531766	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID545831	Antimicrobial activity against Streptococcus agalactiae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID283124	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV4	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID433370	Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425078	Antimicrobial activity against beta lactamase-positive Bacteroides vulgatus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID164408	Antibacterial activity against Pseudomonas aeruginosa 1771M	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID511582	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID495718	Activity of Escherichia coli CTX-M-15 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID519261	Half life pancreatitis Sprague-Dawley rat peritoneal fluid at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID544897	Antimicrobial activity against AmpC- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID533369	Antimicrobial activity against Bacteroides vulgatus by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID285627	Antimicrobial activity against Pseudomonas aeruginosa 9A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID422682	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID351198	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii expressing ISAba1	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Global challenge of multidrug-resistant Acinetobacter baumannii.
AID533128	Antimicrobial activity against Bacteroides caccae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID511291	Activity of Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID324361	Activity of Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID546167	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-07 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584721	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3050 harboring pyrD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID561386	Antibacterial activity against Escherichia coli isolate ARL04-413 harboring beta-lactamase CMY 2 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID66924	In vitro antibacterial activity against VREFs.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID573565	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID565527	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID432999	Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID95726	In vivo antibacterial activity against Klebsiella aerogenes 1522E	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID1855556	Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition of bacterial growth incubated for 24 hrs by CLSI broth microdilution method	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID203296	Antibacterial activity against MRCNS	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID557464	Antimicrobial activity in Prevotella disiens by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID518184	Antimicrobial activity against Pseudomonas aeruginosa 18S/H harboring beta-lactamase Class C by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524452	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530322	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID541510	Antimicrobial activity against Haemophilus parainfluenzae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID565520	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID544900	Antimicrobial activity against Klebsiella oxytoca clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID557734	Antimicrobial activity in Peptostreptococcus anaerobius by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID565726	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID495699	Activity of Pseudomonas aeruginosa SPM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID533412	Antimicrobial activity against Finegoldia magna assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID533631	Antimicrobial activity against Propionibacterium acnes by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID532396	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID573541	Antibacterial activity against Klebsiella pneumoniae Kp38045 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534878	Antimicrobial activity against Enterobacter cloacae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535835	Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID433154	Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520975	Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID529854	Antibacterial activity against MexA-MexB-OprM-overproducing and OprD-deficient Pseudomonas aeruginosa N041 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID279812	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID533566	Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID69004	In vitro synergistic activity against Escherichia coli C600N + (OXA-10) {PSE-2}	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID524125	Antibacterial activity against beta-lactamase-negative Escherichia coli E348 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID69014	In vitro synergistic activity against Escherichia coli GC6267 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID584704	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0401 harboring mutation in Noncatalytic dihydroorotase-like protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID289888	Antibacterial activity against Streptococcus durans D	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID496004	Antimicrobial activity against drug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID508721	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C2 PTOL1 harboring beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID573342	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574956	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID360049	Antimicrobial activity against Enterococcus faecium D344S by agar dilution method after 48 hrs	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID534176	Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID545398	Antimicrobial activity against Pseudomonas aeruginosa PS4 with PFGE phenotype 9B expressing beta-lactamase IMP-18 obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID584319	Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID558596	Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID576324	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008142 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID565533	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID556682	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 9 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID495734	Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523940	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532214	Antibacterial activity against nonreplicate Proteus mirabilis clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID574490	Antimicrobial activity against Bacteroides vulgatus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID556692	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pACM204 plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID573512	Antibacterial activity against Klebsiella pneumoniae isolate Kp4614	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID584697	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5002 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID285638	Antimicrobial activity against Pseudomonas aeruginosa 13D3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533425	Antimicrobial activity against Peptostreptococcus sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID544961	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID495792	Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID557964	Antimicrobial activity in Clostridium difficile by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID586235	Antimicrobial activity against Escherichia coli J53	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID425964	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 48 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID283123	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID511143	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 17	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID574975	Antimicrobial activity against Actinomyces meyeri after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID401691	Antibacterial activity against Staphylococcus aureus 503	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID516144	Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584695	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5000 harboring wapR mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID575284	Antimicrobial activity against Burkholderia cepacia by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID559071	Antibacterial activity against Acinetobacter lwoffii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID584554	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID279187	Ratio of kcat to Km of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID509866	Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID534303	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID341108	Antibacterial activity against Escherichia coli 26R793 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID1373304	Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID95722	In vitro antibacterial activity against Klebsiella aerogenes 1522E by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID524099	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A865	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545559	Antibacterial activity against Escherichia coli EIR2b selected at 2 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID565715	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID340730	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase TEM-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID546058	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID323378	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID544894	Antimicrobial activity against class A extended spectrum beta-lactamase- and class D OXA- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID569260	Antimicrobial activity against Staphylococcus aureus	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID524093	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P358	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573494	Antibacterial activity against Enterobacter cloacae isolate El3518 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID524080	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P323	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285664	Antimicrobial activity against Pseudomonas aeruginosa 22D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID433168	Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533121	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315DeltaIP heteroresistant subpopulations by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID518466	Antimicrobial activity against Pseudomonas aeruginosa 621 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID542721	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as resistant isolates	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID372611	Antibacterial activity against Escherichia coli DH5alpha by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID558626	Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID33217	In vitro synergistic activity against Aeromonas sobria (Asb A, OXA-12, Asb M)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID405083	Inhibition of Citrobacter freundii PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID558039	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID564958	Antimicrobial activity against Acinetobacter baumannii isolate Ab181 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID574522	Antimicrobial activity against Prevotella buccae after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID557730	Antimicrobial activity in Micromonas micros by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID534414	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546175	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-15 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID460799	Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID285442	Activity of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID535137	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID520883	Activity of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as compound hydrolysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID575266	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID587732	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID565531	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID564018	Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID574993	Antimicrobial activity against Bifidobacterium sp. after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID542064	Antibacterial activity against Klebsiella pneumoniae C expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID573373	Antibacterial activity against multidrug-resistant Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID533564	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA774 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1570732	Antimicrobial activity against Enterococcus faecium AUS0004 at 10 ug/disk incubated for 20 +/- 4 hrs by agar disk diffusion method	2019	Bioorganic & medicinal chemistry, 11-01, Volume: 27, Issue:21	Synthesis and evaluation of 1,3,4-oxadiazole derivatives for development as broad-spectrum antibiotics.
AID523512	Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573131	Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID518197	Antimicrobial activity against fpvA deficient Pseudomonas aeruginosa (560546)9 M.P. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID573594	Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID395738	Antimicrobial activity against Haemophilus influenzae Rd transformed with ftsI gene from imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID424321	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID559268	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID524110	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A908	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544949	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC and extended-spectrum beta-lactamase by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID531511	Antibacterial activity against Bacteroides merdae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID564225	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID521838	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID279815	Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID70087	Antibacterial activity against Escherichia coli 078	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID545336	Displacement of [14C]benzylpenicillin from PBP3 in Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID517969	Antimicrobial activity against Klebsiella pneumoniae 26768WU harboring beta-lactamase SHV-5 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534097	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID574948	Antimicrobial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID533635	Antimicrobial activity against Propionibacterium sp. by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID575001	Antimicrobial activity against Eubacterium lentum assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID499057	Antimicrobial activity against Escherichia coli PU102T expressing TEM-1, CTX-M-14, CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID584843	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID209124	Antibacterial activity against Streptococcus pyogenes	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID583234	Antibacterial activity against Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID1124635	Antibacterial activity against penicillin-resistant Staphylococcus aureus MB2314 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID249285	Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range=0.008-0.25)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID425331	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID546053	Antimicrobial activity against Proteus vulgaris by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID549041	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC1 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID433014	Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1649621	Substrate activity at VIM-2 (unknown origin) assessed as Kcat for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1318934	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 80621	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID545820	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID558615	Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID520383	Antimicrobial activity Escherichia coli DH5alpha expressing metallo-beta-lactamase VIM-11 by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID207930	Compound was evaluated for the antibacterial activity against methicillin-resistant coagulase-negative staphylococci (MRCNS).	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID511158	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 14 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID584513	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_06490 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID529490	Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID531518	Antibacterial activity against Bacteroides uniformis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID563967	Antibacterial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID1539479	Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2452 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID524115	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A890	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562472	Antimicrobial activity against Klebsiella pneumoniae isolate 2641/08 obtained from urine of patient with ischemic cardiomyopathy and several comorbidities by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID433010	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495715	Kcat/Km ratio of Acinetobacter baumannii OXA-23	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID279261	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID422664	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511008	AUC in New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID565727	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID573548	Antibacterial activity against Escherichia coli Ec158 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID425087	Antimicrobial activity against beta lactamase-positive Prevotella buccae isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID433159	Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID570791	Antimicrobial activity against Acinetobacter baumannii HE130 expressing bla-OXA-23 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID541507	Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID528784	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID541022	Activity at Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 by UV-spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID558621	Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID567280	Activity of Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID555199	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID533404	Antimicrobial activity against Clostridium subterminale assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID546412	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-29 with PDC-8 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID574730	Antimicrobial activity against Porphyromonas asaccharolytica after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID575003	Antimicrobial activity against Eubacterium lentum assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID433018	Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID489655	Antibacterial activity against Escherichia coli at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID524117	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A891	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545619	Antimicrobial activity against Pseudomonas aeruginosa PS41 with PFGE phenotype 11D obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID531770	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID433190	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534103	Ratio of MIC for imipenem-susceptible Acinetobacter baumannii Ab F PFGE type B transconjugant to MIC for imipenem-susceptible Acinetobacter baumannii Ab F PFGE type B transconjugant in presence of 200 nM NaCl	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID511140	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 14	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID564943	Antimicrobial activity against Acinetobacter baumannii isolate Ab11 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID495709	Kcat/Km ratio of Pseudomonas aeruginosa OXA-10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524506	Antibacterial activity against Acinetobacter baumannii A896 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584516	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2487 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID295833	Antibacterial activity against Pasteurella multocida after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID324852	Antimicrobial activity against Acinetobacter baumannii D54 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID545845	Antimicrobial activity against Morganella morganii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID534868	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574482	Antimicrobial activity against Bacteroides fragilis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574965	Antimicrobial activity against Actinomyces odontolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1824303	Antimicrobial activity against Enterobacter cloacae T2218 expressing GIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID433005	Antibacterial activity against Corynebacterium striatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495682	Antimicrobial activity against Pseudomonas aeruginosa OC 12115 expressing beta-lactamase SPM-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID532894	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID545396	Antimicrobial activity against Pseudomonas aeruginosa PS2 with PFGE phenotype 10B obtained from urine of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1824301	Antimicrobial activity against Pseudomonas aeruginosa T2283 expressing VIM-2 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID533401	Antimicrobial activity against Clostridium subterminale by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID542397	T>MIC in febrile neutropenic patient with hematological malignancies at 500 mg administered as infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID522012	Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID557448	Antimicrobial activity in Prevotella denticola by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID283395	Antimicrobial activity against Nocardia nova after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID422672	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 19 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID532906	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID561096	Antibacterial activity against Peptostreptococcus micros by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID559273	Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID520879	Antibacterial activity against Achromobacter xylosoxidans DUC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID571894	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573510	Antibacterial activity against Citrobacter freundii isolate Cf1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID518521	Antimicrobial activity against Capnocytophaga sputigena CRBIP 17.39 after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID524134	Antibacterial activity against beta-lactamase-negative Escherichia coli E425 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544682	Antimicrobial activity against AmpC beta-lactamase-producing Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID534174	Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID545838	Antimicrobial activity against Streptococcus viridans group clinical isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID373030	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU78 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID576955	Antimicrobial activity against Shewanella algae Sa9 harboring intI1, intI2, sul1 and sul2 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID112679	In vivo antibacterial activity against MRSA 76 virginia strain at the dose ~1 *10e7 cfu in 5 percent hog gastric mucin along with antibiotic by sc administration at 0 and +4 hrs in mice	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID404954	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii BM4547 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID511298	Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID523771	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID322783	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID562341	Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID523730	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E409	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573572	Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1824306	Antimicrobial activity against Klebsiella pneumoniae T2432 expressing KPC-9 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID532406	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID425327	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID530342	Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-13 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID545333	Antibacterial activity against Pseudomonas aeruginosa ATCC 15692 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID495843	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID573382	Antibacterial activity against beta lactamase-positive Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534100	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate assessed as reduction of MIC by microdilution method in presence of 200 mM NaCl	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID573383	Antibacterial activity against beta lactamase-positive Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534928	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID422656	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID433002	Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID558318	Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID574995	Antimicrobial activity against Bifidobacterium sp. assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573209	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G539A mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID285515	Antibacterial activity against Clostridium difficile by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID533536	Antimicrobial activity against Pseudomonas aeruginosa PA554 expressing GIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID285608	Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498829	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae RJ94 deficient in IMP-4, TEM-1, CTX-M-3, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520705	Antibacterial activity against Acinetobacter baumannii phenotype 1 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID401685	Antibacterial activity against Streptococcus faecium MD 8b	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID495654	Antimicrobial activity against Pseudomonas aeruginosa 531 expressing beta-lactamase BEL-2 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID529658	Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID557507	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID209896	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID360056	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl tetra-aspartate-peptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID573523	Antibacterial activity against Enterobacter cloacae isolate El216 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573574	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID766243	Activity at recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID286235	Antibacterial activity against Shigella flexneri at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID433397	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1816 harboring inactive lytH and inactive llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID544680	Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID582970	Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID1356828	Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2146 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID584707	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0427 harboring oprM mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID573525	Antibacterial activity against Klebsiella oxytoca isolate Ko238 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534178	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID405641	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1826212	Antibacterial activity against NDM-1 producing Enterobacter cloacae T2311 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID511578	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID1318936	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 84745	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID433371	Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID575012	Activity of Pseudomonas aeruginosa beta-lactamase IMP-1 by UV spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID584569	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID524460	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425090	Antimicrobial activity against Porphyromonas levii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID532912	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID573388	Antibacterial activity against Pasteurella multocida by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID517952	Antimicrobial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID511386	Antibacterial activity against ciprofloxacin resistant Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID573362	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID374368	Ratio of Kcat to Km of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID289878	Antibacterial activity against Pseudomonas aeruginosa 9027	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID541504	Antimicrobial activity against beta-lactamase-producing Haemophilus influenzae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID591662	Antimicrobial activity against multidrug-resistant Enterococcus faecium after 18 hrs by agar dilution method	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID558049	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID517963	Antimicrobial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID564956	Antimicrobial activity against Acinetobacter baumannii isolate Ab108 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID279256	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID499053	Antimicrobial activity against carbapenem-resistant Escherichia coli PU96 deficient in TEM-1, CTX-M-14, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529459	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID544671	Antimicrobial activity against Citrobacter koseri clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573340	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID422644	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 44 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID559264	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID519809	Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID544891	Antimicrobial activity against class A extended spectrum beta-lactamase- producing Klebsiella pneumoniae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID373038	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate NJ59 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID529643	Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID405825	Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID558608	Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID546057	Antimicrobial activity against Burkholderia cepacia by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID558600	Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID577232	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB166 with PFGE subgroup A3 containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID584839	Antimicrobial activity against Escherichia coli DH10B by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID68875	In vitro synergistic activity against Escherichia coli ATCC 25922 (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID68877	In vitro synergistic activity against Escherichia coli C600N (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID520329	Activity of Acinetobacter baumannii isolate TZ42/166 VIM-1 assessed as compound hydrolysis	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID535368	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient by broth microdilution method in presence of Tazobactam	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1124631	Stability of the compound in amorphous form assessed as compound remaining after 6 months at 60 mg/ml at 23 degC in presence of 0.1 equiv of NaHCO3	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID557972	Antimicrobial activity in Clostridium tertium by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID55863	Compound was evaluated for its relative half life of hydrolysis to meropenem by partially purified porcine renal dihydropeptidase-I (DHP-I)	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID524312	Antibacterial activity against Acinetobacter baumannii A850 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511387	Antibacterial activity against ciprofloxacin susceptible Escherichia coli by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID495680	Antimicrobial activity against Pseudomonas aeruginosa OC 13996 expressing beta-lactamase IMP-1 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574516	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID68210	In vitro antibacterial activity against Enterobacter cloacae 1321E by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID524492	Antibacterial activity against Pseudomonas aeruginosa P376 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584307	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0584 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID201540	In vivo antibacterial activity against Salmonella Typhimurium	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID534606	Antimicrobial activity against Enterobacteriaceae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546621	Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID557956	Antimicrobial activity in Eggerthella lenta by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID575274	Antimicrobial activity against Streptococcus agalactiae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID209565	Antibacterial activity against Streptococcus faecium MD 8b	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID425972	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID548024	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237H mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID584506	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0807 harboring ampDh3 mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID574043	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID498825	Antimicrobial activity against Citrobacter freundii SZ62T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519811	Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID541799	Antimicrobial activity against Peptostreptococcus anaerobius clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID574756	Antimicrobial activity against Anaerococcus prevotii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID285512	Antibacterial activity against Escherichia coli after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID523947	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535365	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534898	Antimicrobial activity against Citrobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573527	Antibacterial activity against Serratia marcescens isolate Sm265 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID559072	Antibacterial activity against Citrobacter freundii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID545823	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID66923	Antibacterial activity against VREFs	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID295818	Antibacterial activity against Salmonella Typhimurium after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID340736	Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID524076	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P319	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557492	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID524124	Antibacterial activity against beta-lactamase-negative Escherichia coli E347 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573544	Antibacterial activity against Enterobacter cloacae El3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534167	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID517924	Antibacterial activity against Acinetobacter baumannii A891 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529659	Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID529666	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID534483	Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID283125	Antibacterial activity against Escherichia coli C600 expressing ESBL OXA2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID535716	Activity of Escherichia coli TOP10 beta-lactamase AmpC-B2	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID323625	Ratio of Kcat to Km for Aeromonas hydrophila beta lactamase CphA at pH 7.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID425082	Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524083	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P338	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583083	Activity of Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID164544	Compound was evaluated for the antibacterial activity against Pseudomonas aeruginosa.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID523735	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E424	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573343	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID67537	Compound was evaluated for the antibacterial activity against Enterobacter.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID498812	Antimicrobial activity against Escherichia coli ZJ87 expressing KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285325	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID520887	Induction of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as benzyl-penicillin hydrolysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID368754	Antimicrobial activity against Proteus mirabilis Pm1-Pm3 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID573595	Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285576	Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498822	Antimicrobial activity against Klebsiella pneumoniae WH77 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID563583	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID576520	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070654 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID425323	Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID574666	Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID577239	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB134 with PFGE subgroup A2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID524089	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P349	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285327	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID374023	Activity of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID510982	Antimicrobial activity against Acinetobacter baumannii 940	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID523509	Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565504	Antimicrobial activity against beta-lactamase negative ampicillin-resistant -Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID405081	Antimicrobial activity against Escherichia coli CAG12177 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID428271	Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1592959	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID511283	Antimicrobial activity against Acinetobacter sp. clinical isolate assessed as resistance isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID529303	Antimicrobial activity against Acinetobacter genospecies 3 isolate Ac057 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID425088	Antimicrobial activity against Porphyromonas asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID542395	Elimination half life in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID508724	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E2 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID584933	Antimicrobial activity against Pseudomonas aeruginosa harboring pBBR1MCS-3 expressing algU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID533757	Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P60 exhibiting PFGE H pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID557718	Antimicrobial activity in Fusobacterium mortiferum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID360050	Antimicrobial activity against Enterococcus faecium M512 by agar dilution method after 48 hrs	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID499056	Antimicrobial activity against carbapenem-resistant Escherichia coli PU102 deficient in TEM-1, CTX-M-14, CMY-2, aac(6')-Ib, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID548472	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID422652	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID372607	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-158 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID574468	Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID545440	Antimicrobial activity against Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID557424	Antimicrobial activity in Bacteroides distasonis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID285629	Antimicrobial activity against Pseudomonas aeruginosa 9B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID572128	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573540	Antibacterial activity against Morganella morganii Mm38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573119	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285633	Antimicrobial activity against Pseudomonas aeruginosa 10B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID558629	Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID425085	Antimicrobial activity against beta lactamase-positive Prevotella denticola isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID545844	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID324864	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID573524	Antibacterial activity against Escherichia coli isolate Ec221 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID524085	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P352	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544956	Antimicrobial activity against Proteus mirabilis extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID559074	Antibacterial activity against Enterobacter aerogenes by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID517955	Antimicrobial activity against Klebsiella pneumoniae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID545566	Ratio of MIC for Escherichia coli EIR8a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID546060	Antimicrobial activity against Stenotrophomonas maltophilia by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545337	Displacement of [14C]benzylpenicillin from PBP4 in Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID545609	Antimicrobial activity against Pseudomonas aeruginosa PS29 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID575079	Antimicrobial activity against Streptococcus pneumoniae serotype 7F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID433000	Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID396032	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID584579	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID517960	Antimicrobial activity against Burkholderia sp. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID529653	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID368746	Antimicrobial activity against Escherichia coli Ec9 expressing TEM-24b TEM-26 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID405453	Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID322320	Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID433150	Antibacterial activity against Bacteroides uniformis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID205959	Effect of 43 mg/mL of Human Serum Albumin, Fraction V (HSA Fr. V) on antimicrobial activity was assessed against MSSA strain MB 2985	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID575276	Antimicrobial activity against Escherichia coli by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID394495	Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID1528449	Antibacterial activity against Klebsiella pneumoniae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID489660	Antibacterial activity against Bacillus subtilis at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID574023	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID557444	Antimicrobial activity in Prevotella melaninogenica by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID163106	Minimum inhibitory concentration against Pseudomonas aeruginosa 9027 was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID360061	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tetra-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID544909	Antimicrobial activity against Proteus mirabilis clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID542047	Antibacterial activity against Escherichia coli TrC A expressing Klebsiella pneumoniae A blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID498845	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU105 deficient TEM-1, SHV-12, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285645	Antimicrobial activity against Pseudomonas aeruginosa 16D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID528920	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID545443	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID433009	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID519629	Antimicrobial activity against Escherichia coli JM83 without producing beta-lactamase OXA-63 after 3 days by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID558043	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID522013	Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID425106	Antimicrobial activity against Clostridium clostridioforme isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID51147	Compound was tested in vitro for its activity against Methicillin-Resistant Coagulase Negative Staphylococci(MRCNS 9)	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID529663	Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID573836	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID511399	Antibacterial activity against Haemophilus influenzae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID497691	Antimicrobial activity against colistin-resistant Klebsiella pneumoniae isolated from bacteremia patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID372603	Antibacterial activity against Escherichia coli BER1 producing beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID517965	Antimicrobial activity against Escherichia coli K802N harboring beta-lactamase TEM-3 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID521993	Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID531976	Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID374022	Activity of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID557416	Antimicrobial activity in Bacteroides ovatus by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID534416	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID405084	Activity of Citrobacter freundii PER2 beta lactamase	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID285605	Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573517	Antibacterial activity against Serratia marcescens isolate Sm203 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID433167	Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID517948	Antimicrobial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534601	Antimicrobial activity against Enterobacteriaceae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID533365	Antimicrobial activity against Bacteroides uniformis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID584520	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3145 harboring wbpL mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID557714	Antimicrobial activity in Fusobacterium necrophorum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID531333	Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID285577	Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574776	Antimicrobial activity against Clostridium difficile after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID517954	Antimicrobial activity against Klebsiella oxytoca by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID425328	Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID582980	Antimicrobial activity against ampC::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID511666	Antimicrobial activity against beta-lactam resistant beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID524442	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID517961	Antimicrobial activity against Stenotrophomonas maltophilia by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID518519	Antimicrobial activity against Capnocytophaga sputigena isolate NOR after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID575100	Antimicrobial activity against Streptococcus pneumoniae serotype 22F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID495842	Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID496007	Antimicrobial activity against Ceftazidime resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID558328	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID565716	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID560833	Antimicrobial activity against Acinetobacter baumannii isolate Ab2 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID433184	Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534629	Antimicrobial activity against Non-ESBL Escherichia coli assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573155	Antibacterial activity against vancomycin-resistant Enterococcus faecium by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID495744	Kcat/Km ratio of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID573349	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID289897	Antibacterial activity against Escherichia coli 0126	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID575270	Antimicrobial activity against vancomycin-resistant Enterococcus faecium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID584574	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID559070	Antibacterial activity against Acinetobacter calcoaceticus by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573521	Antibacterial activity against Serratia marcescens isolate Sm211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID433191	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID531719	Antibacterial activity against Bacteroides fragilis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID534171	Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID534388	Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID545544	Ratio of MIC for Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem to MIC for Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1356830	Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2473 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID531755	Antibacterial activity against Pseudomonas aeruginosa 2126 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID571924	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID425103	Antimicrobial activity against Clostridium innocuum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID519475	Induction of beta-lactamase L1 expression in Stenotrophomonas maltophilia M2 mutant assessed as L1 activity at 10 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID524407	Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID583088	Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID524301	Antibacterial activity against Pseudomonas aeruginosa P353 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433155	Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID368744	Antimicrobial activity against Escherichia coli Ec7 expressing SHV-12 IRT-6 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID523954	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534918	Antimicrobial activity against Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546063	Antimicrobial activity against beta-lactamase-positive Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID523734	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E437	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584737	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5174 harboring mutation in putative beta-ketoacyl synthase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID586062	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 transformed with shuttle vector carrying beta-lactamase OXA-82 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID1855552	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as zone of growth inhibition incubated for 24 hrs by agar diffusion method	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Design and synthesis of novel benzimidazole derivatives as potential Pseudomonas aeruginosa anti-biofilm agents inhibiting LasR: Evidence from comprehensive molecular dynamics simulation and in vitro investigation.
AID545832	Antimicrobial activity against levofloxacin-resistant Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID562754	Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID425987	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 33 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511151	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 7 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID572132	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID533388	Antimicrobial activity against Clostridium difficile assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574470	Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID565191	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 expressing open reading frame orf3 encoded efflux pump CraA by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.
AID560113	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69-V49 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID559897	Antimicrobial activity against Klebsiella oxytoca KO280 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID295804	Antibacterial activity against Streptococcus durans D after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495700	Activity of Acinetobacter baumannii OXA-23	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID206642	Minimum inhibitory concentration against Staphylococcus aureus	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID433163	Antibacterial activity against Clostridium sphenoides isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID567319	Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID557460	Antimicrobial activity in Prevotella corporis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID583030	Antimicrobial activity against Escherichia coli TOP10 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID499071	Antimicrobial activity against Klebsiella pneumoniae WH97 expressing SHV-33, aac(6')-Ib, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID206859	Antibacterial activity against MSSA (Methicillin-sensitive Staphylococcus aureus)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID323631	Inhibition of Aeromonas hydrophila beta lactamase CphA at pH 10	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID545331	Antibacterial activity against Staphylococcus aureus ATCC 6538P by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID249347	Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=0.5-128)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID394492	Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID529859	Ratio of MIC for Pseudomonas aeruginosa MR08 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID285688	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID523494	Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1124628	Stability of the compound in amorphous form in deionized water assessed as time at which 90% of initial UV-absorbance remains at 60 mg/ml at 23 degC	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID573192	Antimicrobial activity against mexD::lox-deficient Pseudomonas aeruginosa PAOMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID422686	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID583240	Antibacterial activity against Staphylococcus spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID532401	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID534608	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529853	Antibacterial activity against beta-lactamase and MexA-MexB-OprM-overproducing Pseudomonas aeruginosa N045 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID573583	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID245020	Minimum inhibitory concentration against Salmonella Typhimurium	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID433020	Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID323628	Activity of Aeromonas hydrophila beta lactamase CphA at pH 7.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID584559	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID766244	Activity at recombinant Bc2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID535371	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584732	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4269 harboring rpoC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID289902	Antibacterial activity against Salmonella typhi	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1157277	Antibacterial activity against methicillin-resistant Staphylococcus aureus by resazurin-based assay	2014	Journal of natural products, May-23, Volume: 77, Issue:5	Mahorones, highly brominated cyclopentenones from the red alga Asparagopsis taxiformis.
AID495841	Ratio of Kcat to Km for beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID532414	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID534904	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565532	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID520983	Antibacterial activity against Klebsiella pneumoniae GR by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID285622	Antimicrobial activity against Pseudomonas aeruginosa 8A12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID518194	Antimicrobial activity against mexAB-oprM protein and mexZ deficient Pseudomonas aeruginosa PAO267 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID463427	Antimicrobial activity against Pseudomonas aeruginosa at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID533551	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA362	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573122	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1230757	Antibacterial activity against Escherichia coli after 12 hrs by macrodilution broth method	2015	ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6	Amino Acid Thioester Derivatives: A Highly Promising Scaffold for the Development of Metallo-β-lactamase L1 Inhibitors.
AID285639	Antimicrobial activity against Pseudomonas aeruginosa 13D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID69021	In vivo synergistic activity against Escherichia coli GC6265 (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID556699	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID534641	Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID562737	Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID425968	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 14 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID584518	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2797 harboring mutation in putative anti-anti-sigma factor by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545558	Ratio of MIC for Escherichia coli EIR2a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID529661	Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID289903	Antibacterial activity against Salmonella orion	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID559904	Antimicrobial activity against Escherichia coli TF-KP278 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID535720	Activity of Escherichia coli TOP10 beta-lactamase AmpC-A	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID587531	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID394693	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexAB-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID531513	Antibacterial activity against Bacteroides spp. assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1124636	Antibacterial activity against penicillin-sensitive Escherichia coli MB2482 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID531523	Antibacterial activity against Bacteroides eggerthii isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID1826215	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa T2357 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID574687	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID520872	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU67 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID1056839	Antibacterial activity against TEM-1/CTX-M-15 expressing Aeromonas caviae isolate 260 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID529457	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID574006	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID326266	Antibacterial activity against Escherichia coli K12 carrying pR3521 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID285513	Antibacterial activity against Klebsiella pneumoniae	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID544959	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID519260	Half life in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID557944	Antimicrobial activity in Bifidobacterium by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID283110	Antibacterial activity against imipenem-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID531966	Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID548263	Selectivity index, Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID532904	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID559085	Antibacterial activity against Proteus vulgaris by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573513	Antibacterial activity against Escherichia coli isolate Ec158 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID557738	Antimicrobial activity in Peptoniphilus asaccharolyticus by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID394681	Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis sputum isolate 529 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID573195	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring deletion mutation at nucleotide 231-244 in nfxB gene selected at 1 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID573337	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID433188	Antibacterial activity against Corynebacterium simulans isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID496009	Antimicrobial activity against tobramycin resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID544964	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase DHA by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID558607	Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID573397	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495656	Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-2 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID433164	Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID576952	Antimicrobial activity against Shewanella putrefaciens Sp117 harboring intI1,sul1,sul2 and beta-lactamase OXA-48 like genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID528600	Antimicrobial activity against Escherichia coli TOP10 harboring blaKPC-2 and blaTEM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID396030	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID555666	Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID155944	Antibacterial activity expressed as binding to PBP 1b of Pseudomonas aeruginosa	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID285260	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-28 and ESBL by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID523516	Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID532394	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID545610	Antimicrobial activity against Pseudomonas aeruginosa PS30 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID559084	Antibacterial activity against Proteus mirabilis by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID576543	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008027 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID585178	Activity of Beta-lactamase GES-5 E104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID422673	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 18 passages with levofloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID573113	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID535843	Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID573213	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T544C mutant gene selected at 4 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID582967	Antimicrobial activity against beta-lactamase B-deficient Yersinia enterocolitica GY5542 after 20 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID433006	Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520386	Activity at Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID573558	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574949	Antimicrobial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID561932	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate N50 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID524275	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546432	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-3 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID425083	Antimicrobial activity against beta lactamase-positive Prevotella nigrescens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID322776	Antimicrobial activity against Bacteroides thetaiotaomicron isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID496593	Activity at Escherichia coli DH10B beta-lactamase KPC-2 by diode array spectrophotometry	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID542063	Antibacterial activity against Klebsiella pneumoniae B expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID1356836	Antimicrobial activity against Enterobacter cloacae ATCC BAA-2468 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID585181	Ratio of Kcat to Km for Beta-lactamase GES-1 E104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID433358	Antibacterial activity against Clostridium perfringens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID519259	Clearance in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID529517	Antibacterial activity against Pseudomonas aeruginosa isolates by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID583652	Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID533543	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA346	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524446	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511581	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID394689	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing PSE-1, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID544966	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID285667	Antimicrobial activity against Pseudomonas aeruginosa 22C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID557436	Antimicrobial activity in Prevotella bivia by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID583022	Activity of Beta-lactamase DHA-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID545608	Antimicrobial activity against Pseudomonas aeruginosa PS28 with PFGE phenotype 6 expressing beta-lactamase KPC-5 obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID283112	Antibacterial activity against Escherichia coli C600 expressing TEM1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID573526	Antibacterial activity against Klebsiella pneumoniae isolate Kp204 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID374364	Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID207147	Antibacterial activity against MRSA	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID433181	Antibacterial activity against Corynebacterium amycolatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID562753	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID573334	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285684	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with pvdS mutation after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID558332	Antibacterial activity against Campylobacter jejuni isolate P338 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID558786	Antimicrobial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID573376	Antibacterial activity against imipenem-susceptible Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1824291	Antimicrobial activity against Enterobacter cloacae T2311 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID498816	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ49 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534920	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425096	Antimicrobial activity against Micromonas micros isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID557484	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID548028	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237K mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1056835	Antibacterial activity against SIM-1 expressing Acinetobacter baumannii isolate 170 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID534481	Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID495915	Ratio of Kcat to Km for beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID523733	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E415	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID585176	Activity of Beta-lactamase GES-7 K104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID519138	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID574518	Antimicrobial activity against Prevotella intermedia after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584712	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1011 harboring mutation in putative lipoprotein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID69018	In vivo antibacterial activity against Escherichia coli 078	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID325480	Antibacterial activity against streptomycin and gentamycin-resistant Pseudomonas aeruginosa DK101 containing oprD mutant after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID545547	Antibacterial activity against Staphylococcus aureus SMR4a selected at 2 times MIC of meropenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1373290	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID423070	Antibacterial activity against 16_G12 allele containing Pseudomonas aeruginosa PAO1 H1125 mutant strain with recG::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID573123	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID396718	Antibacterial activity against carbapenem-resistant Staphylococcus aureus M-126HR	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis of novel di- and tricationic carbapenems with potent anti-MRSA activity.
AID574667	Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID545824	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID1824300	Antimicrobial activity against Pseudomonas aeruginosa T2282 expressing VIM-2 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID548044	Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID283136	Antibacterial activity against Pseudomonas aeruginosa KG4001 producing MexEF-OprN efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID495696	Activity of Serratia marcescens SME-3	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID530340	Activity of Pseudomonas aeruginosa VIM-1 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID582888	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 3.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID511391	Antibacterial activity against Citrobacter freundii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID524126	Antibacterial activity against beta-lactamase-negative Escherichia coli E350 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID572120	Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID573722	Antibacterial activity against Klebsiella oxytoca Ko238 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID433179	Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID164407	Compound was evaluated for antibacterial activity against Pseudomonas aeruginosa 1592E	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID264474	Antibacterial activity against Haemophilus influenzae	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID559483	Antibacterial activity against Serratia marcescens by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID575005	Antimicrobial activity against Eubacterium sp. after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID423071	Antibacterial activity against Pseudomonas aeruginosa PAO1 H1105/lon+c mutant strain with lon::lux/lon+ mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID433169	Antibacterial activity against Peptostreptococcus anaerobius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID508729	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C8 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID394682	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID425091	Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID577240	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB168 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID522016	Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID511398	Antibacterial activity against Pseudomonas aeruginosa by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID574770	Antimicrobial activity against Clostridium perfringens after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID394683	Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID323388	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 infected in BALB/c mouse blood at 20 mg/kg, iv after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID520726	Activity of Escherichia coli TOP10 beta-lactamase OXA-58 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID573348	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584556	Antimicrobial activity against Acinetobacter lwoffii isolate C expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID546054	Antimicrobial activity against Serratia marcescens by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID557482	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID587525	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml Tazobactam beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID433153	Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID517919	Antibacterial activity against Acinetobacter baumannii A931 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532391	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1765578	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID521491	Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID511016	Half life in New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID490294	Antibacterial activity against Staphylococcus aureus ATCC 25923 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID1528450	Antibacterial activity against Morganella morganii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID518196	Antimicrobial activity against fpvA, fpvB, fptA and pirA gene deficient Pseudomonas aeruginosa 860 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID569261	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 873	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID264468	Antibacterial activity against Streptococcus pyogenes	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID428268	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID245211	Minimum inhibitory concentration against Pseudomonas aeruginosa 1771M strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID524499	Antibacterial activity against Acinetobacter baumannii A867 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID245142	Minimum inhibitory concentration against Streptococcus aureus 503 strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID573723	Antibacterial activity against Klebsiella pneumoniae Kp204 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573128	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574954	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID433013	Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID522388	Activity of Aeromonas enteropelogenes Beta-lactamase TRU1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID278572	Antimicrobial activity against Streptococcus pyogenes ATCC 19615	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID1356820	Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID524408	Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID340731	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase SHV-ES by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID557480	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID535127	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID68872	In vitro synergistic activity against Escherichia coli 300 + (ampR ampC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID285657	Antimicrobial activity against Pseudomonas aeruginosa 19E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID324310	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID524457	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573141	Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1373317	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID433194	Antibacterial activity against Staphylococcus lugdunensis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534621	Antimicrobial activity against Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID586063	Antimicrobial activity against Acinetobacter baumannii F-type isolate transformed with plasmid harboring ISAba1-blaOXA-82 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID324872	Antimicrobial activity against Acinetobacter baumannii C75 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID524272	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID422683	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544951	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase CTX by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID583091	Activity of Escherichia coli XL1-Blue wild-type IMP-1 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID573378	Antibacterial activity against imipenem-susceptible Acinetobacter assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534647	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID571904	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID522387	Antimicrobial activity against Escherichia coli TOP10	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID529574	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid BC-SK after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID433008	Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID279269	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID544918	Antimicrobial activity against Providencia stuartii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573591	Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID565666	Antimicrobial activity against beta-lactamase positive (amoxicillin)clavulanate-resistant Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID559900	Antimicrobial activity against Klebsiella pneumoniae 278 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID559069	Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID428295	Antimicrobial activity against Acinetobacter baumannii BM4579 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID534394	Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID374365	Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID374363	Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID405823	Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID495512	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID558041	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID557722	Antimicrobial activity in Fusobacterium varium by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID425326	Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID531313	Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID557502	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID495633	Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID532399	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID544496	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID289884	Antibacterial activity against Staphylococcus aureus 503	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID289377	Antibacterial activity against Moraxella catarrhalis W-0500	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID278568	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID583015	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID565282	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID283393	Antimicrobial activity against Nocardia abscessus after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID394676	Antibacterial activity against Pseudomonas aeruginosa pus isolate 6 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID574782	Antimicrobial activity against Actinomyces odontolyticus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID575081	Antimicrobial activity against Streptococcus pneumoniae serotype 6C assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID425977	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID285593	Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1824293	Antimicrobial activity against Pseudomonas aeruginosa T2325 expressing IMP-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID584523	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3520 harboring mutation in putative periplasmic metal-binding protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID565514	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID557698	Antimicrobial activity in Prevotella loescheii by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID583016	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID285642	Antimicrobial activity against Pseudomonas aeruginosa 15G2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID567577	Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method in presence of cilastatin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID394684	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID424320	Antimicrobial activity against Dialister micraerophilus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID573542	Antibacterial activity against Escherichia coli Ec9381 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID561628	Antimicrobial activity against ampD1-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID499073	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ93 deficient in ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529864	Ratio of MIC for Pseudomonas aeruginosa COR6 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID574971	Antimicrobial activity against Actinomyces israelii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID545835	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID532407	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID571898	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID432990	Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID544933	Antimicrobial activity against Acinetobacter junii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID495697	Activity of Pseudomonas aeruginosa VIM-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID96430	In vitro synergistic activity against Klebsiella pneumoniae KC2 (TEM-10)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID559270	Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID496005	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
AID573361	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID69010	In vitro synergistic activity against Escherichia coli C600N + (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID558336	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523747	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E484	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519254	Cmax in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID524299	Antibacterial activity against Pseudomonas aeruginosa P328 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523737	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E446	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545428	Antimicrobial activity against Enterobacter cloacae obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID557506	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID1356826	Antimicrobial activity against Klebsiella pneumoniae NCTC 13438 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID532416	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID557517	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID576314	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID560489	Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID573134	Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565338	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID545839	Antimicrobial activity against ESBL-negative Enterobacter aerogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID559090	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii isolate A2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID575188	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID573518	Antibacterial activity against Klebsiella pneumoniae isolate Kp211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID556678	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 5 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID574969	Antimicrobial activity against Actinomyces israelii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID522014	Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID533421	Antimicrobial activity against Anaerococcus prevotii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535718	Activity of Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID584731	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4088 harboring mutation in putative aminotransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545410	Antimicrobial activity against Pseudomonas aeruginosa PS18A with PFGE phenotype 11D obtained from CSF of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID586233	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 6 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID544915	Antimicrobial activity against Providencia rettgeri clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID562749	Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID561094	Antibacterial activity against Clostridium perfringens by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID1056840	Antibacterial activity against CTX-15 expressing Aeromonas caviae isolate 258 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID66586	Compound was evaluated for the antibacterial activity against Enterococcus.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID546172	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-12 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID374024	Ratio of Kcat to Km for Enterobacter cloacae IMI1 beta lactamase Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID495664	Ratio of Kcat to Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID558752	Antibacterial activity against hetero-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus deltaIP by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID520873	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU69 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID524827	Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID1320835	Activity of native signal containing Klebsiella pneumoniae OXA-48 by Michaelis-Menten kinetics assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID533535	Antimicrobial activity against Pseudomonas aeruginosa PA430 expressing VIM-4 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID422674	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 21 passages with gemifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID285579	Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID372604	Antibacterial activity against Escherichia coli BER1 producing TEM-158 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID463426	Antimicrobial activity against Shigella flexneri at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID524458	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID541802	Antimicrobial activity against Peptostreptococcus micros clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID564530	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID534361	Antibacterial activity against Acinetobacter baumannii GIL1 isolate harboring intrinsic blaOXA-51/69-like gene by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.
AID433396	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1648 harboring inactive lytH gene and active llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID547793	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237V mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID511145	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 1 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID283142	Efficacy against Pseudomonas aeruginosa 93 pulmonary infection in mouse assessed as reduction in bacterial counts at 2 mg/kg, sc	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID523946	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534623	Antimicrobial activity against ESBL producing Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID351199	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii expressing ISAba3	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Global challenge of multidrug-resistant Acinetobacter baumannii.
AID373042	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ49 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID495686	Activity of Escherichia coli TEM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495724	Activity of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID422667	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID531752	Antibacterial activity against Pseudomonas aeruginosa 3308 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID545846	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID518460	Antimicrobial activity against Acinetobacter junii 15218 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID573208	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB C116T mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID523931	Antibacterial activity against beta-lactamase-negative Escherichia coli E408 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID561095	Antibacterial activity against Peptostreptococcus anaerobius by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID583028	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID373774	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID495740	Kcat/Km ratio of Klebsiella pneumoniae KPC-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID511397	Antibacterial activity against Acinetobacter baumannii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID565332	Antibacterial activity against Enterobacter hormaechei isolate UCN62	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID405634	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID460801	Antibacterial activity against Acinetobacter baumannii 3304 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID511286	Antimicrobial activity against Pseudomonas aeruginosa isolate obtained from patient's blood assessed as resistance isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID584322	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 300 ug/ml of boronic acid	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID495793	Antimicrobial activity against Escherichia coli DH10B by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID510514	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID285526	Antibacterial activity against Propionibacterium acnes	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID533002	Antibacterial activity against VEB-1a and OXA-10 producing Pseudomonas aeruginosa isolate P151 exhibiting PFGE I pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID559527	Antibacterial activity against Citrobacter freundii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID279268	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279265	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID322775	Antimicrobial activity against Bacteroides ovatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID517916	Antibacterial activity against Acinetobacter baumannii A928 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285628	Antimicrobial activity against Pseudomonas aeruginosa 9A10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID584507	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0908 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID576296	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID530341	Ratio of Kcat to Km for Pseudomonas aeruginosa VIM-1 beta-lactamase	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID520984	Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID341597	Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID534884	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285602	Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID546427	Activity at Pseudomonas aeruginosa PDC-2 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID495517	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID546417	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573352	Antibacterial activity against ceftazidime-susceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524447	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID394494	Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID582889	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 2.8 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID533364	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID546064	Antimicrobial activity against beta-lactamase-negative ampicillin resistant Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID534643	Antimicrobial activity against ESBL producing Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285591	Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535841	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID542719	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID289373	Antibacterial activity against carbapenem-resistant Staphylococcus aureus M126 HR	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID558757	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus deltaIP::vraSH14 harboring vraSH14 S329L mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID520780	Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID289375	Antibacterial activity against Escherichia coli NIHJ JC2	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID341593	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID574512	Antimicrobial activity against Bacteroides vulgatus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID546433	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-5 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID523765	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530817	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID524132	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E437 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564524	Antimicrobial activity against Acinetobacter baumannii KI by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID558587	Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID433156	Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533131	Antimicrobial activity against Bacteroides fragilis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID572136	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1318928	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86067	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID495791	Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID524276	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545833	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID322773	Antimicrobial activity against Bacteroides fragilis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID545841	Antimicrobial activity against ESBL-negative Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID559079	Antibacterial activity against Klebsiella pneumoniae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID264472	Antibacterial activity against methicillin-susceptible Staphylococcus aureus	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID360065	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tri-aspartate-tetra multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID495677	Antimicrobial activity against Enterobacter cloacae OC 4080 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID564945	Antimicrobial activity against Acinetobacter baumannii isolate Ab150 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID573369	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1529369	Antibacterial activity against Bacteroides sp.	2018	MedChemComm, Sep-01, Volume: 9, Issue:9	β-lactam/β-lactamase inhibitor combinations: an update.
AID546055	Antimicrobial activity against Shigella spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID558618	Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID534604	Antimicrobial activity against Enterobacteriaceae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID558581	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1678791	Antibacterial activity against Escherichia coli BL21 (DE3) assessed as inhibition of bacterial growth incubated for 16 hrs by CLSI broth microdilution method	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
AID1824290	Antimicrobial activity against Serratia marcescens T2352 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID285647	Antimicrobial activity against Pseudomonas aeruginosa 19B1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID278066	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID283130	Antibacterial activity against Pseudomonas aeruginosa FP1380 expressing constitutive AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID531679	Antimicrobial activity against Acinetobacter baumannii Ab290 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID425086	Antimicrobial activity against beta lactamase-positive Prevotella corporis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573186	Antimicrobial activity against Pseudomonas aeruginosa PAO1 biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID264469	Antibacterial activity against Streptococcus pneumoniae	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID584738	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5288 harboring glnK mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID245280	Minimum inhibitory concentration against was determined against Pseudomonas aeruginosa 9027 strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID575272	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID583035	Ratio of Kcat to Km for Beta-lactamase CMY-2	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID205547	Minimum inhibitory concentration against Staphylococcus aureus SG 511 was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID285620	Antimicrobial activity against Pseudomonas aeruginosa 5H6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534666	Antimicrobial activity against Proteus mirabilis assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID766240	Activity at recombinant NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID532409	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID125412	Minimum inhibitory concentration against aerobic organism Morganella morganii strain 2834	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID498831	Antimicrobial activity against Escherichia coli C600 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535838	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID425084	Antimicrobial activity against beta lactamase-positive Prevotella melaninogenica isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID250287	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID523724	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E345	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576959	Antimicrobial activity against Shewanella algae Sa82 harboring intI1, intI2, sul1 and sul2 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID558533	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID544673	Antimicrobial activity against Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID574953	Antimicrobial activity against Streptococcus pneumoniae serotype 6C by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID531757	Antibacterial activity against Pseudomonas aeruginosa 1956 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID531524	Antibacterial activity against Bacteroides spp. isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID573212	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID557976	Antimicrobial activity in Clostridium ramosum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID564017	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID533533	Antimicrobial activity against Pseudomonas aeruginosa PA373 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID560128	Antimicrobial activity against Acinetobacter baumannii CIP70.10 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID576538	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008026 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1373296	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID574003	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID523722	Antibacterial activity against Acinetobacter baumannii A903 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285263	Antimicrobial activity against Escherichia coli DH5-alpha TC1295 isolate expressing TEM-1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID495713	Kcat/Km ratio of Pseudomonas aeruginosa IMP-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID519734	Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID534603	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID207151	Antibacterial activity against Methicillin sensitive Staphylococcus aureus-/+ HSA Fr. V	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID555681	Antimicrobial activity against Escherichia coli DH10B by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID585397	Activity at Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID249290	Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range = 0.008-0.5)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID207929	Compound was evaluated for the antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID559546	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia assessed as assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID519293	Antimicrobial activity against Escherichia coli TOP10 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID531516	Antibacterial activity against Bacteroides caccae assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID562949	Antimicrobial activity against Klebsiella pneumoniae PFGE clone F expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID424332	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID368749	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID524106	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A910	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532392	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID574488	Antimicrobial activity against Bacteroides distasonis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID498819	Antimicrobial activity against Klebsiella pneumoniae GZ64T expressing IMP-4 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523941	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557408	Antimicrobial activity in Bacteroides fragilis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID555676	Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID584521	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3247 harboring mutation in putative aspartyl aminopeptidase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523939	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495712	Kcat/Km ratio of Pseudomonas aeruginosa VIM-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID510502	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate C1AC9-24 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID520711	Antibacterial activity against Escherichia coli TOP10 harboring pOXA-58	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID577229	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB095 with PFGE subgroup E containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID573534	Antibacterial activity against Citrobacter amalonaticus Ca3927 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID405790	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID560593	Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID544954	Antimicrobial activity against Escherichia coli extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573823	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524431	Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID574520	Antimicrobial activity against Prevotella bivia after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID532395	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1824272	Antimicrobial activity against Klebsiella pneumoniae clinical isolate T2301 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID405817	Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID573825	Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495723	Activity of Enterobacter cloacae AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID542393	Renal clearance in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID518461	Antimicrobial activity against Enterobacter cloacae S4741B assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523772	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565197	Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID498837	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU8 deficient in SHV-11, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID517949	Antimicrobial activity against Providencia stuartii by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID546411	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-28 with PDC-7 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID425332	Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID520875	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolates isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID523938	Antibacterial activity against beta-lactamase-negative Escherichia coli E425 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559075	Antibacterial activity against Enterobacter cloacae by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573341	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573798	Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1356835	Antimicrobial activity against Escherichia coli ATCC BAA-2469 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID283392	Antimicrobial activity against Nocardia otitidiscaviarum after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID766246	Ratio of Kcat to Km for recombinant VIM-2 (unknown origin)	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID533125	Antimicrobial activity against Bacteroides distasonis by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID574461	Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID529494	Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID561097	Antibacterial activity against Porphyromonas asaccharolytica by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID570783	Antimicrobial activity against multidrug-resistant Acinetobacter baumannii expressing armA and bla oxa-23 gene assessed as resistant isolates by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID433173	Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523891	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring plasmid AT801 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID583235	Antibacterial activity against Enterobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID534625	Antimicrobial activity against Escherichia coli assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID575282	Antimicrobial activity against multiple dug-resistant Acinetobacter baumannii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID518459	Antimicrobial activity against Acinetobacter baumannii HPA74510 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID556677	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 4 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID574524	Antimicrobial activity against Prevotella oralis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584931	Antimicrobial activity against wild type Pseudomonas aeruginosa harboring pBBR1MCS-3 by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID69007	In vitro synergistic activity against Escherichia coli C600N + (SHV-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1225782	Antibacterial activity against Enterobacter cloacae ECL1058 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID520639	Antimicrobial activity against Escherichia coli MRY05-3283 expressing qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID531769	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID556657	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 12 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID250290	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID562473	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase KPC-2/TEM-1 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID534628	Antimicrobial activity against Non-ESBL Escherichia coli assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID230773	Range for minimum inhibitory concentration against Staphylococcus aureus; 0.06->64	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID535060	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID573506	Antibacterial activity against Klebsiella pneumoniae isolate Kp3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID279258	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID205545	Minimum inhibitory concentration against Staphylococcus aureus 503 was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID524481	Antibacterial activity against Pseudomonas aeruginosa P338 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373045	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS15 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID584508	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0958 harboring oprD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID369641	Antibacterial activity against Acinetobacter baumannii B clone by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID368742	Antimicrobial activity against Escherichia coli Ec4 expressing CTX-M-1 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID531317	Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID531335	Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID535752	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID588130	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID285586	Antimicrobial activity against Pseudomonas aeruginosa 65.36-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533428	Antimicrobial activity against Peptostreptococcus sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID404956	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T183 isolate carrying one bla-OXA58 gene copy by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID517974	Antimicrobial activity against Escherichia coli nmcA harboring beta-lactamase NMCA by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID283113	Antibacterial activity against Escherichia coli C600 expressing TEM2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID534883	Antimicrobial activity against Enterobacter cloacae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID544584	Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID1824339	Antimicrobial activity against Escherichia coli T2359 expressing VIM-1 assessed as inhibition of bacterial growth at 0.5XMIC for 6 hrs by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID524274	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534194	Antimicrobial activity against Pseudomonas putida expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID523763	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545347	Displacement of [14C]benzylpenicillin from PBP2 in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID563969	Antibacterial activity against Escherichia coli J53 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID373043	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY7 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID373209	Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID523760	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511154	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 10 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID373211	Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID542720	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae clinical isolate assessed as susceptible isolates	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
AID575269	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID577221	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gatA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID520972	Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID508723	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E1 PpA1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID529846	Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 123-1 by [14C]benzylpenicillin labelled competitive assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID573563	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID510980	Antimicrobial activity against Acinetobacter baumannii 1417	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID524137	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E452 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535834	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID583238	Antibacterial activity against indole positive Proteae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID495737	Kcat/Km ratio of Pseudomonas aeruginosa AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID289898	Antibacterial activity against Escherichia coil V6311/65	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID499050	Antimicrobial activity against Klebsiella pneumoniae PU104T expressing TEM-1, CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID508722	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1C3 PTOL1 harboring acquired beta-lactamase OXA-17 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID542585	Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID575265	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID573354	Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID498821	Antimicrobial activity against Klebsiella pneumoniae WH76T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573201	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T533C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID583084	Activity of Escherichia coli BL21(DE3) VIM-2 W87F mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID584315	Antimicrobial activity against beta-lactamase ompC/ompF deficient Serratia marcescens ATCC 8100 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID559689	Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4 harboring plasmid AT517	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID584313	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0573 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID562757	Ratio of Kcat to Km for Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID529456	Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID523768	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E420	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID510986	Antimicrobial activity against Acinetobacter baumannii 940 after 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID584570	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID425076	Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID546165	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-05 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID278569	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID546059	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID422684	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 37 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID563973	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase NDM-1	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID1056844	Antibacterial activity against TEM-1/CTX-M-15 expressing Enterobacter cloacae isolate 62 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID283134	Antibacterial activity against Pseudomonas aeruginosa KG3056 producing MexCD-OprJ efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID555686	Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID573143	Antibacterial activity against penicillin-susceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID584722	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3262 harboring fklB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID428272	Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID433202	Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID571886	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID524418	Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID532911	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID548254	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID534192	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 and SHV-12 obtained from criticall ill liver transplant recipient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
AID283116	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID524292	Antibacterial activity against Pseudomonas aeruginosa P320 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1824327	Antimicrobial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as assessed as inhibition of bacterial growth at 0.5XMIC measured after 24 hrs by time-kill assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID278573	Antimicrobial activity against Rhodococcus equi ATCC 6939	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci.
AID523948	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E483 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573345	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID547761	Antimicrobial activity against Klebsiella pneumoniae 1534 expressing beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID433356	Antibacterial activity against Porphyromonas somerae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID548259	Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID545343	Displacement of [14C]benzylpenicillin from PBP5 in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID584709	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0764 harboring mucB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID425080	Antimicrobial activity against beta lactamase-positive Prevotella bivia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524077	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P320	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574492	Antimicrobial activity against Bacteroides ovatus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID564525	Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID511577	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID584562	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID587526	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse in presence of 4 ug/ml cavulanate beta-lactamase inhibitor	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID495655	Antimicrobial activity against Pseudomonas aeruginosa 51170 expressing beta-lactamase BEL-1 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID498842	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY75 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524294	Antibacterial activity against Pseudomonas aeruginosa P327 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534295	Antimicrobial activity against Stenotrophomonas maltophilia KJN1 harboring ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID422687	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID425089	Antimicrobial activity against Porphyromonas gingivalis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID545403	Antimicrobial activity against Pseudomonas aeruginosa PS10 with PFGE phenotype 1A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID425094	Antimicrobial activity against beta lactamase-positive Fusobacterium mortiferum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID545437	Antimicrobial activity against extended-spectrum beta-lactamase-negative Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID542399	T>MIC in febrile neutropenic patient with hematological malignancies at 750 mg administered as 120 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID548040	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBK SK(+) by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID373766	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID341594	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID534924	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546182	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-22 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID323689	Antibacterial activity against Acinetobacter baumannii by CLSI method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID546171	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-11 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID531527	Antibacterial activity against Bacteroides vulgatus isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID557960	Antimicrobial activity in Clostridium perfringens by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID574748	Antimicrobial activity against Peptostreptococcus micros assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID542106	Antibacterial activity against Escherichia coli TrC C expressing Klebsiella pneumoniae C blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID56132	Compound stability against human renal DHP-1 relative to imipenem (IMP)	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID423065	Antibacterial activity against 74_D9 allele containing Pseudomonas aeruginosa PAO1 H1105 mutant strain with lon::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID520707	Antibacterial activity against Acinetobacter baumannii phenotype 2 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID498833	Antimicrobial activity against Klebsiella pneumoniae CY1T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID495692	Activity of Pseudomonas aeruginosa AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID588126	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID534101	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate assessed as reduction of MIC by microdilution method in presence of 200 mg/liter cloxacillin	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID575264	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID518003	Antibacterial activity against Nocardia brasiliensis isolated from actinomycetoma patient by broth dilution method in presence of clavulanic acid	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.
AID519806	Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID609149	Antibacterial activity against Streptococcus pyogenes ATCC 19615	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID557742	Antimicrobial activity in Anaerococcus tetradius by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID521489	Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID545842	Antimicrobial activity against ESBL-positive Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545409	Antimicrobial activity against Pseudomonas aeruginosa PS17B with PFGE phenotype 11D expressing beta-lactamase KPC-2 obtained from blood of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID95553	Minimum inhibitory concentration against aerobic organism Klebsiella species strain 2921	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID495909	Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID534102	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii Ab F PFGE type B transconjugant by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID424331	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID510509	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC4AC9-30 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID574951	Antimicrobial activity against Streptococcus pneumoniae serotype 7F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID534396	Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID545356	Antibacterial activity against Staphylococcus aureus SRR2a selected at 2 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID544511	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID559262	Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID559265	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID425101	Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID573786	Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1354446	Antimicrobial activity against Yersinia pestis KIM6+ harboring arabinose inducible type 1 signal peptidase in presence of 2% arabinose	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID573596	Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID425105	Antimicrobial activity against Clostridium bifermentans isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534297	Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID544977	Antimicrobial activity against Klebsiella pneumoniae 52OmpA2Com	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID524319	Antibacterial activity against Acinetobacter baumannii A892 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID528606	Activity of Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID283399	Antimicrobial activity against Nocardia brasiliensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID545826	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID285618	Antimicrobial activity against Pseudomonas aeruginosa 5F8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573355	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID547769	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBC SK(+) carrying wild type beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID532411	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID584689	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4402 harboring argJ mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID278065	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID556679	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 6 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID576330	Antibacterial activity against ESBL-producing Klebsiella pneumoniae by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
AID428270	Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID535844	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID573385	Antibacterial activity against beta lactamase-positive Moraxella catarrhalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID575283	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID567583	Antimicrobial activity against Acinetobacter baumannii by broth dilution method in presence of cilastatin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID564526	Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID584846	Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID324858	Antimicrobial activity against Acinetobacter baumannii A24A after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID323041	Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID510995	Ratio of AUC to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID558014	Antimicrobial activity in Porphyromonas gingivalis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID1124639	Antibacterial activity against penicillin-resistant Enterobacter cloacae MB2646 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID556661	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 16 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID573822	Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID571896	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1356827	Antimicrobial activity against Klebsiella pneumoniae NCTC 13439 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID523728	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E350	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524267	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531514	Antibacterial activity against Bacteroides ovatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID523741	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E430	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523934	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433189	Antibacterial activity against Corynebacterium xerosis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523926	Antibacterial activity against beta-lactamase-negative Escherichia coli E345 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID588083	Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring pAB880	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID368752	Antimicrobial activity against Klebsiella pneumoniae Kp4 expressing SHV-12 SHV-1 and plasmid-mediated cephalosporinase CMY-4	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID394677	Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 7 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID574534	Antimicrobial activity against Prevotella buccae assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID395737	Antimicrobial activity against imipenem-susceptible Haemophilus influenzae Rd by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID545335	Displacement of [14C]benzylpenicillin from PBP2 Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID69001	In vitro synergistic activity against Escherichia coli C600N + (Imi-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID529861	Ratio of MIC for Pseudomonas aeruginosa N044 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID558326	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID425986	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 41 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID535836	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID511144	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 18	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID521486	Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID523767	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E417	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID587981	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240S mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID524090	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P363	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID206633	Compound was tested in vitro for its activity against methicillin-Resistant Staphylococcus Aureus(MRSA 12)	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID285650	Antimicrobial activity against Pseudomonas aeruginosa 19C2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495910	Antimicrobial activity in Escherichia coli TOP10 strain	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID495516	Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID511586	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in ampD gene by selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution metho	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID1528446	Antibacterial activity against Enterobacter cloacae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID584317	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID534925	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535751	Antimicrobial activity against community-acquired Klebsiella pneumoniae obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID548000	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237N mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID565193	Antimicrobial activity against efflux pump CraA deficient Acinetobacter baumannii JVAB01 receiving pJV103 harboring open reading frame orf3 encoded efflux pump CraA by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.
AID495694	Activity of Pseudomonas aeruginosa OXA-10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID572130	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID576299	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID584515	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2023 harboring galU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520868	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU28 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID575078	Antimicrobial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID285337	Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID425321	Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID322323	Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID529491	Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID572144	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID523770	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533373	Antimicrobial activity against Bacteroides eggerthii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID523491	Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID532896	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID535162	Antimicrobial activity against Acinetobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID279254	Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID558325	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID425097	Antimicrobial activity against Peptostreptococcus anaerobius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID545561	Antibacterial activity against Escherichia coli EIR4a selected at 4 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID432993	Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524311	Antibacterial activity against Acinetobacter baumannii A848 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID517980	Antimicrobial activity against Pseudomonas aeruginosa HPA996 harboring beta-lactamase VIM-2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID584734	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4745 harboring nusA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID155949	Antibacterial activity expressed as binding to PBP 5 of Pseudomonas aeruginosa	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID373044	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate CY6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID544927	Antimicrobial activity against Acinetobacter haemolyticus clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID574484	Antimicrobial activity against Bacteroides thetaiotaomicron after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574668	Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID574736	Antimicrobial activity against Fusobacterium nucleatum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID533549	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA360	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID587729	Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID50538	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Citrobacter freundii GN7391	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID373787	Ratio of MIC for Acinetobacter baumannii ISAB ab8(r) to MIC for Acinetobacter baumannii ISAB ab1254(r) in presence of 24 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID533380	Antimicrobial activity against Bacteroides merdae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573125	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID523732	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E412	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID562328	Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID575080	Antimicrobial activity against Streptococcus pneumoniae serotype 11A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID573802	Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285514	Antibacterial activity against Bacteroides fragilis by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID289872	Antibacterial activity against Streptococcus pyogenes 308A	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID574496	Antimicrobial activity against Bacteroides fragilis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID151533	Compound was tested in vitro for antibacterial activity against Pseudomonas aeruginosa	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID295832	Antibacterial activity against Proteus rettgeri 937 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID342018	Antibacterial activity against Klebsiella pneumoniae NK29 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID373767	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID433355	Antibacterial activity against Porphyromonas asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID559545	Antibacterial activity against levofloxacin-susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID289885	Antibacterial activity against Micrococcus luteus ATCC 9341	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID523928	Antibacterial activity against beta-lactamase-negative Escherichia coli E347 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524450	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E362 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID264470	Antibacterial activity against Enterococcus spp	2006	Journal of medicinal chemistry, May-04, Volume: 49, Issue:9	Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.
AID572146	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID565201	Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID545548	Ratio of MIC for Staphylococcus aureus SMR4a to MIC for Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID584306	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0582 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID561093	Antibacterial activity against Bacteroides ovatus by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID565280	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID205976	In vitro antibacterial activity against Sa(I) Staphylococcus aureus ATCC 29213	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID324854	Antimicrobial activity against Acinetobacter baumannii A24 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID372322	Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID587730	Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID433012	Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524139	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373777	Antibacterial activity against Escherichia coli TOP10 expressing imipenem-resistant Acinetobacter baumannii ab1266 blaoxa-66 gene by Etest	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID531777	Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534901	Antimicrobial activity against Citrobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523721	Antibacterial activity against Acinetobacter baumannii A901 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID209456	In vitro antibacterial activity against Streptococcus pyogenes 308A by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID360057	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl penta-aspartate-peptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID573590	Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID586236	Antimicrobial activity against Escherichia coli J53 harboring Klebsiella pneumoniae Kp7 beta-lactamase NDM-1	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID582883	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 0.5 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID522024	Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495666	Antimicrobial activity against Klebsiella pneumoniae OC 4238 overexpressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531530	Antibacterial activity against Bacteroides thetaiotaomicron isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID559484	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID517977	Antimicrobial activity against Acinetobacter baumannii HPA74510 harboring beta-lactamase IMP-4 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID542065	Antibacterial activity against Klebsiella pneumoniae A expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID524073	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P369	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID283144	Efficacy against Pseudomonas aeruginosa 93 assessed as reduction in bacterial counts in mouse urinary tract infection model at 0.5 mg/kg	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1124638	Antibacterial activity against penicillin-sensitive Enterobacter cloacae MB2647 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID289874	Antibacterial activity against Staphylococcus aureus SG511	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID535757	Antimicrobial activity against community-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID558693	Antimicrobial activity against Bacteroides fragilis MN35 after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID574504	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID546424	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-4 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID562947	Antimicrobial activity against Klebsiella pneumoniae PFGE clone D expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID523950	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520729	Activity of Acinetobacter baumannii CIP7010 beta-lactamase OXA-97 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID374367	Activity of Acinetobacter baumannii AC-54/97 metallo-beta-lactamase IMP-2 expressed in Escherichia coli DH5alpha	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID583085	Activity of Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID557489	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID74701	Antibacterial activity against Gram negative bacteria	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID523750	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E359	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535163	Antimicrobial activity against imipenem susceptible Acinetobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID558327	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID559086	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID490293	Antibacterial activity against Bacillus subtilis ATCC 11774 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID495804	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID577233	Antibacterial activity against intI1-negative tigecycline-intermediate Acinetobacter baumannii AB098 with PFGE subgroup F containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID521991	Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID558759	Antibacterial activity against hetero-vancomycin-intermediate Staphylococcus aureus Mu3 by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID573539	Antibacterial activity against Klebsiella pneumoniae Kp38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534170	Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID567318	Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID1373307	Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID585175	Activity of Beta-lactamase GES-1 E104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID205544	Minimum inhibitory concentration against Staphylococcus aureus 285 was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID529656	Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID574033	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID517956	Antimicrobial activity against Proteus penneri by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID533556	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA377	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID545617	Antimicrobial activity against Pseudomonas aeruginosa PS39 with PFGE phenotype 8 expressing beta-lactamase IMP-18 obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID10219	AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID404957	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 193 isolate carrying two bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID68020	Antibacterial activity against Enterobacter cloacae 1321E	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID520728	Activity of Acinetobacter baumannii CIP7010 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID516143	Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID520885	Ratio of Kcat to Km for Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID523487	Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID545556	Ratio of MIC for Escherichia coli ERR8a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID585199	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID425867	Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID531765	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID40800	Minimum inhibitory concentration was determined in heart infusion agar medium against Bacillus subtilis ATCC 6633	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID518726	Antimicrobial activity against Escherichia coli TOP10 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID555557	Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID1449630	Half life in iv dosed human	2017	European journal of medicinal chemistry, May-05, Volume: 131	Recent updates of carbapenem antibiotics.
AID556683	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 10 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID574762	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID283400	Antimicrobial activity against Nocardia sp. after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID396717	Antibacterial activity against methicillin-resistant Staphylococcus aureus M-126	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis of novel di- and tricationic carbapenems with potent anti-MRSA activity.
AID545340	Displacement of [14C]benzylpenicillin from PBP2 in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID540947	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c36 plasmid expressing cephalosporinase CMY-36 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID575281	Antimicrobial activity against Acinetobacter baumannii by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID1225789	Antibacterial activity against Klebsiella pneumoniae KP1083 expressing KPC3/SHV-1/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID533393	Antimicrobial activity against Clostridium innocuum by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID557456	Antimicrobial activity in Prevotella nigrescens by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID249356	Minimum inhibitory concentration against Moraxella catarrhalis (n=22); (Range=0.008-0.25)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID519472	Antimicrobial activity against Stenotrophomonas maltophilia K279a harboring -121 frameshift mutation in ampR gene by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID557710	Antimicrobial activity in Fusobacterium nucleatum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID1676469	Antibacterial against methicillin-resistance Staphylococcus aureus MB5393 by broth dilution method
AID209575	In vivo antibacterial activity against Streptococcus faecium MD 8b	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID69660	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Escherichia coli KC-14/RGN 823	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID535717	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B2	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID588082	Antibacterial activity against Acinetobacter baumannii ATCC 17978	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID495687	Activity of Klebsiella pneumoniae SHV-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID518185	Antimicrobial activity against Serratia marcescens 1T9 harboring beta-lactamase Class C by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID546170	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-10 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1373281	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1449172	Antibacterial activity against Mycobacterium abscessus CIP104536 smooth variant assessed as reduction in viable colony forming unit at 8 ug/ml after 4 days by time-kill assay	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.
AID556680	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 7 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID573394	Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID368734	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID567579	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method in presence of cilastatin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID524101	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A867	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID289896	Antibacterial activity against Escherichia coli 0114	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID535754	Antimicrobial activity against hospital-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID544960	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV by Etest based on multiple determinants	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID545400	Antimicrobial activity against Pseudomonas aeruginosa PS6A with PFGE phenotype 11A obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID164377	Antibacterial activity against Pseudomonas aeruginosa 1529E	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID591661	Antimicrobial activity against multidrug-resistant Enterococcus faecalis after 18 hrs by agar dilution method	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID559898	Antimicrobial activity against Klebsiella oxytoca KO281 harboring beta-lactamase OXY-1 and CMY-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID1318931	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 92014	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID520778	Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID534662	Antimicrobial activity against Non-ESBL Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID250291	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID573210	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID558583	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID575683	Antimicrobial activity against Acinetobacter baylyi ADP1 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.
AID498807	Antimicrobial activity against Klebsiella pneumoniae ZJ71T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524072	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P356	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559683	Antibacterial activity against Acinetobacter baumannii BM4674 isolated from the tibia fracture of a patient by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID517920	Antibacterial activity against Acinetobacter baumannii A897 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID591660	Antimicrobial activity against multidrug-resistant Staphylococcus aureus after 18 hrs by agar dilution method	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
AID548008	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Q mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID532905	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID524291	Antibacterial activity against Pseudomonas aeruginosa P319 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID205366	Minimum inhibitory concentration against aerobic organism Serratia marcescenes strain 2855	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID565529	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID285682	Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID573497	Antibacterial activity against Serratia marcescens isolate Sm2723 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID549038	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC1 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID405643	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID533569	Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID529578	Ratio of Kcat to Km for Chryseobacterium meningosepticum beta-Lactamase GOB-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID546168	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-08 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID562475	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID368750	Antimicrobial activity against Klebsiella pneumoniae Kp2 expressing TEM-15 TEM-17 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID544955	Antimicrobial activity against Klebsiella pneumoniae extended-spectrum beta-lactamase producing isolate by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID544676	Antimicrobial activity against Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID556672	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 27 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID532215	Antibacterial activity against nonreplicate Enterobacter cloacae clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID524306	Antibacterial activity against Pseudomonas aeruginosa P370 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID249274	Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range=0.06-1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID490298	Antibacterial activity against Salmonella typhi ATCC 10749 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID529840	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID545618	Antimicrobial activity against Pseudomonas aeruginosa PS40 with PFGE phenotype 5 expressing beta-lactamase KPC-2, OXA-2 obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID428269	Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID285630	Antimicrobial activity against Pseudomonas aeruginosa 9B5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574471	Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID533567	Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534661	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573401	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID322786	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID588081	Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid directed expression of beta-lactamase OXA-58 under an ISAba3 promoter	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID524494	Antibacterial activity against Acinetobacter baumannii A848 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529485	Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID531314	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID564690	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID535840	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID511687	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PA01 deficient in dacB gene by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID558756	Antibacterial activity against hetero-Methicillin-resistant and tetracycline-resistant and rifampicin-resistant Staphylococcus aureus deltaIP-rifR harboring RpoB H481Y mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID374360	Antimicrobial activity against Aeromonas caviae A324R by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID405091	Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID561091	Antibacterial activity against Bacteroides vulgatus by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID584703	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0011 harboring mutation in putative 2-OH-lauroyltransferase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID429062	Antimicrobial activity against Proteus mirabilis JIE273 expressing 16S rRNA methyltransferase RmtC	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	RmtC 16S rRNA methyltransferase in Australia.
AID511150	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 6 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID534905	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID283108	Antibacterial activity against Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID433160	Antibacterial activity against Clostridium clostridioforme isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID1124641	Antibacterial activity against penicillin-resistant Pseudomonas aeruginosa MB3350 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID1356825	Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-1904 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID322316	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID573724	Antibacterial activity against Serratia marcescens Sm265 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID425993	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID564957	Antimicrobial activity against Acinetobacter baumannii isolate Ab114 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID524825	Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID576540	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080571 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID523736	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E425	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285578	Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID575277	Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID535129	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322781	Antimicrobial activity against Bacteroides stercoris isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID529858	Ratio of MIC for Pseudomonas aeruginosa N043 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID546061	Antimicrobial activity against Moraxella catarrhalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID279272	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1373283	Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID557996	Antimicrobial activity in Clostridium butyricum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID584568	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573149	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID96429	In vitro synergistic activity against Klebsiella pneumoniae GC 6269 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID511583	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID534886	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID209284	Antibacterial activity against Streptococcus pyogenes 77A	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID1475190	Antibacterial activity against Pseudomonas aeruginosa clinical isolate after 18 to 24 hrs	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
AID545412	Antimicrobial activity against Pseudomonas aeruginosa PS20A with PFGE phenotype 11D obtained from skin of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID571684	Antimicrobial activity against ESBL producing Escherichia coli isolated from patient bloodstream assessed as resistant isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
AID583038	Activity of Beta-lactamase AmpC-B2	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID524102	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A911	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534300	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID530321	Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID573339	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID295789	Antibacterial activity against Streptococcus pneumoniae 0025 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID545394	Antimicrobial activity against OprD overproducing Pseudomonas aeruginosa PAO1 expressing mexA and oprD by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1350124	Antibacterial activity against Nocardia carnea clinical isolate by CLSI M07-A9 protocol based assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cybastacines A and B: Antibiotic Sesterterpenes from a Nostoc sp. Cyanobacterium.
AID373751	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ATCC 19606 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID289875	Antibacterial activity against Staphylococcus aureus 285	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID322789	Antimicrobial activity against Bacteroides caccae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID422651	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 26 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID555220	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 103 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID548262	Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID555225	Activity of Acinetobacter genomosp. 3 isolate 103 ADC-16	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID573392	Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID529863	Ratio of MIC for Pseudomonas aeruginosa N041 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID425117	Bactericidal activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID529845	Antibacterial activity against methicillin-resistant Staphylococcus aureus 12386-1 expressing PBP 2a by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID588132	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID523510	Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID1056834	Antibacterial activity against GIM-1 expressing Pseudomonas aeruginosa isolate 197 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID544533	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID573347	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565511	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID533764	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P11 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID576533	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080949 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1653506	Antimicrobial activity against Staphylococcus aureus assessed as zone of inhibition incubated for 20 hrs by agar well diffusion assay	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID499070	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ84 deficient in SHV-11, aac(6')-Ib-cr, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID547773	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237A mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID588080	Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid 1266	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID557514	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID534166	Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID425100	Antimicrobial activity against Peptoniphilus asaccharolyticus isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID534379	Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID373046	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZS5 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID511292	Ratio of Kcat/Km for Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID524448	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E419 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557750	Antimicrobial activity in Lactobacillus by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID533550	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA361	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1373323	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID529827	Antimicrobial activity against Acinetobacter baumannii by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID533763	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P122 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID433375	Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID577236	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB113 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID532412	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID545819	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID530824	Compound hydrolyzing activity of Klebsiella pneumoniae beta-lactamase OXA-48	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID573520	Antibacterial activity against Klebsiella pneumoniae isolate Kp266 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1528445	Antibacterial activity against Enterobacter aerogenes assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID285640	Antimicrobial activity against Pseudomonas aeruginosa 13D11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID510983	Antimicrobial activity against Acinetobacter baumannii 506	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID584693	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4748 harboring tpiA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524489	Antibacterial activity against Pseudomonas aeruginosa P370 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565542	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID546173	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-13 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID283397	Antimicrobial activity against Nocardia transvalensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID545407	Antimicrobial activity against Pseudomonas aeruginosa PS14 with PFGE phenotype 10C obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID574758	Antimicrobial activity against Peptoniphilus asaccharolyticus after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID438298	Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID1225790	Antibacterial activity against Klebsiella pneumoniae KP1084 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID433017	Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID545604	Antimicrobial activity against Pseudomonas aeruginosa PS22 with PFGE phenotype 3A obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID519818	Induction of morphological changes in Escherichia coli MC4100 assessed as induction of sphere formation at antimicrobial MIC after 4 hrs by microscopy	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID534919	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID556689	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 16 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID323629	Activity of Aeromonas hydrophila beta lactamase CphA at pH 8.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID523738	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E450	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574950	Antimicrobial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID162938	Minimum inhibitory concentration against aerobic organism Pseudomonas aeruginosa strain 3350	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID528603	Antimicrobial activity against Escherichia coli J53 harboring blaKPC-2 and blaTEM-1 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID557508	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID508725	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1E3 PpA2 harboring acquired beta-lactamase OXA-101 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID533405	Antimicrobial activity against Clostridium tertium by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID583031	Ratio of Kcat to Km for Beta-lactamase FOX-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID395746	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 184 by standard broth dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID559530	Antibacterial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID584321	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID360052	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl tripeptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID582884	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 6 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID609153	Antibacterial activity against Haemophilus influenzae ATCC 49766	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID295810	Antibacterial activity against Pseudomonas cepacia after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID425320	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID499059	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes PU41 deficient in CTX-M-14, DHA-1, qnrS1, ompC DEc, ompF by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID562740	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID564527	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID520877	Antibacterial activity against Achromobacter xylosoxidans MER by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID542044	Antibacterial activity against Escherichia coli TrC B expressing Klebsiella pneumoniae B blaCTX-M beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID360075	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra-aspartate-tetra-aspartate-tetra-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID534415	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID520715	Antibacterial activity against Acinetobacter baumannii CIP7010 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID559526	Antibacterial activity against Acinetobacter lwoffii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID563970	Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID525038	Activity of Klebsiella pneumoniae Beta-lactamase OXA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Updated functional classification of beta-lactamases.
AID495831	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID559260	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564536	Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID520982	Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID545411	Antimicrobial activity against Pseudomonas aeruginosa PS19A with PFGE phenotype 11C obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID558620	Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID519817	Antimicrobial activity against Pseudomonas aeruginosa 27853 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID1373303	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID564213	Antimicrobial activity against Acinetobacter baumannii ATCC 135040 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID207392	Minimum inhibitory concentration against aerobic organism Staphylococcus aureus strain 2314	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID524307	Antibacterial activity against Pseudomonas aeruginosa P341 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545338	Displacement of [14C]benzylpenicillin from PBP1A in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID518188	Antimicrobial activity against Acinetobacter baumannii HPA I-16 harboring beta-lactamase OXA-27 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535694	Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID522019	Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID576074	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID23338	Compound was evaluated for the rate of hydrolysis by renal dipeptidase relative to hog renal dipeptidase	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID495834	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID545345	Displacement of [14C]benzylpenicillin from PBP1A in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1318930	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86141	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID285691	Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID205667	In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA 76 (clinical isolates)	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
AID425081	Antimicrobial activity against beta lactamase-positive Prevotella disiens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533377	Antimicrobial activity against Bacteroides merdae by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID558331	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID582979	Antimicrobial activity against ampR::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID558601	Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID575102	Antimicrobial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID499066	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ88 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523769	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524477	Antibacterial activity against Pseudomonas aeruginosa P327 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID575268	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID12711	The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID510985	Antimicrobial activity against Acinetobacter baumannii 1327 after 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID523729	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E408	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531682	Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-4 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID532398	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1826245	Antibacterial activity against imipenem-resistant NDM-1-producing Klebsiella pneumoniae T2301 infected in Galleria mellonella larvae assessed as survival rate at 0.12 ug injected via proleg measured after 3 days by Kaplan-Meier method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID203164	Minimum inhibitory concentration was determined in heart infusion agar medium against Serratia marcescens IAM 1136	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID285521	Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID573720	Antibacterial activity against Citrobacter koseri Ck211 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID522011	Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID523714	Antibacterial activity against Acinetobacter baumannii A931 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533554	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA370	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID511162	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 18 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID524455	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531772	Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID548257	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID555227	Activity of Acinetobacter genomosp. 3 isolate 195 ADC-18	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID545834	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573121	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID511152	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 8 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID523719	Antibacterial activity against Acinetobacter baumannii A891 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID295793	Antibacterial activity against Citrobacter freundii 323 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID532903	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID545847	Antimicrobial activity against Proteus rettgeri by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID584706	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0420 harboring bioA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498830	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae WH103 deficient in IMP-4, TEM-1, CTX-M-3, qnrS1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID164378	Antibacterial activity against Pseudomonas aeruginosa 1771M	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID547781	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237I mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID195304	In vitro DHP-I stability of the compound, expressed as relative t1/2 of hydrolysis to meropenem by partially purified porcine renal DHP-I	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID517922	Antibacterial activity against Acinetobacter baumannii A890 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545553	Antibacterial activity against Escherichia coli ERR4a selected at 4 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID285580	Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373033	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-23 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID533532	Antimicrobial activity against Pseudomonas aeruginosa PA550 expressing VIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID556654	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 9 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID564229	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase OXA-143	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID1225785	Antibacterial activity against Klebsiella pneumoniae KP1004 expressing KPC2/TEM1/SHV11 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID283143	Efficacy against Pseudomonas aeruginosa 93 pulmonary infection in mouse assessed as reduction in bacterial counts at 10 mg/kg, sc	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID558050	Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID545351	Displacement of [14C]benzylpenicillin from PBP 6 in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID584526	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3667 harboring mutation in putative cysteine sulfinate desulfinase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523502	Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID322779	Antimicrobial activity against Bacteroides caccae isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID575013	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase IMP-1 by UV spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID201430	Compound was tested in vitro for antibacterial activity against Staphylococcus aureus, pen-res A-9606	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID432996	Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID546174	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-14 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID322313	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID545827	Antimicrobial activity against Enterococcus faecium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID575280	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID524279	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545554	Ratio of MIC for Escherichia coli ERR4a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID518226	Antimicrobial activity against Pseudomonas aeruginosa BA by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID557968	Antimicrobial activity in Clostridium sp. by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID524131	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557270	Antimicrobial activity against Streptococcus pneumoniae 1564 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID7549	Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID1373309	Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID495688	Activity of Escherichia coli CTX-M-15	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID511284	Antimicrobial activity against Acinetobacter sp. isolate obtained from patient's blood assessed as resistance isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID520389	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 over Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID529516	Antibacterial activity against Pseudomonas aeruginosa 1750J expressing beta-lactamase IMP-15 by Etest	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
AID573188	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID285634	Antimicrobial activity against Pseudomonas aeruginosa 10B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID571890	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID425985	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 20 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524464	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID422680	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID609156	Antibacterial activity against Escherichia coli ATCC 25922	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID532893	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID557984	Antimicrobial activity in Clostridium bifermentans by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID285626	Antimicrobial activity against Pseudomonas aeruginosa 9A3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1649620	Substrate activity at NDM-1 (unknown origin) assessed as Kcat/Km ratio for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID545404	Antimicrobial activity against Pseudomonas aeruginosa PS11A with PFGE phenotype 7A obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID559541	Antibacterial activity against ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID564534	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID295787	Antibacterial activity against Streptococcus pyogenes 9889 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID546415	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-32 with PDC-10 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID1124634	Antibacterial activity against penicillin-sensitive Staphylococcus aureus MB2985 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID609154	Antibacterial activity against Citrobacter freundii ATCC 8090	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID95703	Antibacterial activity against Klebsiella aerogenes 1522E	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID519800	Inhibition of Bocillin FL binding to PBP4 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID295831	Antibacterial activity against Proteus rettgeri 936 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID324358	Antibacterial activity against Escherichia coli DH10B expressing SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID574052	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID295790	Antibacterial activity against Haemophilus influenzae 1210 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID531601	Antimicrobial activity against Escherichia coli JM109 harboring pSC1 plasmid expressing beta-lactamase SHV-56 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID1824295	Antimicrobial activity against Citrobacter freundii T2354 expressing VIM-4 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID510513	Antibacterial activity against Escherichia coli ATCC 25922 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID322325	Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID511585	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID588127	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID544957	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID564686	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID285600	Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID528791	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID373768	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID521998	Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573332	Antibacterial activity against Klebsiella pneumoniae isolate Kp2730 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID528783	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID250296	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID584729	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4007 harboring proA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520980	Antibacterial activity against Klebsiella pneumoniae YC by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID559818	Antimicrobial activity against Escherichia coli J53 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID498814	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae FZ47 deficient in IMP-8, TEM-1, SHV-11, CTX-M-14, qnrB2, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID518467	Antimicrobial activity against Stenotrophomonas maltophilia 1AC736 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID164879	In Vitro antibacterial activity against (Pa G242) hyperpermeable Pseudomonas aeruginosa strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID283141	Antibacterial activity against Pseudomonas aeruginosa 93	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID155945	Antibacterial activity expressed as binding to PBP 2 of Pseudomonas aeruginosa	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID520981	Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID534611	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565534	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID584311	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0566 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID511389	Antibacterial activity against Enterobacter cloacae by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID1124637	Antibacterial activity against penicillin-resistant Escherichia coli MB2964 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID534413	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523753	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E361	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID69012	In vitro synergistic activity against Escherichia coli C600N + (ampR ampC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID433003	Antibacterial activity against Corynebacterium minutissimum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524324	Antibacterial activity against Acinetobacter baumannii A928 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533638	Antimicrobial activity against Propionibacterium sp. assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID495671	Antimicrobial activity against wild type Escherichia coli ATCC 25922 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574742	Antimicrobial activity against Peptostreptococcus micros after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID510981	Antimicrobial activity against Acinetobacter baumannii 1327	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID322321	Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID534926	Antimicrobial activity against Ceftazidime susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534900	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID583039	Activity of Beta-lactamase CMY-2	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID323037	Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID285665	Antimicrobial activity against Pseudomonas aeruginosa 22E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID295786	Antibacterial activity against Enterococcus faecalis 2347 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID404959	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 186 isolate carrying three bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID285607	Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID524438	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495510	Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID531332	Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID285610	Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID544683	Antimicrobial activity against Enterobacter aerogenes clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID530326	Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID495673	Antimicrobial activity against Klebsiella pneumoniae OC 5367 expressing beta-lactamase KPC-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524296	Antibacterial activity against Pseudomonas aeruginosa P334 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571918	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1373299	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID283127	Antibacterial activity against Escherichia coli C600 expressing ESBL CTX-M18	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID206651	Compound was evaluated for the anti-MRSA activity as MIC90.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID535061	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pYMAb3 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID535165	Antimicrobial activity against Acinetobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519256	Tmax in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID289899	Antibacterial activity against Escherichia coil 1507	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID495689	Activity of Klebsiella oxytoca Beta-lactamase K1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID558423	Antimicrobial activity against Burkholderia pseudomallei by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activity of doripenem against Burkholderia pseudomallei.
AID499062	Antimicrobial activity against carbapenem-resistant Escherichia coli HX74 deficient in TEM-1, CTX-M-14, CTX-M-3, aac(6')-Ibcr, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524479	Antibacterial activity against Pseudomonas aeruginosa P334 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565337	Antibacterial activity against Enterobacter hormaechei isolate UCN63 after 3 weeks of treatment	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy.
AID495912	Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID562331	Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID528602	Antimicrobial activity against blaKPC-2, blaKLUC-2 and blaTEM-1 producing Enterobacter cloacae 7506 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID549334	Antimicrobial activity against Escherichia coli isolate 100 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID574041	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID558695	Antimicrobial activity against Bacteroides fragilis MN41 after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID574973	Antimicrobial activity against Actinomyces israelii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID295819	Antibacterial activity against Salmonella typhi after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID295829	Antibacterial activity against Proteus mirabilis 174/3 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID425978	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID521485	Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID545402	Antimicrobial activity against Pseudomonas aeruginosa PS9 with PFGE phenotype 3B obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID565519	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID576525	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate HIP10924 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID112680	In vivo antibacterial activity against MSSA MB 2985 strain at the dose ~4 *10e7 cfu in brain heart broth along with antibiotic by sc administration at 0 hour in mice	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID285258	Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1179 isolate expressing pBK-TEM-152 and CMT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID558802	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID519290	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-102 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID524505	Antibacterial activity against Acinetobacter baumannii A884 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546419	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-4 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID535722	Activity of Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID542398	T>MIC in febrile neutropenic patient with hematological malignancies at 500 mg administered as infusion every 4 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID295803	Antibacterial activity against Streptococcus agalactiae B after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID429077	Antibacterial activity against Escherichia coli J53 by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID53770	Relative half life of hydrolysis to meropenem by partially purified porcine renal DHP-I was determined	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID584936	Antimicrobial activity against Pseudomonas aeruginosa harboring pBBR1MCS-3 expressing mucD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID556686	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 13 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID522384	Antimicrobial activity against Aeromonas enteropelogenes ATCC 49803 producing endogenous class C beta-lactamase TRU-1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID404965	Activity of OXA58 from Acinetobacter baumannii 193 isolate carrying two bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID557420	Antimicrobial activity in Bacteroides vulgatus by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID372605	Antibacterial activity against Escherichia coli BER1 producing beta-lactamase pI 5.2 and pI 5.4 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID425104	Antimicrobial activity against Clostridium ramosum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1546207	AUC in rat	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID373760	Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID425099	Antimicrobial activity against Anaerococcus tetradius isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495634	Antimicrobial activity against Escherichia coli DH10B by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID529497	Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID524476	Antibacterial activity against Pseudomonas aeruginosa P322 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558319	Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID573505	Antibacterial activity against Enterobacter cloacae isolate El3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID250286	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID545843	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565507	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID587983	Antibacterial activity against Escherichia coli AS226 carrying pBSDC69A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID533634	Antimicrobial activity against Propionibacterium acnes assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID531756	Antibacterial activity against Pseudomonas aeruginosa 2126 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID511134	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 8	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID564944	Antimicrobial activity against Acinetobacter baumannii isolate Ab133 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID428267	Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID1826210	Antibacterial activity against NDM-7 producing Escherichia coli T2239 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID548032	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237R mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID540943	Antimicrobial activity against Klebsiella pneumoniae HP205 expressing CMY-36 cephalosporinase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID285328	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID511680	Antimicrobial activity against Pseudomonas aeruginosa clinical isolate assessed as resistant isolates selected in vitro after antipseudomonal treatment of intensive care unit patient by by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID545422	Antimicrobial activity against Citrobacter freundii obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID574486	Antimicrobial activity against Bacteroides caccae after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573592	Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID325479	Antibacterial activity against streptomycin-resistant Pseudomonas aeruginosa DK100 after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID433011	Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID535144	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1318935	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 83182	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584932	Antimicrobial activity against Pseudomonas aeruginosa harboring algU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID541495	Antimicrobial activity against Burkholderia cepacia clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID340727	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-2 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID432994	Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID576960	Antimicrobial activity against Shewanella algae Sa392 harboring intI1, intI2, sul1 and sul2 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID422681	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544586	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID563974	Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID433187	Antibacterial activity against Corynebacterium accolens isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524430	Antibacterial activity against Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID541013	Antimicrobial activity against Burkholderia cenocepacia 5007902 expressing beta-lactamase PenB4	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID163424	Minimum inhibitory concentration was determined in heart infusion agar medium against Proteus vulgaris GN 7919	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID523517	Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID573379	Antibacterial activity against beta lactamase-negative Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID519805	Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID495905	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID428290	Antimicrobial activity against Acinetobacter baumannii BM4454 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID535166	Antimicrobial activity against Acinetobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573601	Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID250293	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID553679	Ratio of intracellular to extracellular drug level in human THP1 cells at 250 mg/L after 24 hrs	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID495631	Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID511285	Antimicrobial activity against Pseudomonas aeruginosa clinical isolate assessed as resistance isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals.
AID285649	Antimicrobial activity against Pseudomonas aeruginosa 19B6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID323039	Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID559762	Antimycobacterial activity against Mycobacterium smegmatis MAR4 harboring disrupted PknGMsm gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID574764	Antimicrobial activity against Finegoldia magna after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID563602	Antimicrobial activity against lacZ-negative, Nalidixic acid-, rifampicin-resistant Escherichia coli EC600 by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID521968	Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID533417	Antimicrobial activity against Micromonas micros by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID575279	Antimicrobial activity against Serratia marcescens by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID285674	Antimicrobial activity against Pseudomonas aeruginosa 23C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531521	Antibacterial activity against Bacteroides stercoris isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID322777	Antimicrobial activity against Bacteroides uniformis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID604356	Half life in mouse	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii.
AID584938	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23430 harboring mutation in putative heparinase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID423074	Antibacterial activity against 75_F11 allele containing Pseudomonas aeruginosa PAO1 H1136 mutant strain with PA5455::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID490296	Antibacterial activity against Shigella flexneri ATCC 10782 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID535164	Antimicrobial activity against imipenem non-susceptible Acinetobacter by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285614	Antimicrobial activity against Pseudomonas aeruginosa 3D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574026	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID583018	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli pGLK-1 plasmid carrying FOX-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID556666	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 21 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID295817	Antibacterial activity against Salmonella paratyphi A after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495839	Ratio of Kcat to Km for Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID576957	Antimicrobial activity against Shewanella algae Sa74 harboring intI1, intI2, sul1 and sul2 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID68536	Minimum inhibitory concentration was determined in heart infusion agar medium against beta-lactam producing organism Enterobacter cloacae NTCC9394	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID250294	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID522001	Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573370	Antibacterial activity against ceftazidime-susceptible Serratia marcescens by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524325	Antibacterial activity against Acinetobacter baumannii A908 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373324	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID432997	Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID534412	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID433180	Antibacterial activity against Pseudomonas aeruginosa isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID546056	Antimicrobial activity against Salmonella spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID517951	Antimicrobial activity against Providencia rettgeri by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID396033	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID585198	Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID556651	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 6 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID609152	Antibacterial activity against Streptococcus pneumoniae ATCC 6301	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID68870	In vitro synergistic activity against Escherichia coli 300 (no beta-lactamase, imp mutant)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID509869	Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID368758	Antimicrobial activity against Klebsiella oxytoca expressing TEM-11 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID584578	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID429078	Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID509865	Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID1824328	Antimicrobial activity against Escherichia coli T2359 expressing VIM-1 assessed as assessed as inhibition of bacterial growth at 0.5XMIC measured after 24 hrs by time-kill assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID558619	Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID564685	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID584723	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3433 harboring mutation in putative transcriptional regulator, LysR family by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498805	Antimicrobial activity against Klebsiella pneumoniae ZJ70T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565543	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID285329	Antimicrobial activity against Streptococcus pyogenes ATCC 19615	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci.
AID555213	Antibacterial activity against Acinetobacter genomosp. 3 isolate 195 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID529855	Antibacterial activity against Pseudomonas aeruginosa COR6 expressing MexC-MexD-OprJ gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID533396	Antimicrobial activity against Clostridium innocuum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID373039	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ32 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1356831	Antimicrobial activity against Klebsiella pneumoniae NCTC 13443 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID534866	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID574987	Antimicrobial activity against Bifidobacterium adolescentis after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID490021	Antibacterial activity against Pseudomonas aeruginosa at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID56117	Susceptibility to mammalian dehydropeptidas, DHP-1(Porcine)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID531529	Antibacterial activity against Bacteroides uniformis isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID283109	Antibacterial activity against ceftazidime-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID574750	Antimicrobial activity against Peptostreptococcus micros assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID433001	Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524316	Antibacterial activity against Acinetobacter baumannii A867 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546407	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-24 with PDC-5 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID529847	Binding affinity to PBP2a in methicillin-resistant Staphylococcus aureus 12386-1 by [14C]benzylpenicillin labelled competitive assay	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID283115	Antibacterial activity against Escherichia coli C600 expressing OXA1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID558690	Antimicrobial activity against Bacteroides fragilis MN5 after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID520976	Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID555212	Antibacterial activity against Acinetobacter genomosp. 3 isolate 128 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID534644	Antimicrobial activity against Klebsiella pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID533000	Antibacterial activity against IMP-18 producing Pseudomonas aeruginosa isolate P85 exhibiting PFGE K pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID285662	Antimicrobial activity against Pseudomonas aeruginosa 22D2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID516140	Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID535723	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID546062	Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID563596	Antimicrobial activity against Pseudomonas aeruginosa PAO1 at 4 X MIC after 8 hrs by Live/dead cell viability assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID524120	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A903	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545829	Antimicrobial activity against Corynebacterium jeikeium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID285612	Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID582879	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 2.8 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID1056842	Antibacterial activity against TEM-1/SHV-12/CTX-15 expressing Enterobacter intermedius isolate 243 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID531746	Antibacterial activity against Pseudomonas aeruginosa FE60 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID433359	Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID556685	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 12 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID573198	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAA biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID545408	Antimicrobial activity against Pseudomonas aeruginosa PS15A with PFGE phenotype 10A obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID571916	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID396027	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID529580	Ratio of Kcat to Km for Caulobacter crescentus beta-Lactamase CAU-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID557523	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID558323	Antibacterial activity against Campylobacter jejuni isolate P270 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1824294	Antimicrobial activity against Pseudomonas aeruginosa T1098 expressing IMP-7 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID283140	Reduction in susceptibility against Pseudomonas aeruginosa PAO1 after single passage	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID565722	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID510998	Ratio of Cmax to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID517981	Antimicrobial activity against Providencia rettgeri J96 harboring beta-lactamase IMP-1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID577222	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring phoU::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID523756	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557495	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID555555	Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID1528451	Antibacterial activity against Proteus mirabilis assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID295800	Antibacterial activity against Staphylococcus aureus 503 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID69477	Minimum inhibitory concentration against Escherichia coli 055 was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID499069	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ91 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511135	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 9	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID574985	Antimicrobial activity against Actinomyces naeslundii assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID374361	Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID295811	Antibacterial activity against Escherichia coli 086 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID563590	Inhibition of Pseudomonas aeruginosa PAO1 PBP1c by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID533537	Antimicrobial activity against Acinetobacter baumannii AB551 expressing SIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID544924	Antimicrobial activity against Acinetobacter baumannii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573551	Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574032	Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID562324	Activity of Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID323690	Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
AID285683	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with rpoN mutation after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems.
AID558329	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P305 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523933	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557516	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID558613	Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID559819	Antimicrobial activity against Escherichia coli J53 harboring pCHE-B plasmid expressing blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID401688	Antibacterial activity against Escherichia coli DC2	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID557726	Antimicrobial activity in Finegoldia magna by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID518816	Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID546426	Activity at Pseudomonas aeruginosa PDC-1 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584553	Antimicrobial activity against Acinetobacter lwoffii by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID584840	Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID405082	Antimicrobial activity against Escherichia coli 33587-TC9 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Biochemical characterization of PER-2 and genetic environment of blaPER-2.
AID558535	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID588125	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 3 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID1322245	Induction of inner membrane permeabilization of Pseudomonas aeruginosa ATCC 27853 after 15 mins by propidium iodide staining-based fluorescence assay	2016	Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20	New Broad-Spectrum Antibacterial Amphiphilic Aminoglycosides Active against Resistant Bacteria: From Neamine Derivatives to Smaller Neosamine Analogues.
AID533542	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA342	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID422645	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID425115	Antimicrobial activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523716	Antibacterial activity against Acinetobacter baumannii A929 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573498	Antibacterial activity against Klebsiella pneumoniae isolate Kp7564 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID517917	Antibacterial activity against Acinetobacter baumannii A908 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433161	Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523511	Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID425322	Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID548475	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID574508	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID565720	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID548260	Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID524826	Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID433158	Antibacterial activity against Clostridium aminovalericum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID556648	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 3 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID425092	Antimicrobial activity against Fusobacterium necrophorum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1592957	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID285597	Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1056843	Antibacterial activity against CTX-15 expressing Enterobacter cloacae isolate 51 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID532397	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID496594	Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-2	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID532216	Antibacterial activity against nonreplicate Pseudomonas putida clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID529860	Ratio of MIC for Pseudomonas aeruginosa OCR1 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID574528	Antimicrobial activity against Prevotella intermedia assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID521837	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID557452	Antimicrobial activity in Prevotella intermedia by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID557481	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID534612	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573364	Antibacterial activity against ceftazidime-susceptible Morganella morganii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID340735	Antimicrobial activity against Escherichia coli HB101 harboring pBC-IND-5 plasmid containing metallo-beta-lactamase IND5 assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID510979	Antibacterial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as survival rate at total dose of 120 mg/kg/day, im administered as four divided doses measured after 72 hrs post last dose relative to control	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID534652	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID558040	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID422666	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 35 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID534929	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID572134	Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID574952	Antimicrobial activity against Streptococcus pneumoniae serotype 11A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID433174	Antibacterial activity against Enterobacter cloacae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID285616	Antimicrobial activity against Pseudomonas aeruginosa 3E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534411	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID66741	Inhibitory concentration against purified beta-Lactam resistant PBP5 from Enterococcus durans	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID425118	Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID373759	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID425079	Antimicrobial activity against beta lactamase-positive Bacteroides distasonis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524304	Antibacterial activity against Pseudomonas aeruginosa P349 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529489	Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID558617	Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID285611	Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID433162	Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520390	Activity at Escherichia coli DH5alpha metallo-beta-lactamase VIM-11 assessed as compound hydrolysis per mg of total periplasmic protein by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID528608	Ratio of Kcat to Km for Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID582880	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 2.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID563589	Inhibition of Pseudomonas aeruginosa PAO1 PBP1b by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID289917	Antibacterial activity against Corynebacterium diphtheriae	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID322774	Antimicrobial activity against Bacteroides distasonis isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID560122	Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG4 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID584573	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID522007	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID585395	Activity at Bradyrhizobium japonicum metallo-beta-lactamase BJP-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID576534	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate HIP14358 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID155943	Antibacterial activity expressed as binding to PBP 1a of Pseudomonas aeruginosa	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID341107	Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID558538	Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID394714	Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID553670	Chemical stability of the compound assessed as compound remaining after 24 hrs PBS buffer by HPLC analysis at pH 5.5	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID573800	Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID524503	Antibacterial activity against Acinetobacter baumannii A849 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529499	Antimicrobial activity against Escherichia coli GeneHogs by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID373049	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate JN45 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID325481	Antibacterial activity against Pseudomonas aeruginosa DK101 containing pAU48 expressing oprD after 14 to 16 hrs by broth dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Polyamine effects on antibiotic susceptibility in bacteria.
AID521834	Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID250289	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID577224	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring mmsA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID295796	Antibacterial activity against Acinetobacter baumannii 2289 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID285589	Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID322778	Antimicrobial activity against Bacteroides vulgatus isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID584713	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1195 harboring mutation in putative dimethylarginine dimethylaminohydrolase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID424324	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID521425	Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID531520	Antibacterial activity against Bacteroides fragilis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID558335	Antibacterial activity against Campylobacter jejuni isolate P1093 harboring blaOXA-61::cat gene by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID510511	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-19 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID558592	Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID207148	In vitro antibacterial activity against MRSA.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID545434	Antimicrobial activity against extended-spectrum beta-lactamase-positive Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID532895	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID1356834	Antimicrobial activity against Escherichia coli ATCC BAA-2452 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID1449174	Antibacterial activity against Mycobacterium abscessus CIP104536 smooth variant infected in PMA activated THP-1 macrophages assessed as reduction in viable colony forming unit at 96 ug/ml measured upto 4 days post treatment by fluorescence microscopic met	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.
AID433152	Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID519799	Inhibition of Bocillin FL binding to PBP3 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID522026	Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573581	Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID530345	Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID544490	Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID511114	T>MIC in Acinetobacter baumannii infected C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID584930	Antimicrobial activity against wild type Pseudomonas aeruginosa by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID559269	Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID573516	Antibacterial activity against Serratia marcescens isolate Sm201 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID558631	Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID573380	Antibacterial activity against beta lactamase-negative Haemophilus influenzae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID583099	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 4.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID155948	Antibacterial activity expressed as binding to PBP 4 of Pseudomonas aeruginosa	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID279257	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID495662	Ratio of Kcat to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID535169	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573504	Antibacterial activity against Morganella morganii isolate Mm1229 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID559766	Antimycobacterial activity against PknGMsm-deficient Mycobacterium smegmatis harboring PknG Mtb gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID549040	Antimicrobial activity against carbapenem susceptible Klebsiella pneumoniae isolate KpSCMC2c harboring bla SHV-12 gene isolated from patient with pulmonary infection by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID545822	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID289904	Antibacterial activity against Salmonella give	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID531522	Antibacterial activity against Bacteroides merdae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID555556	Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID576529	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008136 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID360072	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra -aspartate-tetra-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID529657	Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID519630	Antimicrobial activity against Escherichia coli JM83 harboring beta-lactamase OXA-63 after 3 days by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID545614	Antimicrobial activity against Pseudomonas aeruginosa PS35 with PFGE phenotype 11A obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID523507	Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID508741	Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID511155	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 11 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID524495	Antibacterial activity against Acinetobacter baumannii A850 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID463428	Antimicrobial activity against Salmonella typhi at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID360067	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tri-aspartate-penta-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID542400	T>MIC in febrile neutropenic patient with hematological malignancies at 6 mg/day	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID522021	Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495706	Kcat/Km ratio of Escherichia coli CMY-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534382	Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID523514	Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID565525	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID498369	Antimicrobial activity against wild type streptomycin-susceptible Streptococcus gordonii harboring P438R mutation in ptsI assessed as bacterial count at 2 ug/ml after 24 hrs by macrodilution technique	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID545401	Antimicrobial activity against Pseudomonas aeruginosa PS7A with PFGE phenotype 11D obtained from urine of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID279816	Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID573399	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID584558	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1826218	Antibacterial activity against OXA-23 producing Acinetobacter baumannii T2434 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID557486	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID583242	Antibacterial activity against Pseudomonas aeruginosa by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID499048	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ83 deficient in SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID495681	Antimicrobial activity against Pseudomonas aeruginosa OC 7052 expressing beta-lactamase VIM-2 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534651	Antimicrobial activity against ESBL producing Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295791	Antibacterial activity against Escherichia coli 04 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1356829	Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-2472 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID560835	Antimicrobial activity against Acinetobacter baumannii isolate Ab23 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID584726	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3818 harboring suhB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524440	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E460 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565712	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID563592	Inhibition of Pseudomonas aeruginosa PAO1 PBP3 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID206648	Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID322787	Antimicrobial activity against Bacteroides uniformis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID556650	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 5 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID495632	Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
AID535142	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID582882	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 1.2 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID511147	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 3 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID562337	Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID499049	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU104 deficient in TEM-1, SHV-11, CTX-M-15, qnrS1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID574460	Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID285652	Antimicrobial activity against Pseudomonas aeruginosa 19C7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID545564	Ratio of MIC for Escherichia coli EIR4b to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1824271	Antimicrobial activity against Escherichia coli T2544 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID209886	Inhibitory concentration against purified cephalosporin-resistant PBP2x.505 from Streptococcus pneumoniae	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID422658	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 49 passages with clindamycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID495805	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524502	Antibacterial activity against Acinetobacter baumannii A892 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533381	Antimicrobial activity against Bacteroides nordii by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID542060	Antibacterial activity against Klebsiella pneumoniae expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID508726	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1B2 RCA2 harboring acquired beta-lactamase PER-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID535370	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID557690	Antimicrobial activity in Prevotella bergensis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID524138	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523937	Antibacterial activity against beta-lactamase-negative Escherichia coli E424 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523506	Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID545570	Ratio of MIC for Pseudomonas aeruginosa PRR4a to MIC for Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID360051	Inhibition of Enterococcus faecium LD-transpeptidase assessed by formation of Ac2-L-Lys-D-[14C]Ala from Ac2-L-Lys-D-Ala and D-[14C]Ala	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID524483	Antibacterial activity against Pseudomonas aeruginosa P352 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573146	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID511160	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 16 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID542062	Antibacterial activity against Klebsiella pneumoniae D expressing CTX-M group 1 beta-lactamase by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID425109	Antimicrobial activity against Clostridium cadaveris isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID561092	Antibacterial activity against Bacteroides thetaiotaomicron by CLSI M11-A7 agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
AID498362	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrR containing isogenic acrR knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID555450	Antibacterial activity against Escherichia coli DH5alpha by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID574473	Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID546429	Activity at Pseudomonas aeruginosa PDC-5 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584555	Antimicrobial activity against Acinetobacter lwoffii isolate B expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID529852	Antibacterial activity against beta-lactamase-overproducing and OprD-deficient Pseudomonas aeruginosa N044 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID564533	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID528792	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID559278	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Providencia stuartii Ps5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID524439	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1318932	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 108590	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID529841	Antibacterial activity against Pseudomonas aeruginosa clinical isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID584727	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3978 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID575278	Antimicrobial activity against ESBL-production Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID508736	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID295813	Antibacterial activity against Escherichia coli 0126 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID118154	Plasma MIC against staphylococcus aureus infection in mice in presence of human albumin fraction V (21.5 mg/mL)	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID524465	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495722	Activity of Pseudomonas aeruginosa AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID565281	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID285636	Antimicrobial activity against Pseudomonas aeruginosa 12A7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID289877	Antibacterial activity against Escherichia coli TEM	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID584934	Antimicrobial activity against Pseudomonas aeruginosa harboring pBBR-algU complemented gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID425973	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID495798	Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID523718	Antibacterial activity against Acinetobacter baumannii A885 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285651	Antimicrobial activity against Pseudomonas aeruginosa 19C5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID322780	Antimicrobial activity against Bacteroides eggerthii isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID69763	Antibacterial activity against Escherichia coli 078	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID573552	Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID368737	Antimicrobial activity against Escherichia coli Ec1 containing pEc1-A plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID584687	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3721 harboring nalC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524305	Antibacterial activity against Pseudomonas aeruginosa P363 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534489	Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-NG plasmid and ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID285527	Antibacterial activity against Peptostreptococcus sp. by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID575267	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID584836	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID279263	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID549330	Antimicrobial activity against Escherichia coli isolate 16 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID567320	Antimicrobial activity against Escherichia coli ML4909 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID340734	Antimicrobial activity against Escherichia coli HB101 harboring pBC-SK plasmid assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID524454	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535846	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID517959	Antimicrobial activity against Acinetobacter sp. by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID285625	Antimicrobial activity against Pseudomonas aeruginosa 9A1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID520876	Antibacterial activity against Achromobacter xylosoxidans CIP69598 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID522018	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID525548	Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1051 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID544495	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID766241	Activity at recombinant VIM-2 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID519804	Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID565711	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID283114	Antibacterial activity against Escherichia coli C600 expressing SHV1	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID557440	Antimicrobial activity in Prevotella buccae by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID562339	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-5 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID573336	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID588084	Antibacterial activity against Acinetobacter baumannii Ab880 overexpressing beta-lactamase OXA-58 under the control of ISAba825 insertion sequence	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID534624	Antimicrobial activity against Escherichia coli assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID460803	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BAA-1605 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID530813	Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID573196	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring nfxB T248C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID573372	Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID368756	Antimicrobial activity against Enterobacter cloacae Ecl1 expressing TEM-24b AmpC TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1373312	Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID564219	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID585398	Ratio of Kcat to Km for Stenotrophomonas maltophilia 1SML metallo-beta-lactamase L1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID519803	Antimicrobial activity against Escherichia coli MC4100 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID521997	Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID587979	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104D mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID373762	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID69011	In vitro synergistic activity against Escherichia coli C600N + (TEM-10)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID531750	Antibacterial activity against Pseudomonas aeruginosa FK06 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID544962	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase SHV and CTX by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID424327	Antimicrobial activity against Dialister propionicifaciens by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID583098	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID511301	Antibacterial activity against Escherichia coli DH5alpha in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID533545	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA350	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1481712	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL MB 5393 infected in balb/c mouse assessed as reduction in bacterial burden in kidney at 5 mg/kg, sc administered 2 to 8 hrs post challenge measured 24 hrs post challenge	2017	Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9	Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.
AID586234	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID544912	Antimicrobial activity against Proteus vulgaris clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID533562	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA736 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524127	Antibacterial activity against beta-lactamase-negative Escherichia coli E408 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID510507	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-7 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID584312	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0570 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID573835	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID576954	Antimicrobial activity against Shewanella putrefaciens Sp31 harboring intI1 and beta-lactamase OXA-48 like genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID531675	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID207158	Antibacterial activity against Staphylococcus aureus 503	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID511131	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 5	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID549333	Antimicrobial activity against Escherichia coli isolate 36 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID511142	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 16	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID576302	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID279270	Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID433201	Antibacterial activity against Bacteroides stercoris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID577241	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB173 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID518462	Antimicrobial activity against Enterobacter cloacae S9369 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID394493	Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID563966	Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID558422	Antimicrobial activity against Burkholderia pseudomallei by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activity of doripenem against Burkholderia pseudomallei.
AID564222	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid PH1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID1373308	Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID523508	Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID424323	Antimicrobial activity against Dialister pneumosintes assessed as susceptibility breakpoint by CA-SFM method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID495661	Activity at Pseudomonas aeruginosa 531 beta-lactamase BEL-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID548474	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID520973	Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID563977	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase VIM2	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID574526	Antimicrobial activity against Prevotella intermedia assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID495711	Kcat/Km ratio of Serratia marcescens SME-3	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584323	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 20 ug/ml of phenyl-arginine-beta-naphthylamide	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1373320	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID395733	Antimicrobial activity against imipenem-susceptible invasive nontypeable Haemophilus influenzae isolate 244 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID283321	Antimicrobial activity against Escherichia coli XL10/vector	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID289916	Antibacterial activity against Pasteurella multocida	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID524300	Antibacterial activity against Pseudomonas aeruginosa P352 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285595	Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID562809	Antimicrobial activity against Escherichia coli J53	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID1592960	Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID577225	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring yaaA::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID541010	Antimicrobial activity against Burkholderia cenocepacia 212 expressing beta-lactamase PenB3	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID556656	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 11 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID535702	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID574469	Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID584581	Antimicrobial activity against Escherichia coli NEB 5-alpha harboring beta-lactamase OXA-164 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID295805	Antibacterial activity against Bacillus megaterium after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID525546	Antimicrobial activity against Haemophilus influenzae Rd KW20 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID1318927	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86053	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID584739	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5366 harboring pstB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523953	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E360 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574500	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID573331	Antibacterial activity against Klebsiella pneumoniae isolate Kp1945 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID558611	Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID373036	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ52 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID531676	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-3 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID517926	Antibacterial activity against Acinetobacter baumannii A901 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534664	Antimicrobial activity against Proteus mirabilis assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID495676	Antimicrobial activity against wild type Serratia marcescens OC 7554 expressing beta-lactamase SME-3 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID524082	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P337	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574752	Antimicrobial activity against Anaerococcus prevotii after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID517950	Antimicrobial activity against Proteus vulgaris by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID531528	Antibacterial activity against Bacteroides caccae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID584710	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0766 harboring mucD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID522020	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID495730	Activity of Acinetobacter baumannii OXA-23 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID543423	Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID523773	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P332	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557432	Antimicrobial activity in Bacteroides stercoris by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID541790	Antimicrobial activity against Bacteroides thetaiotaomicron clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID295826	Antibacterial activity against Serratia marcescens 6093 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524504	Antibacterial activity against Acinetobacter baumannii A910 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID495674	Antimicrobial activity against wild type Klebsiella oxytoca OC 4076 expressing Beta-lactamase K1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534488	Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-G plasmid and ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID523748	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E357	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584557	Antimicrobial activity against Acinetobacter lwoffii isolate D expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID558591	Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID518193	Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO253 overexpressing MexEF-OprN gene by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID545655	Antimicrobial activity against Stenotrophomonas maltophilia assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID573549	Antibacterial activity against Klebsiella pneumoniae Kp149 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID511153	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 9 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID545830	Antimicrobial activity against Listeria monocytogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID428266	Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID495693	Activity of Enterobacter cloacae AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID373786	Ratio of MIC for Acinetobacter baumannii ISAB ab8(r) to MIC for Acinetobacter baumannii ISAB ab8(r) in presence of 24 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID283111	Antibacterial activity against ciprofloxacin-resistant Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID532899	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID564532	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID575684	Antimicrobial activity against Acinetobacter baylyi ADP1 harboring pMMCU1 plasmid expressing bla-OXA-24 gene by microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.
AID206267	In vitro antibacterial activity against Staphylococcus aureus 209P JC-1.	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID531510	Antibacterial activity against Bacteroides stercoris assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID523890	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID12324	Half life was determined	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID557468	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae 3665 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID517982	Antimicrobial activity against Stenotrophomonas maltophilia B715 harboring beta-lactamase L1and L2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID573582	Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID533392	Antimicrobial activity against Clostridium perfringens assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID541016	Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase PenB1	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID557500	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID155947	Antibacterial activity expressed as binding to PBP 3 of Pseudomonas aeruginosa; Nd= not determined	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
AID524096	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A848	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID289911	Antibacterial activity against Proteus mirabilis 112/3	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID495704	Kcat/Km ratio of Klebsiella oxytoca Beta-lactamase K1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545341	Displacement of [14C]benzylpenicillin from PBP3 in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID555210	Antibacterial activity against Acinetobacter genomosp. 3 isolate 103 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID164379	Antibacterial activity against Pseudomonas aeruginosa 9027	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID495745	Kcat/Km ratio of Acinetobacter baumannii OXA-23 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID556667	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 22 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID524444	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E357 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557412	Antimicrobial activity in Bacteroides thetaiotaomicron by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID557474	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID558807	Antimicrobial activity against extended spectrum beta-lactamase-deficient Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID285585	Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID295824	Antibacterial activity against Enterobacter cloacae 417 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID584564	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID295808	Antibacterial activity against Pseudomonas aeruginosa 110/2 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID548473	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID564529	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID425318	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533546	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA352	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID423063	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 H103 after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID523942	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E456 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558334	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1093 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID523723	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E344	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545621	Antimicrobial activity against Pseudomonas aeruginosa PS44 with PFGE phenotype 13 expressing beta-lactamase IMP-18 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID609150	Antibacterial activity against Enterococcus faecalis ATCC 29212	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID1226404	Activity of Aeromonas veronii metallo-beta-lactamase ImiS	2015	ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4	Azolylthioacetamide: A Highly Promising Scaffold for the Development of Metallo-β-lactamase Inhibitors.
AID559899	Antimicrobial activity against Klebsiella pneumoniae 101A harboring beta-lactamase CMY-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID283390	Antimicrobial activity against Nocardia cyriacigeorgica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID588124	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID279262	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID401689	Antibacterial activity against Pseudomonas aeruginosa 1771M	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID422665	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1765575	Antibacterial activity against Enterococcus faecalis ATCC 29212 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID368735	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID563976	Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID495725	Activity of Klebsiella pneumoniae KPC-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID574472	Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID574989	Antimicrobial activity against Bifidobacterium adolescentis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID289873	Antibacterial activity against Streptococcus pyogenes 77A	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID534626	Antimicrobial activity against Escherichia coli assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID396716	Antibacterial activity against methicillin-resistant Staphylococcus aureus 209P JC1	2009	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 19, Issue:2	Synthesis of novel di- and tricationic carbapenems with potent anti-MRSA activity.
AID587733	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID522025	Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID71048	In vitro antibacterial activity against Escherichia coli NIHJ JC-2.	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID279266	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID433170	Antibacterial activity against Peptostreptococcus micros isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533765	Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P9 exhibiting PFGE A pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID544903	Antimicrobial activity against Serratia marcescens clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID1124640	Antibacterial activity against penicillin-sensitive Pseudomonas aeruginosa MB2835 at 25 ug/disk	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID1373287	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID554984	Antibacterial activity against Acinetobacter genomosp. 3 isolate 14 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID576065	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID541024	Induction of Burkholderia cenocepacia 212 beta-lactamase PenB3 at 0.6 ug/ml in presence of cephalothin as substrate	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID565548	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID585182	Ratio of Kcat to Km for Beta-lactamase GES-7 K104, G170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID584728	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4005 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID573191	Antimicrobial activity against mutS::lox,nfxB gene-deficient Pseudomonas aeruginosa PAOMSNB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID432992	Antibacterial activity against Enterobacter aerogenes isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID522187	Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID498834	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU3 deficient in DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524269	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E476 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID542391	Cmin in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID545560	Ratio of MIC for Escherichia coli EIR2b to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID433195	Antibacterial activity against Streptococcus agalactiae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID423072	Antibacterial activity against 70_H3 allele containing Pseudomonas aeruginosa PAO1 H1129 mutant strain with rnt::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID533409	Antimicrobial activity against Finegoldia magna by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535145	Antimicrobial activity against imipenem non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545567	Antibacterial activity against Escherichia coli EMR2a selected at 2 times MIC of meropenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID548258	Ratio of Kcat/Km for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID545458	Antimicrobial activity against Serratia marcescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID534482	Antimicrobial activity against Stenotrophomonas maltophilia KJG harboring ampG with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID584837	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID495518	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID428274	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID322322	Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID587985	Antibacterial activity against Escherichia coli AS226 carrying pBSD6 mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID511390	Antibacterial activity against Proteus mirabilis by broth dilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
AID433176	Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573784	Antibacterial activity against Prevotella bivia by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID576286	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID584735	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4753 harboring mutation in putative RNA-binding protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585194	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID495822	Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID576317	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID529844	Antibacterial activity against methicillin-resistant Staphylococcus aureus 123-1 expressing PBP 2a by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID529850	Antibacterial activity against OprD-deficient Pseudomonas aeruginosa MR08 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID535136	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID556700	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID394688	Antibacterial activity against beta-lactams resistant OprD-deficient Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID524484	Antibacterial activity against Pseudomonas aeruginosa P353 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID585399	Activity at Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID394678	Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 8 carrying insertion sequence ISPa26 inserted into oprD gene by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID405819	Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1528444	Antibacterial activity against Citrobacter freundii assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID433149	Antibacterial activity against Bacteroides thetaiotaomicron isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433399	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1825 harboring inactive lytH and inactive llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID561629	Antimicrobial activity against ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID360073	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra -aspartate-penta-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID534864	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID660265	Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump	2012	European journal of medicinal chemistry, Jun, Volume: 52	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID533126	Antimicrobial activity against Bacteroides caccae assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID535172	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID535719	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-B2 S287N mutant	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID534885	Antimicrobial activity against Enterobacter cloacae with nonderepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425979	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 49 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID428293	Antimicrobial activity against Acinetobacter baumannii BM4651 expressing deltaadeIJK genes isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID558048	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID558603	Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID495736	Kcat/Km ratio of Escherichia coli CMY-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID555219	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 69 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID285658	Antimicrobial activity against Pseudomonas aeruginosa 19E12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1225783	Antibacterial activity against Klebsiella oxytoca KX1019 expressing KPC2/OXA2 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID511579	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID69006	In vitro synergistic activity against Escherichia coli C600N + (PSE-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID556653	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 8 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID295827	Antibacterial activity against Serratia marcescens 14273 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID542049	Antibacterial activity against rifampicin resistant Escherichia coli J53-2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
AID289909	Antibacterial activity against Serratia marcescens 6093	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID405636	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 6	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID535721	Ratio of Kcat to Km for Escherichia coli TOP10 beta-lactamase AmpC-A	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID584583	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid WH1266 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID573837	Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID544936	Antimicrobial activity against Acinetobacter lwoffii clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID574780	Antimicrobial activity against Clostridium difficile assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524405	Antibacterial activity against carbapenemase-producing Klebsiella pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID395744	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 184 by Etest in presence of 0.390 uM efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID1858576	Antibacterial activity against Mycobacterium abscessus CIP 104536T rough morphotype incubated for 1 to 14 days	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
AID289876	Antibacterial activity against Escherichia coli DC2	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1824297	Antimicrobial activity against Pseudomonas aeruginosa T2357 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID524472	Antibacterial activity against Pseudomonas aeruginosa P373 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID575015	Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by UV spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates.
AID544677	Antimicrobial activity against class A extended spectrum beta-lactamase- producing Escherichia coli clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID535134	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID295828	Antibacterial activity against Proteus mirabilis 112/3 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID523742	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E459	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID279264	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1056841	Antibacterial activity against TEM-1/SHV-12 expressing Aeromonas hydrophila isolate 268 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID509868	Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID517968	Antimicrobial activity against Escherichia coli A harboring beta-lactamase CTX-M 15 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID544958	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTX by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573598	Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID396026	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID573546	Antibacterial activity against Klebsiella oxytoca Ko0426 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1373321	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID573202	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring deletion od C534 in nfxB mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID245141	Minimum inhibitory concentration against Streptococcus aureus 285 strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID583241	Antibacterial activity against Acinetobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID285609	Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531774	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID534605	Antimicrobial activity against Enterobacteriaceae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID534921	Antimicrobial activity against Serratia marcescens assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID285690	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID576521	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081072 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID559918	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG4 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID533539	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA339	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID508734	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID573363	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573187	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID433376	Antibacterial activity against Anaerococcus vaginalis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433389	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SR-17164 with lytH gene inactivated by insertion sequence IS1182 measured after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID541793	Antimicrobial activity against Bacteroides uniformis clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID573721	Antibacterial activity against Escherichia coli Ec221 transconjugant harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID521841	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID523489	Antimicrobial activity against Pseudomonas aeruginosa R20 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID561630	Antimicrobial activity against ampD1-, ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID573496	Antibacterial activity against Enterobacter cloacae isolate El1573 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID544681	Antimicrobial activity against AmpC beta-lactamase-producing Enterobacter cloacae clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID557428	Antimicrobial activity in Bacteroides uniformis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID531751	Antibacterial activity against Pseudomonas aeruginosa 3308 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID532897	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID586061	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID588129	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 7 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID529461	Antimicrobial activity against Escherichia coli J53 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID498803	Antimicrobial activity against Klebsiella pneumoniae ZJ18T expressing KPC-2, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID69322	MIC against aerobic organism Escherichia coli strain 2891	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID497692	Antimicrobial activity against Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID295825	Antibacterial activity against Serratia marcescens 370 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495678	Antimicrobial activity against wild type Pseudomonas aeruginosa ATCC 27853 expressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID490019	Antibacterial activity against Escherichia coli at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID541787	Antimicrobial activity against Bacteroides fragilis clinical isolate after 18 to 22 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
AID524461	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534385	Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID518730	Antimicrobial activity against Pseudomonas stutzeri clinical isolate expressing beta-lactamase DIM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID521490	Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID561627	Antimicrobial activity against Stenotrophomonas maltophilia KJ by twofold serial agar dilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID587977	Antibacterial activity against Escherichia coli AS226 carrying pBSD-H2 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID295812	Antibacterial activity against Escherichia coli 0114 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID429080	Activity at Klebsiella pneumoniae Greece Carbapenem-Hydrolyzing-Lactamase KPC-2 assessed per mg of total protein by spectrophotometrically	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID7633	Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID1056850	Antibacterial activity against TEM-1/SHV-12 expressing Klebsiella pneumoniae isolate 303 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID541019	Antimicrobial activity against Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID562759	Antimicrobial activity against Klebsiella pneumoniae PFGE clone B expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID368748	Antimicrobial activity against Klebsiella pneumoniae Kp1 expressing SHV-4 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1824273	Antimicrobial activity against Escherichia coli clinical isolate T2228 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID584565	Antimicrobial activity against Acinetobacter lwoffii isolate L expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID295802	Antibacterial activity against Streptococcus faecium 77A after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID209885	Inhibitory concentration against purified PBP2x from Streptococcus pneumoniae	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID523490	Antimicrobial activity against Pseudomonas aeruginosa AHP Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID545342	Displacement of [14C]benzylpenicillin from PBP4 in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID424859	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID524270	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574967	Antimicrobial activity against Actinomyces odontolyticus assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID425107	Antimicrobial activity against Clostridium sordellii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID557475	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID545821	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID374366	Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID533389	Antimicrobial activity against Clostridium perfringens by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID519802	Inhibition of Bocillin FL binding to PBP6 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533360	Antimicrobial activity against Bacteroides ovatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID518187	Antimicrobial activity against Acinetobacter baumannii HPA 4737 harboring beta-lactamase OXA-26 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID563594	Inhibition of Pseudomonas aeruginosa PAO1 PBP5/6 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID540942	Antimicrobial activity against Salmonella enterica serotype Newport AM17274 expressing CMY-31 cephalosporinase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID563600	Antimicrobial activity against Klebsiella pneumoniae isolate 048 expressing beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID557988	Antimicrobial activity in Clostridium innocuum by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID556693	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID205669	In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA spain 356 (clinical isolates)	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
AID571908	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID520969	Antibacterial activity against Klebsiella pneumoniae GR by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID68874	In vitro synergistic activity against Escherichia coli 4100 + (CCRA)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID535845	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID558425	Antimicrobial activity against Pseudomonas aeruginosa by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	In vitro activity of doripenem against Burkholderia pseudomallei.
AID1879067	Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID544514	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-4 assessed as hydrolysis rate per mg of extracts at 100 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID584835	Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID574740	Antimicrobial activity against Peptostreptococcus anaerobius after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID535126	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID351027	Antibacterial activity against Pseudomonas aeruginosa at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID524107	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A884	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565723	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID499067	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ89 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID583236	Antibacterial activity against Klebsiella spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID559544	Antibacterial activity against non-levofloxacin susceptible Stenotrophomonas maltophilia assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID517967	Antimicrobial activity against Klebsiella pneumoniae 1357E harboring beta-lactamase TEM-10 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID540949	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBCSK plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID546410	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-27 with PDC-7 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID520725	Activity of Acinetobacter baumannii MAD beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID422882	Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID520777	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID523717	Antibacterial activity against Acinetobacter baumannii A890 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531337	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID285255	Antimicrobial activity against Escherichia coli DH5-alpha CF1179 isolate expressing CMT and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID557519	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID524480	Antibacterial activity against Pseudomonas aeruginosa P337 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524088	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P340	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID545562	Ratio of MIC for Escherichia coli EIR4a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID293788	Antimicrobial activity against Salmonella setubal ATCC 19196 by broth microdilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis, antimicrobial activity, and QSAR studies of furan-3-carboxamides.
AID369576	Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
AID535842	Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID558691	Antimicrobial activity against Bacteroides fragilis MN11 expressing imipenemase activity after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID522005	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285583	Antimicrobial activity against Pseudomonas aeruginosa 65.33-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID555196	Antimicrobial activity against nagZ gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID560131	Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID529851	Antibacterial activity against MexA-MexB-OprM-overproducing Pseudomonas aeruginosa OCR1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID495738	Kcat/Km ratio of Enterobacter cloacae AmpC relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID372323	Antibacterial activity against hypermutable Pseudomonas aeruginosa isolate 12-09-15 by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID518465	Antimicrobial activity against Pseudomonas aeruginosa 527 assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534610	Antimicrobial activity against Ceftazidime non-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529572	Antimicrobial activity against Erwinia carotovora subsp. atroseptica DSM 30184 after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID576289	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID323633	Ratio of Kcat to Km for Aeromonas hydrophila beta lactamase CphA at pH 9.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID565518	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID511130	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 4	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID585195	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID531517	Antibacterial activity against Bacteroides vulgatus assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID573547	Antibacterial activity against Klebsiella oxytoca Ko1156 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID207368	In vitro synergistic activity against Staphylococcus aureus (PC1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID68078	Antibacterial activity against MDREFm	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID324874	Antimicrobial activity against Acinetobacter baumannii C75 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID540945	Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pH205 plasmid expressing cephalosporinase CMY-36 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID574532	Antimicrobial activity against Prevotella bivia assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID495515	Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID360059	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tri-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID422661	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 15 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID544978	Antimicrobial activity against Klebsiella pneumoniae 52OmpA2	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID574754	Antimicrobial activity against Anaerococcus prevotii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID574004	Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285655	Antimicrobial activity against Pseudomonas aeruginosa 19D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID558623	Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID522002	Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285257	Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1295 isolate expressing pBK-TEM-151 and CMT by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID495717	Activity of Klebsiella pneumoniae SHV-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545358	Antibacterial activity against Staphylococcus aureus SIR2a selected at 2 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID573508	Antibacterial activity against Klebsiella oxytoca isolate Ko1156 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID523739	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E452	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425334	Bactericidal activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID374026	Ratio of Kcat to Km for Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID530814	Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID542402	Antimicrobial activity against Enterococcus	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID548012	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237S mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID574768	Antimicrobial activity against Finegoldia magna assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID521487	Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID283119	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM6	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID495904	Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID405427	Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
AID529856	Antibacterial activity against Pseudomonas aeruginosa N091 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID1449135	Antibacterial activity against Mycobacterium abscessus CIP104536 smooth variant expressing tdTomato infected in PMA activated THP-1 macrophages assessed as protection against viral infection after 4 days post treatment by microscopic method	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.
AID565717	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID556665	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 20 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID583025	Antimicrobial activity against Escherichia coli TOP10 transformed by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID585402	Ratio of Kcat to Km for Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID584560	Antimicrobial activity against Acinetobacter lwoffii isolate G expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID524303	Antibacterial activity against Pseudomonas aeruginosa P340 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533548	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA356	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID534888	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545612	Antimicrobial activity against Pseudomonas aeruginosa PS33 with PFGE phenotype 9A obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID521999	Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID583037	Activity of Beta-lactamase ACC-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID373783	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab1254(r) by broth dilution method in presence of 24 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID559263	Antimicrobial activity against Providencia stuartii Ps5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID360054	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl tri-aspartate-peptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID322319	Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID460802	Antibacterial activity against Acinetobacter baumannii AB0043 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID520971	Antibacterial activity against Klebsiella pneumoniae 633 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID360053	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl tetra-peptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID425975	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 14 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID531974	Antibacterial activity against Escherichia coli DH10B by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID576267	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID559277	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID524501	Antibacterial activity against Acinetobacter baumannii A912 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529487	Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID520723	Activity of Acinetobacter baumannii phenotype 1 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID95728	Minimum inhibitory concentration against Klebsiella aerogenes 1522E was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID582877	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 3.8 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID425994	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID529655	Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID1356824	Antimicrobial activity against Klebsiella pneumoniae ATCC BAA-1905 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID558047	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID285676	Antimicrobial activity against Pseudomonas aeruginosa 24G1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573194	Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring duplication mutation at nucleotide 333 in nfxB gene selected at 0.5 ug/ml of azithromycin by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID564528	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID1561470	Antibacterial activity against wild type carbapenem-susceptible Acinetobacter baumannii ATCC 17978 in Mueller-Hinton broth by CLSI protocol based method
AID286233	Antibacterial activity against Escherichia coli at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID528492	Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID559896	Antimicrobial activity against Klebsiella oxytoca KO279 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID573529	Antibacterial activity against Acinetobacter baumannii isolate AbN450 harboring IblaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID519816	Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID558004	Antimicrobial activity in Clostridium hastiforme by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID528601	Antimicrobial activity against Escherichia coli TOP10 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID563587	Induction of ampC mRNA expression in Pseudomonas aeruginosa PAO1 at 0.25 X MIC relative to untreated control	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID558790	Antimicrobial activity against Enterobacter cloacae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID519476	Induction of beta-lactamase L2 expression in Stenotrophomonas maltophilia M2 mutant assessed as L2 activity at 10 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID545339	Displacement of [14C]benzylpenicillin from PBP1B in Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID525547	Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1050 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID495716	Activity of Escherichia coli TEM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584708	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0503 harboring mutation in Putative biotin synthesis protein BioC by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID373773	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID289907	Antibacterial activity against Enterobacter cloacae 417	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID433183	Antibacterial activity against Corynebacterium jeikeium isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524136	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E450 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565420	Antimicrobial activity against ESBL- and MBL-producing and ceftazidime-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infection assessed as resistant isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
AID209764	Minimum inhibitory concentration against Streptococcus pyogenes 308A was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID534299	Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID557497	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID285262	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-1 and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID463425	Antimicrobial activity against Escherichia coli at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID433398	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1663 harboring inactive lytH gene and active llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID559275	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID563593	Inhibition of Pseudomonas aeruginosa PAO1 PBP4 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID565200	Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID1528452	Antibacterial activity against Serratia marcescens assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID555661	Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID245178	Minimum inhibitory concentration against Klebsiella aerogenes 1522E strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID425324	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID524459	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E473 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557504	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID495679	Antimicrobial activity against Pseudomonas aeruginosa OC 4352 overexpressing beta-lactamase AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID583093	Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID532413	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID588079	Antibacterial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid directed expression of beta-lactamase OXA-58 under an ISAba825-ISAba3 hybrid and ISAba3-derived promoter sequence	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID433354	Antibacterial activity against Parabacteroides merdae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433182	Antibacterial activity against Corynebacterium aurimucosum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID519257	Tmax in pancreatitis Sprague-Dawley rat peritoneal fluid at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID520638	Antimicrobial activity against Escherichia coli MRY04-1060 expressing qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID558755	Antibacterial activity against methicillin-susceptible, tetracycline-resistant and chloramphenicol-resistant Staphylococcus aureus H14-KVR by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID490022	Antibacterial activity against Salmonella typhi at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID573200	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB C116T mutant gene selected at 1 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID517983	Antimicrobial activity against Enterobacter cloacae 908R harboring beta-lactamase AmpC by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID360077	Inhibition of Enterococcus faecium LD transpeptidase assessed as enzyme aduct at 3.4 uM by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID436878	Antibacterial activity against imipenem-non resistant Escherichia coli BL21(DE3) after 18 hrs by twofold serial broth dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID546181	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-21 with PDC-4 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID524315	Antibacterial activity against Acinetobacter baumannii A851 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID373769	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID511138	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 12	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID545334	Displacement of [14C]benzylpenicillin from PBP1 in Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID519740	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID587731	Ratio of Kcat to Km for Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID558589	Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID583024	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID285598	Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID524074	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P373	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1350123	Antibacterial activity against Mycobacterium abscessus clinical isolate by CLSI M07-A9 protocol based assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cybastacines A and B: Antibiotic Sesterterpenes from a Nostoc sp. Cyanobacterium.
AID574502	Antimicrobial activity against Bacteroides caccae assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID523943	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E430 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584320	Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method in presence 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID206653	Compound was tested in vitro for its activity against methicillin-Resistant Staphylococcus Aureus(MRSA 12)	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID558536	Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID561384	Antibacterial activity against Escherichia coli isolate ARL05-909 harboring beta-lactamase CMY 29 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID1539480	Antibacterial activity against carbapenem-resistant Escherichia coli BAA-2469 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID156410	Compound was tested for its binding affinity towards Penicillin-binding protein 2a (PBP2a) using [13H]-benzylpenicillin	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID295822	Antibacterial activity against Klebsiella pneumoniae 477 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID524466	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID525550	Antimicrobial activity against ampicillin resistant serotype-e Haemophilus influenzae isolate BB1053 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID577231	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB127 with PFGE subgroup I containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID360076	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra-aspartate-tetra-aspartate-penta-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID425865	Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID530350	Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID559684	Antibacterial activity against Acinetobacter baumannii BM4652	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID565508	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523743	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E451	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564015	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID575076	Antimicrobial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID322324	Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID587728	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID322318	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID540946	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c31 plasmid expressing cephalosporinase CMY-31 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID433365	Antibacterial activity against Propionibacterium acnes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524092	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P341	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530349	Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID285510	Antibacterial activity against Acinetobacter baumannii after 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
AID573573	Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID209901	Antibacterial activity against PRSP	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.
AID395740	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 184 at 1.56 uM by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID558338	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID373770	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID521995	Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID524420	Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID524474	Antibacterial activity against Pseudomonas aeruginosa P319 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID556675	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 2 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID574051	Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID545464	Antimicrobial activity against Pseudomonas fluorescens assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID577242	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB097 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1653507	Antimicrobial activity against Escherichia coli assessed as zone of inhibition incubated for 20 hrs by agar well diffusion assay	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID206745	In vitro antibacterial activity against Staphylococcus aureus SG 503 by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID285264	Antimicrobial activity against Escherichia coli DH5-alpha TC1179 isolate expressing TEM-1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID584838	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID534906	Antimicrobial activity against Citrobacter with nonderepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID422671	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID326268	Antibacterial activity against Escherichia coli DH5-alpha by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID405639	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID565721	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID577243	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB096 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID520698	Antimicrobial activity against Escherichia coli isolate DH10B by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID582878	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 3.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID524308	Antibacterial activity against Pseudomonas aeruginosa P358 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576323	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008226 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID368759	Antimicrobial activity against Escherichia coli Ec6 expressing CTX-M-14 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID510508	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate MC1AC9-26 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID530323	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID558534	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID535135	Antimicrobial activity against Ceftazidime susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1539484	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa ATCC 1744 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID531683	Antimicrobial activity against Acinetobacter baumannii ATCC 15151T by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID559763	Antimycobacterial activity against Mycobacterium smegmatis MC2 155 harboring PknG K181M mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID572124	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID495703	Kcat/Km ratio of Escherichia coli CTX-M-15	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID563591	Inhibition of Pseudomonas aeruginosa PAO1 PBP2 by SDS-PAGE	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID609147	Antibacterial activity against Staphylococcus aureus ATCC 29213	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID164585	Minimum inhibitory concentration was determined in heart infusion agar medium against Pseudomonas aeruginosa PAO-1	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID498371	Antimicrobial activity against wild type streptomycin-susceptible Streptococcus gordonii after 24 hrs by macrodilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID289372	Antibacterial activity against methicillin-resistant Staphylococcus aureus M126	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID522010	Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1318937	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 85322	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID558694	Antimicrobial activity against Bacteroides fragilis MN36 after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID573359	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID587727	Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
AID576274	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID285582	Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID250295	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID545452	Antimicrobial activity against extended-spectrum beta-lactamase-positive Proteus mirabilis assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID285646	Antimicrobial activity against Pseudomonas aeruginosa 16D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495710	Kcat/Km ratio of Klebsiella pneumoniae KPC-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID548261	Activity of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by spectrophotometric analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID524497	Antibacterial activity against Acinetobacter baumannii A865 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524320	Antibacterial activity against Acinetobacter baumannii A849 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535727	Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2 CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID546162	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-02 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID530347	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID544583	Antimicrobial activity against Escherichia coli DH5[alpha] by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID523757	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574979	Antimicrobial activity against Actinomyces meyeri assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID546416	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-1b by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID559901	Antimicrobial activity against Klebsiella pneumoniae 278sp by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID524485	Antibacterial activity against Pseudomonas aeruginosa P365 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511128	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 2	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1592958	Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
AID283147	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM7	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID576280	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID495720	Activity of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID531969	Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID519291	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-103 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID163079	In vitro antibacterial activity against Proteus vulgaris IAM 1025.	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID541004	Antimicrobial activity against Burkholderia cenocepacia 07-34 expressing beta-lactamase PenB1	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID498360	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52145R assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID573338	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID372626	Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID203297	In vitro antibacterial activity against MRCNS.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID523762	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E479	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID532913	Antimicrobial activity against Escherichia coli Genehogs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID203299	Antibacterial activity against methicillin-resistant coagulase negative Staphylococci (MRCNS)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID1373301	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID556663	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 18 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID557702	Antimicrobial activity in Prevotella sp.by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID433166	Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573545	Antibacterial activity against Klebsiella pneumoniae Kp3799 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID425969	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 2527 after 20 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID511149	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 5 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID584519	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3141 harboring wbpM mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID163104	Minimum inhibitory concentration against Pseudomonas aeruginosa 1592E was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID524081	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P334	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584586	Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring plasmid WH1266 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID524314	Antibacterial activity against Acinetobacter baumannii A865 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584715	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_59780 harboring rcsC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523746	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Escherichia coli E483	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID560488	Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
AID565540	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID373776	Antibacterial activity against Escherichia coli TOP10 expressing imipenem-susceptible Acinetobacter baumannii ab1254 blaoxa-66 gene by Etest	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID583027	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID584310	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0564 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID573797	Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID520731	Activity of Escherichia coli DH10B beta-lactamase OXA-97 assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID529862	Ratio of MIC for Pseudomonas aeruginosa N045 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID433199	Antibacterial activity against Bacteroides caccae isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID425329	Bactericidal activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID1539482	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-2146 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID207931	Compound was evaluated for the antibacterial activity against methicillin-sensitive Staphylococcus aureus (MSSA).	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID586232	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 5 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID404962	Antimicrobial activity against Klebsiella pneumoniae isolate expressing VIM1 gene	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID546161	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-01 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573535	Antibacterial activity against Enterobacter cloacae El1573 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID425864	Antimicrobial activity against Carnobacterium divergens CIP101029 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID341969	Antimicrobial activity against Escherichia coli AJE0508 isolate carrying ISCR1 element related blaCTX-M-14 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene.
AID433395	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1832 harboring inactive lytH and inactive llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID557496	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID66401	Antibacterial activity against vancomycin-resistant Enterococcal faecium strain	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID520776	Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID56119	Compound was evaluated for relative rate of hydrolysis to imipenem by partially purified porcine renal Dehydropeptidase-1	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID201537	Antibacterial activity against Salmonella Typhimurium	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID495698	Activity of Pseudomonas aeruginosa IMP-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID557509	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID373028	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU86 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID1528458	Antibacterial activity against Stenotrophomonas maltophilia assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID518199	Antimicrobial activity against Pseudomonas aeruginosa BA(C2-107) selected after 25 ug/ml of compound exposure by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID585396	Ratio of Kcat to Km for Bradyrhizobium japonicum metallo-beta-lactamase BJP-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID289883	Antibacterial activity against Staphylococcus aureus 209P	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID535173	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID558616	Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID532403	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID562327	Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID517972	Antimicrobial activity against Pseudomonas aeruginosa 1937E harboring beta-lactamase PSE-4 and class C enzymes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID517979	Antimicrobial activity against Pseudomonas aeruginosa HPA10586 harboring beta-lactamase VIM-1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID573403	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID583095	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID533534	Antimicrobial activity against Pseudomonas aeruginosa PA399 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID545620	Antimicrobial activity against Pseudomonas aeruginosa PS43 with PFGE phenotype 2 expressing beta-lactamase KPC-2, OXA-2 obtained from skin of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID373024	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID495667	Antimicrobial activity against wild type Klebsiella pneumoniae OC 15263 expressing beta-lactamase SHV-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID564953	Antimicrobial activity against Acinetobacter baumannii isolate Ab91 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID404960	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T186 isolate carrying three bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID495719	Activity of Klebsiella oxytoca Beta-lactamase K1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID249360	Minimum inhibitory concentration against Streptococcus pneumoniae (n=22); (Range = 0.008-0.5)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID200342	Minimum inhibitory concentration against aerobic organism Salmonella strain 826	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID535753	Antimicrobial activity against community-acquired Klebsiella pneumoniae expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID433192	Antibacterial activity against Staphylococcus epidermidis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573511	Antibacterial activity against Morganella morganii isolate Mm1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID250297	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID360066	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tri-aspartate-tetra-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID573126	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID531753	Antibacterial activity against Pseudomonas aeruginosa 2439 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID524285	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534902	Antimicrobial activity against Citrobacter assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID520869	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU33 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID524453	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E480 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558630	Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID495840	Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID1225784	Antibacterial activity against Klebsiella oxytoca KX1017 expressing KPC2/OXA2/SHV30 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID562810	Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID542401	Antimicrobial activity against Pseudomonas aeruginosa	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID295815	Antibacterial activity against Escherichia coli TEM after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID585179	Activity of Beta-lactamase GES-6 K104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID1350126	Antibacterial activity against Tsukamurella pulmonis clinical isolate by CLSI M07-A9 protocol based assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cybastacines A and B: Antibiotic Sesterterpenes from a Nostoc sp. Cyanobacterium.
AID1373319	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID285619	Antimicrobial activity against Pseudomonas aeruginosa 5G3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID433177	Antibacterial activity against Proteus mirabilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523952	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E359 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1528457	Antibacterial activity against Pseudomonas aeruginosa assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID528604	Antimicrobial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID425119	Bactericidal activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID198157	Compound was tested in vitro for antibacterial activity against Serratia marcescens A-20019	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID528788	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID545397	Antimicrobial activity against Pseudomonas aeruginosa PS3 with PFGE phenotype 12 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID583100	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 5.0 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID404961	Activity of Acinetobacter baumannii BM547 OXA58 assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID56141	Tested for stability of compound to swine renal DHP-1 relative to imipenem (IMP)	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID518200	Antimicrobial activity against Pseudomonas aeruginosa BA(C1-106) selected after 25 ug/ml of compound exposure by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID584714	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_07490/07510 harboring mutation in intergenic region by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1318901	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86052	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID529460	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID563598	Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolates by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
AID534630	Antimicrobial activity against ESBL producing Escherichia coli assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID545565	Antibacterial activity against Escherichia coli EIR8a selected at 8 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID373771	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID516139	Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID583233	Antibacterial activity against Citrobacter spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID577004	Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as viable bacterial count by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID523501	Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID546620	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID489659	Antibacterial activity against Staphylococcus aureus at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID517970	Antimicrobial activity against Klebsiella oxytoca 1028E harboring beta-lactamase K1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534903	Antimicrobial activity against Citrobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID490295	Antibacterial activity against Escherichia coli ATCC 11229 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID285666	Antimicrobial activity against Pseudomonas aeruginosa 22E3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID560119	Antimicrobial activity against Acinetobacter baumannii by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID490024	Antibacterial activity against Bacillus subtilis at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID558609	Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID1373285	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID535710	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 S287N mutant protein by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID498843	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae XJ81 deficient in TEM-1, SHV-12, DHA-1, aac(6')-Ib, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID609243	Antifungal activity against Candida albicans ATCC 90028	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID558330	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID522028	Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID115934	In vivo antibacterial activity against MRSA 76 virginia strain at the dose ~1 *10e7 cfu in 5 percent hog gastric mucin along with antibiotic by sc administration at 0 and +4 hrs in mice	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID322792	Antimicrobial activity against Bacteroides stercoris assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID424863	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID524496	Antibacterial activity against Acinetobacter baumannii A864 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID556668	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 23 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID511669	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID289374	Antibacterial activity against penicillin-resistant Staphylococcus aureus PRC9	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID519807	Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID295816	Antibacterial activity against Escherichia coli 1507 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID564216	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring plasmid PH98 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
AID283138	Antibacterial activity against Pseudomonas aeruginosa PAO4222	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID535847	Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID542396	T>MIC in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID532402	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID532417	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID587978	Antibacterial activity against Escherichia coli AS226 carrying pBSDN104A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID544950	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID1853393	Antibacterial acitivity against clinical isolate imipenem-resistant Klebsiella pneumoniae T2301 expressing NDM-1 assessed as inhibition of bacterial growth at 8 ug/ml incubated for 24 hrs by spectrophotometric analysis	2021	RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID584702	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5443 harboring uvrD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID368736	Antimicrobial activity against Enterobacter aerogenes Ea2 expressing TEM-3 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID573538	Antibacterial activity against Citrobacter amalonaticus Ca38009 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID283122	Antibacterial activity against Escherichia coli C600 expressing ESBL SHV2	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID518002	Antibacterial activity against Nocardia brasiliensis isolated from actinomycetoma patient by broth dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.
AID558810	Antimicrobial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID545616	Antimicrobial activity against Pseudomonas aeruginosa PS37 with PFGE phenotype 11D obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID548255	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID558322	Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni NCTC 11168 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID571695	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID1824298	Antimicrobial activity against Klebsiella pneumoniae T2216 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID522003	Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID573507	Antibacterial activity against Klebsiella oxytoca isolate Ko0426 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID546618	Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID394680	Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis sputum isolate 286 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID560590	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID573120	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID556660	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 15 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1188371	Antibacterial activity against Acinetobacter baumannii ATCC BAA-1605 assessed as complete inhibition of bacterial growth after 16 hrs by microdilution method	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	Small-molecule suppression of β-lactam resistance in multidrug-resistant gram-negative pathogens.
AID573501	Antibacterial activity against Morganella morganii isolate Mm38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID565506	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID425110	Antimicrobial activity against beta lactamase-positive Bacteroides fragilis isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495810	Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID165036	In vitro antibacterial activity against Pseudomonas aeruginosa 1592E by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID524079	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P327	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523930	Antibacterial activity against beta-lactamase-negative Escherichia coli E350 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID547992	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237Y mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID584561	Antimicrobial activity against Acinetobacter lwoffii isolate H expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID340726	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-15 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID519810	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by CLSI protocol based broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID559524	Antibacterial activity against Acinetobacter baumannii assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID162937	Minimum inhibitory concentration against aerobic organism Pseudomonas aeruginosa strain 2835	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID558042	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID511161	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 17 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID561933	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate RUH134 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID576961	Antimicrobial activity against Shewanella algae Sa2 harboring intI1, intI2 and sul1 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID565662	Antimicrobial activity against beta-lactamase negative ampicillin-resistant Haemophilus influenzae assessed as susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
AID524318	Antibacterial activity against Acinetobacter baumannii A912 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531316	Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID533541	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA341	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1195019	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 incubated at 37 degC for 24 hrs by broth macrodilution method	2015	Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10	Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge Dysidea.
AID342020	Antibacterial activity against Escherichia coli J53 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID1356833	Antimicrobial activity against Escherichia coli ATCC BAA-2340 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID584512	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_43090 harboring mutation in hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498836	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU5 deficient in SHV-12, DHA-1, aac(6')-Ib-cr, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID534306	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID499054	Antimicrobial activity against carbapenem-resistant Escherichia coli PU101 deficient in TEM-1, CTX-M-14, CMY-2, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID323042	Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID529492	Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID1824302	Antimicrobial activity against Pseudomonas aeruginosa T2229 expressing SPM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID423066	Antibacterial activity against 24_A2 allele containing Pseudomonas aeruginosa PAO1 H1106 mutant strain with lon::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID511293	Inhibition of Pseudomonas aeruginosa GES-13 beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID289895	Antibacterial activity against Escherichia coli 086	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID533001	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa isolate P67 exhibiting PFGE J pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID547801	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237W mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID556658	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 13 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1056837	Antibacterial activity against TEM-1/SHV-12 expressing Escherichia coli isolate 237 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID10241	Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID285594	Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID295807	Antibacterial activity against Pseudomonas aeruginosa 77/2 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID495747	Inhibition of Pseudomonas aeruginosa AmpC assessed as inhibition of nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID68878	In vitro synergistic activity against Escherichia coli C600N + (IRT-2)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID525545	Antimicrobial activity against Haemophilus influenzae Rd KW20 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID576542	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008135 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID557477	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID498806	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ71 deficient in KPC-2, TEM-1, SHV-11, CTX-M-14, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID495907	Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID373754	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID245210	Minimum inhibitory concentration against Pseudomonas aeruginosa 1592E strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID535683	Antibacterial activity against armA-positive Enterobacter cloacae expressing KPC-2 beta-lactamase by CLSI method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Plasmid-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacteriaceae isolates in Shanghai, China.
AID531515	Antibacterial activity against Bacteroides distasonis assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID574726	Antimicrobial activity against Prevotella oralis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID51148	Compound was tested in vitro for its activity against Methicillin-Resistant Coagulase Negative Staphylococci(MRCNS 9)	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID529482	Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID495807	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID565283	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID373781	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab1254(r) by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID573193	Antimicrobial activity against mutS::lox,mexD::lox-deficient Pseudomonas aeruginosa PAOMSMxD biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID584842	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID490023	Antibacterial activity against Staphylococcus aureus at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID1826211	Antibacterial activity against NDM-1 producing Klebsiella pneumoniae T2301 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID557520	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID558622	Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID585196	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID546178	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-18 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID584844	Antimicrobial activity against Escherichia coli DH10B by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID558696	Antimicrobial activity against Bacteroides fragilis MN4a	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID1373322	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1826219	Antibacterial activity against KPC-2 producing Escherichia coli T2435 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID545431	Antimicrobial activity against Escherichia coli obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID567321	Antimicrobial activity against Escherichia coli ML4901 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID573353	Antibacterial activity against ceftazidime-susceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574760	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID279813	Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID558324	Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID425984	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID249346	Minimum inhibitory concentration against Klebsiella pneumoniae (n=30); (Range=0.06-0.1)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID534646	Antimicrobial activity against Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573402	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID545568	Ratio of MIC for Escherichia coli EMR2a to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520966	Antibacterial activity against Klebsiella pneumoniae YC by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID289880	Antibacterial activity against Klebsiella aerogenes 1522E	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID324856	Antimicrobial activity against Acinetobacter baumannii A24 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID524135	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E446 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533565	Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID425121	Bactericidal activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID521966	Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID559821	Antimicrobial activity against Pseudomonas aeruginosa PU21 harboring pCHE-A plasmid expressing blaGES-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID609241	Antibacterial activity against Propionibacterium acnes ATCC 11827	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID576308	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID340737	Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID531768	Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID285672	Antimicrobial activity against Pseudomonas aeruginosa 24E5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID360071	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra -aspartate-penta multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID518464	Antimicrobial activity against Pseudomonas aeruginosa BA assessed as number of passages required for MIC to rise above 4 times original MIC	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID562474	Antimicrobial activity against rifampicin-resistant Escherichia coli A15 transconjugant expressing beta-lactamase SHV-12 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID557493	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID374362	Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
AID162788	In vitro synergistic activity against Pseudomonas aeruginosa Ps505A1 (AmpC derepressed)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID583096	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID295784	Antibacterial activity against Staphylococcus aureus 1218 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID1195024	Antimicrobial activity against Klebsiella pneumoniae	2015	Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10	Polybrominated diphenyl ethers with potent and broad spectrum antimicrobial activity from the marine sponge Dysidea.
AID584525	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3620 harboring mutS mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID534887	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID522022	Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID556691	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 harboring pDrive plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID530815	Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID1824296	Antimicrobial activity against Enterobacter cloacae T2353 expressing VIM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID495729	Activity of Pseudomonas aeruginosa SPM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID245228	Minimum inhibitory concentration against Streptococcus pyogenes SG 511 strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID360055	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as lactoyl penta-peptide level	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID69005	In vitro synergistic activity against Escherichia coli C600N + (P99)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID555211	Antibacterial activity against Acinetobacter genomosp. 3 isolate 109 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID573799	Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID395730	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID499045	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ68T deficient in CTX-M-15, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID423073	Antibacterial activity against 63_H5 allele containing Pseudomonas aeruginosa PAO1 H1133 mutant strain with nfxB::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID533759	Antibacterial activity against OXA-10, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P22 exhibiting PFGE F pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID279184	Antibacterial activity against Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID520882	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID520696	Antimicrobial activity against Escherichia coli DH10B harboring p041060 carrying qepA gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID533547	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA355	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID404958	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii T193 isolate carrying two bla-OXA58 gene copies by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID520382	Antimicrobial activity Escherichia coli DH5alpha harboring bacteriophage T4 plasmid alpha omega by agar macrodilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID524475	Antibacterial activity against Pseudomonas aeruginosa P320 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID556649	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 4 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1649623	Substrate activity at VIM-2 (unknown origin) assessed as Kcat/Km ratio for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID584937	Antimicrobial activity against Pseudomonas aeruginosa harboring pBBR-mucD complemented gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID583237	Antibacterial activity against Proteus mirabilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID524133	Antibacterial activity against beta-lactamase-negative Escherichia coli E424 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573530	Antibacterial activity against Citrobacter youngae isolate CyB38 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID69009	In vitro synergistic activity against Escherichia coli C600N + (Sme-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID490020	Antibacterial activity against Shigella flexneri at 50 ug/ml after 24 hrs by agar-well diffusion assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Some new biologically active metal-based sulfonamide.
AID498367	Antimicrobial activity against wild type streptomycin-susceptible Streptococcus gordonii assessed as bacterial count at 2 ug/ml after 24 hrs by macrodilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID555216	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 20 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID565713	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID373027	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA6 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID524112	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A931	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522017	Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID558537	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID508730	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C9 GM1 harboring acquired beta-lactamase OXA-144 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID544492	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID1225788	Antibacterial activity against Klebsiella pneumoniae KP1087 expressing KPC2/CTX-M-15/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID574459	Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID56123	Relative hydrolysis to meropenem by partially purified porcine renal Dehydropeptidase-1 was reported.	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID523944	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E459 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529493	Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID405635	Antibacterial activity against Escherichia coli MC4100 by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID548016	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237D mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID372610	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-1 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID563968	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID545550	Ratio of MIC for Escherichia coli ERR2a selected to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID524100	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A851	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID496591	Antimicrobial activity against Escherichia coli DH10B harboring beta lactamase KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID499055	Antimicrobial activity against Escherichia coli PU101T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID516147	Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID64909	Compound was tested in vitro for antibacterial activity against Escherichia coli A-15119	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID529462	Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID565509	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1649622	Substrate activity at VIM-2 (unknown origin) assessed as Km for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID286234	Antibacterial activity against Bacillus subtils at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID433357	Antibacterial activity against Prevotella bivia isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID524473	Antibacterial activity against Pseudomonas aeruginosa P335 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID368740	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-D plasmid expressing CTX-M-15 TEM-1 OXA-1gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID533540	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA340	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID545606	Antimicrobial activity against Pseudomonas aeruginosa PS25 with PFGE phenotype 1A obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID546425	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-5 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID574766	Antimicrobial activity against Finegoldia magna assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID584698	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5003 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID521839	Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID368757	Antimicrobial activity against Morganella morganii expressing TEM-24b AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID585185	Ratio of Kcat to Km for Beta-lactamase GES-6 K104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID573725	Antibacterial activity against Citrobacter youngae CyB38 transconjugant harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID530816	Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID289887	Antibacterial activity against Streptococcus agalactiae B	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID96428	In vitro synergistic activity against Klebsiella pneumoniae (ACT-1 + 3 blas, IPM=S)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID562752	Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-15 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID574977	Antimicrobial activity against Actinomyces meyeri assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID519255	Cmax in pancreatitis Sprague-Dawley rat peritoneal fluid at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID524441	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E465 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID523726	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E347	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID560117	Antibacterial activity against Escherichia coli TOP10 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID433366	Antibacterial activity against Anaerococcus prevotii isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID529582	Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID529575	Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID250300	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID395977	Toxicity in nosocomial pneumonia patient assessed as induction of seizures in presence of cilastin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
AID534301	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID523929	Antibacterial activity against beta-lactamase-negative Escherichia coli E348 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID766242	Activity at recombinant IMP-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells assessed as compound hydrolysis by Michaelis-Menten plot analysis	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID285621	Antimicrobial activity against Pseudomonas aeruginosa 8A2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523759	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E472	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID567282	Ratio of Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID532415	Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID573499	Antibacterial activity against Citrobacter amalonaticus isolate Ca38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573599	Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574465	Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID495675	Antimicrobial activity against wild type Serratia marcescens OC 7555 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545571	Antibacterial activity against Pseudomonas aeruginosa PIR2a selected at 2 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID523935	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E415 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511668	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID340738	Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID577230	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB110 with PFGE subgroup C containing carbapenemase OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID524290	Antibacterial activity against Pseudomonas aeruginosa P335 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533117	Antimicrobial activity against Staphylococcus aureus 10*3d1 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID70745	In Vitro antibacterial activity against (Ec L) Escherichia coli Beta-lactam lacking strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID323379	Antimicrobial activity against Pseudomonas aeruginosa clinical isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID576271	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID583087	Ratio of Kcat to Km for Escherichia coli XL1-Blue VIM-2 A64W mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID584705	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0402 harboring pyrB mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID463430	Antimicrobial activity against Bacillus subtilis at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID561931	Antibacterial activity against blaOXA-24-positive Acinetobacter baumannii isolate VA-566/00 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii.
AID495714	Kcat/Km ratio of Pseudomonas aeruginosa SPM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520978	Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID529496	Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID573532	Antibacterial activity against Klebsiella pneumoniae Kp2730 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID326265	Antibacterial activity against Escherichia coli 3521r carrying pR352 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID524482	Antibacterial activity against Pseudomonas aeruginosa P328 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573795	Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID373755	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID374025	Activity of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID70246	Compound was evaluated for the antibacterial activity against Escherichia coli.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID511133	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 7	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID205207	Compound was evaluated for the antibacterial activity against Serratia.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID395734	Antimicrobial activity against imipenem-susceptible invasive nontypeable Haemophilus influenzae isolate 248 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID535837	Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID562950	Antimicrobial activity against Klebsiella oxytoca expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID585193	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID557694	Antimicrobial activity in Prevotella salivae by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID283135	Antibacterial activity against Pseudomonas aeruginosa KG4545 producing MexXY efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID541007	Antimicrobial activity against Burkholderia cenocepacia 09-54 expressing beta-lactamase PenB2	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID546176	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-16 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID576958	Antimicrobial activity against Shewanella algae Sa10 harboring intI1, intI2, sul1 and sul2 genes by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID206010	Minimum inhibitory concentration was determined in heart infusion agar medium against Staphylococcus aureus 209P JC-1	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID562326	Activity of Aeromonas hydrophila metallo-betalactamase CphA N233A mutant expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID498835	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae PU4 deficient in SHV-1, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523892	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-23 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID564535	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID562738	Antimicrobial activity against Escherichia coli K-12 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID576062	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID532908	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID584711	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0770 harboring rnc mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID529848	Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID285669	Antimicrobial activity against Pseudomonas aeruginosa 24D5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID573834	Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1373282	Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID360060	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tetra multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID558813	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID573205	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID209887	Inhibitory concentration against purified cephalosporin-resistant PBP2x.604 from Streptococcus pneumoniae	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID587986	Antibacterial activity against Escherichia coli AS226 after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID289892	Antibacterial activity against Pseudomonas aeruginosa 110/2	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID575082	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID1562262	Antimycobacterial activity against Mycobacterium smegmatis atR10 assessed as decrease in drug resistance development at 10 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID574005	Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495794	Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID577223	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISphoA/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID562471	Antimicrobial activity against Klebsiella pneumoniae isolate 2337/08 obtained from patient with ischemic cardiomyopathy and several comorbidities	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
AID565549	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID323634	Ratio of Kcat to Km for Aeromonas hydrophila beta lactamase CphA at pH 10.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID576522	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS080884 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID323038	Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
AID574463	Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID495746	Inhibition of Escherichia coli CMY-2 assessed as inhibition of nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID556669	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 24 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID559274	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID340729	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-14 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID285443	Ratio of kcat to Km of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B relative to benzyl-penicillin	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID164578	In vitro antibacterial activity against Ps. auruginosa 26.	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID422495	Antimicrobial activity against Escherichia coli BL21 (DE3) harboring pAT514 by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID69013	In vitro synergistic activity against Escherichia coli GC 6266 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID532393	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID559688	Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID511141	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 15	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID524498	Antibacterial activity against Acinetobacter baumannii A851 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID548253	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID557518	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID565541	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID518724	Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase DIM-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID524293	Antibacterial activity against Pseudomonas aeruginosa P322 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565530	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID360078	Inhibition of Enterococcus faecium LD-transpeptidase assessed by formation of Ac2-L-Lys-D-[14C]Ala from Ac2-L-Lys-D-Ala and D-[14C]Ala at 0.5 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID582975	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID283128	Antibacterial activity against Escherichia coli C600	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID529581	Ratio of Kcat to Km for Janthinobacterium lividum THIN-B	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID577237	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB118 with PFGE subgroup B2 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID584696	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5001 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498838	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae SZ61 deficient in TEM-1, SHV-1a, CMY-2, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID285671	Antimicrobial activity against Pseudomonas aeruginosa 24E2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID565725	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID528916	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID245081	Minimum inhibitory concentration against Escherichia coli 078 strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID368755	Antimicrobial activity against Proteus mirabilis Pm4 expressing TEM-21 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID1373284	Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID583094	Activity of Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID495705	Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520724	Activity of Acinetobacter baumannii phenotype 2 beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID342019	Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae.
AID557686	Antimicrobial activity in Prevotella veroralis by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID495663	Activity at Pseudomonas aeruginosa 51170 beta-lactamase BEL-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID524289	Antibacterial activity against Pseudomonas aeruginosa P373 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID524445	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574738	Antimicrobial activity against Fusobacterium mortiferum after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID575101	Antimicrobial activity against Streptococcus pneumoniae serotype 23B assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID520717	Antibacterial activity against Acinetobacter baumannii CIP7010 harboring pOXA-97 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID546166	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-06 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID285615	Antimicrobial activity against Pseudomonas aeruginosa 3D10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID535833	Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID524313	Antibacterial activity against Acinetobacter baumannii A864 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522009	Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID544491	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID585400	Ratio of Kcat to Km for Fluoribacter gormanii 1K07 metallo-beta-lactamase FEZ-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID565522	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1350125	Antibacterial activity against Nocardia cyriacigeorgica clinical isolate by CLSI M07-A9 protocol based assay	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Cybastacines A and B: Antibiotic Sesterterpenes from a Nostoc sp. Cyanobacterium.
AID519743	Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID433363	Antibacterial activity against Clostridium malenominatum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495668	Antimicrobial activity against Escherichia coli OC 6697 expressing beta-lactamase CMY-2 and containing plasmid AmpC assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID1356823	Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID576277	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID554990	Antibacterial activity against Acinetobacter genomosp. 3 isolate 65 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID206630	Compound was evaluated for the anti-MRCNS activity as MIC50.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID1373298	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524443	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522000	Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID533372	Antimicrobial activity against Bacteroides vulgatus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID531749	Antibacterial activity against Pseudomonas aeruginosa FK06 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID573519	Antibacterial activity against Escherichia coli isolate Ec211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID395732	Antimicrobial activity against imipenem-susceptible invasive nontypeable Haemophilus influenzae isolate 187 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID557272	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae 3676 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID373048	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ84 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID582972	Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID528921	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene and other bla gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID7546	Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID535758	Antimicrobial activity against hospital-acquired Escherichia coli expressing extended spectrum beta-lactamase obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID584309	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0547 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID584566	Antimicrobial activity against Acinetobacter lwoffii isolate M expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID324311	Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
AID66906	Antibacterial activity against vancomycin-resistant Enterococcus faecalis strain	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID495669	Antimicrobial activity against Escherichia coli OC 11732 expressing extended-spectrum beta-lactamase CTX-M-15 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID285338	Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID562739	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID517978	Antimicrobial activity against Pseudomonas aeruginosa HPA101-1477 harboring beta-lactamase IMP-1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID587500	Antibacterial activity against drug-resistant Citrobacter freundii isolate producing metallo-beta-lactamase NDM-1 with carbapenemase activity isolated from urine culture of cerebral vascular malformation patient	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India.
AID542390	Cmax in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID660261	Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM120	2012	European journal of medicinal chemistry, Jun, Volume: 52	Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID545658	Antimicrobial activity against Acinetobacter sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID93901	Minimum inhibitory concentration was determined in heart infusion agar medium against Klebsiella pneumoniae PCI 602	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID495913	Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID531972	Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
AID585401	Activity at Chryseobacterium meningosepticum NCTC 10585 metallo-beta-lactamase GOB-1	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
AID489658	Antibacterial activity against Salmonella typhi at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID289886	Antibacterial activity against Streptococcus faecium 77A	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID433197	Antibacterial activity against Streptococcus pyogenes isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID556688	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 15 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID67856	Minimum inhibitory concentration against aerobic organism Enterobacter aerogenes strain 2828	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID293790	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis, antimicrobial activity, and QSAR studies of furan-3-carboxamides.
AID405821	Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID68522	Minimum inhibitory concentration against Enterobacter cloacae 1321E was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID283131	Antibacterial activity against Pseudomonas aeruginosa PAO1456 expressing constitutive AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID523713	Antibacterial activity against Acinetobacter baumannii A898 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID544489	Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID559922	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-V49 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID584748	Antimicrobial activity against Acinetobacter baumannii ATCC 17978 harboring beta-lactamase OXA-58 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID534296	Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID540948	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pB-c2 plasmid expressing cephalosporinase CMY-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID534175	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID524114	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A929	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534779	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus by disk diffusion method in presence of imipenem	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID565539	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID555218	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 65 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID562948	Antimicrobial activity against Klebsiella pneumoniae PFGE clone E expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID520326	Inhibition of VIM-1 activity in Escherichia coli extracts at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID432995	Antibacterial activity against Klebsiella pneumoniae isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID68030	Antibacterial activity against Enterobacter cloacae 1321E	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID279260	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID558627	Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID351028	Antibacterial activity against Salmonella typhi at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID523740	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E456	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529488	Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID549043	Antimicrobial activity against carbapenem susceptible Klebsiella pneumoniae isolate KpSCMC2c harboring bla SHV-12 gene isolated from patient with pulmonary infection by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID518728	Activity of Pseudomonas stutzeri beta-lactamase DIM-1 by UV-spectrophotometry	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
AID322315	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID289882	Antibacterial activity against Staphylococcus aureus giorgio	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID293785	Antimicrobial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis, antimicrobial activity, and QSAR studies of furan-3-carboxamides.
AID373047	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FZ4A18 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID498832	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae CY1 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524463	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573129	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID549331	Antimicrobial activity against Escherichia coli isolate 32 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID546423	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-3 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID510984	Antimicrobial activity against Acinetobacter baumannii 1417 after 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID425333	Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID511105	Cmax in C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID558052	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID534865	Antimicrobial activity against Non-ESBL Proteus mirabilis assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID425967	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID558792	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella pneumoniae assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID534391	Antibacterial activity against Escherichia coli JM109 by microdilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID535367	Antimicrobial activity against Pseudomonas aeruginosa isolated from non-ICU patient by broth microdilution method in presence of Tazobactam	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID322784	Antimicrobial activity against Bacteroides distasonis assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID587527	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-361 infected in sc dosed CD-1 mouse	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID405793	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 1.5 hrs by CLSI method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID541025	Induction of Burkholderia cenocepacia 5007902 beta-lactamase PenB34 at 0.6 ug/ml in presence of cephalothin as substrate	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID584567	Antimicrobial activity against Acinetobacter lwoffii isolate A expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID423069	Antibacterial activity against 53_F11 allele containing Pseudomonas aeruginosa PAO1 H1124 mutant strain with PA5279::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID535071	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID405792	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 5/6	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID573197	Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAB biofilm harboring nfxB G125T mutant gene selected at 0.5 ug/ml of azithromycin after 1 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1373310	Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID523493	Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524271	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285617	Antimicrobial activity against Pseudomonas aeruginosa 5F2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID562813	Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID559267	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID557992	Antimicrobial activity in Clostridium sordellii by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID425966	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3274 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID423067	Antibacterial activity against 69_C12 allele containing Pseudomonas aeruginosa PAO1 H1109 mutant strain with recA::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID498810	Antimicrobial activity against carbapenem-resistant Escherichia coli ZJ86 deficient in KPC-2, TEM-1, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID517971	Antimicrobial activity against Pseudomonas aeruginosa 1973E harboring beta-lactamase PSE-1 and class C enzymes by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535839	Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID560836	Antimicrobial activity against Acinetobacter baumannii isolate Ab3 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID584509	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1348 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID279183	Antibacterial activity against Escherichia coli DH10B expressing recombinant beta lactamase LAP1	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID517918	Antibacterial activity against Acinetobacter baumannii A898 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID571910	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID574462	Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID571888	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID428294	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeIJK genes with pAT807 isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID583021	Activity of Beta-lactamase FOX-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID285679	Antimicrobial activity against Pseudomonas aeruginosa 29G7 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID574772	Antimicrobial activity against Clostridium perfringens assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID534907	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID571922	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534173	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID559905	Antimicrobial activity against Escherichia coli DH5alpha by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID510971	Antimicrobial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as reduction in bacterial count in blood at total dose of 120 mg/kg/day, im administered as four divided doses after 72 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID534417	Antimicrobial activity against methicillin-susceptible Streptococcus pneumoniae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573335	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID425866	Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID561385	Antibacterial activity against Escherichia coli isolate ARL06-39 harboring beta-lactamase CMY 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID495795	Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID67231	In Vitro antibacterial activity against (Ef) Enterococcus faecalis ATCC 29212	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID360070	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra -aspartate-tetra multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID533762	Antibacterial activity against OXA-2 and OXA-19 producing Pseudomonas aeruginosa isolate P66 exhibiting PFGE C pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID495721	Activity of Escherichia coli CMY-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID766245	Ratio of Kcat to Km for recombinant NDM-1 (unknown origin)	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID405791	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 4	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID424322	Antimicrobial activity against Dialister micraerophilus assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID424329	Antimicrobial activity against Dialister propionicifaciens assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID545605	Antimicrobial activity against Pseudomonas aeruginosa PS23 with PFGE phenotype 4A expressing beta-lactamase KPC-2 obtained from blood of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID324860	Antimicrobial activity against Acinetobacter baumannii A24B after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID556698	Antimicrobial activity against multidrug resistant Escherichia coli ATCC 35218 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID556646	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID533531	Antimicrobial activity against Pseudomonas aeruginosa PA386 expressing IMP-13 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID489656	Antibacterial activity against Shigella flexneri at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID495797	Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID524130	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E412 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID540944	Antimicrobial activity against Escherichia coli DH5[alpha] transformant harboring pA172 plasmid expressing cephalosporinase CMY-31 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
AID557476	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID401686	Antibacterial activity against Staphylococcus aureus SG511	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID583029	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID1765573	Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID433367	Antibacterial activity against Anaerococcus tetradius isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID523518	Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID285592	Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID401683	Antibacterial activity against Streptococcus pyogenes 308A	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID511667	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID424330	Antimicrobial activity against Dialister invisus assessed as susceptibility breakpoint by CLSI method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID524078	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P322	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573393	Antibacterial activity against ceftazidime-susceptible Providencia sp. assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID69659	Minimum inhibitory concentration was determined in heart infusion agar medium against Escherichia coli NIHJ JC-2	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID532217	Antibacterial activity against nonreplicate Acinetobacter baumannii clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID524113	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A897	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285441	Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID557678	Antimicrobial activity in Prevotella baroniae by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID565521	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID586065	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 transformed with plasmid harboring ISAba1-blaOXA-82 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID518186	Antimicrobial activity against Acinetobacter baumannii HPA 327009 harboring beta-lactamase OXA-25 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID587980	Antibacterial activity against Escherichia coli AS226 carrying pBSDS237A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID519292	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-105 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID584582	Antimicrobial activity against Escherichia coli NEB 5-alpha harboring beta-lactamase OXA-58 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID489657	Antibacterial activity against Pseudomonas aeruginosa at 1 mg/ml after 24 hrs by agar-well diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Metal based biologically active compounds: design, synthesis, and antibacterial/antifungal/cytotoxic properties of triazole-derived Schiff bases and their oxovanadium(IV) complexes.
AID584725	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3800 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID535062	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-5 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID209902	In vitro antibacterial activity against PRSP.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID565724	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID152327	Compound was tested in vitro for antibacterial activity against Proteus vulgaris A-21559	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID289894	Antibacterial activity against Pseudomonas cepacia	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID285599	Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID562338	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID1562260	Antimycobacterial activity against Mycobacterium smegmatis atR37 assessed as decrease in drug resistance development at 10 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID295835	Antibacterial activity against Corynebacterium diphtheriae after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID557513	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID250298	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID424858	Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID529304	Antimicrobial activity against Acinetobacter baumannii isolate Ac058 expressing beta-lactamase Oxa-58 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
AID534627	Antimicrobial activity against Non-ESBL Escherichia coli assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1124632	Stability of the compound in crystalline form assessed as compound remaining after 6 months at 10 mg/ml at 23 degC in presence of 0.1 equiv of NaHCO3	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID521836	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID572900	Antibacterial activity against blaVIM-2-positive Pseudomonas aeruginosa by CLSI Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Molecular epidemiology of outbreak-related pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene.
AID324312	Antimicrobial activity against Serratia marcescens AW isolated from parotidectomy patient	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SME-2-producing Serratia marcescens isolate from Switzerland.
AID396214	Total clearance in nosocomial pneumonia patient at 1 g administered every 8 hrs for 3 days as shot-term iv infusion for 40 mins or at a loading dose of 1 g and maintenance dose of 2 g administered daily for 3 days as continuous iv infusion presence of cil	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
AID557512	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID429079	Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
AID535133	Antimicrobial activity against Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID557706	Antimicrobial activity in Porphyromonas asaccharolytica by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID576068	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID573528	Antibacterial activity against Acinetobacter isolate A74510 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID524491	Antibacterial activity against Pseudomonas aeruginosa P358 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID564019	Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID531680	Antimicrobial activity against Acinetobacter baumannii Ab290 harboring TVICU53 plasmid by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID583036	Ratio of Kcat to Km for Beta-lactamase ACT-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID373763	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID324866	Antimicrobial activity against Acinetobacter baumannii A24D after 4 days in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID524298	Antibacterial activity against Pseudomonas aeruginosa P338 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373294	Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524121	Antibacterial activity against beta-lactamase-negative Escherichia coli E344 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555554	Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
AID495806	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID373761	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID583026	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli EC-6 plasmid carrying AmpC-B2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID394679	Antibacterial activity against Pseudomonas aeruginosa tracheal aspirate isolate 12 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID567283	Ratio of Kcat to Km for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Km for Acinetobacter baumannii ADC-11 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID573801	Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID495695	Activity of Klebsiella pneumoniae KPC-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID499058	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX24 deficient in TEM-1, DHA-1, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID323632	Ratio of Kcat to Km for Aeromonas hydrophila beta lactamase CphA at pH 8.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID533384	Antimicrobial activity against Bacteroides nordii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1824304	Antimicrobial activity against Escherichia coli T2435 expressing KPC-2 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID405818	Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID508735	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring acquired beta-lactamase OXA-2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID524003	Antimicrobial activity against Acinetobacter baumannii ATCC 15151 harboring ISAba1-blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID542392	Clearance in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID569256	Antimycobacterial activity against Mycobacterium bovis BCG str. Tokyo 172	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID530602	Antibacterial activity against Escherichia coli J53 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID524470	Antibacterial activity against Pseudomonas aeruginosa P356 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373288	Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID295801	Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID573564	Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID545395	Antimicrobial activity against Pseudomonas aeruginosa PS1 with PFGE phenotype 9C expressing beta-lactamase IMP-18 and OXA-2 obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID499064	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae GX56 deficient in ompC and expressing low levels of ompF DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID519473	Induction of beta-lactamase L1 expression in Stenotrophomonas maltophilia M1 mutant assessed as L1 activity at 10 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID588131	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 2 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID286238	Antibacterial activity against Salmonella typhi at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID237224	Relative half life of hydrolysis to meropenem by partially purified porcine renal DHP-I	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID283391	Antimicrobial activity against Nocardia farcinica after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID573509	Antibacterial activity against Citrobacter amalonaticus isolate Ca1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID534927	Antimicrobial activity against Ceftazidime non-susceptible Serratia marcescens assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573204	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T41C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID524091	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P370	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546619	Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
AID283133	Antibacterial activity against Pseudomonas aeruginosa KG2212 producing MexAB-OprM efflux pump	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID463429	Antimicrobial activity against Staphylococcus aureus at 1 mg/ml by agar-well diffusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.
AID70748	In Vitro antibacterial activity against (Ec TEM2) Escherichia coli Beta-lactam producing strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID524593	Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID521992	Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID285648	Antimicrobial activity against Pseudomonas aeruginosa 19B3 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID433388	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM1648 with deltarel-lytH region after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID584690	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4459 harboring mutation in Conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID585435	Antimicrobial activity against Pseudomonas aeruginosa PA14 mutS gene hypermutant by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID559542	Antibacterial activity against non-ciprofloxacin-susceptible Pseudomonas aeruginosa assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID573330	Antibacterial activity against Klebsiella pneumoniae isolate Kp1239 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID7561	Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID250288	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID532400	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID205975	In vitro antibacterial activity against Sa MR(II) homogeneous methicillin resistant Staphylococcus aureus	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID283126	Antibacterial activity against Escherichia coli C600 expressing ESBL CTX-M3	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID360068	Inhibition of Enterococcus faecium M512 PBPfm transpeptidase activity assessed as tetra-aspartate-tri multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID557525	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID562741	Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID425120	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID511137	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 11	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1824270	Antimicrobial activity against Escherichia coli T2359 expressing NDM-1 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID577228	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB039 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID1373315	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID7533	Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID547797	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237F mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID520327	Antimicrobial activity against Acinetobacter baumannii isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID68876	In vitro synergistic activity against Escherichia coli ATCC 35218 (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID1373335	Inhibition of recombinant human GABA A alpha2beta2gamma2 receptor expressed in CHO-K1 cells at 300 uM incubated at room temperature for 15 mins before the GABA addition fluorescence spectrometry	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID498840	Antimicrobial activity against Klebsiella pneumoniae GZ66T expressing SHV-11, DHA-1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524119	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A901	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID360062	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-penta multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID574464	Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID531599	Antimicrobial activity against Klebsiella pneumoniae Kp2792 expressing beta-lactamase SHV-56 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID571906	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID558604	Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID574530	Antimicrobial activity against Prevotella bivia assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID283132	Antibacterial activity against Pseudomonas aeruginosa PAO4069 expressing inducible AmpC	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID521484	Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID495908	Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID369642	Antibacterial activity against Acinetobacter baumannii C clone by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID1373318	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID523731	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E458	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1373302	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID295797	Antibacterial activity against Pseudomonas aeruginosa 5455 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID546420	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-5 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID498823	Antimicrobial activity against Klebsiella pneumoniae WH77T expressing IMP-4, TEM-1, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID433368	Antibacterial activity against Finegoldia magna isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID522386	Antimicrobial activity against Escherichia coli NI540 carrying cloned class C beta-lactamase TRU-1 gene	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID529647	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID587982	Antibacterial activity against Escherichia coli AS226 carrying pBSDD240A mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID433362	Antibacterial activity against Clostridium innocuum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID565545	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID574514	Antimicrobial activity against Bacteroides ovatus assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID324360	Antibacterial activity against Acinetobacter johnsonii 7037 expressing SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID558333	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID1056845	Antibacterial activity against TEM-1/SHV-12 expressing Enterobacter cloacae isolate 306 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID289913	Antibacterial activity against Proteus vulgaris 868	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID546163	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-03 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID286237	Antibacterial activity against Pseudomonas aeruginosa at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID523949	Antibacterial activity against beta-lactamase-positive ESBL-negative Escherichia coli E484 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID425974	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 24 after 50 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID203038	Minimum inhibitory concentration against aerobic organism Shigella species strain 2880	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID556670	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 25 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID498828	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae SZ92 deficient in IMP-4, TEM-1, CTX-M-14, DHA-1, qnrB10/B4-like, aac(6')-Ib, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524109	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A928	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID574042	Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID285439	Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID433004	Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID521842	Antibacterial activity against Escherichia coli J53 by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID518823	Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID535755	Antimicrobial activity against community-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID573124	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID405637	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 5	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID562760	Antimicrobial activity against Klebsiella pneumoniae PFGE clone C expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID559261	Antimicrobial activity against Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID560132	Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay relative to benzylpenicillin	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID66895	Antibacterial activity against Enterococcus faecalis	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID519801	Inhibition of Bocillin FL binding to PBP5 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID405824	Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID582968	Antimicrobial activity against beta-lactamase A and B-deficient Yersinia enterocolitica GY5718 after 20 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID162719	Compound was evaluated for the antibacterial activity against Proteus	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID532404	Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID425111	Antimicrobial activity against beta lactamase-positive Bacteroides thetaiotaomicron isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523500	Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID510512	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate W2AC8-S10 expressing OXA-51	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID422648	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID534648	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID523945	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E451 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID576535	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS080792 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID518523	Antimicrobial activity against Escherichia coli TOP10 after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID523758	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E509	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557271	Antimicrobial activity against Streptococcus pneumoniae 2688 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID533568	Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID210400	In vivo antibacterial activity against Streptococcus pyogenes 77A	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID433360	Antibacterial activity against Clostridium cadaveris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID564021	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-2 by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID524280	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E417 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID546169	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-09 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID433393	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM563 harboring active lytH gene and inactive llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID583017	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli ECB-1 plasmid carrying ACC-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID433390	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SR-17164 harboring intact lytH gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID534490	Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-EcG plasmid and ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID499072	Antimicrobial activity against Citrobacter freundii RJ78 expressing CMY-2, qnrA1, aac(6')-Ib-cr, ompC by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565719	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID582969	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID573189	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID524490	Antibacterial activity against Pseudomonas aeruginosa P341 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID433377	Antibacterial activity against low-level methicillin-resistant Staphylococcus aureus SR-17238 after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID524281	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E420 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534599	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID565544	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID573597	Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID557952	Antimicrobial activity in Actinomyces by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID558754	Antibacterial activity against methicillin-susceptible, tetracycline-resistant and chloramphenicol-resistant Staphylococcus aureus deltaIP-KVR by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID529842	Antibacterial activity against imipenem-resistant Pseudomonas aeruginosa clinical isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID562750	Antimicrobial activity against Escherichia coli K-12 by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID544497	Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP10	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID520970	Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID524122	Antibacterial activity against beta-lactamase-negative Escherichia coli E345 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID563595	Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as appearance of long filaments at 0.5 X MIC after 2 hrs by Live/dead cell viability assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID534649	Antimicrobial activity against Non-ESBL Klebsiella pneumoniae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID372612	Antibacterial activity against rifampin-resistant Escherichia coli C600 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID295809	Antibacterial activity against Pseudomonas aeruginosa 880/2 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID559920	Antibacterial activity against Escherichia coli TOP10 harboring recombinant plasmid RTG4-S69 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID555202	Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID523504	Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID283396	Antimicrobial activity against Nocardia veterana after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID203438	Antibacterial activity against methicillin-resistant coagulase negative Staphylococci (MRCNS)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID573500	Antibacterial activity against Klebsiella pneumoniae isolate Kp38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID295794	Antibacterial activity against Enterobacter cloacae 34 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID532389	Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID571696	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID289900	Antibacterial activity against Salmonella paratyphi A	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID531677	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-4 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID583097	Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID531600	Antimicrobial activity against Escherichia coli JM109 harboring pE1 plasmid expressing beta-lactamase SHV-11 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID529645	Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID564951	Antimicrobial activity against Acinetobacter baumannii isolate Ab33 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID549337	Antimicrobial activity against Escherichia coli ATCC 25922 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID422688	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3413 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID372606	Antibacterial activity against rifampin-resistant Escherichia coli C600 transconjugant producing beta-lactamase of pI 5.2 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID519140	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene assessed as resistant strains by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID557479	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID558606	Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID69478	Minimum inhibitory concentration against Escherichia coli 1507E was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID549335	Antimicrobial activity against Escherichia coli isolate Z1 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID517984	Antimicrobial activity against Escherichia coli Libyien harboring beta-lactamase CMY-2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID524283	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E457 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529483	Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID557470	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae 1076 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID586057	Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID520387	Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID588123	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 1 expressing beta-lactamase NDM-1 obtained from urine of patient by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID564691	Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates assessed as susceptible isolates by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.
AID576290	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1528456	Antibacterial activity against Moraxella catarrhalis assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID510510	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate N2AC9-18 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID583239	Antibacterial activity against Serratia spp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Synthesis and spectrum of the neoglycoside ACHN-490.
AID373758	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID557515	Displacement of Biocillin FL from Streptococcus pneumoniae 1076 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID584318	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID289376	Antibacterial activity against Klebsiella pneumoniae PCI602	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID499060	Antimicrobial activity against Enterobacter aerogenes PU41T expressing CTX-M-14, DHA-1, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524123	Antibacterial activity against beta-lactamase-negative Escherichia coli E346 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID495707	Kcat/Km ratio of Pseudomonas aeruginosa AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID520968	Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID206268	In vitro antibacterial activity against Staphylococcus aureus 3004 Methicillin-resistant Staphylococcus aureus.	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis and antibacterial evaluation of novel 2-[N-Imidoylpyrrolidinyl] carbapenems.
AID495742	Kcat/Km ratio of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID534410	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID529651	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID283117	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM4	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID1373295	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1354447	Antimicrobial activity against Yersinia pestis KIM6+ harboring arabinose inducible type 1 signal peptidase	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Optimization of a β-Lactam Scaffold for Antibacterial Activity via the Inhibition of Bacterial Type I Signal Peptidase.
AID200874	Minimum inhibitory concentration against Salmonella Typhimurium was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID425116	Antimicrobial activity against Clostridium difficile isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID428291	Antimicrobial activity against Acinetobacter baumannii BM4652 expressing adeABC adeIJK double mutant isolated from patient with urinary tract infection by E test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
AID498826	Antimicrobial activity against Citrobacter freundii SZ63 expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535132	Antimicrobial activity against Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID557498	Displacement of Biocillin FL from Streptococcus pneumoniae 1077 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID285339	Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America.
AID286236	Antibacterial activity against Staphylococcus aureus at 100 ug/100 uL after 24 hrs	2007	Journal of natural products, May, Volume: 70, Issue:5	Microbial transformation of (-)-guaiol and antibacterial activity of its transformed products.
AID368745	Antimicrobial activity against Escherichia coli Ec8 expressing TEM-21 AmpC gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID516145	Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID545461	Antimicrobial activity against Pasteurella sp. assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID584308	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0583 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1649626	Substrate activity at IMP-1 (unknown origin) assessed as Kcat/Km ratio for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID368738	Antimicrobial activity against Escherichia coli Ec2 containing pEc1-B plasmid expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID530324	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID582893	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 0.5 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID523927	Antibacterial activity against beta-lactamase-negative Escherichia coli E346 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534632	Antimicrobial activity against ESBL producing Escherichia coli assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID394686	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID534172	Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID534487	Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK415 plasmid and ampN with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID534302	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID524103	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A912	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584572	Antimicrobial activity against Acinetobacter lwoffii isolate F expressing beta-lactamase OXA-164 isolated from tracheostoma of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID533559	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA382	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID495735	Kcat/Km ratio of Klebsiella pneumoniae Beta-lactamase TEM-26 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID545344	Displacement of [14C]benzylpenicillin from PBP6 Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID564022	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-161 by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
AID1824338	Antimicrobial activity against Klebsiella pneumoniae T2301 expressing NDM-1 assessed as inhibition of bacterial growth at 0.5XMIC for 6 hrs by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1858577	Antibacterial activity against Mycobacterium Mycobacterium abscessus CIP 104536T infected in mouse RAW264.7 cells assessed as cell viability incubated for 4 to 5 days	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
AID576537	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008024 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID295837	Antibacterial activity against Salmonella oranienburg after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID283121	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM9	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID544967	Antimicrobial activity against Proteus mirabilis expressing beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID573533	Antibacterial activity against Enterobacter cloacae El3518 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID373765	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID530818	Antibacterial activity against amoxicillin and amoxicillin-clavulanate resistant Klebsiella pneumoniae UCL-1 assessed as zone of inhibition by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
AID528599	Antimicrobial activity against blaKPC-2 and blaTEM-1 producing Escherichia coli 2138 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
AID530327	Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID207639	Antibacterial activity against Staphylococcus aureus SG 511	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID560591	Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID401690	Antibacterial activity against Klebsiella oxytoca 1082	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID573207	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G461A mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID498809	Antimicrobial activity against Klebsiella pneumoniae ZJ99T expressing KPC-2, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID565510	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID425980	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 14 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID285573	Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID548004	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237P mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID558597	Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID573796	Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID584511	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_23420 harboring mutation in putative zinc-binding dehydrogenase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1561471	Antibacterial activity against wild type beta-lactam-resistant Klebsiella pneumoniae in Mueller-Hinton broth by CLSI protocol based method
AID519797	Inhibition of Bocillin FL binding to PBP1B in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID207156	Antibacterial activity against Staphylococcus aureus 285	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID511020	Half life in C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID562758	Antimicrobial activity against Klebsiella pneumoniae PFGE clone A expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID368733	Antimicrobial activity against Enterobacter aerogenes Ea1 expressing TEM-24b AmpC +/- TEM-1 or TEM-2 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID519808	Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa PAO1 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID533563	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA758 isolated from patient with cystic fibrosis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID1528454	Antibacterial activity against Burkholderia cepacia assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID289912	Antibacterial activity against Proteus mirabilis 174/3	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID289906	Antibacterial activity against Enterobacter cloacae	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID584724	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3649 harboring mutation in putative membrane-associated zinc metalloprotease by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID529830	Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolates by microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.
AID524462	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557521	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID1056852	Antibacterial activity against CTX-15 expressing Stenotrophomonas maltophilia isolate 125 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID523751	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E360	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557746	Antimicrobial activity in Anaerococcus prevotii by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID545552	Ratio of MIC for Escherichia coli ERR2b to MIC for Escherichia coli NIHJ	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID63906	Compound was tested in vitro for antibacterial activity against Enterobacter cloacae A-9695	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Synthesis and in vitro activity of 1 beta-methyl C-2 quaternary heterocyclic alkylthio carbapenems.
AID544531	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID360058	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate tri multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID498824	Antimicrobial activity against Citrobacter freundii SZ62 expressing IMP-4, TEM-1, CMY-2, qnrS1, aac(6')-Ib-cr by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID571698	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID545346	Displacement of [14C]benzylpenicillin from PBP1B in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID432998	Antibacterial activity against Proteus rettgeri isolated from patient with diabetic foot infection after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID520779	Antibacterial activity against Escherichia coli EC600 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID545348	Displacement of [14C]benzylpenicillin from PBP3 in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID571892	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID517985	Antimicrobial activity against Pseudomonas aeruginosa BA harboring beta-lactamase Class C by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID425112	Antimicrobial activity against beta lactamase-positive Prevotella intermedia isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID394496	Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID285574	Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495691	Activity of Escherichia coli CMY-2	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID585180	Activity of Beta-lactamase GES-13 K104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID573557	Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID295836	Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID372608	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-12 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID524288	Antibacterial activity against Pseudomonas aeruginosa P369 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID115945	In vivo inhibitory activity against Staphylococcus aureus MB2985 (methicillin-susceptible) in mouse systemic infection model	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID404967	Activity of OXA58 from Acinetobacter baumannii 186 isolate carrying three bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID433196	Antibacterial activity against Streptococcus dysgalactiae subsp. equisimilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID495803	Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID522008	Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID577234	Antibacterial activity against intI1-positive tigecycline-intermediate Acinetobacter baumannii AB099 with PFGE subgroup H containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID546179	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-19 with PDC-3 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573115	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID565199	Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID582892	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 1.2 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID293786	Antimicrobial activity against Klebsiella pneumoniae ATCC 1003 by broth microdilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis, antimicrobial activity, and QSAR studies of furan-3-carboxamides.
AID529486	Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID395741	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest in presence of 0.781 uM efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID369643	Antibacterial activity against Acinetobacter haemolyticus expressing carbapenemase-encoding blaOXA-40 gene by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID524104	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A892	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522006	Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID520709	Antibacterial activity against Acinetobacter baumannii MAD by disk diffusion method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID520871	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU57 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID546164	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-04 with PDC-2 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID573206	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T562C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID69002	In vitro synergistic activity against Escherichia coli C600N + (L1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID511129	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 3	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID558796	Antimicrobial activity against extended spectrum beta-lactamase-deficient Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID584692	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4550 harboring fimU mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID523766	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E481	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558758	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant and rifampicin-resistant Staphylococcus aureus deltaIP-rifR::vraSH14 by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID283120	Antibacterial activity against Escherichia coli C600 expressing ESBL TEM8	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
AID555226	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 103 ADC-16	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID433175	Antibacterial activity against Klebsiella oxytoca isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433200	Antibacterial activity against Bacteroides ovatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID573114	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID576519	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate AIS081058 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID584736	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5130 harboring mutation in putative rhodanese-like domain protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID546409	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-26 with PDC-6 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID574466	Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID511118	T>MIC in Acinetobacter baumannii infected New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID557501	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID495511	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID559539	Antibacterial activity against Proteus mirabilis assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID582885	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 5 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID586064	Antimicrobial activity against Acinetobacter baumannii F-type isolate by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID279182	Antibacterial activity against Enterobacter cloacae S3 isolate by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID405642	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1a	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID341595	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID351026	Antibacterial activity against Staphylococcus aureus at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID534909	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1225787	Antibacterial activity against Klebsiella pneumoniae KP1082 expressing KPC2/SHV-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID510504	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-2 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID571902	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID519813	Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID559276	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID495903	Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID509854	Antibacterial activity against Acinetobacter baumannii ATCC 17978 assessed as bacterial growth at 0.0625 mg/L in presence of 150 mM NaCl	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID586231	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae isolate 4 expressing beta-lactamase NDM-1 obtained from urine of patient by liquid microdilution method	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.
AID289918	Antibacterial activity against Corynebacterium pyogenes	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID71108	In vitro antibacterial activity against Escherichia coli 1507E by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID289908	Antibacterial activity against Serratia marcescens 370	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID521426	Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID556673	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae ATCC 11296 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID373037	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate DL34 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID523725	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E346	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID559687	Antibacterial activity against ESBL-positive Escherichia coli Top10 harboring plasmid AT517	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID544517	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-5 assessed as hydrolysis rate per mg of extracts at 100 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID547996	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237C mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID524286	Antibacterial activity against Pseudomonas aeruginosa P332 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529660	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID565424	Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
AID583090	Activity of Escherichia coli XL1-Blue IMP-1 W64A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID572140	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534486	Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK-NG plasmid by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID1765574	Antibacterial activity against Bacillus subtilis ATCC 23857 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID520388	Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID524111	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A898	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID396031	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID517923	Antibacterial activity against Acinetobacter baumannii A885 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID548020	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237E mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID562325	Ratio of Kcat to Km for Aeromonas hydrophila metallo-betalactamase CphA expressed in Escherichia coli BL21(DE3) by spectrophotometric analysis in presence of < 0.4 uM zinc ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	The structure of the dizinc subclass B2 metallo-beta-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site.
AID558605	Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID546418	Antimicrobial activity against Pseudomonas aeruginosa KG2505a harboring recombinant pBB-PDC-3 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID250292	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID498815	Antimicrobial activity against Klebsiella pneumoniae FZ47T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID524323	Antibacterial activity against Acinetobacter baumannii A896 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID530346	Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID548256	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID499063	Antimicrobial activity against Escherichia coli HX74T expressing CTX-M-3 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID533368	Antimicrobial activity against Bacteroides uniformis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID529495	Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID523951	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E358 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID522366	Antimicrobial activity against wild type Proteus mirabilis N2 mutant after 16 to 18 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.
AID559543	Antibacterial activity against levofloxacin susceptible Serratia marcescens assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID525039	Activity of pseudomonas aeruginosa Beta-lactamase OXA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Updated functional classification of beta-lactamases.
AID518522	Antimicrobial activity against Capnocytophaga sputigena CIP 104301T after 2 days by agar dilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena.
AID559525	Antibacterial activity against Acinetobacter calcoaceticus assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID1858575	Antibacterial activity against Mycobacterium abscessus CIP 104536T smooth morphotype incubated for 1 to 14 days	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
AID285588	Antimicrobial activity against Pseudomonas aeruginosa 65.36-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID564947	Antimicrobial activity against Acinetobacter baumannii isolate Ab12 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID570789	Antimicrobial activity against Acinetobacter baumannii AB017 transformant harboring bla-OXA-23 gene by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
AID394687	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexXY-OprM pump by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID573130	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID521967	Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
AID372347	Antibacterial activity against Pseudomonas aeruginosa PAO1/MEM mutant by CLSI broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID164880	In Vitro antibacterial activity against (Pa) Pseudomonas aeruginosa ATCC 27853	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID289379	Antibacterial activity against Pseudomonas aeruginosa PAO1	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID524493	Antibacterial activity against Pseudomonas aeruginosa P326 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584575	Antimicrobial activity against Acinetobacter lwoffii isolate I expressing beta-lactamase OXA-58 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID534484	Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ harboring ampG with xylE-Gmomega cassette insertion by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID584691	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4527 harboring pilC mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID495513	Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID573351	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID518817	Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID531775	Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID68871	In vitro synergistic activity against Escherichia coli 300 + (TEM-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID532898	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID556674	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 1 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID583023	Activity of Beta-lactamase ACT-1	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID368751	Antimicrobial activity against Klebsiella pneumoniae Kp3 expressing SHV-2a TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID498844	Antimicrobial activity against Klebsiella pneumoniae XJ81T expressing TEM-1, SHV-12, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559820	Antimicrobial activity against Escherichia coli J53 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID495514	Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID394713	Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID498370	Antimicrobial activity against erythromycin- and streptomycin-resistant Streptococcus gordonii Tol1 harboring R483P mutation in ptsI assessed as bacterial count at 2 ug/ml after 24 hrs by macrodilution technique	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID498820	Antimicrobial activity against Klebsiella pneumoniae WH76 expressing IMP-4, TEM-1, SHV-14, CTX-M-3, qnrS1 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID529573	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pLBII carrying beta-lactamase CAR-1 gene after 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID555209	Antibacterial activity against Acinetobacter genomosp. 3 isolate 90 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID165037	In vitro antibacterial activity against Pseudomonas aeruginosa 1771M by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID1826214	Antibacterial activity against NDM-5 producing Escherichia coli T2351 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID495739	Kcat/Km ratio of Pseudomonas aeruginosa OXA-10 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529857	Antibacterial activity against Pseudomonas aeruginosa N092 expressing MexE-MexD-OprN gene and OprD mutant gene and harboring nfxC mutant gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID511126	Antimicrobial activity against Acinetobacter baumannii clinical isolate	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID322791	Antimicrobial activity against Bacteroides merdae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID545405	Antimicrobial activity against Pseudomonas aeruginosa PS12 with PFGE phenotype 7B obtained from sputum of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID1373305	Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID517973	Antimicrobial activity against Serratia marcescens S6 harboring beta-lactamase SME-1.AmpC by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID534104	Antibacterial activity against Acinetobacter baumannii PFGE type A isolate by Etest MBL strip method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
AID535756	Antimicrobial activity against hospital-acquired Escherichia coli obtained from patient with intra-abdominal infection assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
AID557473	Displacement of Biocillin FL from Streptococcus pneumoniae 3413 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID565524	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534881	Antimicrobial activity against Enterobacter cloacae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID497693	Antimicrobial activity against colistin-susceptible Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
AID523888	Antimicrobial activity against Acinetobacter baumannii 6AB11 harboring ISAba1-blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID554988	Antibacterial activity against Acinetobacter genomosp. 3 isolate 56 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID1225781	Antibacterial activity against Escherichia coli EC1007 expressing KPC3 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID535168	Antimicrobial activity against imipenem susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1225786	Antibacterial activity against Klebsiella pneumoniae KP1008 expressing KPC2 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID295820	Antibacterial activity against Salmonella orion after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID395731	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 184 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID495825	Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID524309	Antibacterial activity against Pseudomonas aeruginosa P376 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID529865	Ratio of MIC for Pseudomonas aeruginosa N092 to MIC for Pseudomonas aeruginosa PAO1	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID533760	Antibacterial activity against OXA-30, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P19 exhibiting PFGE F pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID544494	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID521835	Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID522385	Antimicrobial activity against Aeromonas enteropelogenes M1 hyperproducing beta-lactamase AmpC	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes.
AID535832	Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID1449631	Anti-inflammatory activity in mouse model of CLP-induced sepsis assessed as survival time at 25 ug/g, sc in presence of atorvastatin (Rvb = 20 +/- 1.66 hrs)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Recent updates of carbapenem antibiotics.
AID558612	Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID546408	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-25 with PDC-6 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID534908	Antimicrobial activity against Citrobacter with derepressed AmpC beta-lactamsae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573374	Antibacterial activity against multidrug-resistant Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID576293	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID562751	Antimicrobial activity against Escherichia coli DH5alpha harboring pBC-CTX-M-71 plasmid by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID295830	Antibacterial activity against Proteus vulgaris 868 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID565198	Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
AID584584	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring beta-lactamase OXA-164 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID368741	Antimicrobial activity against Escherichia coli Ec3 expressing CTX-M-15 TEM-1 OXA-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID404964	Activity of OXA58 from Acinetobacter baumannii T183 isolate carrying one bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID523496	Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID529849	Antibacterial activity against beta-lactamase-overproducing Pseudomonas aeruginosa N043 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
AID405471	Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain.
AID524478	Antibacterial activity against Pseudomonas aeruginosa P323 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520979	Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID524488	Antibacterial activity against Pseudomonas aeruginosa P363 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID535704	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A S287N mutant protein by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID547785	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237L mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID557471	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae 1077 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID535140	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID1356832	Antimicrobial activity against Klebsiella pneumoniae NCTC 13442 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID533130	Antimicrobial activity against Bacteroides distasonis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID525549	Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1052 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
AID529498	Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID425114	Antimicrobial activity against beta lactamase-positive Fusobacterium nucleatum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID533758	Antibacterial activity against PER-1 producing Pseudomonas aeruginosa isolate P170 exhibiting PFGE G pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID1124627	Stability of the compound in crystalline form in deionized water assessed as time at which 90% of initial UV-absorbance remains at 10 mg/ml at 23 degC	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics.
AID285631	Antimicrobial activity against Pseudomonas aeruginosa 10A6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID585197	Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant by Etest method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID433198	Antibacterial activity against Bacteroides fragilis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID555223	Activity of Acinetobacter genomosp. 3 isolate 65 ADC-14	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID609155	Antibacterial activity against Enterobacter cloacae ATCC 13047	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID279271	Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID495670	Antimicrobial activity against Escherichia coli DH5-alpha expressing beta-lactamase TEM-1 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID322785	Antimicrobial activity against Bacteroides ovatus assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID574724	Antimicrobial activity against Prevotella buccae assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID523889	Antimicrobial activity against Acinetobacter baumannii 6AB15 harboring ISAba1-blaOXA-23 and blaOXA-66 gene by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
AID341596	Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
AID523505	Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID545574	Ratio of MIC for Pseudomonas aeruginosa PMR2a to MIC for Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID285689	Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
AID422493	Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID523503	Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID495809	Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID322314	Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID422657	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID519287	Antimicrobial activity against Acinetobacter radioresistens isolates by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID584694	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4946 harboring mutL mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID587612	Antimicrobial activity against carbapenemases KPC-producing Klebsiella pneumoniae VA-406 infected in sc dosed CD-1 mouse	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
AID549336	Antimicrobial activity against Escherichia coli isolate 49 harboring bla CTX-M-3a gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
AID519627	Antimicrobial activity against Brachyspira pilosicoli 80.10 without producing beta-lactamase OXA-63 by disc diffusion method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID584524	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3589 harboring mutation in acetyl-coenzyme A (CoA) acetyltransferase (thiolase) by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID564955	Antimicrobial activity against Acinetobacter baumannii isolate Ab185 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID373782	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab8(r) by broth dilution method in presence of 24 ug/ml efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID573600	Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID511580	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD, ampDh3 and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID565279	Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
AID1562259	Antimycobacterial activity against Mycobacterium smegmatis atR33 assessed as decrease in drug resistance development at 10 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID206793	Minimum inhibitory concentration against Staphylococcus aureus	2004	Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6	New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.
AID543427	Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID285673	Antimicrobial activity against Pseudomonas aeruginosa 24E6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1649618	Substrate activity at NDM-1 (unknown origin) assessed as Kcat for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID164881	In Vitro antibacterial activity against (Pa) hyperpermeable Pseudomonas aeruginosa Beta-lactam lacking strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID573495	Antibacterial activity against Citrobacter amalonaticus isolate Ca3927 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID205974	In vitro antibacterial activity against Sa MR(I) heterogeneous methicillin resistant Staphylococcus aureus	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID433352	Antibacterial activity against Bacteroides vulgatus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID285604	Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID576539	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS081042 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID576531	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008139 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID562755	Activity of Klebsiella pneumoniae AH27 CTX-M-15 beta-lactamase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID203148	In vivo synergistic activity against Serratia marcescens GC 4132 (Amp C)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID279267	Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID529665	Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID519798	Inhibition of Bocillin FL binding to PBP2 in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID524310	Antibacterial activity against Pseudomonas aeruginosa P326 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID556676	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 3 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID519812	Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID529463	Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID518189	Antimicrobial activity against Pseudomonas aeruginosa B4 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID545615	Antimicrobial activity against Pseudomonas aeruginosa PS36 with PFGE phenotype 11B obtained from urine of patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID70088	Antibacterial activity against Escherichia coli 1507E	1998	Bioorganic & medicinal chemistry letters, Jul-07, Volume: 8, Issue:13	Synthesis and biological properties of new 1 beta-methylcarbapenems.
AID528787	Antimicrobial activity against extended-spectrum beta lactamase producing Escherichia coli expressing beta-lactamase CTX-M-3, CTX-M-15 and CTX-M-55 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID499046	Antimicrobial activity against Klebsiella pneumoniae ZJ68T expressing CTX-M-15 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID69003	In vitro synergistic activity against Escherichia coli C600N + (MIR-1)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID517927	Antibacterial activity against Acinetobacter baumannii A903 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519262	Selectivity ratio of AUC in pancreatitis Sprague-Dawley rat peritoneal fluid to AUC in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID285590	Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373032	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate FW-F1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID534631	Antimicrobial activity against ESBL producing Escherichia coli assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID511290	Antibacterial activity against Escherichia coli DH5alpha	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID535064	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-7 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID565517	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID524129	Antibacterial activity against beta-lactamase-positive ESBL-positive Escherichia coli E458 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1765577	Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID529579	Ratio of Kcat to Km for Legionella gormanii ATCC 33297T beta-Lactamase FEZ-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID535691	Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID71105	In vitro antibacterial activity against Escherichia coli 078 by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID545551	Antibacterial activity against Escherichia coli ERR2b selected at 2 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID548036	Antimicrobial activity against Escherichia coli DH10B by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID556659	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 14 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID498361	Antimicrobial activity against rifampin resistant Klebsiella pneumoniae 52deltaacrB containing isogenic acrB knockout assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.
AID534889	Antimicrobial activity against Enterobacter cloacae with derepressed AmpC beta-lactamsae assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID582971	Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID564531	Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Extended-spectrum cephalosporinase in Acinetobacter baumannii.
AID564949	Antimicrobial activity against Acinetobacter baumannii isolate Ab58 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID584935	Antimicrobial activity against Pseudomonas aeruginosa harboring mucD mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID351025	Antibacterial activity against Bacillus subtilis at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID495690	Activity of Klebsiella pneumoniae Beta-lactamase TEM-26	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID572142	Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534485	Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK415 plasmid by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
AID585186	Ratio of Kcat to Km for Beta-lactamase GES-13 K104, N170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID565709	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID562340	Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-2 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID519289	Antimicrobial activity against Escherichia coli TOP10 harboring Beta-lactamase OXA-23 by Etest	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID577238	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB125 with PFGE subgroup A1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID395735	Antimicrobial activity against imipenem-susceptible invasive nontypeable Haemophilus influenzae isolate 251 by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID558783	Antimicrobial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID433178	Antibacterial activity against Proteus vulgaris isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID433394	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SR-17164 harboring inactive lytH gene and active llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID533400	Antimicrobial activity against Clostridium paraputrificum assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID573371	Antibacterial activity against ceftazidime-susceptible Serratia marcescens assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID576265	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID562334	Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
AID587984	Antibacterial activity against Escherichia coli AS226 carrying pBSDF160T mutant after 18 hrs by broth microdilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.
AID433353	Antibacterial activity against Parabacteroides distasonis isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533555	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA376	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID554985	Antibacterial activity against Acinetobacter genomosp. 3 isolate 20 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID404955	Antimicrobial activity against carbapenem-resistant Acinetobacter baumannii 183 isolate carrying one bla-OXA58 gene copy by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID544963	Antimicrobial activity against Klebsiella pneumoniae expressing extended-spectrum beta-lactamase and beta-lactamase AmpC by Etest	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID565718	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1765580	Antibacterial activity against Acinetobacter baumannii ATCC 19606 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID285575	Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID425317	Bactericidal activity against Clostridium perfringens isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID548471	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID207880	Inhibitory concentration against purified beta-Lactam-resistant PBP2 from Staphylococcus epidermidis	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID511136	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 10	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID583082	Ratio of Kcat to Km for Escherichia coli BL21(DE3) wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID557485	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID535131	Antimicrobial activity against Pseudomonas aeruginosa assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573377	Antibacterial activity against imipenem-susceptible Acinetobacter assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285587	Antimicrobial activity against Pseudomonas aeruginosa 65.36-2 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID558602	Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID557469	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae 3009 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID573366	Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID323384	Effect on Pseudomonas aeruginosa ATCC 27853 induced sepsis in BALB/c mouse assessed as mortality at 20 mg/kg, iv for 72 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID250285	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID511002	Ratio of Cmax to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID425098	Antimicrobial activity against Anaerococcus prevotii isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID523515	Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID433392	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SRM551 harboring active lytH and llm gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID405638	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 4	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID533558	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA381	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID532213	Antibacterial activity against nonreplicate Enterobacter aerogenes clinical isolate by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID1373316	Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1528448	Antibacterial activity against Klebsiella oxytoca assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID535059	Antimicrobial activity against Acinetobacter genomic species 13TU by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID535138	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID555221	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 109 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID533557	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA380	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID559091	Antimicrobial activity against bla OXA-66 gene-deficient Acinetobacter baumannii isolate A2 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID557267	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae 24 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID583019	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Escherichia coli DH10B plasmid carrying DHA-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID520713	Antibacterial activity against Escherichia coli TOP10 harboring pOXA-97	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID70744	In Vitro antibacterial activity against (Ec DC2) hyperpermeable Escherichia coli strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID499065	Antimicrobial activity against carbapenem-resistant Enterobacter aerogenes WH85 deficient in TEM-1, CTX-M-3, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511139	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 13	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1373280	Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID531602	Antimicrobial activity against Escherichia coli JM109 harboring pE1MD plasmid expressing beta-lactamase SHV-56 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID583086	Ratio of Kcat to Km for Escherichia coli XL1-Blue IMP-1 W64A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID522364	Antimicrobial activity against PpmrI knockout mutant Proteus mirabilis dIp after 16 to 18 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.
AID528917	Antimicrobial activity against extended-spectrum beta lactamase producing Klebsiella pneumoniae expressing beta-lactamase CTX-M-14 and CTX-M-27 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.
AID574498	Antimicrobial activity against Bacteroides thetaiotaomicron assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID283398	Antimicrobial activity against Nocardia carnea after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID558539	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID460800	Antibacterial activity against Acinetobacter baumannii UH8407 after 16 to 20 hrs by microdilution susceptibility test	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii.
AID544585	Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155
AID534645	Antimicrobial activity against Klebsiella pneumoniae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584848	Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER2	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID584688	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA4109 harboring ampR mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545357	Ratio of MIC for Staphylococcus aureus SRR2a to MIC for Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID405089	Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.
AID533134	Antimicrobial activity against Bacteroides fragilis assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1649625	Substrate activity at IMP-1 (unknown origin) assessed as Km for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID531771	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID401684	Antibacterial activity against Streptococcus pyogenes 77A	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID322317	Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
AID564952	Antimicrobial activity against Acinetobacter baumannii isolate Ab63 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID285440	Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID498368	Antimicrobial activity against penicillin- and streptomycin-resistant Streptococcus gordonii Tol1 harboring Tol1 mutation in ptsI assessed as bacterial count at 2 ug/ml after 24 hrs by macrodilution assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID533115	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315DeltaIP by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID510975	Antimicrobial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as reduction in bacterial count per gram of lung at total dose of 120 mg/kg/day, im administered as four divided doses after 72 hrs (RVb = 10.6+/-0.27 No_unit)	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID609148	Antibacterial activity against Staphylococcus epidermidis ATCC 12228	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID531767	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID201539	In vitro antibacterial activity against Salmonella Typhimurium by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID209755	Minimum inhibitory concentration against aerobic organism Streptococcus pyogenes strain 2874	1982	Journal of medicinal chemistry, Apr, Volume: 25, Issue:4	Quaternary heterocyclylamino beta-lactams: a generic alternative to the classical acylamino side chain.
AID582890	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 2.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID524128	Antibacterial activity against beta-lactamase-negative Escherichia coli E409 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID360069	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra-aspartate-tri-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID495726	Activity of Serratia marcescens SME-3 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID498839	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae GZ66 deficient in SHV-11, DHA-1, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID324870	Antimicrobial activity against Acinetobacter baumannii B46 in presence of efflux pump inhibitor phenyl-arginine-beta-naphthylamide by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID394675	Antibacterial activity against Pseudomonas aeruginosa blood isolate 1 carrying insertion sequence ISPa26 by disk susceptibility test	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
AID555214	Antibacterial activity against Acinetobacter genomosp. 3 isolate 243 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID532909	Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID565538	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1, and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID557490	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID571900	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID373764	Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID523408	Antimicrobial activity against oprD-deficient Pseudomonas aeruginosa PAO1 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
AID571694	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID534923	Antimicrobial activity against Serratia marcescens assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID250299	Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID535139	Antimicrobial activity against Ceftazidime non-susceptible Pseudomonas aeruginosa assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID532902	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID558692	Antimicrobial activity against Bacteroides fragilis MN32 imipenemase activity after 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Gene Context and DNA rearrangements in the carbapenemase locus of division II strains of Bacteroides fragilis.
AID577227	Antibacterial activity against intI1-positive tigecycline-susceptible Acinetobacter baumannii AB018 with PFGE subgroup G containing carbapenemase OXA-58 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID155839	Binding affinity against PBP2a receptor by competition analysis with [3H]benzylpenicillin using cell membrane fractions from the MRSA COL strain.	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID584510	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA14_15600 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID351023	Antibacterial activity against Escherichia coli at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID571914	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID524282	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E453 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573515	Antibacterial activity against Serratia marcescens isolate Sm220 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID524471	Antibacterial activity against Pseudomonas aeruginosa P369 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID583101	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 6.0 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID516146	Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID573203	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID535167	Antimicrobial activity against Acinetobacter assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559540	Antibacterial activity against Proteus vulgaris assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID524116	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A885	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID531748	Antibacterial activity against Pseudomonas aeruginosa EryR harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID564954	Antimicrobial activity against Acinetobacter baumannii isolate Ab153 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID521427	Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
AID577226	Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring gabD::ISlacZ/haha mutation by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.
AID520870	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU47 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID574027	Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID565515	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID523498	Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID583020	Antimicrobial activity against OmpC/OmpF porin deficient Escherichia coli HB4 transformed with Enterobacter asburiae CIP 105006 plasmid carrying ACT-1 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID289371	Antibacterial activity against Staphylococcus aureus 209P JC1	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID405633	Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1b	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID495702	Kcat/Km ratio of Klebsiella pneumoniae SHV-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID523497	Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID576541	Antimicrobial activity against OmpK35,OmpK36-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008141 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID285680	Antimicrobial activity against Pseudomonas aeruginosa 29G8 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID559761	Antimycobacterial activity against Mycobacterium smegmatis MC2 155 by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Protein kinase G is required for intrinsic antibiotic resistance in mycobacteria.
AID519815	Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID546421	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-1 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID279273	Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID521840	Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID558624	Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID584314	Antimicrobial activity against beta-lactamase ompC intact/ompF deficient Serratia marcescens isolate YMC0579 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID373752	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID531776	Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID422670	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1076 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID556655	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 10 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID206011	Minimum inhibitory concentration was determined in heart infusion agar medium against Staphylococcus aureus(MRSA)	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID572138	Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID524449	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID510991	Ratio of AUC to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic New Zealand rabbit meningitis model at 120 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID373775	Antibacterial activity against Escherichia coli TOP10 by Etest	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID498872	Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID495657	Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-1 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID1320836	Activity of native signal containing Klebsiella pneumoniae OXA-48 assessed as ratio of Kcat to Km by Michaelis-Menten kinetics assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID395743	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by Etest in presence of 0.390 uM efflux pump inhibitor carbonyl cyanide m-chlorophenyl-hydrazone	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID549042	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC2 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID545557	Antibacterial activity against Escherichia coli EIR2a selected at 2 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID573503	Antibacterial activity against Escherichia coli isolate Ec9381 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID1373314	Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1539481	Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae ATCC BAA-1705 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID543411	Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID518195	Antimicrobial activity against mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexJK, mexXY, opmH and pscC gene deficient Pseudomonas aeruginosa PAO750 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID523761	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E475	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID323386	Effect on Pseudomonas aeruginosa clinical isolate induced sepsis in BALB/c mouse assessed as mortality at 20 mg/kg, iv for 72 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID573118	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID324862	Antimicrobial activity against Acinetobacter baumannii A24C after 4 days by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID425863	Antimicrobial activity against Carnobacterium divergens CIP101029 at 0.5 McFarland inoculum size by E-test	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID545572	Ratio of MIC for Pseudomonas aeruginosa PIR2a to MIC for Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID544513	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID532408	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID510506	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-6 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID511288	Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID285654	Antimicrobial activity against Pseudomonas aeruginosa 19D9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495799	Ratio of Kcat to Km of KPC-2 using nitrocefin hydrolysis	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID534922	Antimicrobial activity against Serratia marcescens assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID546160	Antimicrobial activity against Pseudomonas aeruginosa PAO1 with PDC-1 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID519139	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL gene and mec type IV gene assessed as susceptible strains by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID1765576	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID1528447	Antibacterial activity against Escherichia coli assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID322790	Antimicrobial activity against Bacteroides eggerthii assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
AID532410	Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
AID396028	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID530348	Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID522367	Antimicrobial activity against PpmrI knockout mutant Proteus mirabilis dIpc complemented with PPmrI gene after 16 to 18 hrs by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.
AID555671	Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
AID530325	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
AID576320	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID1826217	Antibacterial activity against IMP-1 producing Pseudomonas aeruginosa T2325 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID564950	Antimicrobial activity against Acinetobacter baumannii isolate Ab177 overexpressing beta-lactamase OXA-51 gene mediated by novel insertion sequence ISAba9	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9.
AID535697	Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
AID558599	Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID68873	In vitro synergistic activity against Escherichia coli 4100 (no beta-lactamase)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID518191	Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID535141	Antimicrobial activity against imipenem susceptible Pseudomonas aeruginosa assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID324868	Antimicrobial activity against Acinetobacter baumannii B46 by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
AID433391	Antibacterial activity against high-level methicillin-resistant Staphylococcus aureus SR-17164 harboring lytH::IS1182 gene after 24 hrs by serial twofold dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Staphylococcus aureus clinical isolate with high-level methicillin resistance with an lytH mutation caused by IS1182 insertion.
AID524321	Antibacterial activity against Acinetobacter baumannii A910 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID572060	Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID524486	Antibacterial activity against Pseudomonas aeruginosa P340 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID555224	Ratio of Kcat to Km for Acinetobacter genomosp. 3 isolate 65 ADC-14	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID422649	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3676 by NCCLS M7-A7 method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID289378	Antibacterial activity against beta lactamase positive amoxicillin/clavulanic acid-resistant Haemophilus influenzae PRC44	2007	Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19	CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity.
AID509870	Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations.
AID516141	Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID495733	Kcat/Km ratio of Escherichia coli CTX-M-15 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID511300	Antibacterial activity against Escherichia coli DH5alpha pB-ges-1in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID1225791	Antibacterial activity against Klebsiella pneumoniae KP1088 expressing KPC3/SHV-11/TEM-1 by broth microdilution method	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
AID279814	Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China.
AID200849	Antibacterial activity against Salmonella Typhimurium	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID523495	Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID585434	Antimicrobial activity against Pseudomonas aeruginosa PA14 by EUCAST method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.
AID395745	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 by standard broth dilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID583033	Ratio of Kcat to Km for Beta-lactamase AmpC-B2	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID531519	Antibacterial activity against Bacteroides thetaiotaomicron assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID544510	Antibacterial activity against Escherichia coli TOP10 by agar dilution method in presence of clavulanic acid	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID524273	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID521488	Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID576527	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008137 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID279186	Activity of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1.
AID573368	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID523492	Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID524468	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E511 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584585	Antimicrobial activity against Acinetobacter baumannii ATCC 19606 harboring beta-lactamase OXA-58 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID559903	Antimicrobial activity against Escherichia coli TF-KO281 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID499047	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ69 deficient in SHV-28, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID523727	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Escherichia coli E348	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520697	Antimicrobial activity against Escherichia coli DH10B harboring p05283 carrying qepA and rmtB gene by agar dilution CLSI method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Plasmid-mediated qepA gene among Escherichia coli clinical isolates from Japan.
AID545613	Antimicrobial activity against Pseudomonas aeruginosa PS34 with PFGE phenotype 4A obtained from blood of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID556664	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 19 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID522023	Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID163105	Minimum inhibitory concentration against Pseudomonas aeruginosa 1771M was determined by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24	Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
AID588078	Ratio of MIC for Acinetobacter baumannii ATCC 17978 harboring plasmid pWHP825 to MIC for Acinetobacter baumannii ATCC 17978 harboring plasmid 1266	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	ISAba825, a functional insertion sequence modulating genomic plasticity and bla(OXA-58) expression in Acinetobacter baumannii.
AID401687	Antibacterial activity against Staphylococcus aureus 285	2005	Journal of natural products, May, Volume: 68, Issue:5	Cytotoxic bisindole alkaloids from a marine sponge Spongosorites sp.
AID520719	Antibacterial activity against Escherichia coli DH10B	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID373778	Ratio of MIC for Escherichia coli TOP10 expressing imipenem-susceptible Acinetobacter baumannii ab1254 blaoxa-66 gene to MIC for Escherichia coli TP10	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID558625	Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID582966	Antimicrobial activity against beta-lactamase A-deficient Yersinia enterocolitica GY5717 after 20 hrs by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Contribution of BlaA and BlaB beta-lactamases to antibiotic susceptibility of Yersinia enterocolitica biovar 1B.
AID583653	Antibacterial activity against Escherichia coli TOP10	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID289915	Antibacterial activity against Proteus rettgeri 937	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID522027	Antimicrobial activity against Escherichia coli isolate J53 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID558610	Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID373031	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU4A22 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID529484	Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID533553	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA368	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID573356	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID529458	Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID574467	Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
AID556662	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 17 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID396025	Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing pAP1 containing Escherichia coli ampD by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID324362	Ratio of kcat to Km for Acinetobacter johnsonii SCO1	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID433193	Antibacterial activity against Staphylococcus haemolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID533756	Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P102 exhibiting PFGE H pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID524302	Antibacterial activity against Pseudomonas aeruginosa P365 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID554989	Antibacterial activity against Acinetobacter genomosp. 3 isolate 60 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID69008	In vitro synergistic activity against Escherichia coli C600N + (SHV-4)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID422650	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3665 after 38 passages with moxifloxacin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID534168	Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID544488	Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID534177	Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID10762	Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID205668	In vitro inhibition of growth of methicillin-resistant Staphylococcus aureus MRSA ATCC 335893 (clinical isolates)	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position.
AID520878	Antibacterial activity against Achromobacter xylosoxidans LOL by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID574746	Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524317	Antibacterial activity against Acinetobacter baumannii A911 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID557503	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID559685	Antibacterial activity against Acinetobacter baumannii BM4652 harboring plasmid IP847	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID293787	Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	Synthesis, antimicrobial activity, and QSAR studies of furan-3-carboxamides.
AID285637	Antimicrobial activity against Pseudomonas aeruginosa 12B2 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID529649	Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID498372	Antimicrobial activity against penicillin- and streptomycin-resistant Streptococcus gordonii Tol1 harboring Tol1 mutation in ptsI after 24 hrs by macrodilution assay	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.
AID534304	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID545546	Ratio of MIC for Staphylococcus aureus SMR2a to MIC for Staphylococcus aureus ATCC 6538P	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID1765579	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated for 18 hrs by CLSI based broth dilution method	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Novel Broad-Spectrum Antimicrobial Peptide Derived from Anoplin and Its Activity on Bacterial Pneumonia in Mice.
AID529576	Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID576956	Antimicrobial activity against Shewanella algae Sa78 harboring sul2 gene by CLSI method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Reservoir of antimicrobial resistance determinants associated with horizontal gene transfer in clinical isolates of the genus Shewanella.
AID563588	Induction of ampC mRNA expression in Pseudomonas aeruginosa PAO1 at 0.5 X MIC relative to untreated control	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
AID206067	Antibacterial activity against Streptococcus pyogenes 308A	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID524094	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P376	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558038	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID368753	Antimicrobial activity against Klebsiella pneumoniae Kp5 expressing plasmid-mediated cephalosporinase ACC-1 and TEM-1	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID582891	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 1.7 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID67716	In vitro synergistic activity against Enterobacter aerogenes GC 6268 clinical isolate	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID529662	Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID556697	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pACM204 plasmid by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID584847	Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER6	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID555222	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 195 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID560554	Antimicrobial activity against Proteus vulgaris Pv5 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID495672	Antimicrobial activity against Klebsiella pneumoniae OC 4094 expressing extended-spectrum Beta-lactamase TEM-26 assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID576305	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID573537	Antibacterial activity against Klebsiella pneumoniae Kp7564 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID582978	Antimicrobial activity against ampD::lox, ampDh2::lox,ampDh3::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID531512	Antibacterial activity against Bacteroides eggerthii assessed as percent resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
AID725544	Potentiation of imipenem antimicrobial activity against methicillin-resistant Staphylococcus aureus at 10 ug/ml after 20 hrs by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Discovery of nosokophic acid, a predicted intermediate of moenomycins, from nosokomycin-producing Streptomyces sp. K04-0144.
AID250284	Susceptibility testing against Pseudomonas aeruginosa ATCC 27853; S=Susceptible	2005	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8	Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.
AID425113	Antimicrobial activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID546430	Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-1 by spectrophotometer	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID289914	Antibacterial activity against Proteus rettgeri 936	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID532900	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID574983	Antimicrobial activity against Actinomyces naeslundii assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1824307	Antimicrobial activity against Escherichia coli T2433 expressing OXA-48 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID556690	Antimicrobial activity against multidrug resistant Enterobacter aerogenes ATCC 15038 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID495684	Antimicrobial activity against wild type Acinetobacter baumannii OC 16708 deficient in beta-lactamase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID56129	Susceptibility to hog kidney dehydropeptidase-I.	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.
AID558614	Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID584503	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0667 harboring mutation in putative metallopeptidase by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID519628	Antimicrobial activity against beta-lactamase OXA-63 producing Brachyspira pilosicoli isolate BM4442 isolated from feces of patient with diarrhea by disc diffusion method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID534869	Antimicrobial activity against ESBL producing Proteus mirabilis assessed as resistant isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524295	Antibacterial activity against Pseudomonas aeruginosa P323 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID533416	Antimicrobial activity against Peptoniphilus asaccharolyticus assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID1649624	Substrate activity at IMP-1 (unknown origin) assessed as Kcat for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID495819	Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID498808	Antimicrobial activity against Klebsiella pneumoniae ZJ99 expressing KPC-2, CTX-M-3, qnrS1, ompK35 DE by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID499061	Antimicrobial activity against carbapenem-resistant Escherichia coli PU43 deficient in TEM-1, CTX-M-14, aac(6')-Ib, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID573543	Antibacterial activity against Morganella morganii Mm1229 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID373035	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ55 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID523764	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565710	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID1824292	Antimicrobial activity against Escherichia coli T2351 expressing NDM-5 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID558046	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID285623	Antimicrobial activity against Pseudomonas aeruginosa 8C4 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID565523	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID519479	Induction of beta-lactamase L1 expression in Stenotrophomonas maltophilia K279a at 0.1 to 0.8 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID544509	Metabolic stability in Escherichia coli TOP10 harboring beta-lactamase KPC-2 assessed as hydrolysis rate per mg of extracts at 100 uM after 5 mins by spectrophotometric analysis	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
AID524469	Antibacterial activity against Pseudomonas aeruginosa P332 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520775	Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
AID495728	Activity of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID562812	Antimicrobial activity against Escherichia coli DH5[alpha]	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID373034	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate BJ3-9 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID524419	Antibacterial activity against extended spectrum beta-lactamase-producing Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID425319	Bactericidal activity against beta lactamase-positive Finegoldia magna isolated from intra-abdominal infection and pelvic inflammatory disease patients assessed as 99.9% bacterial killing at 2 times MIC after 48 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID285670	Antimicrobial activity against Pseudomonas aeruginosa 24E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID207163	Antibacterial activity against Staphylococcus aureus SG 511	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID569255	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2011	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3	Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives.
AID584316	Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID560592	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID523754	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E362	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565547	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID524297	Antibacterial activity against Pseudomonas aeruginosa P337 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID395980	Central volume of distribution in nosocomial pneumonia patient at 1 g administered every 8 hrs for 3 days as shot-term iv infusion for 40 mins or at a loading dose of 1 g and maintenance dose of 2 g administered daily for 3 days as continuous iv infusion	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
AID498802	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ18 deficient in KPC-2, SHV-28, DHA-1, ompK35 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID557511	Displacement of Biocillin FL from Streptococcus pneumoniae 3676 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID285660	Antimicrobial activity against Pseudomonas aeruginosa 19F1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID576524	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate AIS070446 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID1373300	Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID558793	Antimicrobial activity against extended spectrum beta-lactamase-expressing Escherichia coli assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID285663	Antimicrobial activity against Pseudomonas aeruginosa 22D6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498818	Antimicrobial activity against Klebsiella pneumoniae GZ64 expressing IMP-4, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID373757	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID496592	Antimicrobial activity against Escherichia coli DH10B by CLSI method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID545607	Antimicrobial activity against Pseudomonas aeruginosa PS26 with PFGE phenotype 3A expressing beta-lactamase OXA-2 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID555193	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm after 18 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa.
AID533544	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA349	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID520328	Activity of Acinetobacter baumannii VIM-1 assessed as compound hydrolysis	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests.
AID525036	Activity of Acinetobacter baumannii Beta-lactamase OXA	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Updated functional classification of beta-lactamases.
AID547765	Antimicrobial activity against Escherichia coli DH10B harboring plasmid pBR322-catI carrying beta-lactamase KPC-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID576523	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008140 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID283394	Antimicrobial activity against Nocardia beijingensis after 72 hrs by microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
AID574732	Antimicrobial activity against Fusobacterium varium after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID558628	Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID584324	Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method in presence of 250 ug/ml of cloxacillin	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
AID1056838	Antibacterial activity against CTX-15 expressing Escherichia coli isolate 4024 after 18 to 24 hrs by two-fold broth microdilution assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and antimicrobial profile of N-substituted imidazolium oximes and their monoquaternary salts against multidrug resistant bacteria.
AID1539483	Antibacterial activity against carbapenem-resistant Acinetobacter baumannii ATCC BAA 1605 clinical isolates after 18 to 20 hrs in aerobic condition by CLSI-based broth microdilution assay
AID521843	Antibacterial activity against Escherichia coli J53 by Etest method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
AID556652	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 7 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID562748	Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method in presence of beta-lactamase inhibitor clavulanic acid	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
AID511127	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 1	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID499052	Antimicrobial activity against Escherichia coli PU60T expressing CMY-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID583089	Ratio of Kcat to Km for Escherichia coli XL1-Blue wild-type VIM-2 beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID546422	Antimicrobial activity against Pseudomonas aeruginosa 12B harboring recombinant pBB-PDC-2 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID495683	Antimicrobial activity against Pseudomonas aeruginosa OC 4083 expressing beta-lactamase OXA-10 and containing Oxacillinase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID95547	Compound was evaluated for the antibacterial activity against Klebsiella.8.	1999	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19	2-Naphthylcarbapenems: broad spectrum antibiotics with enhanced potency against MRSA.
AID558753	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus H14 harboring vraS S329L mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID70746	In Vitro antibacterial activity against (Ec SHV) Escherichia coli Beta-lactam producing strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID360064	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-tri-aspartate-tri-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID575103	Antimicrobial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID583651	Antibacterial activity against Escherichia coli isolate 271	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
AID69019	In vivo antibacterial activity against Escherichia coli 1507E	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID571693	Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID510505	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M3AC9-4 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID542394	Volume of distribution in febrile neutropenic patient with hematological malignancies at 500 mg administered as 30 mins infusion every 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
AID557269	Antimicrobial activity against Streptococcus pneumoniae 1394 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID164065	Antibacterial activity against Pseudomonas aeruginosa was determined; Active	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID531603	Antimicrobial activity against Escherichia coli JM109 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID531754	Antibacterial activity against Pseudomonas aeruginosa 2439 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID323390	Antibacterial activity against Pseudomonas aeruginosa clinical isolates infected in BALB/c mouse blood at 20 mg/kg, iv after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.
AID572122	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID517925	Antibacterial activity against Acinetobacter baumannii A894 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID1546208	Clearance in rat	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Current scenario of tetrazole hybrids for antibacterial activity.
AID373756	Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID556696	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] harboring pDrive plasmid expressing ampC gene by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID295806	Antibacterial activity against Pseudomonas aeruginosa 9027 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID323630	Activity of Aeromonas hydrophila beta lactamase CphA at pH 9.0	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID289879	Antibacterial activity against Salmonella Typhimurium	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID574744	Antimicrobial activity against Peptostreptococcus anaerobius assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524084	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P328	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID534298	Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID567317	Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chromosomally encoded blaCMY-2 located on a novel SXT/R391-related integrating conjugative element in a Proteus mirabilis clinical isolate.
AID520730	Activity of Escherichia coli DH10B beta-lactamase assessed per mg of protein at 100 uM	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID360063	Inhibition of Enterococcus faecium M512 LDtfm transpeptidase activity assessed as tri-aspartate-penta-aspartate multimer containing L-Lys3 to D-Asp-L-Lys3 cross links at 8 ug/ml	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID422883	Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID511148	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 4 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID555208	Antibacterial activity against Acinetobacter genomosp. 3 isolate 69 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID524284	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E507 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID541023	Ratio of Kcat to Km for Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
AID531336	Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
AID533761	Antibacterial activity against OXA-28 producing Pseudomonas aeruginosa isolate P174 exhibiting PFGE E pattern by 2-fold agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
AID557499	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP2A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID533552	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA364	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID565512	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID534607	Antimicrobial activity against ceftazidime-susceptible Enterobacteriaceae assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID584577	Antimicrobial activity against Acinetobacter lwoffii isolate K expressing beta-lactamase OXA-58 isolated from blood culture of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID530600	Antibacterial activity against Aeromonas sp. isolate A72 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID68374	In vitro synergistic activity against Enterobacter cloacae (Imi-1+AmpC)	1999	Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14	The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors.
AID424857	Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
AID519737	Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
AID573127	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID557494	Displacement of Biocillin FL from Streptococcus pneumoniae 3243 PBP2X	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID524097	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A850	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID565714	Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 and wild type OprD gene by Etest method in presence of cloxacillin	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID283322	Antimicrobial activity against Escherichia coli XL10/pSHV-31	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands.
AID534663	Antimicrobial activity against ESBL producing Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID524456	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E474 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285677	Antimicrobial activity against Pseudomonas aeruginosa 29F6 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523410	Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
AID533408	Antimicrobial activity against Clostridium tertium assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID545545	Antibacterial activity against Staphylococcus aureus SMR2a selected at 2 times MIC of meropenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID559529	Antibacterial activity against Enterobacter aerogenes assessed as percent susceptible isolates by CLSI M7-A7 method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
AID524278	Antibacterial activity against beta-lactamase-positive ESBL-positive Klebsiella pneumoniae E478 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID283220	Antimicrobial activity against Pseudomonas aeruginosa PA0905	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
AID395979	Plasma concentration in nosocomial pneumonia patient at loading dose of 1 g and maintenance dose of 2 g administered daily for 3 days as continuous infusion measured after 72 hrs in presence of cilastatin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
AID511156	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 12 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID609242	Antibacterial activity against Bacteroides fragilis ATCC 25285	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
AID285668	Antimicrobial activity against Pseudomonas aeruginosa 24D1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523409	Antimicrobial activity against Pseudomonas aeruginosa PAO1 expressing derepressed chromosomal AmpC mutant by broth macrodilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
AID534665	Antimicrobial activity against Proteus mirabilis assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID573190	Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB biofilm by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID207376	In vivo antibacterial activity against Staphylococcus aureus SG 511	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID559272	Antimicrobial activity against Proteus vulgaris Pv9 expressing beta-lactamase PER-1 by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID117515	Compound was evaluated in vivo for percent binding to human albumin fraction V.	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID245192	Minimum inhibitory concentration against Streptococcus pyogenes 308A strain	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID289901	Antibacterial activity against Salmonella oranienberg	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID533424	Antimicrobial activity against Anaerococcus prevotii assessed as resistant isolates by agar dilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
AID558337	Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
AID562951	Antimicrobial activity against Enterobacter cloacae expressing beta-lactamase KPC-2 by Etest	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
AID425988	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3243 after 29 passages with Telithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID524087	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Pseudomonas aeruginosa P365	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID558595	Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID495837	Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID575077	Antimicrobial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID573211	Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 0.5 ug/ml of azithromycin after 3 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID70747	In Vitro antibacterial activity against (Ec TEM1) Escherichia coli Beta-lactam producing strain	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID511584	Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
AID372348	Antibacterial activity against hypermutable Pseudomonas aeruginosa 12-09-15/MEM mutant by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
AID573522	Antibacterial activity against Citrobacter koseri isolate Ck211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID425108	Antimicrobial activity against Clostridium paraputrificum isolated from intra-abdominal infection and pelvic inflammatory disease patients after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.
AID495685	Antimicrobial activity against Acinetobacter baumannii OC 11738 expressing beta-lactamase OXA-23 and containing Carbapenemase assessed as inhibition of growth by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID584522	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3259 harboring mutation in conserved hypothetical protein by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID524277	Antibacterial activity against beta-lactamase-positive ESBL-negative Klebsiella pneumoniae E477 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID511287	Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID584517	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2621 harboring clpS mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID559089	Antimicrobial activity against carbapenem-susceptible Acinetobacter baumannii isolate A1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.
AID557522	Displacement of Biocillin FL from Streptococcus pneumoniae 3665 PBP3	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID523752	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-negative Klebsiella pneumoniae E419	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID520391	Activity at Escherichia coli DH5alpha metallo-beta-lactamase VIM-2 assessed as compound hydrolysis per mg of total periplasmic protein by spectrometry	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
AID524322	Antibacterial activity against Acinetobacter baumannii A884 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID518192	Antimicrobial activity against mexAB-oprM protein and mexCD-oprJ deficient Pseudomonas aeruginosa PAO238 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID766249	Ratio of Kcat to Km for recombinant Bc2 (unknown origin)	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID1373297	Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1318929	Antibacterial activity against multidrug-resistant/tobramycin-susceptible Pseudomonas aeruginosa isolate 86079	2016	Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18	Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
AID573357	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID498817	Antimicrobial activity against Klebsiella pneumoniae FZ49T expressing IMP-8, TEM-1, CTX-M-14, qnrB2, aac(6')-Ib by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559902	Antimicrobial activity against Escherichia coli TF-KO279 harboring beta-lactamase OXY-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	First detection of plasmid-encoded blaOXY beta-lactamase.
AID557510	Displacement of Biocillin FL from Streptococcus pneumoniae 2527 PBP2B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID556694	Antimicrobial activity against multidrug resistant Escherichia coli DH5[alpha] by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID1879068	Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID555217	Antibacterial activity against Escherichia coli DH5alpha carrying ampC gene of Acinetobacter genomosp. 3 isolate 56 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID558598	Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID520967	Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID285659	Antimicrobial activity against Pseudomonas aeruginosa 19E9 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID545349	Displacement of [14C]benzylpenicillin from PBP4 in Pseudomonas aeruginosa ATCC 15692	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID369640	Antibacterial activity against Acinetobacter baumannii A clone expressing carbapenemase-encoding blaOXA-40 gene by Etest method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
AID558590	Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID285584	Antimicrobial activity against Pseudomonas aeruginosa 65.33-3 tracheal isolates from mechanically ventilated tuberculosis patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID324359	Antibacterial activity against Escherichia coli DH10B by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
AID351024	Antibacterial activity against Shigella flexneri at 10 ug/disk by agar well diffusion method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	A facile synthesis of novel biologically active 4-hydroxy-N'-(benzylidene)-2H-benzo[e][1,2]thiazine-3-carbohydrazide 1,1-dioxides.
AID544976	Antimicrobial activity against Klebsiella pneumoniae 52145	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides.
AID285644	Antimicrobial activity against Pseudomonas aeruginosa 15H5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID556647	Antimicrobial activity against multidrug resistant Enterobacter aerogenes isolate 2 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID582881	Activity of beta-lactamase VIM-2 W87F mutant expressed in Escherichia coli XL1-Blue isolated from 1.7 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID433172	Antibacterial activity against Escherichia coli isolated from patient with diabetic foot infection assessed as percent resistant isolates after 18 to 24 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID574997	Antimicrobial activity against Bifidobacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID571688	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID340725	Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-1 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland.
AID583014	Antimicrobial activity against Escherichia coli TOP10 transformed with Escherichia coli ECB2 plasmid carrying CMY-2 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.
AID67760	Minimum inhibitory concentration was determined in heart infusion agar medium against Enterococcus faecalis ATCC 19433	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	5,6-Cis-penems: broad-spectrum anti-methicillin-resistant Staphylococcus aureus beta-lactam antibiotics.
AID510987	Antimicrobial activity against Acinetobacter baumannii 506 after 24 hrs by time-kill assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID584527	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA3704 harboring wspE mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID545563	Antibacterial activity against Escherichia coli EIR4b selected at 4 times MIC of imipenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID531747	Antibacterial activity against Pseudomonas aeruginosa EryR by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID534882	Antimicrobial activity against Enterobacter cloacae assessed as intermediate isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID559686	Antibacterial activity against Escherichia coli Top10	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	GES-11, a novel integron-associated GES variant in Acinetobacter baumannii.
AID520721	Antibacterial activity against Escherichia coli DH10B harboring pOXA-97	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97.
AID295795	Antibacterial activity against Serratia marcescens 3349 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID565528	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID289889	Antibacterial activity against Bacillus subtilts ATCC 6633	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID576526	Antimicrobial activity against Carbapenem-resistant Klebsiella pneumoniae isolate ART2008028 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID374021	Ratio of Kcat to Km for Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID165039	In vitro antibacterial activity against Pseudomonas aeruginosa 9027 by agar dilution method using Mueller-Hinton	2000	Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13	Synthesis and biological properties of new 1beta-methylcarbapenems having tetrazolothioether moiety.
AID582977	Antimicrobial activity against ampD::lox, ampDh2::lox and ampDh3::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID530601	Antibacterial activity against Escherichia coli J53 harboring plasmid pAM carrying beta-lactamase PER-1 by Etest	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Expanded-spectrum beta-lactamase PER-1 in an environmental Aeromonas media isolate from Switzerland.
AID510503	Antibacterial activity against Acinetobacter calcoaceticus/baumannii complex isolate M2AC9-31 expressing KPC beta lactamase	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Detection of KPC in Acinetobacter spp. in Puerto Rico.
AID535707	Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID405820	Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID571912	Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City.
AID559817	Antimicrobial activity against Enterobacter cloacae CHE-2 harboring blaGES-5 and blaSHV-5 gene by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID490297	Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 at 10 mg/disk by agar well-diffusion method	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Diorganotin(IV) derivatives of ONO tridentate Schiff base: synthesis, crystal structure, in vitro antimicrobial, anti-leishmanial and DNA binding studies.
AID557487	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP1B	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID562811	Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
AID584571	Antimicrobial activity against Acinetobacter lwoffii isolate E expressing beta-lactamase OXA-164 isolated from tracheal secretion of patient by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID531678	Antimicrobial activity against Acinetobacter baumannii TVICU53 by broth dilution test	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii.
AID584576	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID531745	Antibacterial activity against Pseudomonas aeruginosa PAO1 by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID576530	Antimicrobial activity against OmpK35-deficient Carbapenem-resistant Klebsiella pneumoniae isolate ART2008022 expressing KPC beta lactamase by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae.
AID206628	Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID556759	Antimicrobial activity against extended spectrum beta-lactamase CTX-M-2-producing Pseudomonas aeruginosa isolate P6208 by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
AID557266	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae 2527 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID249277	Minimum inhibitory concentration against Pseudomonas aeruginosa (n=60); (Range=0.5-128)	2005	Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1	Novel 1beta-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt.
AID285364	Susceptibility of qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital.
AID557472	Displacement of Biocillin FL from Streptococcus pneumoniae 24 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID585184	Ratio of Kcat to Km for Beta-lactamase GES-5 E104, S170 mutant	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID558045	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID557268	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae 3413 by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID534169	Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID560115	Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase RTG3 gene by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID521996	Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID1826186	Antibacterial activity against GIM-1 producing Enterobacter cloacae T2218 clinical isolates assessed as inhibition of bacterial growth by microdilution method	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
AID559822	Antimicrobial activity against Pseudomonas aeruginosa PU21 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Integron mobilization unit as a source of mobility of antibiotic resistance genes.
AID561387	Antibacterial activity against Escherichia coli isolate ARL05-705 harboring beta-lactamase CMY 7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	CMY-29 and CMY-30, two novel plasmid-mediated AmpC beta-lactamases.
AID574778	Antimicrobial activity against Clostridium difficile assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID396029	Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
AID285259	Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-29 and ESBL by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID573514	Antibacterial activity against Klebsiella pneumoniae isolate Kp149 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID573365	Antibacterial activity against ceftazidime-susceptible Morganella morganii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285643	Antimicrobial activity against Pseudomonas aeruginosa 15G10 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285641	Antimicrobial activity against Pseudomonas aeruginosa 13E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID575099	Antimicrobial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID508727	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 1D5 SA1 harboring acquired beta-lactamase VIM-2 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID523955	Antibacterial activity against beta-lactamase-negative Klebsiella pneumoniae E361 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID285613	Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID373025	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PU73 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID495743	Kcat/Km ratio of Pseudomonas aeruginosa IMP-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID511010	AUC in C57BL/6 mouse pneumonia model at 30 mg/kg, im	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID518190	Antimicrobial activity against oprD protein deficient Pseudomonas aeruginosa C2 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID433369	Antibacterial activity against Peptoniphilus asaccharolyticus isolated from patient with diabetic foot infection assessed as percent resistant isolates after 44 to 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID532901	Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
AID542584	Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
AID565526	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID557682	Antimicrobial activity in Prevotella oralis group by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID573344	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID495828	Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID556687	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate 14 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Occurrence of efflux mechanism and cephalosporinase variant in a population of Enterobacter aerogenes and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
AID69764	Antibacterial activity against Escherichia coli 1507E	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID428273	Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
AID295788	Antibacterial activity against Streptococcus agalactiae 32 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID529481	Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID558593	Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Comparative antipneumococcal activities of sulopenem and other drugs.
AID113846	Effective dose against Staphylococcus aureus MB2985 (methicillin-susceptible) in mouse systemic infection model	1999	Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20	The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.
AID575083	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID373040	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate ZJ58 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID373210	Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID549039	Antimicrobial activity against multidrug resistant Klebsiella pneumoniae isolate KpSCMC2 harboring int1, bla IMP-4, bla SHV-12, armA and sul1 gene isolated from patient with pulmonary infection by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Two clinical strains of Klebsiella pneumoniae carrying plasmid-borne blaIMP-4, blaSHV-12, and armA isolated at a Pediatric Center in Shanghai, China.
AID576283	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID498813	Antimicrobial activity against Escherichia coli ZJ87T expressing KPC-2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID520423	Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU18 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections.
AID534771	Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
AID1373313	Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID433185	Antibacterial activity against Corynebacterium urealyticum isolated from patient with diabetic foot infection assessed as percent resistant isolates after 48 hrs by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
AID499068	Antimicrobial activity against carbapenem-resistant Enterobacter cloacae NJ90 deficient in CTX-M-14, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID559266	Antimicrobial activity against rifampin-resistant Escherichia coli J53 transconjugated with Proteus vulgaris Pv8 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID573819	Antibacterial activity against Veillonella parvula by by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID394685	Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID553669	Chemical stability of the compound assessed as compound remaining after 24 hrs in PBS buffer by HPLC analysis at pH 7.4	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics.
AID545425	Antimicrobial activity against Enterobacter aerogenes obtained from patient with complicated intra-abdominal infection assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID405640	Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.
AID1649619	Substrate activity at NDM-1 (unknown origin) assessed as Km for compound hydrolysis by diode array spectrophotometry	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID289881	Antibacterial activity against Enterobactor cloacae 1321E	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID1562261	Antimycobacterial activity against Mycobacterium smegmatis atR9 assessed as decrease in drug resistance development at 10 ug/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID524487	Antibacterial activity against Pseudomonas aeruginosa P349 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID295814	Antibacterial activity against Escherichia coli V6311/65 after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID340733	Antimicrobial activity against Chryseobacterium indologenes NF16 isolate assessed as drug level at which microbial resistance was observed by agar dilution method	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID584718	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA2615 harboring ftsK mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID520974	Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID423068	Antibacterial activity against 6_G1 allele containing Pseudomonas aeruginosa PAO1 H1121 mutant strain with PA4961::lux mutation after 24 hrs by broth microdilution technique	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas aeruginosa to ciprofloxacin.
AID520985	Antibacterial activity against Klebsiella pneumoniae 633 by Etest method in presence of beta-lactamase inhibitor clavulanic acid	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
AID560555	Antimicrobial activity against Proteus vulgaris Pv7 expressing beta-lactamase PER-1 by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.
AID162789	In vivo antibacterial activity against Pseudomonas aeruginosa 1592E	1999	Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16	Synthesis and biological evaluation of novel 1beta-methylcarbapenems having a new moiety at C-2.
AID574034	Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID289905	Antibacterial activity against Klebsiella pneumonise 477	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID323256	Antimicrobial activity against carbapenem-intermediate or resistant Acinetobacter baumannii assessed as percent susceptible isolates	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
AID422659	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1077 after 29 passages with azithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID560125	Antimicrobial activity against Acinetobacter baumannii CIP70.10 harboring beta-lactamase RTG3 gene by disk diffusion method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID584563	Antimicrobial activity against Acinetobacter lwoffii isolate J expressing beta-lactamase OXA-58 isolated from bedsore by vitek 2 system	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID425983	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 1635 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID531758	Antibacterial activity against Pseudomonas aeruginosa 1956 harboring pNF225 carrying nfxB by twofold serial dilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
AID495708	Kcat/Km ratio of Enterobacter cloacae AmpC	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID495808	Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
AID373779	Ratio of MIC for Escherichia coli TOP10 expressing imipenem-resistant Acinetobacter baumannii ab1266 blaoxa-66 gene to MIC for Escherichia coli TP10	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID279255	Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID529577	Ratio of Kcat to Km for Pseudomonas maltophilia ULA-511 beta-Lactamase L-1	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
AID557980	Antimicrobial activity in Clostridium cadaveris by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID576071	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID524098	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A864	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID519258	Volume of distribution in pancreatitis Sprague-Dawley rat blood at 30 mg/kg, iv after 30 mins	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Microdialysis study of imipenem distribution in the peritoneal fluid of rats with experimental acute pancreatitis.
AID575340	Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID524432	Antibacterial activity against ciprofloxacin-resistant Enterobacteriaceae clinical isolates isolated from patient with nosocomial pneumonia assessed as cure rate at test-of-cure visit by mMITT analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
AID495900	Activity of Pseudomonas aeruginosa VIM-2 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID529480	Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
AID531773	Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
AID545399	Antimicrobial activity against Pseudomonas aeruginosa PS5 with PFGE phenotype 7A expressing beta-lactamase KPC-2 obtained from sputum of ICU patient by agar dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
AID574494	Antimicrobial activity against Bacteroides fragilis assessed as percent susceptible isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID524108	Ratio of mutant prevention concentration to minimum Inhibitory concentration for Acinetobacter baumannii A896	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID582924	Ratio of Kcat to Km for Escherichia coli BL21(DE3) VIM-2 W87A mutant beta-lactamase by spectrophotometer	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID115935	In vivo antibacterial activity against MSSA MB 2985 strain at the dose ~4 *10e7 cfu in brain heart broth along with antibiotic by administration at 0 hour in mice	1999	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22	Dicationic 2-fluorenonylcarbapenems: potent anti-MRS agents with improved solubility and pharmacokinetic properties.
AID511146	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 2 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID495701	Kcat/Km ratio of Escherichia coli TEM-1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID517966	Antimicrobial activity against Escherichia coli CF102 harboring beta-lactamase TEM-3 by broth dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
AID557478	Displacement of Biocillin FL from Streptococcus pneumoniae 3009 PBP1A	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
AID573199	Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T380C mutant gene selected at 0.5 ug/ml of azithromycin after 2 passages by Etest method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
AID1528455	Antibacterial activity against Haemophilus influenzae assessed as reduction in bacterial growth by broth microdilution method	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID499051	Antimicrobial activity against carbapenem-resistant Escherichia coli PU60 deficient in TEM-1, CMY-2, ompC/F by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID511157	Antibacterial activity against beta-lactamase IMP-13 producing Pseudomonas aeruginosa isolate 13 assessed as zone of inhibition by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.
AID1356821	Antimicrobial activity against Klebsiella pneumoniae ATCC 43816 by broth microdilution method	2018	Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17	Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID554991	Antibacterial activity against Acinetobacter genomosp. 3 isolate 67 by Etest method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Genetic variability among ampC genes from acinetobacter genomic species 3.
AID519474	Induction of beta-lactamase L2 expression in Stenotrophomonas maltophilia M1 mutant assessed as L2 activity at 10 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID495658	Antimicrobial activity against Escherichia coli TOP10 by solid agar dilution method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID519796	Inhibition of Bocillin FL binding to PBP1A in Escherichia coli MC4100 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID545549	Antibacterial activity against Escherichia coli ERR2a selected at 2 times MIC of tomopenem by microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
AID520881	Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID535848	Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
AID766247	Ratio of Kcat to Km for recombinant IMP-1 (unknown origin)	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Assay platform for clinically relevant metallo-β-lactamases.
AID573536	Antibacterial activity against Serratia marcescens Sm2723 transconjugant harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia.
AID584716	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA1483 harboring cycH mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID498827	Antimicrobial activity against Citrobacter freundii SZ63T expressing IMP-4, qnrS1by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID535171	Antimicrobial activity against imipenem non-susceptible Acinetobacter assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID519814	Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa 27853 membranes	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
AID70749	In Vitro antibacterial activity against (Ec) Escherichia coli ATCC 25922	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	2-Substituted penems with amino acid-related side chains: synthesis and antibacterial activity of a new series of beta-lactam antibiotics.
AID563971	Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID558044	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID285656	Antimicrobial activity against Pseudomonas aeruginosa 19E1 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID395978	Protein binding in human serum by ultrafiltration technique in presence of cilastatin	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
AID520886	Induction of Achromobacter xylosoxidans CIP69598 beta-lactamase OXA-114a expressed in Escherichia coli TOP10 assessed as imipenem hydrolysis	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID558799	Antimicrobial activity against extended spectrum beta-lactamase-expressing Klebsiella oxytoca assessed as percent susceptible isolates by CLSI method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
AID523932	Antibacterial activity against beta-lactamase-negative Escherichia coli E409 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID584580	Antimicrobial activity against Escherichia coli NEB 5-alpha harboring plasmid WH1266 by Etest	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
AID1653505	Antimicrobial activity against Mycobacterium leprae assessed as zone of inhibition incubated for 20 hrs by agar well diffusion assay	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID326267	Antibacterial activity against Escherichia coli DH5-alpha carrying pSCO1 encoding SCO1 by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID511289	Antibacterial activity against Escherichia coli DH5alpha pB-ges-1	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID519480	Induction of beta-lactamase L2 expression in Stenotrophomonas maltophilia K279a at 0.1 to 0.8 mg/L after 2 hrs by RT-PCR method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID395739	Antimicrobial activity against imipenem-resistant invasive nontypeable Haemophilus influenzae isolate 183 at 1.56 uM by Etest	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.
AID529664	Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
AID424328	Antimicrobial activity against Dialister invisus by agar dilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Antimicrobial susceptibilities and clinical sources of Dialister species.
AID582973	Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID372609	Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-35 by microdilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
AID535713	Antibacterial activity against Escherichia coli TOP10 by agar dilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.
AID285256	Antimicrobial activity against Escherichia coli DH5-alpha CF1295 isolate expressing CMT and TEM1 by disk diffusion assay	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
AID523488	Antimicrobial activity against Pseudomonas aeruginosa R70 Etest	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
AID69139	Inhibitory concentration against purified penicillin-binding protein(PBP) 1bgamma of Escherichia coli	1996	Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9	Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID523745	Ratio of mutant prevention concentration to minimum Inhibitory concentration for beta-lactamase-positive ESBL-positive Escherichia coli E465	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID573350	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID574734	Antimicrobial activity against Fusobacterium necrogenes after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID285653	Antimicrobial activity against Pseudomonas aeruginosa 19C12 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID531318	Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID576262	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by Etest	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
AID558051	Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital.
AID575009	Antimicrobial activity against Eubacterium sp. assessed as percent resistant isolates after 48 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
AID1824305	Antimicrobial activity against Citrobacter freundii expressing T2431 KPC-3 assessed as inhibition of bacterial growth by CLSI protocol based broth microdilution assay	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID524500	Antibacterial activity against Acinetobacter baumannii A911 after 24 hrs by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID582886	Activity of beta-lactamase VIM-2 in Escherichia coli XL1-Blue isolated from 4.3 hrs grown culture	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
AID511299	Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid in presence of 4 ug/ml Tazobactam	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID394497	Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID404963	Activity of OXA58 from Acinetobacter baumannii 183 isolate carrying one bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID523925	Antibacterial activity against beta-lactamase-negative Escherichia coli E344 assessed as mutant prevention concentration after overnight incubation	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Mutant prevention concentrations of four carbapenems against gram-negative rods.
AID575417	Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID584701	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA5192 harboring pckA mutant gene by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID573360	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID547777	Antimicrobial activity against Escherichia coli DH10B harboring beta-lactamase KPC-2 T237G mutant by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID373026	Antimicrobial activity against imipenem and meropenem-resistant Acinetobacter baumannii isolate PUA1 by CLSI agar dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
AID521994	Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Spread of OXA-48-encoding plasmid in Turkey and beyond.
AID404966	Activity of OXA58 from Acinetobacter baumannii T193 isolate carrying two bla-OXA58 gene copy assessed as hydrolytic specific activity per mg of protein	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Multicopy blaOXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii.
AID584841	Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method in presence of 4 ug/ml of clavulanic acid	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID565516	Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 wild-type OprD porin gene by Etest method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa.
AID95701	Antibacterial activity against Klebsiella aerogenes 1522E	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis and biological activity of novel 1beta-methylcarbapenems with oxyiminopyrrolidinylamide moiety.
AID295821	Antibacterial activity against Salmonella give after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID545455	Antimicrobial activity against Pseudomonas aeruginosa assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID1373293	Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID495906	Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
AID582974	Antimicrobial activity against dacB::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
AID285624	Antimicrobial activity against Pseudomonas aeruginosa 8B11 tracheal isolates from mechanically ventilated chronic respiratory insufficiency patient	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID508728	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa isolate 3C1 VAL6 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
AID558000	Antimicrobial activity in Clostridium clostridioforme by CLSI agar dilution method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Antianaerobic activity of sulopenem compared to six other agents.
AID565192	Antimicrobial activity against Acinetobacter baumannii JVAB01 expressing disrupted open reading frame orf3 mutant deficient in efflux pump CraA by Etest	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii.
AID495731	Kcat/Km ratio of Escherichia coli TEM-1 relative to Cephaloridine	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
AID577235	Antibacterial activity against intI1-positive tigecycline-resistant Acinetobacter baumannii AB106 with PFGE subgroup B1 containing carbapenemase OXA-23 and OXA-51 by Etest	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
AID535063	Antimicrobial activity against Acinetobacter genomic species 13TU ATCC 17903 harboring pOXA-58-6 plasmid by agar dilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
AID519288	Activity of beta lactamase OXA23 in Acinetobacter baumannii Ab13 assessed as compound hydrolysis rate per mg of protein by spectrophotometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp.
AID534305	Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
AID544965	Antimicrobial activity against Proteus mirabilis expressing extended-spectrum beta-lactamase by Etest based on single determinant	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
AID563975	Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase IMP1	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
AID360074	Inhibition of Enterococcus faecium M512 PBP5fm transpeptidase activity assessed as tetra -aspartate-tetra -aspartate-tri-aspartate multimer containing D-Ala4 to D-Asp-L-Lys3 cross links at 128 ug/ml by mass spectrometry	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem.
AID422675	Antimicrobial activity against drug-resistant Streptococcus pneumoniae isolate 3009 after 25 passages with clarithromycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
AID368743	Antimicrobial activity against Escherichia coli Ec5 expressing CTX-M-2 TEM-1 gene	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers.
AID543419	Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID563601	Antimicrobial activity against Escherichia coli isolate CKP048 transconjugant harboring beta-lactamase KPC-2, DHA-1, qnrB4 and armA by Etest	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
AID546413	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-30 with PDC-8 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID295834	Antibacterial activity against Corynebacterium pyogenes after 18 to 24 hrs by agar dilution method	2007	European journal of medicinal chemistry, Sep, Volume: 42, Issue:9	Novel lbeta-methylcarbapenems having cyclic sulfonamide moieties: synthesis and evaluation of in vitro antibacterial activity.
AID535372	Antimicrobial activity against Pseudomonas aeruginosa isolated from ICU patient assessed as susceptible isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
AID341106	Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12.
AID519471	Antimicrobial activity against Stenotrophomonas maltophilia K279a expressing beta-lactamase L1 and L2 by agar dilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
AID546414	Antimicrobial activity against Pseudomonas aeruginosa isolate Pae-beta-31 with PDC-9 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID546406	Antimicrobial activity against AmpC overproducing Pseudomonas aeruginosa isolate Pae-beta-23 with PDC-5 variant by Etest	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
AID289891	Antibacterial activity against Pseudomonas aeruginosa 77/2	2007	European journal of medicinal chemistry, Mar, Volume: 42, Issue:3	Synthesis and antibacterial evaluation of 1beta-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds.
AID438297	Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID498804	Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZJ70 deficient in KPC-2, SHV-11, CTX-M-14, ompK35/36 by CLSI method	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
AID405090	Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
AID373780	Antibacterial activity against imipenem-resistant Acinetobacter baumannii ISAB ab8(r) by broth dilution method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
AID725545	Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 20 hrs by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Discovery of nosokophic acid, a predicted intermediate of moenomycins, from nosokomycin-producing Streptomyces sp. K04-0144.
AID545449	Antimicrobial activity against extended-spectrum beta-lactamase-positive Klebsiella oxytoca assessed as percent susceptible isolates by agar dilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
AID584504	Antimicrobial activity against Pseudomonas aeruginosa PA14 PA0479 harboring mutation in putative transcriptional regulator, LysR family by Etest method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
AID1373292	Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method	2018	Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	706 (15.66)	18.7374
1990's	1055 (23.40)	18.2507
2000's	1164 (25.82)	29.6817
2010's	1168 (25.90)	24.3611
2020's	416 (9.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	391 (8.17%)	5.53%
Reviews	189 (3.95%)	6.00%
Case Studies	522 (10.91%)	4.05%
Observational	18 (0.38%)	0.25%
Other	3,664 (76.59%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.38	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	1.98	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.03	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
adenine [no description available]	2.43	2	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.46	2	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
beta-alanine [no description available]	6.2	10	1	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
benzoic acid Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.	2.13	1	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
betaine glycine betaine : The amino acid betaine derived from glycine.	2.52	2	0	amino-acid betaine; glycine derivative	fundamental metabolite
carnitine [no description available]	2.07	1	0	amino-acid betaine	human metabolite; mouse metabolite
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.57	2	0	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.07	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.08	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
4-nitrophenylphosphate nitrophenylphosphate: RN given refers to mono(4-nitrophenyl) ester of phosphoric acid. 4-nitrophenyl phosphate : An aryl phosphate resulting from the mono-esterification of phosphoric acid with 4-nitrophenol.	1.98	1	0	aryl phosphate	mouse metabolite
3-hydroxybutyric acid 3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.	1.97	1	0	(omega-1)-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; hydroxybutyric acid	human metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	2.47	2	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
guaiacol Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747). methylcatechol : Any member of the class of catechols carrying one or more methyl substituents.. guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.	2.07	1	0	guaiacols	disinfectant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; expectorant; plant metabolite
malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.	2.21	1	0	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.04	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
fosmidomycin fosmidomycin: from Streptomyces lavendulae; RN given refers to parent cpd; structure in second source. fosmidomycin : Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.	2.06	1	0	hydroxamic acid; phosphonic acids	antimicrobial agent; bacterial metabolite; EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.49	2	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.99	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
glycine [no description available]	2.41	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
histamine [no description available]	2.07	1	0	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
hydroxylamine amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.	1.98	1	0	hydroxylamines	algal metabolite; bacterial xenobiotic metabolite; EC 1.1.3.13 (alcohol oxidase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; nitric oxide donor; nucleophilic reagent
iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..	2.08	1	0	diatomic iodine	nutrient
2-keto-3-deoxyoctonate [no description available]	1.97	1	0
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.74	3	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.13	1	0	cyclitol; hexol
acetanilide acetanilide: a phenylacetamide; use ACETANILIDES for the plural group meaning of the singular term. N-phenylacetamide : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.	2.07	1	0	acetamides; anilide	analgesic
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.03	1	0	metal allergen; nickel group element atom	epitope; micronutrient
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.03	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
phenol [no description available]	1.97	1	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	2.05	1	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
picolinic acid picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.	2.47	2	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
porphobilinogen [no description available]	1.98	1	0	aralkylamino compound; dicarboxylic acid; pyrroles	Escherichia coli metabolite; metabolite; mouse metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	3.31	1	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	2.07	1	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2	1	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
quinolinic acid Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.	2.03	1	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
sulfites Sulfites: Inorganic salts of sulfurous acid.. sulfites : Any sulfurous acid derivative that is a salt or an ester of sulfurous acid.. organosulfonate oxoanion : An organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid.. sulfite : A sulfur oxoanion that is the conjugate base of hydrogen sulfite (H2SO3).	2.49	2	0	divalent inorganic anion; sulfur oxide; sulfur oxoanion
spermidine [no description available]	2.03	1	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	2.03	1	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
succinic acid Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851). succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.	2.38	2	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
taurine [no description available]	2.4	2	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
2-mercaptoacetate [no description available]	2.05	1	0	sulfur-containing carboxylic acid
thymine [no description available]	2.1	1	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.95	4	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2.4	2	0	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist	1.98	1	0
1-hydroxy-3-amino-2-pyrrolidone 1-hydroxy-3-amino-2-pyrrolidone: a CNS depressant; structure in first source	2.02	1	0
menthol Menthol: A monoterpene cyclohexanol produced from mint oils.	2.25	1	0	p-menthane monoterpenoid; secondary alcohol	volatile oil component
1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases	2.97	4	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.04	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.39	2	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
beta-resorcylic acid beta-resorcylic acid: RN given refers to parent cpd; structure	2.08	1	0
mercaptoethanol Mercaptoethanol: A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation.	2.03	1	0	alkanethiol; primary alcohol	geroprotector
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.46	2	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
p-chloromercuribenzoic acid p-Chloromercuribenzoic Acid: An organic mercurial used as a sulfhydryl reagent.	2.05	1	0	chlorine molecular entity; mercuribenzoic acid
phenytoin [no description available]	2.7	3	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
hydroxyindoleacetic acid (5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.	1.96	1	0	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	2.07	1	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.46	2	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.74	3	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	3.16	5	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetarsol [no description available]	2.07	1	0	acetamides; anilide
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.04	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
ethacridine Ethacridine: A topically applied anti-infective agent.	2.47	2	0	acridines
4-(acetylamino)benzeneacetic acid [no description available]	2.07	1	0	acetamides; anilide
adiphenine adiphenine: was heading 1963-94; use DIPHENYLACETIC ACIDS to search ADIPHENINE 1966-94	2.07	1	0	diarylmethane
aklomide aklomide: structure	2.07	1	0	carbonyl compound; organohalogen compound
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.75	3	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alfuzosin alfuzosin: structure given in first source	2.04	1	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	2.04	1	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.45	2	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.74	3	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	2.07	1	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.45	2	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	2.04	1	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.07	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	2.43	2	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	2.91	4	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.75	3	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.05	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.45	2	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	3.17	5	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.07	1	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.07	1	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amprolium Amprolium: A veterinary coccidiostat that interferes with THIAMINE metabolism.. amprolium : An organic chloride salt having 1-[(4-amino-2-propylpyrimidin-5-yl)methyl]-2-methylpyridin-1-ium as the counterion. Used for prevention of coccidiosis in poultry and cattle.. amprolium(1+) : A pyridinium ion that is the cationic portion of amprolium, a veterinary drug which is used for prevention of coccidiosis in poultry and cattle.	2.07	1	0	pyridinium ion	coccidiostat
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.04	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
antazoline Antazoline: An antagonist of histamine H1 receptors.. antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.	2.07	1	0	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.97	4	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol [no description available]	2.07	1	0	aporphine alkaloid
arecoline Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.	2.07	1	0	enoate ester; methyl ester; pyridine alkaloid; tetrahydropyridine	metabolite; muscarinic agonist
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.46	2	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.07	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.74	3	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.42	2	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.04	1	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	12.08	103	5
bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.	2.07	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benserazide Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.	2.47	2	0	carbohydrazide; catechols; primary alcohol; primary amino compound	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.06	1	0	1-benzofurans; aromatic ketone	uricosuric drug
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.07	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzothiazide benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.	2.07	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.07	1	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
betaxolol [no description available]	2.97	4	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	2.07	1	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bevantolol bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.	2.04	1	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	2.45	2	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	2.07	1	0	diarylmethane
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.45	2	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bretylium bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.07	1	0	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
bromazepam Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.	2.45	2	0	organic molecular entity
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.47	2	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bromopride bromopride: RN given refers to parent cpd; structure	2.04	1	0	benzamides
seratrodast [no description available]	2.07	1	0	organic molecular entity
brotizolam brotizolam: structure	2.04	1	0	organic molecular entity
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.45	2	0	aromatic ketone
bumetanide [no description available]	2.75	3	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.04	1	0	quinazolines
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	2.45	2	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	2.07	1	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	2.75	3	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
butacaine butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92	2.07	1	0	benzoate ester
butamben butamben: structure. butamben : An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders.	2.07	1	0	amino acid ester; benzoate ester; primary amino compound; substituted aniline	local anaesthetic
caffeine [no description available]	2.97	4	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.75	3	0	aromatic ether; nitrile; polyether; tertiary amino compound
metrizoate Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.	2.04	1	0	monocarboxylic acid	radioopaque medium
carbamylcholine [no description available]	2.07	1	0
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.07	1	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	2.07	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.71	3	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carteolol Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.	2.07	1	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carvedilol [no description available]	2.45	2	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	3.34	6	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
cefuroxime Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.	7.14	20	5	carbamate ester; cephalosporin
cefixime Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.. cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.	2.92	4	0
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.45	2	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	2.45	2	0	benzodiazepine
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.45	2	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	2.06	1	0	benzothiadiazine	antihypertensive agent; diuretic
chloroxine chloroxine : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp.	2.41	1	0	monohydroxyquinoline; organochlorine compound	antibacterial agent; antifungal drug; antiseborrheic
chloroxylenol chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.	2.07	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.45	2	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.75	3	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.75	3	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	2.45	2	0	isoindoles; monochlorobenzenes; sulfonamide
cifenline [no description available]	2.45	2	0	diarylmethane
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.75	3	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
aricine [no description available]	2.07	1	0	cinchona alkaloid
cinoxacin Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.	1.96	1	0	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	16.6	429	15	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.45	2	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	5.16	4	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.06	1	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	2.07	1	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.46	2	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	2.45	2	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.04	1	0	clonidine; imidazoline
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	2.04	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	3.84	3	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cloxyquin cloxyquin: has antitubercular activity; structure in first source	2.55	2	0	organochlorine compound; quinolines
cromolyn cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.	2.47	2	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
cyclandelate Cyclandelate: A direct-acting SMOOTH MUSCLE relaxant used to dilate BLOOD VESSELS.. cyclandelate : The ester obtained by formal condensation of mandelic acid and 3,3,5-tricyclohexanol. It is a direct-acting smooth muscle relaxant used to dilate blood vessels.	2.07	1	0	carboxylic ester; secondary alcohol	vasodilator agent
cyclobenzaprine cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.	2.07	1	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
dapi DAPI: RN given refers to parent cpd.	2.05	1	0	indoles	fluorochrome
dapsone [no description available]	4.27	5	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
debrisoquin Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.	2.07	1	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.75	3	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.46	2	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	2.04	1	0	primary amine
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.06	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.75	3	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
dibenzothiophene dibenzothiophene : A mancude organic heterotricyclic parent that consists of a thiophene ring flanked by two benzene rings ortho-fused across the 2,3- and 4,5-positions.	2.07	1	0	dibenzothiophenes; mancude organic heterotricyclic parent	keratolytic drug
dibucaine Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.	2.07	1	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.16	5	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	2.07	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	2.07	1	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.04	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dilacor xr 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate : A lactam that is 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group.	2.07	1	0	acetate ester; aromatic ether; benzothiazepine; lactam; tertiary amino compound
dimethadione Dimethadione: An anticonvulsant that is the active metabolite of TRIMETHADIONE.	2.07	1	0	oxazolidinone
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.04	1	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
diphenylpyraline diphenylpyraline: RN given refers to parent cpd; structure. allergen : A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.. diphenylpyraline : A member of the class of piperidines that is the benzhydryl ether derivative of 1-methyl-4-hydroxypiperidine. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. It is also used as the teoclate salt (piprinhydrinate) as an ingredient in compound preparations for the symptomatic relief of coughs and the common cold.	2.07	1	0	piperidines; tertiary amine	cholinergic antagonist; H1-receptor antagonist
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.06	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	2.45	2	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	2.47	2	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.43	7	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
2-amino-7-phosphonoheptanoic acid 2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation	1.98	1	0
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.45	2	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	2.07	1	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	2.45	2	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	2.04	1	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	2.04	1	0	dibenzooxepine; tertiary amino compound	antidepressant
doxylamine Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.	2.07	1	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	2.07	1	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyclonine [no description available]	2.07	1	0	aromatic ketone; piperidines	topical anaesthetic
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	2.75	3	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.51	2	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
econazole Econazole: An imidazole derivative that is commonly used as a topical antifungal agent.. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.. 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group.	2.47	2	0	dichlorobenzene; ether; imidazoles; monochlorobenzenes
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	4.79	10	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	2.47	2	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
profenamine profenamine: was heading 1972-94 (see under PHENOTHIAZINES 1972-90); use PHENOTHIAZINES to search ETHOPROPAZINE 1972-94. profenamine : A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease.	2.07	1	0	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.07	1	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.	2.07	1	0	imidazolidine-2,4-dione	anticonvulsant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	2.07	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
etilefrine Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.	2.45	2	0	phenols
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	2.06	1	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	2.06	1	0	2-aminopurines; acetate ester	antiviral drug; prodrug
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	2.47	2	0	carbamate ester	anticonvulsant; neuroprotective agent
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.45	2	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	2.07	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.75	3	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma	2.45	2	0	azaspiro compound
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.04	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.75	3	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.92	4	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	5.53	12	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.45	2	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	2.07	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.75	3	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	2.04	1	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.71	3	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.86	3	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.07	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.07	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	4.04	4	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.97	4	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	2.75	3	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gabexate Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.	3.81	3	0	benzoate ester
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	12.67	171	13
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	2.07	1	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.07	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	2.75	3	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.45	2	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.75	3	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
glyphosate glyphosate: active cpd in herbicidal formulation Roundup; inhibits EC 2.5.1.19, 5-enolpyruvylshikimate-3-phosphate synthase; structure. glyphosate : A phosphonic acid resulting from the formal oxidative coupling of the methyl group of methylphosphonic acid with the amino group of glycine. It is one of the most commonly used herbicides worldwide, and the only one to target the enzyme 5-enolpyruvyl-3-shikimate phosphate synthase (EPSPS).	2.41	1	0	glycine derivative; phosphonic acid	agrochemical; EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor; herbicide
granisetron [no description available]	2.45	2	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	2.07	1	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	2.07	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	2.45	2	0	acetamides
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	2.21	1	0	carboxamidine; guanidines; one-carbon compound
gw8510 GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source	2.1	1	0
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	3.13	5	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.04	1	0	barbiturates
hexoprenaline Hexoprenaline: Stimulant of adrenergic beta 2 receptors. It is used as a bronchodilator, antiasthmatic agent, and tocolytic agent.	2.07	1	0
hexamethylene bisacetamide N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208	2.07	1	0	acetamides
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.6	1	0	phenanthridines	fluorochrome; intercalator
hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.	2.07	1	0	thioxanthenes	mutagen; schistosomicide drug
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	2.46	2	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.06	1	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	2.75	3	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.49	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	2.45	2	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.07	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hypericin [no description available]	2.04	1	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.97	4	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	2.07	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	3.79	2	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifenprodil ifenprodil: NMDA receptor antagonist	1.98	1	0	piperidines
ifosfamide [no description available]	2.78	3	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.04	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.46	2	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	2.07	1	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.97	4	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoquinol Iodoquinol: One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide.. iodoquinol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.	2.07	1	0	monohydroxyquinoline; organoiodine compound	antiamoebic agent; antibacterial agent; antiprotozoal drug; antiseptic drug
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.46	2	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	2.04	1	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.46	2	0	organic molecular entity
iotroxic acid iotroxic acid: RN given refers to parent cpd; structure	2.06	1	0	organic molecular entity
iproniazid [no description available]	2.07	1	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.04	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	2.06	1	0	benzenes
isoetharine Isoetharine: Adrenergic beta-2 agonist used as bronchodilator for emphysema, bronchitis and asthma.	2.07	1	0	catecholamine
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	5.08	7	0	carbohydrazide	antitubercular agent; drug allergen
2-propanol 2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.. propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.	2.06	1	0	secondary alcohol; secondary fatty alcohol	protic solvent
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.46	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoxsuprine Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.	2.07	1	0	alkylbenzene
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.04	1	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	3.87	3	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.04	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.45	2	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.69	3	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.74	3	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	2.74	3	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.07	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	1.98	1	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.75	3	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	2.05	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.74	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.07	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.75	3	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	2.39	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	2.45	2	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.75	3	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
ly 171883 LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.	2.07	1	0	acetophenones; aromatic ether; phenols; tetrazoles	anti-asthmatic drug; leukotriene antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.04	1	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.45	2	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	2.07	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
memantine [no description available]	2.07	1	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	2.04	1	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenesin Mephenesin: A centrally acting muscle relaxant with a short duration of action.. 1-(2-methylphenyl)glycerol : A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.	2.07	1	0	aromatic ether; glycerol ether
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	2.07	1	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	2.04	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	2.04	1	0	organic molecular entity
benzoic acid [2-methyl-2-(propylamino)propyl] ester [no description available]	2.07	1	0	benzoate ester
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	2.46	2	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	2.47	2	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.97	4	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	2.45	2	0	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	2.46	2	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	2.07	1	0	aromatic ether; carbamate ester; secondary alcohol
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.04	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.45	2	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	2.74	3	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	2.45	2	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	13.13	109	18	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	2.07	1	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.04	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.47	2	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	4.27	5	0	dichlorobenzene; ether; imidazoles
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.45	2	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
milrinone [no description available]	2.45	2	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.47	2	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	2.45	2	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	2.07	1	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.99	4	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.45	2	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	2.06	1	0	monoterpenoid
muscimol Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.. muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.	2.68	3	0	alkaloid; isoxazoles; primary amino compound	fungal metabolite; GABA agonist; oneirogen; psychotropic drug
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.46	2	0	acetamides; benzamides	anti-arrhythmia drug
nadolol [no description available]	2.07	1	0	tetralins
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	5.82	8	3	benzoic acids; guanidines
nafronyl Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.	2.07	1	0	naphthalenes
naftopidil [no description available]	2.07	1	0	piperazines
nalidixic acid [no description available]	4.77	30	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naphazoline Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.	2.07	1	0	naphthalenes
naratriptan naratriptan: structure given in first source	2.45	2	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	2.75	3	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.04	1	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.07	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.75	3	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.75	3	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.75	3	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilvadipine [no description available]	2.07	1	0	dihydropyridine; isopropyl ester; methyl ester; nitrile
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.45	2	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	2.45	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.45	2	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.46	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitromide nitromide: antibacterial agent for prevention & treatment of Salmonella pullorum infections in chickens & turkeys & for fowl typhoid & paratyphoid; used in feed; structure	2.07	1	0
nizatidine [no description available]	2.45	2	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.75	3	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	7.17	49	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.45	2	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one [no description available]	2.07	1	0	isoquinolines
nylidrin Nylidrin: A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.	2.07	1	0	alkylbenzene
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	12.07	94	9	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.73	3	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	2.45	2	0	carbazoles
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	2.07	1	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxethazaine [no description available]	2.07	1	0	amino acid amide
oxibendazole oxibendazole: structure	2.07	1	0	benzimidazoles; carbamate ester
oxiracetam oxiracetam: structure in first source	2.45	2	0	organonitrogen compound; organooxygen compound
oxolinic acid quinolone antibiotic : An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.	2.41	2	0	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
oxprenolol Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.	2.07	1	0	aromatic ether
benoxinate benoxinate: RN given refers to parent cpd; structure. oxybuprocaine : A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology.	2.07	1	0	amino acid ester; benzoate ester; substituted aniline; tertiary amino compound	drug allergen; local anaesthetic; topical anaesthetic
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.04	1	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.61	2	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	2.46	2	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.45	2	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.75	3	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pargyline Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.	2.07	1	0	aromatic amine
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.75	3	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.04	1	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	2.04	1	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.07	1	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.46	2	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacemide phenacemide: anti-epileptic drug; structure	2.07	1	0	acetamides
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.04	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.1	5	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	2.1	1	0	aromatic amine
phthalylsulfathiazole phthalylsulfathiazole: minor descriptor (63-86); on-line & INDEX MEDICUS search SULFATHIAZOLES (66-86); RN given refers to parent cpd. phthalylsulfathiazole : A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.	2.06	1	0	1,3-thiazoles; dicarboxylic acid monoamide; sulfonamide antibiotic; sulfonamide
moxonidine moxonidine: structure given in first source	2.74	3	0	organohalogen compound; pyrimidines
1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate [no description available]	2.07	1	0	pyrroloindole
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.04	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.07	1	0	pyridines
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	2.45	2	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.07	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
pipemidic acid Pipemidic Acid: Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections.. pipemidic acid : A pyridopyrimidine that is 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid substituted at position 2 by a piperazin-1-yl group and at position 8 by an ethyl group. A synthetic broad-spectrum antibacterial, it is used for treatment of gastrointestinal, biliary, and urinary infections.	3.76	2	0	amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.07	1	0	organonitrogen compound; organooxygen compound
pirbuterol pirbuterol: structure	2.06	1	0	pyridines
pirenzepine Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.	2.07	1	0	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
piretanide piretanide: potent inhibitor of chloride transport; structure	2.46	2	0	aromatic ether
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
practolol Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.	2.47	2	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
duodote duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents	2.07	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
praziquantel azinox: Russian drug	2.07	1	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.75	3	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.	2.04	1	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.46	2	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	2.07	1	0	diarylmethane
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	3.1	5	0	benzoic acids; sulfonamide	uricosuric drug
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	2.07	1	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.45	2	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	2.07	1	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	2.46	2	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	2.45	2	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.04	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.04	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.46	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.04	1	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.97	4	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	2.07	1	0	carbotricyclic compound	antidepressant
pyridostigmine [no description available]	2.45	2	0	pyridinium ion
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2.07	1	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
pyrimethamine Maloprim: contains above 2 cpds	3.87	3	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
quetiapine [no description available]	2.06	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.45	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine [no description available]	2.74	3	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.07	1	0	benzothiazoles
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.75	3	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	2.04	1	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.07	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
roxarsone Roxarsone: An arsenic derivative which has anticoccidial action and promotes growth in animals.. roxarsone : An organoarsonic acid where the organyl group is 4-hydroxy-3-nitrophenyl.	2.07	1	0	2-nitrophenols; organoarsonic acid	agrochemical; animal growth promotant; antibacterial drug; coccidiostat
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.06	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
salicylamide salamide: a major impurity of hydrochlorothiazide; structure in first source	2.07	1	0	phenols; salicylamides	antirheumatic drug; non-narcotic analgesic
salicylsalicylic acid salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.	2.07	1	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	3.26	6	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.74	3	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.74	3	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	2.07	1	0	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
imatinib [no description available]	2.46	2	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.04	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
succinylsulfathiazole succinylsulfathiazole: intestinal antimicrobial agent; structure	2.47	2	0	1,3-thiazoles
sulfacetamide Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen.	2.48	2	0	N-sulfonylcarboxamide; substituted aniline	antibacterial drug; antiinfective agent; antimicrobial agent; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position.	2.07	1	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamerazine [no description available]	2.07	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen
sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.	2.07	1	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	2.45	2	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	4.51	23	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.05	1	0
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.45	2	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.75	3	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.76	3	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sultopride [no description available]	2.06	1	0	salicylamides
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	2.45	2	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.45	2	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.45	2	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	3.91	12	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
telenzepine telenzepine: structure given in first source	2.07	1	0	benzodiazepine
temozolomide [no description available]	2.04	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	2.45	2	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.74	3	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.07	1	0	diarylmethane
tetracaine Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.	2.07	1	0	benzoate ester; tertiary amino compound	local anaesthetic
tetrahydroxy-1,4-quinone tetrahydroxy-1,4-quinone: structure. tetrahydroxy-1,4-benzoquinone : A hydroxybenzoquinone in which all four protons of the benzoquinone structure are substituted by hydroxy groups. A systemic keratolytic, it is normally supplied as its hydrate (CHEBI:137471).	2.07	1	0	hydroxybenzoquinone	keratolytic drug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.87	3	0	phthalimides; piperidones
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	2.07	1	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
2-thiosalicylic acid 2-thiosalicylic acid: a degradation product of thimerosal; RN given refers to parent cpd. thiosalicylic acid : A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid.	2.07	1	0	sulfanylbenzoic acid	antipyretic; non-narcotic analgesic
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	3.59	2	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.46	2	0	aziridines
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.43	2	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	2.45	2	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	2.45	2	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	2.07	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolazoline Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.. tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group.	2.07	1	0	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.97	4	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolnaftate [no description available]	2.07	1	0	monothiocarbamic ester	antifungal drug
tosufloxacin tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.	3.23	6	0	1,8-naphthyridine derivative; amino acid; aminopyrrolidine; monocarboxylic acid; organofluorine compound; primary amino compound; quinolone antibiotic; tertiary amino compound
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	2.45	2	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	2.04	1	0	amino acid
trapidil Trapidil: A coronary vasodilator agent.	2.47	2	0	triazolopyrimidines
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	2.45	2	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.04	1	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.45	2	0	triazolobenzodiazepine	sedative
trifluoperazine [no description available]	2.07	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.07	1	0	aromatic ketone
triflupromazine Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.	2.07	1	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
trimebutine Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.	2.07	1	0	trihydroxybenzoic acid
trimeprazine Trimeprazine: A phenothiazine derivative that is used as an antipruritic.	2.07	1	0	phenothiazines
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	6.53	35	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	2.04	1	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	2.04	1	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
trioxsalen Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.. lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.. antipsoriatic : A drug used to treat psoriasis.. trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.	2.07	1	0	psoralens	dermatologic drug; photosensitizing agent
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.07	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tropicamide Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.	2.07	1	0	acetamides
tulobuterol [no description available]	2.07	1	0	organochlorine compound
urapidil [no description available]	2.97	4	0	piperazines
urethane [no description available]	2.07	1	0	carbamate ester	fungal metabolite; mutagen
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	2.75	3	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
viloxazine Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.	2.04	1	0	aromatic ether
xylazine Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.	2.07	1	0	1,3-thiazine; methylbenzene; secondary amino compound	alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative
xylometazoline xylometazoline: RN given refers to parent cpd; structure	2.07	1	0	alkylbenzene
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	2.45	2	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	2.45	2	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.45	2	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.31	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	5	12	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
estriol hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.	2.07	1	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.07	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	4.75	30	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	2.07	1	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	2.03	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
piperonyl butoxide [no description available]	2.07	1	0	benzodioxoles	pesticide synergist
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.28	6	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2.07	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	9.93	103	2	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
metaraminol Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.	2.07	1	0	phenylethanolamines	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
pentylenetetrazole Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.	3.1	5	0	organic heterobicyclic compound; organonitrogen heterocyclic compound
biguanides Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.	2.06	1	0	guanidines
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	3.09	5	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	3.28	6	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	7.17	68	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	1.99	1	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	4.04	4	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	3.24	6	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cetrimonium bromide cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.	2.13	1	0	organic bromide salt; quaternary ammonium salt	detergent; surfactant
vincristine [no description available]	2.04	1	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	2.05	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	3.1	1	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.78	3	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.46	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.06	1	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.67	3	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	8.29	86	1	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	5.6	23	0	kanamycins	bacterial metabolite
ethopabate Ethopabate: An inhibitor of folate metabolism. It is used as a coccidiostat in poultry.	2.07	1	0	amidobenzoic acid
galactose galactopyranose : The pyranose form of galactose.	1.99	1	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	6.5	35	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.04	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	4.89	34	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	2.4	2	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acepromazine Acepromazine: A phenothiazine that is used in the treatment of PSYCHOSES.. acepromazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by an acetyl group at position 2 and a 3-(dimethylamino)propyl group at position 10.	2.07	1	0	aromatic ketone; methyl ketone; phenothiazines; tertiary amino compound	phenothiazine antipsychotic drug
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	2.07	1	0	amphetamines	alpha-adrenergic agonist; antihypotensive agent
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	8.35	38	1	penicillin allergen; penicillin	antibacterial drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	6.49	24	2	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
zoxazolamine Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.	2.07	1	0	benzoxazole
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.83	3	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
berlition berlition: antioxidant preparation containing alpha-lipoic acid, used in the neuroprotective therapy of chronic brain ischemia for correction of free-radical processes. (R)-lipoic acid : The (R)-enantiomer of lipoic acid. A vitamin-like, C8 thia fatty acid with anti-oxidant properties.. lipoic acid : A heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position.	2.07	1	0	dithiolanes; heterocyclic fatty acid; lipoic acid; thia fatty acid	cofactor; nutraceutical; prosthetic group
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.03	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	2.07	1	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.46	2	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	7.74	50	1	penicillin	antibacterial agent; antibacterial drug
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	2.07	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	2.76	3	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	11.48	228	5	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	2.69	3	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	2	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.07	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	2.03	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2.4	2	0	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	2.44	2	0	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.02	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
chlorquinaldol Chlorquinaldol: Local anti-infective agent used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria. In animals, it causes central nervous system damage and is not administered parenterally. It is also used as antiseptic, fungistat, or deodorant.. chlorquinaldol : A monohydroxyquinoline that is quinolin-8-ol which is substituted by a methyl group at position 2 and by chlorine at positions 5 and 7. An antifungal and antibacterial, it was formerly used for topical treatment of skin conditions and vaginal infections.	2.41	1	0	monohydroxyquinoline; organochlorine compound	antibacterial drug; antiprotozoal drug; antiseptic drug
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	3.13	5	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
bromoethane bromoethane : A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses.	2.05	1	0	bromoalkane; bromohydrocarbon; volatile organic compound	alkylating agent; carcinogenic agent; local anaesthetic; refrigerant; solvent
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.08	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
bromthymol blue Bromthymol Blue: A pH sensitive dye that has been used as an indicator in many laboratory reactions.. bromothymol blue : A member of the class of 2,1-benzoxathioles that is 2,1-benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 3-bromo-4-hydroxy-5-isopropyl-2-methylphenyl groups.	2.13	1	0	2,1-benzoxathiole; arenesulfonate ester; organobromine compound; polyphenol; sultone	acid-base indicator; dye; two-colour indicator
mepenzolate bromide [no description available]	2.07	1	0	diarylmethane
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.45	2	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
acedapsone Acedapsone: Acetylated sulfone that is slowly metabolized to give long-term, low blood levels of DAPSONE. It has antimicrobial and antimalarial action, but is mainly used as a depot leprostatic agent.. acedapsone : A sulfone that is dapsone in which both of the amino groups been acetylation. An antimicrobial drug, it also has antimalarial activity.	3.31	1	0	acetamides; anilide; secondary carboxamide; sulfone	antimalarial; antimicrobial drug
3-mercaptopropionic acid 3-Mercaptopropionic Acid: An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.. 3-mercaptopropanoic acid : A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3.	2.05	1	0	mercaptopropanoic acid	algal metabolite
isoprene isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.	2.03	1	0	alkadiene; hemiterpene; volatile organic compound	plant metabolite
dichloroacetic acid [no description available]	2.04	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
pantothenic acid Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE.. pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.. vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.. (R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group.. (R)-pantothenic acid : A pantothenic acid having R-configuration.	2.07	1	0	pantothenic acid; vitamin B5	antidote to curare poisoning; geroprotector; human blood serum metabolite
bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.	3.31	1	0	bisphenol; sulfone	endocrine disruptor; metabolite
sulfachlorpyridazine Sulfachlorpyridazine: A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.. sulfachloropyridazine : A sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.	2.07	1	0	organochlorine compound; pyridazines; sulfonamide	antibacterial drug; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.71	3	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	7.82	12	1	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd	2.41	1	0
pyocyanine Pyocyanine: Antibiotic pigment produced by Pseudomonas aeruginosa.. pyocyanine : An iminium betaine that is 5-methylphenazin-5-ium which is substituted at position 1 by an oxidanidyl group. An antibiotic pigment produced by Pseudomonas aeruginosa.	2.78	3	0	iminium betaine; phenazines	antibacterial agent; bacterial metabolite; biological pigment; virulence factor
phensuximide phensuximide: major descriptor (73-84); on-line search SUCCINIMIDES (73-84); Index Medicus search PHENSUXIMIDE (73-84); RN given refers to cpd without isomeric designation	2.07	1	0	pyrrolidines
acriflavine chloride 3,6-diamino-10-methylacridinium chloride : The 10-methochloride salt of 3,6-diaminoacridine. Note that a mixture of this compound with 3,6-diaminoacridine (proflavine) is known as acriflavine or neutral acriflavine.	2.46	2	0	organic chloride salt	antibacterial agent; antiseptic drug; carcinogenic agent; histological dye; intercalator
dimethisoquin [no description available]	2.07	1	0	isoquinolines
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	3.17	5	0	penicillin allergen; penicillin
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	2.44	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	12.34	95	17	penicillanic acids
thymol Thymol: A phenol obtained from thyme oil or other volatile oils used as a stabilizer in pharmaceutical preparations, and as an antiseptic (antibacterial or antifungal) agent.. thymol : A phenol that is a natural monoterpene derivative of cymene.	2.21	1	0	monoterpenoid; phenols	volatile oil component
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.37	2	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
pyronine Pyronine: Xanthene dye used as a bacterial and biological stain. Synonyms: Pyronin; Pyronine G; Pyronine Y. Use also for Pyronine B. which is diethyl-rather than dimethylamino-.. pyronin Y : An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.	2.05	1	0	iminium salt; organic chloride salt	histological dye
proflavine Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.	2.07	1	0	aminoacridines	antibacterial agent; antiseptic drug; carcinogenic agent; chromophore; intercalator
synephrine [no description available]	2.07	1	0	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite
2,5-pyridinedicarboxylic acid 2,5-Pyridinedicarboxylic acid: RN given refers to parent cpd. isocinchomeronic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 5.	2.03	1	0	pyridinedicarboxylic acid
pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.	2.07	1	0	pyridinium salt
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	3.31	1	0	aromatic amine	allergen; carcinogenic agent
benzonatate benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.	2.07	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
acrolein [no description available]	2.25	1	0	enal	herbicide; human xenobiotic metabolite; toxin
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	1.97	1	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.06	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	2.04	1	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.45	2	0	bromide salt
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.07	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
1-amino-2-naphthol-4-sulfonic acid 4-amino-3-hydroxynaphthalene-1-sulfonic acid: reagent for removal of chromium(VI) from aqueous solution	2.41	1	0	aminonaphthalene; naphthalenesulfonic acid	mutagen
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	3.16	5	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
3-tert-butyl-4-hydroxyanisole 3-tert-butyl-4-hydroxyanisole : An aromatic ether that is 4-methoxyphenol in which one of the hydrogens ortho- to the phenolic hydroxy group is replaced by a tert-butyl group.	2.05	1	0	aromatic ether; phenols	antioxidant; human xenobiotic metabolite
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	2.07	1	0	quinolines
chloroprocaine chloroprocaine: RN given refers to parent cpd; structure. chloroprocaine : Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding.	2.07	1	0	benzoate ester; monochlorobenzenes	central nervous system depressant; local anaesthetic; peripheral nervous system drug
indolebutyric acid indolebutyric acid: RN given refers to parent cpd. indole-3-butyric acid : A indol-3-yl carboxylic acid that is butanoic acid carrying a 1H-indol-3-yl substituent at position 1.	2.13	1	0	indol-3-yl carboxylic acid	auxin; plant hormone; plant metabolite
4,4'-thiodianiline 4,4'-thiodianiline: structure	3.31	1	0	substituted aniline
protocatechualdehyde protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure	2.07	1	0	dihydroxybenzaldehyde
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.07	1	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	3.79	11	0	penicillin allergen; penicillin	antibacterial drug
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.07	1	0	dithiocarbamic acids	chelator; copper chelator
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	2.04	1	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.06	1	0	catechin	antioxidant; plant metabolite
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.21	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.59	2	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.98	4	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
propantheline bromide [no description available]	2.07	1	0	xanthenes
nitroblue tetrazolium Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.	1.97	1	0	organic cation
pirinitramide Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.	2.04	1	0	nitrile
edrophonium bromide [no description available]	2.04	1	0
dexamethasone 21-phosphate dexamethasone 21-phosphate: has anti-inflammatory activity. dexamethasone phosphate : A steroid phosphate that is the 21-O-phospho derivative of dexamethasone.	2.13	1	0	11beta-hydroxy steroid; 17-hydroxy steroid; 3-oxo-Delta(4) steroid; fluorinated steroid; steroid phosphate; tertiary alpha-hydroxy ketone	glucocorticoid receptor agonist
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.04	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	2.04	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.04	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
fluorometholone Fluorometholone: A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluorometholone : A member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.	2.07	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone	anti-inflammatory drug
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	2.04	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone ketobemidone: structure	2.04	1	0	piperidines
fusarium Fusarium: A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.	1.97	1	0
dihydralazine Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)	2.07	1	0	phthalazines
3,4-pyridinedicarboxylic acid 3,4-pyridinedicarboxylic acid: structure in first source	2.03	1	0	pyridinedicarboxylic acid
carvacrol carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).	2.63	2	0	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
2,4-pyridinedicarboxylic acid lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.	2.03	1	0	pyridinedicarboxylic acid
dipicolinic acid dipicolinic acid : A pyridinedicarboxylic acid carrying two carboxy groups at positions 2 and 6.	3.55	8	0	pyridinedicarboxylic acid	bacterial metabolite
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.11	1	0	thiazolidine
oleanolic acid [no description available]	2.11	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	2.06	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	2.07	1	0	diarylmethane
gluconic acid gluconic acid: zinc gluconate has anti-inflammatory activity; RN given refers to (D)-isomer; all RRs refers to (D)-isomer unless otherwise noted. ketogluconic acid : A gluconic acid that contains a ketonic carbonyl group.. D-gluconic acid : A gluconic acid having D-configuration.	1.98	1	0	gluconic acid	chelator; Penicillium metabolite
copper gluconate Gluconates: Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters.	1.98	1	0	organic molecular entity
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.73	3	0	C-nitro compound; imidazoles	antitubercular agent
4-(benzoylamino)-2-hydroxybenzoic acid 4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt	2.07	1	0	benzamides
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	2.04	1	0	thiazoles
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.04	1	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.4	2	0	dialdehyde	biomarker
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	2.03	1	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.41	1	0	phenoxazine
aminopenicillanic acid aminopenicillanic acid: RN given refers to parent cpd; structure. 6-aminopenicillanic acid : A penicillanic acid compound having a (6R)-amino substituent. The active nucleus common to all penicillins, it may be substituted at the 6-amino position to form the semisynthetic penicillins, resulting in a variety of antibacterial and pharmacologic characteristics.	1.96	1	0	amino acid zwitterion; penicillanic acids	allergen
lithium carbonate Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.	2.04	1	0	carbonate salt; lithium salt	antimanic drug
monoacetyldapsone monoacetyldapsone: used in leprosy chemotherapy. monoacetyldapsone : A secondary carboxamide resulting from acetylation of one of the amino groups of dapsone.	3.31	1	0	acetamides; anilide; secondary carboxamide; sulfone
lactulose [no description available]	2.06	1	0	glycosylfructose	gastrointestinal drug; laxative
megestrol acetate [no description available]	2.07	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	4.79	9	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
methyl isocyanate methyl isocyanate: structure. methyl isocyanate : The isocyanate that is methane modified by a single isocyanato substituent.	2.6	1	0	isocyanates	allergen; apoptosis inducer
trimetozine [no description available]	2.07	1	0	morpholines
benzydamine Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.	2.06	1	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	8.29	60	0	cyclic ketone; erythromycin
docosanol Tadenan: from powdered bark of Pygaeum africanum (Rosaceae), see also heading for docosanol (a priciple ingredient of extract). docosan-1-ol : A long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It is a non-prescription medicine approved by the FDA to shorten healing time of cold sores.. docosanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of twenty-two carbon atoms.	2.07	1	0	docosanol; long-chain primary fatty alcohol	antiviral drug; plant metabolite
biphenyl-3-carboxylic acid biphenyl-3-carboxylic acid: structure in first source	2.13	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.04	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
8-hydroxy-2-methylquinoline 8-hydroxy-2-methylquinoline: structure in first source	2.41	1	0	hydroxyquinoline
lormetazepam lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine [no description available]	2.45	2	0
2-aminobenzimidazole 2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd. 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group.	2.41	1	0	benzimidazoles	marine xenobiotic metabolite
4-phenylpyridine [no description available]	2.13	1	0	phenylpyridine
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	4.44	6	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
tetramethylpyrazine tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii).	2.07	1	0	alkaloid; pyrazines	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
ethidium bromide [no description available]	2.74	3	0	organic bromide salt	geroprotector; intercalator; trypanocidal drug
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.03	1	0
zinc oxide Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.	2.98	3	0	zinc molecular entity
thorium dioxide Thorium Dioxide: Thorium oxide (ThO2). A radiographic contrast agent that was used in the early 1930s through about 1954. High rates of mortality have been linked to its use and it has been shown to cause liver cancer.	1.98	1	0	thorium molecular entity
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	15.24	240	16	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	1.99	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
flurandrenolone Flurandrenolone: A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)	2.07	1	0	21-hydroxy steroid
metylperon metylperon: RN given refers to parent cpd	2.04	1	0	aromatic ketone
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	3.01	4	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	2.04	1	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	2.47	2	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	2.47	2	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.04	1	0	aromatic ketone
flumethasone Flumethasone: An anti-inflammatory glucocorticoid used in veterinary practice.	2.07	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-inflammatory drug
guanoxan guanoxan: was MH 1976-92 (see under GUANIDINES 1976-90); use GUANIDINES to search GUANOXAN 1976-92; antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage	2.06	1	0	benzodioxine
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.07	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
chlordesmethyldiazepam [no description available]	2.04	1	0	benzodiazepine
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.04	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.45	2	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	3.13	5	0	dichlorobenzene; penicillin	antibacterial drug
5-methoxyindoleacetic acid 5-methoxyindoleacetic acid: serotonin metabolite. 5-methoxyindole-3-acetic acid : A member of the class of indole-3-acetic acids in which the hydrogen at position 5 of indole-3-acetic acid has been replaced by a methoxy group.	1.96	1	0	aromatic ether; indole-3-acetic acids	antibacterial agent; Brassica napus metabolite; carcinogenic agent; human urinary metabolite; marine xenobiotic metabolite; rat metabolite
cephaloglycin Cephaloglycin: A cephalorsporin antibiotic.. cefaloglycin : A cephalosporin antibiotic containing at the 7beta-position of the cephem skeleton an (R)-amino(phenyl)acetamido group.	2.37	2	0	beta-lactam antibiotic allergen; cephalosporin	antimicrobial agent
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.07	1	0	2-phenylcyclopropan-1-amine
streptomycin [no description available]	6.12	23	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.	3.01	3	0	C-nitro compound; monohydroxyquinoline	antifungal agent; antiinfective agent; antimicrobial agent; renal agent
cladribine [no description available]	2.04	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
beclomethasone [no description available]	2.07	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	4.81	32	0	penicillin allergen; penicillin	antibacterial drug
vantocil polihexanide: RN given refers to parent cpd	2.06	1	0
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	3.15	5	0	penicillin allergen; penicillin	antibacterial drug
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	2.74	3	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
terodiline [no description available]	2.45	2	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene 1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd	2.04	1	0
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.42	2	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
mercury Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero.	2.02	1	0	elemental mercury; zinc group element atom	neurotoxin
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	3.08	4	0	copper group element atom; elemental silver	Escherichia coli metabolite
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	2.21	1	0	titanium group element atom
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	2.9	3	0	copper group element atom; elemental gold
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.74	3	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	2.73	3	0	N-acetyl-D-glucosamine	epitope
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	3.24	6	0	D-galactosamine; primary amino compound	toxin
metocurine iodide [no description available]	2.04	1	0	aromatic ether
zinc sulfate Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.	2.99	4	0	metal sulfate; zinc molecular entity	fertilizer
copper sulfate Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.	2.21	1	0	metal sulfate	emetic; fertilizer; sensitiser
silver nitrate Silver Nitrate: A silver salt with powerful germicidal activity. It has been used topically to prevent OPHTHALMIA NEONATORUM.	2.55	2	0	inorganic nitrate salt; silver salt	astringent
calcium sulfate Calcium Sulfate: A calcium salt that is used for a variety of purposes including: building materials, as a desiccant, in dentistry as an impression material, cast, or die, and in medicine for immobilizing casts and as a tablet excipient. It exists in various forms and states of hydration. Plaster of Paris is a mixture of powdered and heat-treated gypsum.	2.41	2	0	calcium salt; inorganic calcium salt
reproterol reproterol: RN given refers to cpd without isomeric designation; structure	2.06	1	0	oxopurine
(1S,2R)-tranylcypromine (1S,2R)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1S,2R)-enantiomer of tranylcypromine.	2.07	1	0	2-phenylcyclopropan-1-amine
apazone Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.	2.04	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
parbendazole parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd	2.07	1	0	benzimidazoles; carbamate ester
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.45	2	0	selegiline; terminal acetylenic compound	geroprotector
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.07	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.41	7	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	2.74	3	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	2.39	2	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
fluorides [no description available]	2.13	1	0	halide anion; monoatomic fluorine
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.07	1	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
metergoline Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.	2.07	1	0	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
fenclozic acid fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd	2.07	1	0
taurolidine [no description available]	2.4	2	0	thiadiazinane
capobenic acid [no description available]	2.07	1	0	benzamides
cephapirin Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.	2.71	3	0	cephalosporin	antibacterial drug
diftalone [no description available]	2.07	1	0
carbimazole Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.	2.07	1	0	1,3-dihydroimidazole-2-thiones; carbamate ester	antithyroid drug; prodrug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.06	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.07	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.5	2	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
4-methoxyamphetamine 4-methoxyamphetamine: para-methoxy derivative to amphetamine with hallucinogenic properties; minor descriptor (75-86); on line & INDEX MEDICUS search AMPHETAMINES (75-86); RN given refers to parent compound without isomeric designation	1.98	1	0
du-21220 Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.	2.04	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
rose bengal b disodium salt [no description available]	2.07	1	0
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	9.51	47	3	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	10.42	134	4	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.74	3	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.46	2	0	tryptamines
almitrine Almitrine: A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.. almitrine : A triamino-1,3,5-triazine compound having allylamino substituents at the 2- and 4-positions and a 4-(bis(p-fluorophenyl)methyl)-1-piperazinyl group at the 6-position.	2.06	1	0	piperazines; triamino-1,3,5-triazine	central nervous system stimulant
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	2.07	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
4-ethynylbiphenyl 4-ethynylbiphenyl: structure given in first source	2.01	1	0
toloxatone toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.	2.04	1	0	oxazolidinone; primary alcohol; toluenes
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	2.06	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.04	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
sisomicin Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).	4.87	10	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
amdinocillin Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.	3.94	13	0	penicillin	antibacterial drug; antiinfective agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	11.19	154	8	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.04	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.12	5	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	2.07	1	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	8.35	112	3	penicillin allergen; penicillin	antibacterial drug
trimazosin trimazosin: RN given refers to parent cpd; structure	2.04	1	0	N-arylpiperazine
ribavirin Rebetron: Rebetron is tradename	3.38	2	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
miloxacin miloxacin: structure in second source	2.13	1	0	quinolines
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.45	2	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	17.05	368	20	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol [no description available]	2.04	1	0
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	2.97	4	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.97	4	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.45	2	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.	2.46	2	0	penicillin
bezafibrate [no description available]	2.07	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.74	3	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.45	2	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.04	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	2.07	1	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
meptazinol Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.	2.04	1	0	azepanes
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	2.45	2	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	2.93	4	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol medroxalol: RN given refers to parent cpd without isomeric designation	2.04	1	0	salicylamides
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	2.04	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	7.7	19	1	cephalosporin	antibacterial drug
lorcainide [no description available]	2.45	2	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.42	2	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.	2.04	1	0	cephalosporin	antibacterial drug
cefonicid Cefonicid: A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.. cefonicid : A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	1.97	1	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	15.82	366	25	penicillin allergen; penicillin	antibacterial drug
cefotiam Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.. cefotiam : A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.	4.79	10	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.04	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.34	6	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	10.67	75	10	cephalosporin	antibacterial drug
indalpine indalpine: selective 5-hydroxytryptamine uptake inhibitor; RN given refers to parent cpd	2.07	1	0	indoles
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
moxalactam Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.	10.08	59	7	cephalosporin; oxacephem	antibacterial drug
lidamidine lidamidine: synonym WHR-1142A refers to HCl; structure	2.07	1	0	ureas
endralazine BQ 22-708: RN given refers to parent cpd	2.04	1	0	benzamides
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.45	2	0	cephalosporin	antibacterial drug
encainide Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.	2.45	2	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.07	1	0	benzofurans
nedocromil Nedocromil: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with ASTHMA, including EOSINOPHILS; NEUTROPHILS; MACROPHAGES; MAST CELLS; MONOCYTES; AND PLATELETS.	2.47	2	0	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.98	13	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	9.07	25	4	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
octenidine [no description available]	2.06	1	0	dihydropyridine
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	2.45	2	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
dazoxiben dazoxiben: RN given refers to parent cpd	2.07	1	0
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	5.33	13	1
recainam recainam: structure given in first source	2.74	3	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.96	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.45	2	0	aminopyridine
tolrestat tolrestat: RN & structure given in first source	2.47	2	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.04	1	0	aromatic ketone
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.07	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.45	2	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.75	3	0	dimethoxybenzene
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.74	3	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.04	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	2.45	2	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	2.07	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	2.07	1	0	imidazoles
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	3.84	3	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
dopexamine dopexamine: RN given refers to parent cpd; structure given in first source	2.07	1	0	catecholamine
amifloxacin amifloxacin: structure in UD	2.37	2	0	quinolines
trospectomycin trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer	2.04	1	0	dioxanes
difloxacin difloxacin: RN & structure given in first source. difloxacin : A quinolone that is pefloxacin in which the ethyl group at position 1 of the quinolone has been replaced by a p-fluorophenyl group. A broad-spectrum antibiotic effective against both Gram-positive and Gram-negative bacteria, it is used (usually as the monohydrochloride salt) for the treatment of bacterial infections in dogs.	1.96	1	0	fluoroquinolone antibiotic; monocarboxylic acid; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; Mycoplasma genitalium metabolite
sarafloxacin sarafloxacin: RN & structure given in first source	1.96	1	0	quinolines
lonapalene RS 43179: used in treatment of psoriasis	2.07	1	0	naphthalenes; organochlorine compound
ipsapirone [no description available]	2.07	1	0	N-arylpiperazine
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.45	2	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
rufloxacin rufloxacin: structure in first source	1.98	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
sematilide sematilide: RN refers to HCl; structure given in first source	2.75	3	0
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	2.04	1	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
temafloxacin temafloxacin: structure given in first source. temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death.. 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.	3.08	5	0	amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	7.66	10	2	quinolines
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.74	3	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source	2.45	2	0	organic molecular entity
sparfloxacin [no description available]	3.88	12	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	2.07	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
remacemide remacemide: structure given in first source	2.44	2	0	stilbenoid
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.74	3	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	2.45	2	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.46	2	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	2.04	1	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
tenidap tenidap: structure given in first source; RN refers to (Z)-isomer	2.06	1	0
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.45	2	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.04	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	2.04	1	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.04	1	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	2.04	1	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
atorvastatin [no description available]	2.82	3	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	2.74	3	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
irinotecan [no description available]	2.04	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.97	4	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.04	1	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	2.74	3	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.45	2	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	2.45	2	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	2.04	1	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
thiolactic acid thiolactic acid: RN given refers to parent cpd	2.45	2	0	mercaptopropanoic acid
acridine orange Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.	2.05	1	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.07	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
cisatracurium cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R,2'R)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
fosinoprilat fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.	2.04	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	6.1	9	1
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.07	1	0
cefprozil [no description available]	2.45	2	0	cephalosporin; semisynthetic derivative	antibacterial drug
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.75	3	0	D-glucopyranose	epitope; mouse metabolite
trimethoprim sulfamethizole trimethoprim sulfamethizole: used in treating liver pulmonary lesions	2.03	1	0
ursolic acid [no description available]	2.11	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.05	1	0	organic bromide salt	colorimetric reagent; dye
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.83	3	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.06	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
4-amino-4'-hydroxylaminodiphenylsulfone 4-amino-4'-hydroxylaminodiphenylsulfone: RN given refers to unlabeled cpd	3.31	1	0	sulfonic acid derivative
fenclofenac fenclofenac: RN given refers to parent cpd	2.07	1	0	aromatic ether
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.04	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
proxicromil proxicromil: RN given refers to parent cpd; structure	2.07	1	0
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	18.05	407	22	cephalosporin	fungal metabolite
imipramine n-oxide imipramine N-oxide: RN given refers to parent cpd; structure	2.04	1	0	dibenzooxazepine
ritipenem ritipenem: carbapenem antibiotic; structure given in first source	6.47	17	1
terizidone terizidone: minor descriptor (1975-1984); on-line & Index Medicus search OXAZOLES (1975-1984); RN given refers to parent cpd without isomeric designation	3.21	1	0
tretoquinol Tretoquinol: An adrenergic beta-agonist used as a bronchodilator agent in asthma therapy.	2.04	1	0	isoquinolines
flomoxef flomoxef: structure given in first source; RN given refers to sodium salt. flomoxef : A second-generation oxacephem antibiotic in which the oxazine ring is substituted at C-3 with a hydroxyethyl-substituted tetrazolylthiomethyl group and the azetidinone ring carries 7alpha-methoxy and 7beta-{2-[(difluoromethyl)thiomethyl]acetamido} substituents.	5.63	18	1	N-acyl-amino acid; organonitrogen heterocyclic antibiotic; oxacephem	antibacterial drug
torbafylline torbafylline: structure given in first source	2.07	1	0
fropenem [no description available]	4.17	16	0	faropenem
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	2.45	2	0	glutamic acid derivative
intoplicine intoplicine: structure in first source	2.04	1	0	pyridoindole
pazufloxacin [no description available]	2.95	4	0	quinolines
repaglinide [no description available]	2.45	2	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.45	2	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.04	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
acediasulfone acediasulfone: antibacterial drug for treatment of ear infections; structure in first source	3.31	1	0	alpha-amino acid
ethinyl estradiol-17-sulfate ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer	2.04	1	0
1,7-phenanthroline [no description available]	2.47	2	0	phenanthroline
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.53	2	0	1,2,3-triazole
ethinylestradiol-3-sulfate ethinylestradiol-3-sulfate: binds to albumin at 2 sites	2.04	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
cefpimizole cefpimizole: semisynthetic cephalosporin	1.99	1	0	peptide
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	2.45	2	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
cefcanel cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure	2.45	2	0
arbekacin arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.	5.64	18	1	aminoglycoside; kanamycins	antibacterial agent; antibacterial drug; antimicrobial agent; protein synthesis inhibitor
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.04	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride epristeride: structure given in first source	2.45	2	0	steroid acid
brodimoprim brodimoprim: inhibits dihydrofolate reductase. brodimoprim : An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.	3.31	1	0	aminopyrimidine; bromobenzenes; methoxybenzenes	antibacterial drug; antiinfective agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
talinolol [no description available]	2.45	2	0	ureas
epiroprim epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source	3.31	1	0
6-azathymine 6-azathymine: structure given in first source. 6-azathymine : A nucleobase analogue that is thymine in which the CH group at position 6 is replaced by nitrogen.	2.1	1	0	1,2,4-triazines; cyclic ketone; nucleobase analogue	EC 2.6.1.40 [(R)-3-amino-2-methylpropionate--pyruvate transaminase] inhibitor; Mycoplasma genitalium metabolite
morpholinopropane sulfonic acid 3-(N-morpholino)propanesulfonic acid : A Good's buffer substance, pKa = 7.2 at 20 degreeC.	1.98	1	0	MOPS; morpholines; organosulfonic acid
denaverine denaverine: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
cefminox cefminox : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and 2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido side-groups located respectively at positions 3 and 7beta of the cephem nucleus. A broad-spectrum bactericide, it is especially effective against Gram-negative and anaerobic bacteria.	2.41	2	0	cephamycin; tetrazoles
pafenolol pafenolol: structure given in first source	2.06	1	0
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	2.06	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
enrofloxacin Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.	2.79	3	0	cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone	antibacterial agent; antimicrobial agent; antineoplastic agent
diprafenone diprafenone: structure given in first source	2.04	1	0	aromatic compound
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	2.04	1	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	2.75	3	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	8.33	52	2	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	2.04	1	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
sanfetrinem sanfetrinem: orally absorbed hexetil ester of GV-104326	2.71	3	0
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	3.23	5	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	3.58	2	0	organonitrogen compound; organooxygen compound
mepindolol mepindolol: 2-methyl deriv of pindolol; RN given refers to parent cpd; structure	2.07	1	0	indoles
fpl 52791 FPL 52791: also has anti-allergic properties; related to sodium cromoglycate; structure	2.07	1	0
penicillin n penicillin N: RN given refers to (2S-(2alpha,5alpha,6beta(S*)))-isomer; structure in Merck, 9th ed, #6887	2.07	1	0	penicillin
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.45	2	0	benzofurans
aspoxicillin aspoxicillin: structure given in first source	1.98	1	0	peptide
epanolol epanolol: structure given in first source	2.07	1	0	acetamides
panipenem panipenem: synthetic cpd; structure given in first source	6.63	40	0	organic molecular entity
perindoprilat perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.	2.04	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
7-hydroxystaurosporine [no description available]	2.04	1	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.75	3	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
neamine neamine: fragment of NEOMYCIN B; structure in first source. neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.	2.13	1	0	2,6-dideoxy-alpha-D-glucoside; aminoglycoside	antibacterial agent
gentamicin c1 [no description available]	2.31	1	0
gentamicin c1a [no description available]	4.67	7	0	gentamycin C
9-aminocamptothecin [no description available]	2.04	1	0	pyranoindolizinoquinoline
sch 34343 Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer	3.85	12	0
pd 131628 PD 131628: CI-990 is L-alanylamide prodrug of PD-131628; structure given in first source	2.67	3	0
topsentin topsentin: structure given in first source; a marine natural product	2.02	1	0
squalamine squalamine: from dogfish shark Squalus acanthias; structure given in first source	2.04	1	0	bile acid
1,10-phenanthroline-5,6-dione 1,10-phenanthroline-5,6-dione: has antineoplastic, intercalating, and trypanocidal activities; structure given in first source	2.31	1	0
eperezolid [no description available]	3.09	1	0
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	15.28	116	9	carbapenems
pyrrolidine dithiocarbamic acid [no description available]	2.06	1	0
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	6.03	13	0	carbamate ester; oxazolidinone	metabolite
8-hydroxy-2-quinolinecarboxylic acid [no description available]	2.41	1	0	quinolines
indole-5-carboxylic acid [no description available]	2.13	1	0	indolecarboxylic acid	plant metabolite
4-nitro-4'-aminodiphenyl sulfone 4-nitro-4'-aminodiphenyl sulfone: dapsone metabolite; structure given in first source	3.31	1	0
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.45	2	0	hydroxy-1,2-naphthoquinone
4-carboxybiphenyl ether 4-carboxybiphenyl ether: structure given in first source. 4-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is para to the carboxy group.	2.13	1	0	phenoxybenzoic acid
rivastigmine [no description available]	2.46	2	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	2.45	2	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	2.04	1	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	2.75	3	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	8.63	51	1	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.75	3	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	3.56	1	1	iditol	fungal metabolite
moexipril [no description available]	2.06	1	0	peptide
3-aminobenzeneboronic acid [no description available]	2.13	1	0
mci 9038 [no description available]	2.04	1	0	peptide
brexanolone brexanolone: a mixture of allopregnanolone and sulfobutylether‐beta‐cyclodextrin for treatment of postpartum depression. brexanolone : A 3-hydroxy-5alpha-pregnan-20-one in which the hydroxy group at position 3 has alpha-configuration. It is a metabolite of the sex hormone progesterone and used for the treatment of postpartum depression in women.	2.25	1	0	3-hydroxy-5alpha-pregnan-20-one	antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative
quinacillin quinacillin: RN given refers to (2S-(2 alpha,5 alpha,6 beta))-isomer. quinacillin : A semisynthetic penicillase-resistant penicillin with antibacterial activity; it binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall.	1.96	1	0	penicillin; quinoxaline derivative	antibacterial drug
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	3.64	9	0
levcromakalim [no description available]	2.07	1	0	1-benzopyran
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.07	1	0	D-glucuronic acid	algal metabolite
2,8-dihydroxyquinoline [no description available]	2.41	1	0	dihydroxyquinoline; monohydroxyquinoline; quinolone
hexylcaine hydrochloride [no description available]	2.07	1	0
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2	1	0	cobalt group element atom; metal allergen	micronutrient
sr141716 [no description available]	2.07	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.46	2	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
fpl 55712 FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors	2.07	1	0	aromatic ketone
sivelestat sivelestat: inhibitor of neutrophil elastase; structure given in first source	2.07	1	0	N-acylglycine; pivalate ester
asulacrine asulacrine: derivative of amsacrine; structure given in first source	2.04	1	0	acridines
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.	2.45	2	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine 2-hydroxyimipramine: RN given refers to parent cpd	2.04	1	0	dibenzoazepine
ecteinascidin 743 [no description available]	2.04	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
1-hexadecyl-2-acetyl-glycero-3-phosphocholine Platelet Activating Factor: A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.. 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine : A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.	3.13	1	0	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
florfenicol florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.	2.55	2	0	organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone	antimicrobial agent
ginkgolide a [no description available]	2.1	1	0	diterpene lactone
panipenem-betamipron panipenem-betamipron: useful perenteral antibiotic against respiratory tract infections; structure given in first source	6.2	10	1
bay y3118 Bay Y3118: structure given in first source	1.98	1	0
gamma-glutamylaminomethylsulfonic acid [no description available]	1.98	1	0
ci 934 CI 934: structure given in first source	1.97	1	0
fpl-52694 FPL-52694: mast cell stabilizer; RN given refers to parent cpd; FPL-52694 is mono-Na salt; structure given in first source	2.07	1	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.05	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	2.46	2	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	2.04	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	13.43	104	14	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib [no description available]	2.04	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
ramatroban [no description available]	2.07	1	0	organic molecular entity
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	2.44	2	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
methotrexate [no description available]	4.4	6	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
cefbuperazone cefbuperazone: RN given refers to parent cpd(6R-(6alpha,7alpha,7(2R,3S)))-isomer; structure. cefbuperazone : A second-generation cephamycin antibiotic having [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and {N-[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]-D-threonyl}amino side groups located at positions 3 and 7beta respectively.	2.04	1	0	cephalosporin; peptide
xaliproden xaliproden : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine which is substituted on the nitrogen by a 2-(2-naphthyl)ethyl group and at position 4 by a m-trifluoromethylphenyl group.	2.07	1	0	(trifluoromethyl)benzenes; naphthalenes; tertiary amino compound; tetrahydropyridine	serotonergic agonist
tamsulosin [no description available]	2.45	2	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
pd 138312 PD 138312: structure in first source	1.98	1	0
cgp 31608 CGP 31608: structure given in first source; CGP 32879 is the (5S,6R,8S)-isomer	3.47	8	0
n-isobutyrylcysteine N-isobutyrylcysteine: RN given refers to L-isomer	2.07	1	0
sulperazone sulperazone: combination of above two cpds	4.35	2	2
sulbactam [no description available]	11.3	113	8	penicillanic acids
dexpanthenol dexpanthenol: The alcohol of pantothenic acid	2.07	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
cornuside cornuside: a bisiridoid glucoside from Cornus officinalis Sieb et Zucc; structure given in first source	2.05	1	0
quilostigmine quilostigmine: RN given for (3aS,cis)-isomer; structure in first source	2.07	1	0	pyrroloindole
l 640876 L 640876: semisynthetic antibiotic; structure given in first source; RN given refers to (6R-trans)-isomer	1.96	1	0
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	1.98	1	0	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
centa CENTA: structure; beta-lactamase chromogenic cephalosporin reagent	2.77	3	0
imiloxan [no description available]	2.07	1	0	benzodioxine
dilevalol (R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.	2.04	1	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
carbapenems [no description available]	18.7	535	23
aspartame [no description available]	2.07	1	0	carboxylic acid; dipeptide zwitterion; dipeptide; methyl ester	apoptosis inhibitor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; environmental contaminant; micronutrient; nutraceutical; sweetening agent; xenobiotic
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	13.33	208	1	beta-lactam antibiotic allergen; beta-lactam
tempol [no description available]	2.07	1	0	aminoxyls; hydroxypiperidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; catalyst; hepatoprotective agent; nephroprotective agent; neuroprotective agent; radical scavenger
hre 664 HRE 664: synthetic penem antibiotic; structure given in first source	1.97	1	0
docetaxel [no description available]	2.04	1	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
irofulven irofulven: structure in first source	2.04	1	0	cyclohexenones
ym 872 YM 872: structure in first source	2.04	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	13.55	122	3	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	13.79	189	1	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
dx 8951 [no description available]	2.04	1	0	pyranoindolizinoquinoline
cilomilast [no description available]	2.45	2	0	methoxybenzenes
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	2.45	2	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan tezosentan: structure in first source	2.04	1	0
vatalanib [no description available]	2.07	1	0	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
sabarubicin sabarubicin: structure given in first source	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	7.18	47	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	2.46	2	0	dihydropyridine
solifenacin [no description available]	2.45	2	0	isoquinolines
hyoscyamine Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.	2.07	1	0	tropane alkaloid
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.45	2	0	morpholines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.47	2	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.1	1	0	oxygen hydride; oxygen radical; reactive oxygen species
lactitol lactitol : A glycosyl alditol consisting of beta-D-galactopyranose and D-glucitol joined by a 1->4 glycosidic bond. It is used as a laxative, as an excipient, and as replacement bulk sweetener in some low-calorie foods.	2.07	1	0	glycosyl alditol	cathartic; excipient; laxative
fpl 52757 FPL 52757: FPL 52758 is Na salt of FPL 52757; structure in first source; RN given refers to parent cpd	2.07	1	0
abanoquil [no description available]	2.04	1	0
tetraphenylphosphonium chloride [no description available]	2.05	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.07	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	2.04	1	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	3.31	1	0	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
temocillin temocillin: beta-lactam antibiotic with unusual spectrum of antibacterial activity & exceptional stability to bacterial beta-lactamases; RN given refers to di-Na salt (2S-(2alpha,5alpha,6alpha))-isomer; structure in first source. temocillin : A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.	3.58	8	0	penicillin
fpl 59257 FPL 59257: abolishes cough response & partly inhibits bronchoconstriction produced by leukotrienes C & D	2.07	1	0
pyridine-2-azo-4-dimethylaniline cephalosporin pyridine-2-azo-4-dimethylaniline cephalosporin: cephalosporin which changes from purple to yellow upon cleavage of its beta-lactam ring; structure given in first source	1.98	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.97	4	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	2.46	2	0	piperidinecarboxamide; ropivacaine	local anaesthetic
erlotinib [no description available]	2.07	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.52	2	0	divalent inorganic anion; phosphite ion
zeneca zd 6169 Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source	2.07	1	0
cs 834 CS 834: orally active carbapenem; structure in first source; an ester-type prodrug of R-95867	1.99	1	0
abt 719 [no description available]	3.09	1	0
topsentin a topsentin A: number of carbony group = 1 for topsentin A and no carbonyl group for nortopsentin B and D; structure in first source	2.02	1	0
melagatran [no description available]	2.45	2	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
sibenadet sibenadet: structure in first source	2.07	1	0
oxytocin, asp(5)- [no description available]	2.05	1	0
latrepirdine latrepirdine: structure	2.07	1	0	methylpyridines; pyridoindole	geroprotector
tesaglitazar tesaglitazar: structure in first source	2.45	2	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	2.07	1	0	indanes
lapatinib [no description available]	2.07	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.04	1	0
fosfluconazole fosfluconazole: prodrug of fluconazole	2.04	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
sorafenib [no description available]	2.07	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
colistimethate sodium [no description available]	2.99	4	0
cp 101,606 traxoprodil mesylate: a selective NMDA antagonist; structure given in first source	2.04	1	0
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.05	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
cortisone [no description available]	2.41	2	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
guaiol guaiol: structure in first source	2.03	1	0	guaiane sesquiterpenoid
cellulose triacetate cellulose triacetate: for hemodialysis filtration	2.05	1	0
nsc-89199 estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.	2.45	2	0	carbamate ester; organochlorine compound; steroid phosphate
phenethicillin phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.	2.46	2	0	penicillin allergen; penicillin
rosoxacin rosoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by an ethyl group at position 1 and by a pyridin-4-yl group at position 7. An antibacterial drug, active against Neisseria gonorrhoeae, it has been used for treating urinary tract infections and certain sexually transmitted diseases.	1.96	1	0	pyridines; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antiinfective agent
acivicin [no description available]	2.04	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	7.86	67	3
bortezomib [no description available]	2.04	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.05	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bromodeoxytopsentin bromodeoxytopsentin: from sponge Topsentia pachastrelloides; structure in first source. bromodeoxytopsentin : An aromatic ketone that is imidazole which is substituted by a 1H-indole-3-carbonyl group and a 6-bromo-1H-indol-3-yl group at positions 2 and 4, respectively. Isolated from the Mediterranean shallow-water sponge, Topsentia genetrix. It is a potent inhibitor of MRSA pyruvate kinase and exhibits antibacterial properties.	2.02	1	0	aromatic ketone; bromoindole; imidazoles; indole alkaloid	antibacterial agent; EC 2.7.1.40 (pyruvate kinase) inhibitor; marine metabolite
povidone-iodine Povidone-Iodine: An iodinated polyvinyl polymer used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol. The iodine may be radiolabeled for research purposes.	3.5	2	0
rimiterol rimiterol: was heading 1977-94 (see under CATECHOLS 1977-90); use CATECHOLS to search RIMITEROL 1977-94; predominantly a beta 2 stimulant, therefore affects the cardiovascular system less than isoproterenol, but its action is of shorter duration than that of albuterol	2.06	1	0	catechols
mbx 1066 MBX 1066: structure in first source	2.05	1	0
fibrin Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.	2.66	3	0	peptide
raffinose Raffinose: A trisaccharide occurring in Australian manna (from Eucalyptus spp, Myrtaceae) and in cottonseed meal.. raffinose : A trisaccharide composed of alpha-D-galactopyranose, alpha-D-glucopyranose and beta-D-fructofuranose joined in sequence by 1->6 and 1<->2 glycosidic linkages, respectively.	2.06	1	0	raffinose family oligosaccharide; trisaccharide	mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.05	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
cysteinylglycine cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83. L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism.	2.02	1	0	dipeptide zwitterion; dipeptide	Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.47	2	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
salicin [no description available]	2.07	1	0	aromatic primary alcohol; aryl beta-D-glucoside; benzyl alcohols	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.45	2	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
thienamycin thienamycin: beta-lactam antibiotic; RN given refers to cpd without isomeric designation	3.48	8	0	carbapenems
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	21.03	918	40	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
sq 27860 carbapenem-3-carboxylic acid: from species of Serratia & Erwinia; carbapenam antibiotic; structure given in first source. 1-carbapenem-3-carboxylic acid : A carbapenemcarboxylic acid that is the 3-carboxy derivative of 2,3-didehydro-1-carbapenam.	2.04	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	3.31	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
mycothiol mycothiol: a glyco-inositol-cysteine found in MYCOBACTERIUM BOVIS which conjugates exogenous compounds for detoxication; it is a microbe counterpart to eucaryotic GLUTATHIONE; acted on by mycothiol disulfide reductase and mycothiol S-conjugate amidase and MDF dehydrogenase;. mycothiol S-conjugate : Any S-conjugate of mycothiol.. mycothiol : A pseudodisaccharide, 1D-myo-inosityl-alpha-D-glucopyranoside, in which the hydroxy group at the 2-position of the glucose moiety is replaced by an (N-acetyl-L-cysteinyl)amido group.	2.13	1	0
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	11.76	205	3	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.71	3	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium [no description available]	2.07	1	0
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.45	2	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	2.04	1	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.04	1	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.04	1	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	7.34	31	4
miglitol [no description available]	2.45	2	0	piperidines
7-aminocephalosporanic acid 7beta-aminocephalosporanic acid : The alpha,beta-unsaturated monocarboxylic acid that is the active nucleus for the synthesis of cephalosporins and intermediates.	1.96	1	0	alpha,beta-unsaturated monocarboxylic acid; amino acid zwitterion
linezolid [no description available]	7.53	60	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
(S)-bicalutamide (S)-bicalutamide : A N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide that is the (S)-enantiomer of bicalutamide.	2.07	1	0	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
phenylalanine arginine beta-naphthylamide phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source	2.78	3	0	peptide
devazepide Devazepide: A derivative of benzodiazepine that acts on the cholecystokinin A (CCKA) receptor to antagonize CCK-8's (SINCALIDE) physiological and behavioral effects, such as pancreatic stimulation and inhibition of feeding.. devazepide : An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.	2.07	1	0	1,4-benzodiazepinone; indolecarboxamide	antineoplastic agent; apoptosis inducer; cholecystokinin antagonist; gastrointestinal drug
actinonin actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure	2.06	1	0
tolterodine [no description available]	2.45	2	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
halcinonide Halcinonide: A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.	2.07	1	0	organic molecular entity	SMO receptor agonist
metrizamide Metrizamide: A solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.	2.07	1	0	amino sugar
sultamicillin sultamicillin: contains ampicillin & sulbactam	5.48	20	0	penicillanic acid ester
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	2.04	1	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.04	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.25	1	0	cyclodextrin
acarbose [no description available]	2.74	3	0	amino cyclitol; glycoside
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.31	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.46	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	1.99	1	0	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.45	2	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.45	2	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	2.45	2	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.04	1	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.31	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.41	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	14.05	108	15
brivudine brivudine: anti-herpes agent	2.06	1	0
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	11.08	60	3	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	7.75	33	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
bms 214662 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.	2.04	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
eptifibatide [no description available]	2.04	1	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.75	3	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine [no description available]	2.04	1	0	2'-deoxyribonucleoside
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.45	2	0
teniposide [no description available]	2.04	1	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.04	1	0	carbohydrate derivative; nucleobase-containing molecular entity
pa 824 pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source	2.25	1	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	3.31	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	3.86	12	0	cephalosporin; semisynthetic derivative	antibacterial drug
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2.04	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
5-carboxy-8-hydroxyquinoline 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source	2.41	1	0	quinolines
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.46	2	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	4.75	5	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.04	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
9-benzyl-2-chloro-6-(2-furyl)purine 9-benzyl-2-chloro-6-(2-furyl)purine: structure in first source	3.31	1	0
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	5.46	15	1	kanamycins	antibacterial agent; protein synthesis inhibitor
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	2.79	3	0	antibiotic antifungal drug; echinocandin	antiinfective agent
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.6	1	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
n,n'-ethylenediamine disuccinic acid N,N'-ethylenediamine disuccinic acid: from Actinomycetes MG417-CF17; structure given in first source	2.66	2	0
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	2.96	1	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
dipyrone Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.	2	1	0	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
ditiocarb sodium [no description available]	2.06	1	0	organic molecular entity
cefpiramide cefpiramide: antipseudomonal cephalosporin derivative. cefpiramide : A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.	2.37	2	0	carboxylic acid; cephalosporin	antibacterial drug
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.25	1	0	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
glycosides [no description available]	2.13	1	0
isomethyleugenol Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)	1.99	1	0	isomethyleugenol
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	2.6	1	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	5.16	11	1	penicillin allergen; penicillin	antibacterial drug
amygdalin (R)-amygdalin : An amygdalin in which the stereocentre on the cyanohydrin function has R-configuration.	2.06	1	0	amygdalin	antineoplastic agent; apoptosis inducer; plant metabolite
cefsulodin Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.. cefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.	4.86	11	0	cephalosporin; organosulfonic acid; primary carboxamide	antibacterial drug
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	2.04	1	0	indolyl carboxylic acid
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.04	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	2.04	1	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.74	3	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
chlorprothixene Chlorprothixene: A thioxanthine with effects similar to the phenothiazine antipsychotics.. (Z)-chlorprothixene : A chlorprothixene in which the double bond adopts a (Z)-configuration.	2.07	1	0	chlorprothixene
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	2.46	2	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.04	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
methylthiouracil Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism.	2.07	1	0	pyrimidone
crotamiton [no description available]	2.07	1	0
n-benzoylalanine N-benzoylalanine: RN given refers to parent cpd (L-Ala)-isomer. N-benzoylalanine : An N-acylamino acid that is the N-benzoyl derivative of alanine.. N-benzoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of L-alanine with the carboxy group of benzoic acid.	1.98	1	0	N-acyl-L-alanine; N-benzoylalanine	metabolite
purine-nucleoside phosphorylase nucleoside phosphorylase: from Klebsiella sp.; acts on both purine & pyrimidine nucleosides & catalyzes the production of AraA from uridine arabinoside (AraU) & adenine	2	1	0
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.45	2	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	2.07	1	0	diarylmethane
thiothixene [no description available]	2.07	1	0	N-methylpiperazine	anticoronaviral agent
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.83	3	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	2.07	1	0	diarylmethane
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.46	2	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.07	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.07	1	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.45	2	0	isoquinolines
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.94	4	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
streptozocin [no description available]	2.06	1	0
tamoxifen [no description available]	3.62	2	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
nadp [no description available]	2.13	1	0
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.89	3	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
cancidas [no description available]	2.04	1	0
5-nitro-8-(1-pyrrolidinyl)quinoline [no description available]	2.41	1	0	nitro compound; quinolines
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	3.49	8	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
scopolamine [no description available]	2.07	1	0	3-hydroxy carboxylic acid
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	5.34	7	2	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.4	2	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	2.07	1	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
hmr 3647 [no description available]	3.29	6	0
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	2.04	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine [no description available]	2.45	2	0	aromatic ether
dolasetron [no description available]	2.04	1	0	indolyl carboxylic acid
or 1259 [no description available]	2.04	1	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
almokalant almokalant: structure given in first source	2.07	1	0
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.04	1	0	steroid	estrogen
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.41	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	2.75	3	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
cystine [no description available]	2.17	1	0
isepamicin [no description available]	3.51	8	0
ifetroban ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative	2.04	1	0	benzenes; monocarboxylic acid
lamifiban lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass	2.04	1	0	N-acylglycine
vx-745 [no description available]	2.07	1	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
deracoxib SC 046: structure in first source. deracoxib : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl and 3-fluoro-4-methoxyphenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.	2.07	1	0	organofluorine compound; pyrazoles; sulfonamide	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.07	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
2-aminohippuric acid [no description available]	2.07	1	0	N-acylglycine
carbonyl 3-chlorophenylhydrazone carbonyl 3-chlorophenylhydrazone: inhibitor of ATP synthesis; inhibits iron-containing nitrile hydratases	2.1	1	0
telavancin telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.	2.46	2	0	glycopeptide	antibacterial drug; antimicrobial agent
3,5-dibromo-2-(2,4-dibromophenoxy)phenol 3,5-dibromo-2-(2,4-dibromophenoxy)phenol: isolated from the marine sponge Callyspongidae; inhibits contraction of smooth muscle in ileum; structure in first source	2.11	1	0
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist	1.98	1	0	naphthalenes; sulfonic acid derivative
rs-130830 RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor	2.07	1	0
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	3.14	5	0	organic sodium salt	detergent; protein denaturant
6-cyano-7-nitroquinoxaline-2,3-dione 6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.	1.98	1	0	quinoxaline derivative
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.75	3	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	2.46	2	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin [no description available]	2.44	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	4.05	3	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.07	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.25	1	0	trihydroxyflavone	antineoplastic agent; metabolite
vitamin k semiquinone radical vitamin K semiquinone radical: found in active preparations of vitamin K-dependent carboxylase. vitamin K : Any member of a group of fat-soluble 2-methyl-1,4-napthoquinones that exhibit biological activity against vitamin K deficiency. Vitamin K is required for the synthesis of prothrombin and certain other blood coagulation factors.	2.07	1	0
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.07	1	0	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
alprostadil [no description available]	3.38	1	1	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
leukotriene e4 Leukotriene E4: A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene E4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).	1.97	1	0	amino dicarboxylic acid; L-cysteine thioether; leukotriene; non-proteinogenic L-alpha-amino acid; secondary alcohol
gamma-linolenic acid gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed). gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.	1.99	1	0	linolenic acid; omega-6 fatty acid	human metabolite; mouse metabolite; plant metabolite
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	5.88	18	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	8.08	70	1	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.45	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	2.45	2	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	2.45	2	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	2.04	1	0	isoquinolines
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.45	2	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	2.45	2	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
fisetin [no description available]	2.41	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.04	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
rosmarinic acid rosmarinic acid: RN given refers to parent cpd; promote OT project. (R)-rosmarinic acid : A stereoisomer of rosmarinic acid having (R)-configuration.. rosmarinic acid : The 1-carboxy-2-(2,4-dihydroxyphenyl)ethyl ester of trans-caffeic acid.	2.05	1	0	rosmarinic acid	geroprotector; plant metabolite
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.04	1	0	homodetic cyclic peptide
copalyl diphosphate copalyl diphosphate: structure in first source. 5alpha,9alpha,10beta-labda-8(20),13-dien-15-yl diphosphate : The 5alpha,9alpha,10beta-diastereomer of copalyl diphosphate.	2.13	1	0	copalyl diphosphate
cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.	3.31	1	0	epoxide; monocarboxylic acid amide	antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor
pheniramine maleate Naphcon A: tradename; contains above compounds; ophthalmic solution	2.07	1	0	organic molecular entity
miocamycin Miocamycin: A macrolide antibiotic that has a wide antimicrobial spectrum and is particularly effective in respiratory and genital infections.	1.97	1	0
7432 s Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.	1.97	1	0	cephalosporin; dicarboxylic acid	antibacterial drug
indocyanine green [no description available]	2.04	1	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	2.07	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
homatropine [no description available]	2.07	1	0	tropane alkaloid
codeine [no description available]	2.46	2	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.75	3	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	2.07	1	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	3.51	2	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.04	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.46	2	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	2.46	2	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.07	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.07	1	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.04	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.04	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
ar c67085mx PSB-0413: a selective antagonist radioligand for platelet P2Y12 receptors	2.07	1	0
cicaprost cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R,4R),5beta,6aalpha))-isomer	2.04	1	0	monoterpenoid
desoximetasone Desoximetasone: A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.. desoximetasone : Dexamethasone in which the hydroxy group at the 17alpha position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis.	2.07	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
dexmedetomidine [no description available]	2.04	1	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.04	1	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
lysophosphatidylcholines lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.	2.13	1	0	1-O-acyl-sn-glycero-3-phosphocholine
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	1.97	1	0	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	2.4	2	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	2.45	2	0	phenylalanine derivative
sb 223412 SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source	2.07	1	0
vinorelbine [no description available]	2.04	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
andrographolide [no description available]	2.21	1	0	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite
su 11248 [no description available]	2.07	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.04	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.45	2	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
barium Barium: An element of the alkaline earth group of metals. It has an atomic symbol Ba, atomic number 56, and atomic weight 138. All of its acid-soluble salts are poisonous.	2.07	1	0	alkaline earth metal atom; elemental barium
bismuth Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.	1.99	1	0	metal atom; pnictogen
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.46	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.04	1	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.71	3	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.04	1	0	phenanthrenes
cefixime [no description available]	2.97	4	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.74	3	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	2.06	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	2.06	1	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
batimastat batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.	2.31	1	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.04	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
zimeldine Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)	2.07	1	0	styrenes
bedaquiline bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.	2.94	3	0	aromatic ether; naphthalenes; organobromine compound; quinolines; tertiary alcohol; tertiary amino compound	antitubercular agent; ATP synthase inhibitor
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.06	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	3.32	6	0	cysteinium	fundamental metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	2.46	2	0	carbon group element atom; metalloid atom; nonmetal atom
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	2.75	3	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefuroxime [no description available]	5.6	69	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	7.63	70	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	15.27	283	10	cephalosporin; oxime O-ether	antibacterial drug
hr 810 cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	8.27	37	0	cephalosporin; cyclopentapyridine
ceftazidime [no description available]	10.53	222	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	2.06	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
tiotropium tiotropium : A quaternary ammonium ion obtained by methylation of the tertiary amino group of (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane. Used (in the form of the bromide hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.	2.07	1	0
cefetamet cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.	2.45	2	0	cephalosporin
(6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid [no description available]	2.21	1	0	dicarboxylic acid; secondary carboxamide
oxyfedrine Oxyfedrine: A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.	2.06	1	0	aromatic ketone
vx680 [no description available]	2.13	1	0	N-arylpiperazine
guanabenz Guanabenz: An alpha-2 selective adrenergic agonist used as an antihypertensive agent.	2.47	2	0	dichlorobenzene
famotidine [no description available]	2.46	2	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	13.4	284	7	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	9.18	152	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
nw 1029 Ralfinamide: Sodium Channel Blocker; structure in first source	2.07	1	0
ginkgolide b [no description available]	2.45	2	0
cefpodoxime [no description available]	2.96	4	0	carboxylic acid; cephalosporin	antibacterial drug
cefuzonam cefuzonam: article gives L-105 as synonym, however L 105 is a rifamycin derivative according to Chemline. cefuzonam : A second generation cephalosporin antibiotic.	3.24	6	0	cephalosporin	antibacterial drug
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	2.04	1	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
cgp 39551 CGP 39551: N-methyl-D-aspartate receptor antagonist; structure given in first source	1.98	1	0
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.74	3	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	1.98	1	0	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
eniporide eniporide: inhibits NHE-1 isoform; structure in first source	2.04	1	0
bambermycins Bambermycins: Antibiotic complex obtained from Streptomyces bambergiensis containing mainly Moenomycins A and C. They are used as feed additives and growth promoters for poultry, swine, and cattle.	2.08	1	0
cilastatin [no description available]	23.1	846	239	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
s 1006 S 1006: structure given in first source. cefcapene : A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibacterial.	2.05	1	0	1,3-thiazoles; carbamate ester; carboxylic acid; cephalosporin; enamide; secondary carboxamide	antibacterial drug
nitrocefin nitrocefin: chromogenic cephalosporin used for detection of beta-lactamase activity; Cefinase is name for nitrocefin on paper disc; RN given refers to (6R-(3(E),6 alpha,7 beta))-isomer; structure for mono-Na salt in second source	4.57	24	0
brl 28500 ticarcillin-clavulanic acid: combination of ticarcillin and clavulanic acid; used against gram-negative rods	5.46	8	2
3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid SDZ EAA 494: N-methyl-D-aspartate receptor antagonist	1.98	1	0
cefditoren pivoxil [no description available]	2.05	1	0	1,3-thiazoles; cephams; oxime O-ether; pivaloyloxymethyl ester	antibacterial drug; prodrug
ici d1542 ICI D1542: redirects arachidonic acid metabolism; an inhibitor of thromboxane A2 synthetase and of thromboxane receptors	2.07	1	0
stemphone stemphone: structure given in first source	2.44	2	0
2-(3-methanesulfonylamino-1-propenyl)pyrrolidin-4-ylthiol-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylic acid DA 1131: structure in first source	2.01	1	0
ixabepilone [no description available]	2.04	1	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
gavestinel [no description available]	2.07	1	0
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	4.37	21	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
opc-67683 OPC-67683: an antitubercular agent	2.21	1	0	piperidines
verlukast verlukast: LTD4 receptor antagonist	2.04	1	0
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.06	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
ceftizoxime [no description available]	2.45	2	0	cephalosporin	antibacterial drug
cefclidin cefclidin: structure given in first source. cefclidin : A fourth-generation cephalosporin antibiotic having (4-carbamoyl-1-azoniabicyclo[2.2.2]octan-1-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	3.07	5	0	cephalosporin; thiadiazoles
1-methyl-d-lysergic acid butanolamide [no description available]	2.07	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	3.4	7	0	monobactam	antibacterial drug
apalcillin [no description available]	1.96	1	0	1,5-naphthyridine derivative; penicillin
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	3.57	8	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	1.97	1	0	isoquinoline alkaloid fundamental parent; morphinane alkaloid
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.04	1	0	lipid As
dantrolene [no description available]	2.46	2	0
cefdinir [no description available]	2.94	4	0	cephalosporin; ketoxime	antibacterial drug
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.04	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
tipredane [no description available]	2.07	1	0	3-hydroxy steroid	androgen
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2.04	1	0	diarylmethane
fce 22891 FCE 22891: structure in first source	3.36	1	1
sitafloxacin sitafloxacin: structure in first source	4.31	4	1
napsagatran napsagatran: structure given in first source	2.04	1	0
temsirolimus [no description available]	2.04	1	0	macrolide lactam
bms188797 [no description available]	2.04	1	0
corosolic acid [no description available]	2.11	1	0	triterpenoid	metabolite
bentiromide bentiromide: chymotrypsin labile peptide used diagnostically as an index of exocrine pancreas function. bentiromide : The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.	2.07	1	0	dipeptide	diagnostic agent; indicator; reagent
labdane labdane: from Croton joufra; structure in first source	2.13	1	0	diterpene; terpenoid fundamental parent
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	3.03	4	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
cefmenoxime Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmenoxime : A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.	3.99	4	0	cephalosporin	antibacterial drug
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.04	1	0	imidazolidine-2,4-dione
cefozopran [no description available]	2.45	2	0	cephalosporin; imidazopyridazine; thiadiazoles
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	2.74	3	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
desacetylcefotaxime desacetylcefotaxime: RN given refers to parent cpd (6R-(6alpha,7alpha(Z)))-isomer	3.06	1	0
n-acetylglucosaminono-1,5-lactone o-(phenylcarbamoyl)oxime N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime: structure given in first source	2.15	1	0
gr 69153 GR 69153: broad-spectrum cephalosporin incorporating a catechol-substituted 7-aminothiazolyl-oxime; structure given in first source	1.97	1	0
ceftazidime monobactam ceftazidime monobactam: ceftazidime monobactam analog; structure given in first source	1.96	1	0
cefoselis cefoselis: structure given in first source. cefoselis : A cephalosporin compound having [2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl]methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. A 4th generation broad-spectrum cephalosporin.	2.69	3	0
nvp pdf 713 [no description available]	2.03	1	0
tebipenem tebipenem: an oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae; structure in first source	4.25	5	0
utibapril utibapril: structure given in first source; prodrug for FPL 63547 diacid	2.07	1	0
lexipafant lexipafant: an imidazolyl derivative which forms part of a fused heterocyclic system	3.13	1	0
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	6.16	40	0
tomopenem [no description available]	2.73	3	0
avibactam avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	7.04	23	1	azabicycloalkane; hydroxylamine O-sulfonic acid; monocarboxylic acid amide; ureas	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
zd 9379 ZD 9379: structure given in first source	2.07	1	0
ly 450139 [no description available]	2.07	1	0	peptide
bb-83698 BB-83698: peptide deformylase inhibitor	2.04	1	0
ppi-0903 ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections.	3.59	8	0	1,3-thiazoles; cephalosporin; iminium betaine; organic phosphoramidate; oxime O-ether; thiadiazoles	antibacterial drug; antimicrobial agent; prodrug
cangrelor cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.	2.07	1	0	adenosine 5'-phosphate; aryl sulfide; nucleoside triphosphate analogue; organochlorine compound; organofluorine compound; secondary amino compound	P2Y12 receptor antagonist; platelet aggregation inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	3.12	5	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
sch 527123 [no description available]	2.07	1	0
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	3.28	6	0	carboxylic acid; cephalosporin	antibacterial drug
rwj 54428 RWJ 54428: structure in first source	2.43	2	0
zotarolimus zotarolimus: synthetic analog of rapamycin; structure in first source	2.04	1	0	lactam; macrolide
lipid a Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).	1.98	1	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
l 084 L 084: an oral carbapenem with a 1-(1,3-thiazolin-2-yl)azetidin-3-ylthio group at the C-2 position; structure in first source	2	1	0	carbapenems; pivaloyloxymethyl ester
gentamicin sulfate [no description available]	5.87	91	0
bn 52020 [no description available]	2.45	2	0
rhodamine 123 [no description available]	2.05	1	0	organic chloride salt; xanthene dye	fluorochrome
cp 70429 sulopenem: a penem antibiotic	3.25	6	0
linaprazan linaprazan: structure in first source	2.07	1	0
2-phenylbenzothiazole PBT2 compound: a metal-protein-attenuating compound that may be useful in treating Alzheimer's disesae	2.41	1	0
fidaxomicin Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.	2.6	1	0
lecozotan lecozotan: structure in first source	2.07	1	0
besifloxacin [no description available]	2.05	1	0	quinolines
ar c155858 AR C155858: an MCT1 inhibitor; structure in first source	2.07	1	0
me1036 ME1036: structure in first source	2.04	1	0
anoplin anoplin: an antimicrobial peptide from the venom of the solitary wasp Anoplius samariensis; peptide sequence in first source	2.31	1	0
ici 213689 ICI 213689: a meropenem metabolite	1.97	1	0
baci-im [no description available]	2.99	4	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
ribose ribopyranose : The pyranose form of ribose.	1.97	1	0	D-ribose; ribopyranose
l 749345 L 749345: structure given in first source. ertapenem sodium : The monosodium salt of ertapenem. It is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. It is more stable to renal dehydropeptidase I tham imipenem, and so unlike imipenem, its use with cilastatin, which inhibits the enzyme, is not required.	3.61	3	0	organic sodium salt	antibacterial drug
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.07	1	0	methoxybenzenes; substituted aniline
polymyxin b(1) [no description available]	2.63	2	0
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	2.5	2	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
danusertib [no description available]	2.13	1	0	piperazines
tedizolid phosphate tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	2.17	1	0	carbamate ester; organofluorine compound; oxazolidinone; phosphate monoester; pyridines; tetrazoles	antimicrobial agent; prodrug; protein synthesis inhibitor
finafloxacin finafloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, 7 and 8 by cyclopropyl, fluoro, hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl and cyano groups respectively; an antibiotic used for treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.	2.25	1	0	cyclopropanes; monocarboxylic acid; nitrile; organofluorine compound; quinolone; secondary amino compound; tertiary amino compound	antibacterial drug; antimicrobial agent
vindesine [no description available]	2.04	1	0
cefdinir Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.. cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups.	2.4	2	0
ru 66647 telithromycin: a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;	2.03	1	0
scopolamine hydrobromide [no description available]	2.75	3	0
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	2.4	2	0
sch 29482 Sch 29482: penem antibiotic; bactericidal & stable to beta-lactamases; structure given in first source	2.66	3	0
ach 702 ACH 702: an anti-tubercular agent; structure in first source	2.05	1	0
bisaramil [no description available]	2.04	1	0
melitten Melitten: Basic polypeptide from the venom of the honey bee (Apis mellifera). It contains 26 amino acids, has cytolytic properties, causes contracture of muscle, releases histamine, and disrupts surface tension, probably due to lysis of cell and mitochondrial membranes.	2.47	2	0
teicoplanin teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.	2.04	1	0
tachyplesin peptide, tachypleus tridentatus tachyplesin peptide, Tachypleus tridentatus: isolated from the hemocytes of the horseshoe crab (Tachypleus tridentatus); cationic peptide; 17 amino acid residues given in first source	2.03	1	0
ranalexin ranalexin: an antimicrobial peptide from bullfrog Rana catesbeiana; a 20-amino acid peptide which contains a single intramolecular disulfide bond that forms a heptapeptide ring within the molecule; amino acid sequence given in first source	2.41	2	0
cecropin b protein, insecta cecropin B protein, Insecta: from cecropia moth, Hyalophora cecropia; small basic protein; has potent antibacterial activity against E coli & other Gram-negative bacteria; also found in a variety of other insects; structure given in first source; also prevents development of malarial oocysts in mosquito vector	2.02	1	0
magainin 1 peptide, xenopus magainin I: Antibiotic peptide. Thought to preferentially bind to anionic phosholipids.	3.09	1	0
pexiganan [no description available]	2.45	2	0
forapin Forapin: used as ointment for treatment of myositis & arthritis; contains bee venom, salicylate, nicotinate & vanillylnonamide	2.31	1	0	peptidyl amide; polypeptide	animal metabolite; antineoplastic agent; apoptosis inducer; EC 2.7.11.13 (protein kinase C) inhibitor; hepatoprotective agent; neuroprotective agent; venom
tannins Tannins: Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing.	2.13	1	0
ly-146032 [no description available]	3.43	7	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin [no description available]	2.04	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
ge 2270 a GE 2270 A: from Planobispora rosea; inhibits bacterial protein synthesis in vitro by affecting specifically the GTP-bound form of elongation factor Tu; structure given in first source	3.09	1	0
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	2.05	1	0	glycoside
vx-770 ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.	2.25	1	0	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug
azd 7545 AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).	2.07	1	0	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
cilastatin, imipenem drug combination Cilastatin, Imipenem Drug Combination: Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.	20.01	398	123
d13-9001 D13-9001: structure in first source	2.21	1	0
lucifer yellow lucifer yellow: RN given refers to di-Li salt	2.06	1	0	organic lithium salt	fluorochrome
chitosan [no description available]	2.47	2	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	2.13	1	0	organosulfonic acid
tazobactam sodium tazobactam sodium : An organic sodium salt having tazobactam(1-) as the counterion; used in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	2	1	0	organic sodium salt	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sodium houttuyfonate sodium houttuyfonate: structure in first source	2.1	1	0
sy 5555 SUN 5555: structure given in first source	2.39	2	0
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.07	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sodium hypochlorite Sodium Hypochlorite: It is used as an oxidizing and bleaching agent and as a disinfectant. (From Grant & Hackh's Chemical Dictionary, 5th ed). sodium hypochlorite : An inorganic sodium salt in which hypochlorite is the counterion. It is used as a bleaching and disinfecting agent and is commonly found in household bleach.	3.66	3	0	inorganic sodium salt	bleaching agent; disinfectant
sodium bisulfite sodium bisulfite: has been used externally for parasitic skin diseases and as gastrointestinal antiseptic; structure. sodium hydrogensulfite : An inorganic sodium salt having hydrogensulfite as the counterion.	2.08	1	0	inorganic sodium salt; sulfite salt	allergen; food antioxidant; food colour retention agent; mutagen; reducing agent
cytomel liothyronine sodium : The sodium salt of liothyronine. Thought to be more active than levothyroxine and with a rapid (few hours) onset and short duration of action, liothyronine sodium is used in the treatment of hypothyroidism, particularly in cases of hypothyroid coma.	2.07	1	0	organic sodium salt
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	11.98	89	4
piperacillin, tazobactam drug combination Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.	10.2	70	6
bli-489 BLI-489: structure in first source	2.76	2	0
quinupristin-dalfopristin quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively	2.4	2	0	organic molecular entity
bo 2727 BO 2727: structure in first source	2.9	4	0	carbapenems
forsythoside b forsythoside B: structure in first source	2.07	1	0
cyslabdan cyslabdan: potentiates imipenem activity against methicillin-resistant S. aureus; isolated from Streptomyces; structure in first source	4.94	6	0
nxl 104 avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.	3.27	1	0	organic sodium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
pc190723 PC190723: Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source	2.07	1	0
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	2.04	1	0	oligopeptide	antineoplastic agent; GnRH antagonist
achn 490 plazomicin: structure in first source	4.62	7	0
a 967079 A 967079: a TRPA1 channel antagonist; structure in first source	2.07	1	0
mk-7655 relebactam: structure in first source	15.07	116	8
piperidines Piperidines: A family of hexahydropyridines.	3.02	4	0
pht 427 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide: an antineoplastic agent; structure in first source	2.07	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	3.37	1	1
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	10.84	104	3
fr 264205 ceftolozane: cephalosporin anti-bacterial agent with enhanced activity against Pseudomonas aeruginosa. ceftolozane : A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.	4.55	19	0
bocillin fl BOCILLIN FL: used for detecting pencillin-binding proteins; structure in first source	2.07	1	0
bal 30072 BAL 30072: a siderophore with antibacterial activity; structure in first source	2.78	3	0
cefteram cefteram: structure given in first source. cefteram : A cephalosporin compound having (5-methyl-2H-tetrazol-2-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a third-generation cephalosporin antibiotic.	2.4	2	0
arylomycin a-c16 [no description available]	2.17	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.69	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.66	9	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	5.35	54	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	2.04	1	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.46	2	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	13.37	93	10
dicumarol Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.	2.07	1	0	hydroxycoumarin	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist
roquinimex roquinimex: structure in first source	2.45	2	0	aromatic amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.45	2	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.45	2	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.45	2	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	4.25	5	0	benzenes; hydroxycoumarin; methyl ketone
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	2.04	1	0
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.04	1	0
viridicatumtoxin viridicatumtoxin: isolated from cultures of Penicillium viridicatum; RN given refers to 2'alpha,7'beta,11'abeta,12'beta-(-) isomer. viridicatumtoxin : A tetracycline-like polyketide antibiotic that is produced by several species of Penicillium and Aspergillus.	3.17	1	0
tigecycline [no description available]	13.09	103	11
omadacycline omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source	2.6	1	0	tetracyclines
dolutegravir [no description available]	2.13	1	0	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
eravacycline eravacycline: has antibacterial activity	4.35	4	0	tetracyclines
rpx7009 RPX7009: a beta-lactamase inhibitor; structure in first source	6.41	22	0
calca protein, human CALCA protein, human: RefSeq NM_001741	2.11	1	0
colistin sulfate [no description available]	2.03	1	0
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	5.4	18	0
phleomycin d1 phleomycin D1 : A glycopeptide originally isolated from the bacterium Streptomyces verticillus which contains a (4'R)-4',5'-dihydro-2,4'-bi-1,3-thiazole-2',4-diyl moiety with a a 4-guanidylbutylaminocarbonyl group attached to the 4-position of the terminal thiazole ring. Like all phleomycins, phleomycin D1 can form complexes with redox-active metals such as Co, Cu, and Fe.	2.07	1	0	bi-1,3-thiazole; chelate-forming peptide; disaccharide derivative; glycopeptide; guanidines	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; bacterial metabolite
cefiderocol cefiderocol: structure in first source. cefiderocol : A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.	5.64	10	0	carboxylic acid; cephalosporin	antibacterial drug; siderophore
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	1.98	1	0
antimicrobial peptide ib-367 antimicrobial peptide IB-367: a structural analog of protegrin-1; reduces the local microflora densities & may improve clinical outcomes in patients at risk for the development of oral mucositis	2.1	1	0
daptomycin [no description available]	4.71	10	0
peoniflorin peoniflorin: from Radix and of Paeonia suffruticosa	2.05	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	6.42	7	2
exudates Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)	3.76	10	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.25	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	5.88	7	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.5	2	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine diphosphate Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.	2.43	2	0	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	2.25	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
inosinic acid Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.	2.83	3	0	inosine phosphate; purine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.07	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	11.1	90	2	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.95	4	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.97	4	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.45	2	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	4.21	5	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.75	3	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	2.07	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.45	2	0	2-aminopurines; propane-1,3-diols	antiviral drug
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	2.45	2	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.45	2	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	2.75	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
rifapentine rifapentine: cyclopentyl derivative of rifampicin	2.13	1	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	3.31	1	0
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	2.06	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	2.45	2	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
efrotomycin efrotomycin: from Streptomyces lactamdurans; structure	1.96	1	0
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.04	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.04	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	3.3	6	0	cephalosporin; thiadiazoles	antimicrobial agent
rifabutin [no description available]	3.87	3	0
3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin KRM 1648: structure in first source	3.31	1	0	phenoxazine
krm 1657 KRM 1657: structure given in first source	3.31	1	0
bis(3',5')-cyclic diguanylic acid [no description available]	2.5	2	0	cyclic purine dinucleotide; guanyl ribonucleotide	immunomodulator; signalling molecule
carbadox Carbadox: An antibacterial agent that has been used in veterinary practice for treating swine dysentery and enteritis and for promoting growth. However, its use has been prohibited in the UK following reports of carcinogenicity and mutagenicity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p125)	2.07	1	0	quinoxaline derivative
fenobam fenobam: in USAN fenobam refers to monohydrate	2.07	1	0	ureas
eye [no description available]	2.38	2	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.97	1	0
spirohexaline spirohexaline: produced by Penicillium sp. FKI-3368; structure in first source	3.17	1	0
dactinomycin cefozopran: RN given refers to the (6R-(6alpha,7beta(Z)))-isomer; RN for cpd without isomeric designation not available 10/91. cefozopran : A fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	6.02	10	1
temporin temporin: isolated from frogs Rana temporaria & R. clamitans; has many isoforms; amino acid sequence in first source	2.43	2	0

Condition	Relationship Strength	Studies	Trials
Infections, Staphylococcal [description not available]	14.01	113	7
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	14.01	113	7
Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER.	12.36	304	2
Extravascular Hemolysis [description not available]	2.97	4	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.97	4	0
Infections, Pneumococcal [description not available]	3.71	10	0
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	3.71	10	0
Disease, Pulmonary [description not available]	8.34	27	1
Infections, Pseudomonas [description not available]	14.38	411	9
Infection, Wound [description not available]	6.83	23	3
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	8.02	44	2
Lung Diseases Pathological processes involving any part of the LUNG.	8.34	27	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	14.38	411	9
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	14.55	112	23
Cystic Fibrosis of Pancreas [description not available]	7.78	39	1
B cepacia Infection [description not available]	3.13	5	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	7.78	39	1
Health Care Associated Infection [description not available]	17.32	369	28
Infections, Klebsiella [description not available]	11.73	179	2
Cross Infection Any infection which a patient contracts in a health-care institution.	17.32	369	28
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	11.73	179	2
Cerebral Nocardiosis [description not available]	6.99	71	0
E coli Infections [description not available]	10.7	115	3
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	10.7	115	3
Cronobacter Infections [description not available]	14.23	160	3
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	14.23	160	3
Bacterial Infections, Gram-Positive [description not available]	10.68	54	8
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	10.68	54	8
Ventilator-Associated Pneumonia [description not available]	13.98	51	20
Pneumonia, Ventilator-Associated Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.	13.98	51	20
Community Acquired Infection [description not available]	10.47	29	6
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	14.29	176	14
Blood Poisoning [description not available]	14.08	150	27
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	14.08	150	27
Critical Illness A disease or state in which death is possible or imminent.	12.9	43	8
Infections, Serratia [description not available]	4.05	14	0
Flavobacteriaceae Infections Infections with bacteria of the family FLAVOBACTERIACEAE.	3.34	6	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	8.37	113	0
Bacterial Pneumonia [description not available]	14.17	108	14
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	14.17	108	14
Haemophilus Infections Infections with bacteria of the genus HAEMOPHILUS.	3.62	9	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	7.9	21	4
Bacterial Infections, Gram-Negative [description not available]	15.02	146	15
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	15.02	146	15
Infections, Proteus [description not available]	4.81	12	0
Diabetic Feet [description not available]	7.73	14	5
Bacterial Disease [description not available]	20.7	431	141
Bacterial Infections Infections by bacteria, general or unspecified.	20.7	431	141
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	7.73	14	5
Acute Edematous Pancreatitis [description not available]	11.3	34	9
Acute Disease Disease having a short and relatively severe course.	12.96	60	13
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	11.3	34	9
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	7.28	14	1
Bacteroides Infections Infections with bacteria of the genus BACTEROIDES.	4.88	34	0
Hematologic Malignancies [description not available]	5.69	10	2
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	12.88	92	38
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	5.69	10	2
Infective Endocarditis [description not available]	7.17	11	1
Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.	7.17	11	1
Campylobacter Infection [description not available]	5.41	14	0
Bacterial Meningitides [description not available]	8.29	32	0
Meningitis, Bacterial Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.	8.29	32	0
Diabetic Glomerulosclerosis [description not available]	2.44	2	0
Chronic Kidney Failure [description not available]	7.42	25	2
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.44	2	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	7.42	25	2
Communicable Diseases, Emerging Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.	2.77	3	0
Actinomycetoma [description not available]	3.3	6	0
Mycetoma A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.	3.3	6	0
Benign Neoplasms [description not available]	10.55	56	24
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	10.55	56	24
Encephalitis, Polio [description not available]	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1	0
Acute Liver Injury, Drug-Induced [description not available]	2.42	2	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.42	2	0
Fungal Diseases [description not available]	6.62	10	2
Mycoses Diseases caused by FUNGI.	6.62	10	2
Plasmodium falciparum Malaria [description not available]	2.1	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1	0
Anemia, Fanconi [description not available]	2.13	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1	0
Infections, Mycobacterium [description not available]	2.54	2	0
Mycobacterium Infections Infections with bacteria of the genus MYCOBACTERIUM.	2.54	2	0
Absence Seizure [description not available]	12.33	53	5
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	12.33	53	5
Infections, Respiratory [description not available]	12.34	60	15
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	12.34	60	15
Hansen Disease [description not available]	3.12	1	0
Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.	3.12	1	0
Contact Dermatitis [description not available]	2.21	1	0
Itching [description not available]	2.45	2	0
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.45	2	0
Tuberculosis, Drug-Resistant [description not available]	5.44	9	0
Koch's Disease [description not available]	3.68	2	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	3.68	2	0
Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.	5.44	9	0
Congenital Zika Syndrome [description not available]	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Atypical Mycobacterial Infection, Disseminated [description not available]	8.2	41	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	9.36	41	6
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	11.67	81	18
Pneumonia Infection of the lung often accompanied by inflammation.	11.67	81	18
Infections, Soft Tissue [description not available]	6.68	12	5
Soft Tissue Infections Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)	6.68	12	5
Acute Myelogenous Leukemia [description not available]	4.9	8	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	4.9	8	1
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	6.12	5	2
Infectious Endophthalmitis Infectious condition of the internal eye.	5.14	17	0
Complication, Postoperative [description not available]	11.76	58	14
Bacterial Eye Infections [description not available]	6.26	24	0
Endophthalmitis Suppurative inflammation of the tissues of the internal structures of the eye frequently associated with an infection.	5.14	17	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	11.76	58	14
Osteoarthritis of Knee [description not available]	4.28	2	1
Ache [description not available]	4.09	3	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	4.09	3	1
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	4.28	2	1
Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.	6.6	10	2
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	2.47	2	0
Thrombopenia [description not available]	3.7	3	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.7	3	0
Burkholderia pseudomallei Infection [description not available]	9.59	33	5
Arthritides, Bacterial [description not available]	4.9	8	1
Infections, Prosthesis-Related [description not available]	3.85	11	0
Infectious Diseases [description not available]	2.41	1	0
Diabetes Mellitus, Adult-Onset [description not available]	4.34	7	0
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	2.41	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	4.34	7	0
Enteritis Inflammation of any segment of the SMALL INTESTINE.	2.41	1	0
Innate Inflammatory Response [description not available]	5.11	10	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	5.11	10	1
Cardiac Failure [description not available]	2.89	3	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.89	3	0
Chemotherapy-Induced Febrile Neutropenia FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.	4.92	2	1
2019 Novel Coronavirus Disease [description not available]	3.3	4	0
Surgical Incision [description not available]	2.41	1	0
Chronic Kidney Diseases [description not available]	3.8	3	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	3.8	3	0
Infection, Postoperative Wound [description not available]	11.05	45	12
Brain Abscess A circumscribed collection of purulent exudate in the brain, due to bacterial and other infections. The majority are caused by spread of infected material from a focus of suppuration elsewhere in the body, notably the PARANASAL SINUSES, middle ear (see EAR, MIDDLE); HEART (see also ENDOCARDITIS, BACTERIAL), and LUNG. Penetrating CRANIOCEREBRAL TRAUMA and NEUROSURGICAL PROCEDURES may also be associated with this condition. Clinical manifestations include HEADACHE; SEIZURES; focal neurologic deficits; and alterations of consciousness. (Adams et al., Principles of Neurology, 6th ed, pp712-6)	6.16	22	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	5.33	7	0
Keratitis Inflammation of the cornea.	4.31	4	0
Shoulder Pain Unilateral or bilateral pain of the shoulder. It is often caused by physical activities such as work or sports participation, but may also be pathologic in origin.	2.6	1	0
Epicondylitis, Lateral Humeral [description not available]	2.69	2	0
Tennis Elbow A condition characterized by pain in or near the lateral humeral epicondyle or in the forearm extensor muscle mass as a result of unusual strain. It occurs due repetitive stresses on the elbow from activities such as tennis playing.	2.69	2	0
Canine Diseases [description not available]	3.17	5	0
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	3.01	2	0
Bile Duct Obstruction [description not available]	2.44	2	0
Cholestasis Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).	2.44	2	0
Joint Pain [description not available]	4.45	4	1
Arthritis, Degenerative [description not available]	2.42	2	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.42	2	0
Arthralgia Pain in the joint.	4.45	4	1
Enteric Fever [description not available]	2.6	1	0
Typhoid Fever An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.	2.6	1	0
Otitis Media, Purulent [description not available]	2.96	4	0
Otitis Media, Suppurative Inflammation of the middle ear with purulent discharge.	2.96	4	0
Clostridioides difficile Infection [description not available]	3.28	6	0
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	3.28	6	0
Pus [description not available]	5.55	9	2
Infections, Staphylococcal Skin [description not available]	4.03	5	0
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	4.03	5	0
Mastoiditis Inflammation of the honeycomb-like MASTOID BONE in the skull just behind the ear. It is usually a complication of OTITIS MEDIA.	2.21	1	0
Intra-Abdominal Infections [description not available]	9.08	20	3
Intraabdominal Infections Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery.	9.08	20	3
Allergic Contact Dermatitis [description not available]	2.25	1	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	2.25	1	0
Primary Peritonitis [description not available]	12.32	73	27
Anastomotic Leak Breakdown of the connection and subsequent leakage of effluent (fluids, secretions, air) from a SURGICAL ANASTOMOSIS of the digestive, respiratory, genitourinary, and cardiovascular systems. Most common leakages are from the breakdown of suture lines in gastrointestinal or bowel anastomosis.	2.25	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	12.32	73	27
Gas Gangrene A severe condition resulting from bacteria invading healthy muscle from adjacent traumatized muscle or soft tissue. The infection originates in a wound contaminated with bacteria of the genus CLOSTRIDIUM. C. perfringens accounts for the majority of cases (over eighty percent), while C. noyvi, C. septicum, and C. histolyticum cause most of the other cases.	2.91	4	0
Libman-Sacks Disease [description not available]	4.47	8	0
Bacterial Skin Diseases [description not available]	6.94	10	3
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	4.47	8	0
Skin Diseases, Bacterial Skin diseases caused by bacteria.	6.94	10	3
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	9.03	9	3
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	9.03	9	3
Catheter-Associated Infections [description not available]	3.2	5	0
Pachymeningitis [description not available]	7.44	18	1
Endotoxin Shock [description not available]	7.41	26	1
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	7.44	18	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	7.41	26	1
Calculosis [description not available]	2.25	1	0
Actinomyces Infections [description not available]	4.01	5	0
Empyema, Thoracic [description not available]	3.83	11	0
Empyema, Pleural Suppurative inflammation of the pleural space.	3.83	11	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	9.4	70	2
Carcinoma, Small Cell Lung [description not available]	2.25	1	0
Cancer of Lung [description not available]	7.17	13	3
Bacterial Endocarditides [description not available]	10.12	43	2
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	10.12	43	2
Lung Neoplasms Tumors or cancer of the LUNG.	7.17	13	3
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.25	1	0
Injuries, Soft Tissue [description not available]	2.25	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	7.72	21	1
Actinomycetales Infections Infections with bacteria of the order ACTINOMYCETALES.	4.08	15	0
Extensively Drug-Resistant Tuberculosis Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.	4.14	5	0
Emesis [description not available]	5.7	7	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	5.7	7	1
Aneurysm, Bacterial [description not available]	3.17	1	0
Bacterial Infections, Central Nervous System [description not available]	2.25	1	0
Infections, Coronavirus [description not available]	3.47	2	0
Lung Injury, Acute [description not available]	2.57	2	0
Cytokine Release Syndrome A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.	2.25	1	0
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	2.25	1	0
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	3.47	2	0
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.57	2	0
Infections, Salmonella [description not available]	3.41	7	0
Abscess, Pulmonary [description not available]	3.53	8	0
Devic Disease [description not available]	2.31	1	0
Lung Abscess Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.	3.53	8	0
Neuromyelitis Optica A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.	2.31	1	0
Allergic Angiitis [description not available]	2.31	1	0
Churg-Strauss Syndrome Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.	2.31	1	0
Cardiomyopathies, Primary [description not available]	3.23	1	0
Great Pox [description not available]	3.23	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	3.23	1	0
Syphilis A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.	3.23	1	0
Bilateral Headache [description not available]	2.31	1	0
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	2.31	1	0
Delayed Effects, Prenatal Exposure [description not available]	2.31	1	0
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.31	1	0
Arthropathies [description not available]	2.43	2	0
Joint Diseases Diseases involving the JOINTS.	2.43	2	0
Acute Kidney Failure [description not available]	8.31	19	3
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	8.31	19	3
Parodontosis [description not available]	3.39	2	0
Pericementitis [description not available]	2.72	3	0
Gingivitis Inflammation of gum tissue (GINGIVA) without loss of connective tissue.	2.41	1	0
Periodontal Diseases Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.	3.39	2	0
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	2.72	3	0
Deep Vein Thrombosis [description not available]	2.31	1	0
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	3.87	4	0
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	3.87	4	0
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	2.31	1	0
Adverse Drug Event [description not available]	5.81	4	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	5.81	4	1
Pyrexia [description not available]	12.22	62	34
Cholangiitis, Sclerosing [description not available]	2.15	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	12.22	62	34
Cholangitis, Sclerosing Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.	2.15	1	0
Necrotizing Pyelonephritis [description not available]	7.4	10	3
Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.	7.4	10	3
Group A Strep Infection [description not available]	6.57	27	2
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	6.57	27	2
Glycosuria The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).	2.41	2	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.43	2	0
Episcleritis [description not available]	2.48	2	0
Scleritis Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.	2.48	2	0
Digestive System Fistula An abnormal passage communicating between any components of the digestive system, or between any part of the digestive system and surrounding organ(s).	2.15	1	0
Antidiuretic Hormone, Inappropriate Secretion [description not available]	2.15	1	0
Inappropriate ADH Syndrome A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.	2.15	1	0
Avian Diseases [description not available]	2.17	1	0
Infection [description not available]	11.33	19	6
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	11.33	19	6
Tendinitis Inflammation of TENDONS. It is characterized by the degeneration of tendons accompanied by an inflammatory repair response, fibroblastic proliferation, and formation of granulation tissue. Tendinitis is not a clinical diagnosis and can be confirmed only by histopathological findings.	4.53	5	1
Pain, Chronic [description not available]	2.17	1	0
Glenoid Labral Tears [description not available]	2.17	1	0
Calcification, Pathologic [description not available]	2.17	1	0
Rotator Cuff Injuries Injuries to the ROTATOR CUFF of the shoulder joint.	2.17	1	0
Calcinosis Pathologic deposition of calcium salts in tissues.	2.17	1	0
Tendinopathy Clinical syndrome describing overuse tendon injuries characterized by a combination of PAIN, diffuse or localized swelling, and impaired performance.	4.53	5	1
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	2.17	1	0
Antibiotic-Associated Colitis [description not available]	3.51	8	0
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	3.51	8	0
Peritoneal Carcinomatosis [description not available]	3.56	1	1
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	3.56	1	1
Bacillus anthracis Infection [description not available]	2.8	3	0
Anthrax An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.	2.8	3	0
Erythrophagocytic Lymphohistiocytosis, Familial [description not available]	3.04	4	0
Lymphohistiocytosis, Hemophagocytic A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.	3.04	4	0
Granuloma, Hodgkin [description not available]	2.94	4	0
Drug-Induced Stevens Johnson Syndrome [description not available]	2.17	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2.94	4	0
Stevens-Johnson Syndrome Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.	2.17	1	0
Keratitis, Ulcerative [description not available]	4.06	5	0
Nearsightedness [description not available]	3.09	1	0
Corneal Ulcer Loss of epithelial tissue from the surface of the cornea due to progressive erosion and necrosis of the tissue; usually caused by bacterial, fungal, or viral infection.	4.06	5	0
Myopia A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.	3.09	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	5.05	5	2
Black Death [description not available]	2.53	2	0
Glanders A contagious disease of horses that can be transmitted to humans. It is caused by BURKHOLDERIA MALLEI and characterized by ulceration of the respiratory mucosa and an eruption of nodules on the skin.	2.17	1	0
Plague An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.	2.53	2	0
Sterility, Male [description not available]	2.21	1	0
Infertility, Male The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.	2.21	1	0
Vibrio cholerae Infection [description not available]	2.21	1	0
Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.	2.21	1	0
Cardiac Toxicity [description not available]	2.21	1	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.21	1	0
Benign Intracranial Hypertension [description not available]	2.21	1	0
Pseudotumor Cerebri A condition marked by raised intracranial pressure and characterized clinically by HEADACHES; NAUSEA; PAPILLEDEMA, peripheral constriction of the visual fields, transient visual obscurations, and pulsatile TINNITUS. OBESITY is frequently associated with this condition, which primarily affects women between 20 and 44 years of age. Chronic PAPILLEDEMA may lead to optic nerve injury (see OPTIC NERVE DISEASES) and visual loss (see BLINDNESS).	2.21	1	0
Pneumothorax, Primary Spontaneous [description not available]	2.52	2	0
Infections, Trichomonas [description not available]	2.21	1	0
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	2.71	3	0
Pneumothorax An accumulation of air or gas in the PLEURAL CAVITY, which may occur spontaneously or as a result of trauma or a pathological process. The gas may also be introduced deliberately during PNEUMOTHORAX, ARTIFICIAL.	2.52	2	0
Trichomonas Infections Infections in birds and mammals produced by various species of Trichomonas.	2.21	1	0
Starvation Lengthy and continuous deprivation of food. (Stedman, 25th ed)	2.21	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	9.46	39	5
Angiosarcoma [description not available]	2.11	1	0
MODS [description not available]	5.81	8	3
Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)	2.11	1	0
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	5.81	8	3
Disease Exacerbation [description not available]	5.6	6	1
Acute Bacterial Prostatitis [description not available]	2.51	2	0
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	2.51	2	0
Allergy, Drug [description not available]	6.45	16	1
Eosinophilia, Tropical [description not available]	2.08	1	0
Symptom Cluster [description not available]	2.92	4	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	6.45	16	1
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.08	1	0
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	2.08	1	0
Syndrome A characteristic symptom complex.	2.92	4	0
Bacteroidaceae Infections Infections with bacteria of the family BACTEROIDACEAE.	3.85	4	0
Abscess, Periodontal [description not available]	2.1	1	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	8.47	24	4
Myelomonocytic Leukemia, Chronic [description not available]	2.08	1	0
Leukemia, Myelomonocytic, Chronic A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.	2.08	1	0
Leukemia, Pre-B-Cell [description not available]	2.47	2	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	2.47	2	0
Colicky Pain [description not available]	3.86	4	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	3.86	4	0
Bronchial Pneumonia [description not available]	2.68	3	0
Chronic Illness [description not available]	5.96	14	2
Rheumatism [description not available]	3.87	2	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	5.96	14	2
Rheumatic Diseases Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.	3.87	2	1
Tricuspid Incompetence [description not available]	2.08	1	0
Phlegmon [description not available]	7.46	11	5
Orbital Diseases Diseases of the bony orbit and contents except the eyeball.	4.05	5	0
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	7.46	11	5
Bovine Diseases [description not available]	2.46	2	0
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	2.08	1	0
Ovine Diseases [description not available]	2.08	1	0
Swine Diseases Diseases of domestic swine and of the wild boar of the genus Sus.	2.08	1	0
Food Poisoning [description not available]	2.08	1	0
Acute Cholecystitis [description not available]	3.89	2	1
Acalculous Cholecystitis Inflammation of the GALLBLADDER wall in the absence of GALLSTONES.	2.08	1	0
Cholecystitis, Acute Acute inflammation of the GALLBLADDER wall. It is characterized by the presence of ABDOMINAL PAIN; FEVER; and LEUKOCYTOSIS. Gallstone obstruction of the CYSTIC DUCT is present in approximately 90% of the cases.	3.89	2	1
Complications, Neoplastic Pregnancy [description not available]	2.08	1	0
Endomyometritis Inflammation of both the ENDOMETRIUM and the MYOMETRIUM, usually caused by infections after a CESAREAN SECTION.	5.86	13	2
Fibroid [description not available]	2.08	1	0
Infection, Puerperal [description not available]	6.17	18	2
Cancer of the Uterus [description not available]	2.08	1	0
Dehiscence, Surgical Wound [description not available]	2.48	2	0
Endometritis Inflammation of the ENDOMETRIUM, usually caused by intrauterine infections. Endometritis is the most common cause of postpartum fever.	5.86	13	2
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.08	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	8.13	23	2
Uterine Neoplasms Tumors or cancer of the UTERUS.	2.08	1	0
Airflow Obstruction, Chronic [description not available]	4.32	7	0
Anthracosis A diffuse parenchymal lung disease caused by accumulation of inhaled CARBON or coal dust. The disease can progress from asymptomatic anthracosis to massive lung fibrosis. This lung lesion usually occurs in coal MINERS, but can be seen in urban dwellers and tobacco smokers.	2.99	4	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	4.32	7	0
Diathesis [description not available]	2.94	4	0
Erysipelas An acute infection of the skin caused by species of STREPTOCOCCUS. This disease most frequently affects infants, young children, and the elderly. Characteristics include pink-to-red lesions that spread rapidly and are warm to the touch. The commonest site of involvement is the face.	2.08	1	0
Intertrigo A superficial dermatitis occurring on skin surfaces in contact with each other, such as the axillae, neck creases, intergluteal fold, between the toes, etc. Obesity is a predisposing factor. The condition is caused by moisture and friction and is characterized by erythema, maceration, burning, and exudation.	2.08	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.08	1	0
Uveitis, Anterior Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced.	2.08	1	0
Chronic Liver Failure [description not available]	2.1	1	0
End Stage Liver Disease Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.	2.1	1	0
Equine Diseases [description not available]	2.1	1	0
Blood Pressure, High [description not available]	3.01	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	3.01	1	0
Adenocarcinoma, Basal Cell [description not available]	5.2	6	2
Colorectal Cancer [description not available]	3.8	2	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	5.2	6	2
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.8	2	1
Infections, Legionella pneumophila [description not available]	4	14	0
Acquired Autoimmune Hemolytic Anemia [description not available]	2.45	2	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.1	1	0
Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.	2.45	2	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.1	1	0
Acquired Immune Deficiency Syndrome [description not available]	5.79	8	1
Weight Reduction [description not available]	2.43	2	0
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	5.79	8	1
Hemoptysis Expectoration or spitting of blood originating from any part of the RESPIRATORY TRACT, usually from hemorrhage in the lung parenchyma (PULMONARY ALVEOLI) and the BRONCHIAL ARTERIES.	2.1	1	0
Weight Loss Decrease in existing BODY WEIGHT.	2.43	2	0
Fasciitis, Necrotizing A fulminating bacterial infection of the deep layers of the skin and FASCIA. It can be caused by many different organisms, with STREPTOCOCCUS PYOGENES being the most common.	4.2	6	0
Co-infection [description not available]	2.11	1	0
Alcohol Abuse [description not available]	2.49	2	0
Atelectasis [description not available]	2.11	1	0
Infections, Pasteurellaceae [description not available]	2.11	1	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	2.49	2	0
Grippe [description not available]	2.72	3	0
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	2.72	3	0
Liver Abscess, Pyogenic Single or multiple areas of PUS due to bacterial infection within the hepatic parenchyma. It can be caused by a variety of BACTERIA, local or disseminated from infections elsewhere such as in APPENDICITIS; CHOLECYSTITIS; PERITONITIS; and after LIVER TRANSPLANTATION.	2.97	4	0
Complications of Diabetes Mellitus [description not available]	6.66	12	1
Foot Diseases Anatomical and functional disorders affecting the foot.	5.39	5	1
Orientia tsutsugamushi Infection [description not available]	2.1	1	0
Scrub Typhus An acute infectious disease caused by ORIENTIA TSUTSUGAMUSHI. It is limited to eastern and southeastern Asia, India, northern Australia, and the adjacent islands. Characteristics include the formation of a primary cutaneous lesion at the site of the bite of an infected mite, fever lasting about two weeks, and a maculopapular rash.	2.1	1	0
Acute Respiratory Distress Syndrome [description not available]	4.04	5	0
Acute Hypercapnic Respiratory Failure [description not available]	3.12	5	0
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	4.04	5	0
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	3.12	5	0
Cancer of Head [description not available]	2.11	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.11	1	0
Infant, Newborn, Diseases Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.	2.46	2	0
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	5.45	8	2
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	5.45	8	2
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.11	1	0
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.11	1	0
Eczema, Atopic [description not available]	2.11	1	0
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	2.11	1	0
Bleeding [description not available]	3.83	2	1
Hemorrhage Bleeding or escape of blood from a vessel.	3.83	2	1
Urge Incontinence [description not available]	2.11	1	0
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	2.11	1	0
Emphysema A pathological accumulation of air in tissues or organs.	3.86	4	0
Dysuria Painful URINATION. It is often associated with infections of the lower URINARY TRACT.	2.11	1	0
Urinary Incontinence, Urge Involuntary discharge of URINE that is associated with an abrupt and strong desire to void. It is usually related to the involuntary contractions of the detrusor muscle of the bladder (detrusor hyperreflexia or detrusor instability).	2.11	1	0
Hypercapnia A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.	2.11	1	0
Bites [description not available]	3.89	4	0
Infections, Pasteurella [description not available]	2.47	2	0
Germinoblastoma [description not available]	6.54	9	6
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	6.54	9	6
HIV Coinfection [description not available]	4.05	5	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	4.05	5	0
Cirrhosis, Liver [description not available]	4.79	2	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	4.79	2	1
Acne Inversa [description not available]	3.04	1	0
Hidradenitis Suppurativa A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.	3.04	1	0
Bacteriuria The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.	2.72	3	0
Brain Disorders [description not available]	3.51	8	0
Benign Infantile Myoclonic Epilepsy [description not available]	2.13	1	0
Actinic Reticuloid Syndrome [description not available]	2.13	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	3.51	8	0
Epilepsies, Myoclonic A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.	2.13	1	0
Macrophage Activation Syndrome A serious complication of childhood systemic inflammatory disorders that is thought to be caused by excessive activation and proliferation of T-LYMPHOCYTES and MACROPHAGES. It is seen predominantly in children with systemic onset JUVENILE IDIOPATHIC ARTHRITIS.	2.13	1	0
Perforated Appendicitis [description not available]	9.81	16	11
Appendicitis Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.	9.81	16	11
Eosinophilia, Pulmonary [description not available]	2.13	1	0
Pulmonary Eosinophilia A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.	2.13	1	0
Mycoplasma dispar Infection [description not available]	2.45	2	0
Adrenal Gland Hypofunction [description not available]	2.13	1	0
Achalasia [description not available]	2.13	1	0
Adrenal Insufficiency Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.	2.13	1	0
Esophageal Achalasia A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).	2.13	1	0
Psychoses, Drug [description not available]	2.13	1	0
Graft-Versus-Host Disease [description not available]	3.82	2	1
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	3.82	2	1
Recrudescence [description not available]	7.65	22	3
Breathlessness [description not available]	2.13	1	0
Pulmonary Consumption [description not available]	3.72	10	0
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	2.13	1	0
Dyspnea Difficult or labored breathing.	2.13	1	0
Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung.	3.72	10	0
Hemolysis, Elevated Liver Enzymes, Lowered Platelets [description not available]	2.15	1	0
Stillbirth The event that a FETUS is born dead or stillborn.	2.15	1	0
Anemia, Hemolytic, Acquired [description not available]	2.46	2	0
Anti-Phospholipid Antibody Syndrome [description not available]	2.15	1	0
Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).	2.46	2	0
Antiphospholipid Syndrome The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).	2.15	1	0
HELLP Syndrome A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.	2.15	1	0
Neonatal Early-Onset Sepsis [description not available]	2.13	1	0
Neonatal Sepsis Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.	2.13	1	0
Blastomyces brasiliensis Infection [description not available]	3.06	1	0
Fungal Lung Diseases [description not available]	3.34	2	0
Candida Infection [description not available]	2.93	4	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.93	4	0
Embolism, Pulmonary [description not available]	2.04	1	0
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	2.04	1	0
Astrocytosis [description not available]	2.04	1	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.43	2	0
Acute Disseminated Encephalomyelitis [description not available]	2.04	1	0
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	6.79	5	3
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.43	2	0
Discitis Inflammation of an INTERVERTEBRAL DISC or disk space which may lead to disk erosion. Until recently, discitis has been defined as a nonbacterial inflammation and has been attributed to aseptic processes (e.g., chemical reaction to an injected substance). However, recent studies provide evidence that infection may be the initial cause, but perhaps not the promoter, of most cases of discitis. Discitis has been diagnosed in patients following discography, myelography, lumbar puncture, paravertebral injection, and obstetrical epidural anesthesia. Discitis following chemonucleolysis (especially with chymopapain) is attributed to chemical reaction by some and to introduction of microorganisms by others.	2.94	4	0
Ankylosing Vertebral Hyperostosis with Tylosis [description not available]	2.04	1	0
Abscess, Psoas [description not available]	4.02	5	0
Cor Pulmonale [description not available]	2.04	1	0
Kaposi Sarcoma [description not available]	2.05	1	0
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	2.05	1	0
Abscess, Abdominal [description not available]	9.88	17	11
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	9.88	17	11
Complication, Intraoperative [description not available]	3.8	2	1
Adenoma, Prostatic [description not available]	2.69	3	0
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	2.69	3	0
Nervous System Disorders [description not available]	2.96	1	0
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	2.96	1	0
Acute Necrotizing Pancreatitis [description not available]	10.81	26	9
Adrenal Cancer [description not available]	2.05	1	0
Hepatocellular Carcinoma [description not available]	2.73	3	0
Cancer of Liver [description not available]	2.93	4	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.73	3	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.93	4	0
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	2.73	3	0
Atopic Hypersensitivity [description not available]	3.6	3	0
Brain Inflammation [description not available]	2.05	1	0
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	2.05	1	0
Genetic Predisposition [description not available]	2.05	1	0
Delayed Hypersensitivity [description not available]	3.1	5	0
Encephalopathy, Toxic [description not available]	2.05	1	0
Enterocolitis Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.	2.05	1	0
Fever of Unknown Origin Fever in which the etiology cannot be ascertained.	6.08	11	3
Acute Lymphoid Leukemia [description not available]	2.69	3	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.69	3	0
Spinal Diseases Diseases involving the SPINE.	2.41	2	0
Harelip [description not available]	2.05	1	0
Cleft Palate, Isolated [description not available]	2.05	1	0
Cleft Lip Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is thought to be caused by faulty migration of the mesoderm in the head region.	2.05	1	0
Cleft Palate Congenital fissure of the soft and/or hard palate, due to faulty fusion.	2.05	1	0
Segond Fracture [description not available]	3.33	2	0
Fractures, Ununited A fracture in which union fails to occur, the ends of the bone becoming rounded and eburnated, and a false joint occurs. (Stedman, 25th ed)	2.97	1	0
Tibial Fractures Fractures of the TIBIA.	3.33	2	0
Gastrointestinal Stromal Neoplasm [description not available]	2.05	1	0
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	2.05	1	0
Aneurysm, Ruptured The tearing or bursting of the weakened wall of the aneurysmal sac, usually heralded by sudden worsening pain. The great danger of a ruptured aneurysm is the large amount of blood spilling into the surrounding tissues and cavities, causing HEMORRHAGIC SHOCK.	2.05	1	0
Rupture, Spontaneous Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.	4.63	6	1
Hypermobility, Joint [description not available]	2.05	1	0
Breast Cancer [description not available]	2.41	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.41	2	0
Anaplasma Infection [description not available]	2.05	1	0
Acid Aspiration Syndrome [description not available]	5.01	3	3
Pneumonia, Aspiration A type of lung inflammation resulting from the aspiration of food, liquid, or gastric contents into the upper RESPIRATORY TRACT.	5.01	3	3
Scrotal Hydrocele [description not available]	2.05	1	0
Abscess, Hepatic [description not available]	3.7	10	0
Liver Abscess Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.	3.7	10	0
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	5	9	1
Berger Disease [description not available]	2.05	1	0
Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.	2.05	1	0
Foreign Bodies Inanimate objects that become enclosed in the body.	2.06	1	0
Hospital-Acquired Condition [description not available]	2.71	3	0
Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.	5.08	10	1
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	2.06	1	0
Aqueductal Stenosis [description not available]	2.06	1	0
Decreased Muscle Tone [description not available]	2.06	1	0
Cerebrospinal Fluid Effusion, Subdural [description not available]	2.06	1	0
Gangrene Death and putrefaction of tissue usually due to a loss of blood supply.	6.11	6	2
Autosomal Recessive Chronic Granulomatous Disease [description not available]	2.41	2	0
Granulomatous Disease, Chronic A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.	2.41	2	0
Rodent Diseases Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).	2.06	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.06	1	0
Lemierre Disease [description not available]	2.98	1	0
Abdominal Aortic Aneurysm [description not available]	2.06	1	0
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	2.06	1	0
Aortic Aneurysm, Ruptured [description not available]	2.42	2	0
Cholecystoduodenal Fistula [description not available]	2.06	1	0
Aortitis Inflammation of the wall of the AORTA.	2.06	1	0
Vascular Fistula An abnormal passage between two or more BLOOD VESSELS, between ARTERIES; VEINS; or between an artery and a vein.	2.06	1	0
Aortic Diseases Pathological processes involving any part of the AORTA.	2.06	1	0
Hematemesis Vomiting of blood that is either fresh bright red, or older coffee-ground in character. It generally indicates bleeding of the UPPER GASTROINTESTINAL TRACT.	2.06	1	0
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	2.06	1	0
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.06	1	0
Gastric Stasis [description not available]	2.06	1	0
Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.	3.11	5	0
Gastroparesis Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.	2.06	1	0
Adenovirus Infections [description not available]	2.06	1	0
Eye Infections, Viral Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus.	2.06	1	0
Adenoviridae Infections Virus diseases caused by the ADENOVIRIDAE.	2.06	1	0
Keratoconjunctivitis Simultaneous inflammation of the cornea and conjunctiva.	2.06	1	0
Microbial Superinvasion [description not available]	6.07	8	4
Sinusitis, Maxillary [description not available]	2.44	2	0
Maxillary Sinusitis Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS.	2.44	2	0
Bronchiectasis Persistent abnormal dilatation of the bronchi.	2.71	3	0
Cancer of Colon [description not available]	2.06	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.06	1	0
Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.	3.83	2	1
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	3.81	2	1
Eyelid Diseases Diseases involving the EYELIDS.	3.35	2	0
Esophagotracheal Fistula [description not available]	2.07	1	0
Foreign-Body Reaction Chronic inflammation and granuloma formation around irritating foreign bodies.	3.34	2	0
Choledocholithiasis Presence or formation of GALLSTONES in the COMMON BILE DUCT.	2.07	1	0
Bronchiolitis, Exudative [description not available]	2.07	1	0
Cutaneous Phaeohyphomycosis [description not available]	2.07	1	0
Bronchiolitis Obliterans Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.	2.07	1	0
Granulomatosis, Wegener's [description not available]	2.07	1	0
Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.	2.07	1	0
Congenital Thrombotic Thrombocytopenic Purpura [description not available]	2.07	1	0
Infarct of the Spleen [description not available]	2.07	1	0
Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.	2.07	1	0
Corynebacterium Infections Infections with bacteria of the genus CORYNEBACTERIUM.	3.24	6	0
Bone Diseases Diseases of BONES.	3.77	2	1
Anankastic Personality [description not available]	2.01	1	0
Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.	2.01	1	0
Mouth Diseases Diseases involving the MOUTH.	2.39	2	0
Fusobacterium Infections Infections with bacteria of the genus FUSOBACTERIUM.	2.69	3	0
Arthritis, Post-Infectious [description not available]	2.01	1	0
Arthritis, Reactive An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.	2.01	1	0
Dermatoses [description not available]	2.39	2	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.39	2	0
Petechiae Pinhead size (3 mm) skin discolorization due to hemorrhage.	2.01	1	0
Haverhill Fever [description not available]	2.01	1	0
Purpura Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is	2.01	1	0
Benign Neoplasms, Brain [description not available]	2.4	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.4	2	0
Abscess, Peritonsillar [description not available]	2.93	1	0
Biliary Calculi [description not available]	2.01	1	0
Gallstones Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin.	2.01	1	0
Cellulitis, Pelvic [description not available]	3.39	1	1
Parametritis Inflammation of the parametrium, the connective tissue of the pelvic floor, extending from the subserous coat of the uterus laterally between the layers of the BROAD LIGAMENT.	3.39	1	1
Kidney Stones [description not available]	2.4	2	0
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	2.4	2	0
Kidney Calculi Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.	2.4	2	0
Diseases, Occupational [description not available]	2.69	3	0
Wounds, Stab Penetrating wounds caused by a pointed object.	2.41	2	0
Zoonoses Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals.	2.01	1	0
Middle Ear Inflammation [description not available]	2.69	3	0
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	2.69	3	0
Staphylococcal Pneumonia [description not available]	5.76	4	2
Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.	5.76	4	2
Diffuse Parenchymal Lung Disease [description not available]	2.01	1	0
Bleb [description not available]	2.01	1	0
Centriacinar Emphysema [description not available]	2.01	1	0
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	2.01	1	0
Granulocytic Leukemia [description not available]	2.69	3	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.69	3	0
Pink Eye [description not available]	2.01	1	0
Conjunctivitis INFLAMMATION of the CONJUNCTIVA.	2.01	1	0
Chlamydia pneumoniae Infections [description not available]	2.02	1	0
Leucocythaemia [description not available]	7.28	15	8
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	7.28	15	8
Blunt Injuries [description not available]	2.02	1	0
Chronic Bronchitis [description not available]	2.01	1	0
Bronchitis, Chronic A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.	2.01	1	0
Myoclonic Jerk [description not available]	2.69	3	0
Leukocytopenia [description not available]	4.63	6	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	4.63	6	1
Aura [description not available]	3.84	4	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	3.84	4	0
Hypovolemic [description not available]	2.42	2	0
Endotoxemia A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.	4.49	5	1
Hypovolemia An abnormally low volume of blood circulating through the body. It may result in hypovolemic shock (see SHOCK).	2.42	2	0
Convulsions, Grand Mal [description not available]	2.41	2	0
Epilepsy, Tonic-Clonic A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)	2.41	2	0
Angiitis [description not available]	2.02	1	0
Leg Dermatoses A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)	2.02	1	0
Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.	2.02	1	0
Carcinoma, Oat Cell [description not available]	4.86	4	2
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	4.86	4	2
Aspergillus Infection [description not available]	2.4	2	0
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	2.4	2	0
Paranasal Sinus Diseases Diseases affecting or involving the PARANASAL SINUSES and generally manifesting as inflammation, abscesses, cysts, or tumors.	2.02	1	0
Anoxemia [description not available]	2.93	1	0
Carcinoma, Bronchial [description not available]	2.93	1	0
Bronchial Fistula An abnormal passage or communication between a bronchus and another part of the body.	4.26	2	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.93	1	0
Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.	2.93	1	0
Colitis, Granulomatous [description not available]	2.93	1	0
Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.	2.93	1	0
Back Ache [description not available]	2.02	1	0
Bone Cancer [description not available]	2.43	2	0
Benign Cerebellar Neoplasms [description not available]	2.02	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.02	1	0
Brain Ventricular Neoplasms [description not available]	2.02	1	0
Back Pain Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.	2.02	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.43	2	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.02	1	0
Inflammatory Pseudotumor [description not available]	2.93	1	0
Granuloma, Plasma Cell A slow-growing benign pseudotumor in which plasma cells greatly outnumber the inflammatory cells.	2.93	1	0
Local Neoplasm Recurrence [description not available]	2.02	1	0
Blood Diseases [description not available]	7.51	17	9
Hematologic Diseases Disorders of the blood and blood forming tissues.	7.51	17	9
Cholera Infantum [description not available]	5.81	6	4
Liver Dysfunction [description not available]	2.69	3	0
Liver Diseases Pathological processes of the LIVER.	2.69	3	0
Autoimmune Diabetes [description not available]	3.8	2	1
Bronze Diabetes [description not available]	2.41	2	0
Infections, Yersinia [description not available]	2.68	3	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	3.8	2	1
Hemochromatosis A disorder of iron metabolism characterized by a triad of HEMOSIDEROSIS; LIVER CIRRHOSIS; and DIABETES MELLITUS. It is caused by massive iron deposits in parenchymal cells that may develop after a prolonged increase of iron absorption. (Jablonski's Dictionary of Syndromes & Eponymic Diseases, 2d ed)	2.41	2	0
Hepatitis INFLAMMATION of the LIVER.	2.39	2	0
Bladder Cancer [description not available]	2.02	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.02	1	0
Premature Rupture of Fetal Membranes [description not available]	4.07	3	1
Complications, Infectious Pregnancy [description not available]	7.8	16	3
Fetal Membranes, Premature Rupture Spontaneous tearing of the membranes surrounding the FETUS any time before the onset of OBSTETRIC LABOR. Preterm PROM is membrane rupture before 37 weeks of GESTATION.	4.07	3	1
AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.	3.25	6	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.02	1	0
Emergencies Situations or conditions requiring immediate intervention to avoid serious adverse results.	4.84	4	2
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.09	5	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.09	5	0
Blood Pressure, Low [description not available]	2.7	3	0
Circulatory Collapse [description not available]	2.02	1	0
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	2.7	3	0
Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs.	2.02	1	0
Purpura, Thrombopenic [description not available]	2.03	1	0
Purpura, Thrombocytopenic Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.	2.03	1	0
Femoral Fractures Fractures of the femur.	2.94	1	0
Drug Abuse, Intravenous [description not available]	2.94	1	0
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	9.06	27	11
Carcinoma, Epidermoid [description not available]	5.96	5	2
Cancer of Esophagus [description not available]	2.94	1	0
Esophageal Fistula Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.	2.94	1	0
Pleural Diseases Diseases involving the PLEURA.	3.33	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	5.96	5	2
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.94	1	0
Spondylitis Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.	2.42	2	0
Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.	2.68	3	0
Empyema, Gall Bladder [description not available]	8.28	7	6
Intestinal Perforation Opening or penetration through the wall of the INTESTINES.	8.82	11	7
Peptic Ulcer Perforation Penetration of a PEPTIC ULCER through the wall of DUODENUM or STOMACH allowing the leakage of luminal contents into the PERITONEAL CAVITY.	7.45	4	4
Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.	8.28	7	6
Diverticulitis Inflammation of a DIVERTICULUM or diverticula.	7.84	5	5
Inflammatory Response Syndrome, Systemic [description not available]	4.11	3	1
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	4.11	3	1
Abdominal Injuries General or unspecified injuries involving organs in the abdominal cavity.	2.03	1	0
Urinary Tract Diseases [description not available]	1.97	1	0
Puerperal Disorders Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.	1.97	1	0
Altered Level of Consciousness [description not available]	2.03	1	0
Dysmyelopoietic Syndromes [description not available]	2.42	2	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.42	2	0
Exanthem [description not available]	3.6	3	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	3.6	3	0
Cerebellar Diseases Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.	2.03	1	0
Bacillaceae Infections Infections with bacteria of the family BACILLACEAE.	2.41	2	0
Sarcoma, Epithelioid [description not available]	2.03	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	2.03	1	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	2.03	1	0
Abscess, Intracranial, Subdural [description not available]	3.6	3	0
Precordial Catch [description not available]	2.03	1	0
Chest Pain Pressure, burning, or numbness in the chest.	2.03	1	0
Esophageal Diseases Pathological processes in the ESOPHAGUS.	3.79	2	1
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	2.68	3	0
Muscle Disorders [description not available]	2.69	3	0
Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.	2.69	3	0
Depression, Endogenous [description not available]	2.03	1	0
Anasarca [description not available]	3.8	2	1
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	2.03	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	3.8	2	1
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	2.4	2	0
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	2.4	2	0
Bile Duct Diseases Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT.	2.03	1	0
Sinusitis, Sphenoid [description not available]	2.03	1	0
Postintubation Croup [description not available]	2.03	1	0
Laryngitis Inflammation of the LARYNGEAL MUCOSA, including the VOCAL CORDS. Laryngitis is characterized by irritation, edema, and reduced pliability of the mucosa leading to VOICE DISORDERS such as APHONIA and HOARSENESS.	2.03	1	0
Infections, Parvoviridae [description not available]	2.03	1	0
Croup Inflammation involving the GLOTTIS or VOCAL CORDS and the subglottic larynx. Croup is characterized by a barking cough, HOARSENESS, and persistent inspiratory STRIDOR (a high-pitched breathing sound). It occurs chiefly in infants and children.	2.03	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	2.04	1	0
Keratoconus A noninflammatory, usually bilateral protrusion of the cornea, the apex being displaced downward and nasally. It occurs most commonly in females at about puberty. The cause is unknown but hereditary factors may play a role. The -conus refers to the cone shape of the corneal protrusion. (From Dorland, 27th ed)	2.03	1	0
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.04	1	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.04	1	0
Far East Scarlet-like Fever [description not available]	2.04	1	0
Digestive System Disorders [description not available]	4.34	2	2
Digestive System Diseases Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).	4.34	2	2
Tracheitis INFLAMMATION of the TRACHEA that is usually associated with RESPIRATORY TRACT INFECTIONS.	4.73	2	1
Ecthyma An ulcerative pyoderma usually caused by group A beta-hemolytic streptococcal infection at the site of minor trauma. (Dorland, 27th ed)	2.04	1	0
Haemophilus influenzae Meningitis Type B [description not available]	4.27	4	1
Brucella Infection [description not available]	1.96	1	0
Brucellosis Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.	1.96	1	0
Bile Duct Obstruction, Intrahepatic [description not available]	1.98	1	0
Cholestasis, Intrahepatic Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).	1.98	1	0
Toxemia A condition produced by the presence of toxins or other harmful substances in the BLOOD.	1.98	1	0
Experimental Pneumococcal Meningitis [description not available]	3.48	8	0
Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)	3.48	8	0
Infections, Respiratory Syncytial Virus [description not available]	1.98	1	0
Bronchiolitis Inflammation of the BRONCHIOLES.	1.98	1	0
Respiratory Syncytial Virus Infections Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.	1.98	1	0
Pancreatic Diseases Pathological processes of the PANCREAS.	2.68	3	0
Cecal Diseases Pathological developments in the CECUM.	2.4	2	0
Pleurisy INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.	1.98	1	0
Infectious Skin Diseases [description not available]	7.34	8	6
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	7.34	8	6
Colitis Gravis [description not available]	1.98	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	1.98	1	0
Cardiac Death [description not available]	1.98	1	0
Dehydration The condition that results from excessive loss of water from a living organism.	1.98	1	0
Glycosuria, Renal An autosomal inherited disorder due to defective reabsorption of GLUCOSE by the PROXIMAL RENAL TUBULES. The urinary loss of glucose can reach beyond 50 g/day. It is attributed to the mutations in the SODIUM-GLUCOSE TRANSPORTER 2 encoded by the SLC5A2 gene.	1.98	1	0
Amnionitis [description not available]	4.06	3	1
Labor, Premature [description not available]	2.38	2	0
Chorioamnionitis INFLAMMATION of the placental membranes (CHORION; AMNION) and connected tissues such as fetal BLOOD VESSELS and UMBILICAL CORD. It is often associated with intrauterine ascending infections during PREGNANCY.	4.06	3	1
Thoracic Diseases Disorders affecting the organs of the thorax.	2.38	2	0
Female Genital Diseases [description not available]	8.97	28	6
Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).	8.97	28	6
Urinary Calculi Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.	1.98	1	0
Bladder Calculi [description not available]	1.98	1	0
Anti-MuSK Myasthenia Gravis [description not available]	1.98	1	0
Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.	1.98	1	0
Dermatitis Medicamentosa [description not available]	5.07	6	0
Palmoplantaris Pustulosis [description not available]	1.98	1	0
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	1.98	1	0
Cardiac Tamponade Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.	2.38	2	0
Abscess, Amebic, Hepatic [description not available]	1.98	1	0
Esophageal Varices [description not available]	3.37	1	1
Esophageal and Gastric Varices Dilated blood vessels in the ESOPHAGUS or GASTRIC FUNDUS that shunt blood from the portal circulation (PORTAL SYSTEM) to the systemic venous circulation. Often they are observed in individuals with portal hypertension (HYPERTENSION, PORTAL).	3.37	1	1
Bed Sores [description not available]	1.98	1	0
Impetigo Contagiosa [description not available]	1.98	1	0
Pressure Ulcer An ulceration caused by prolonged pressure on the SKIN and TISSUES when one stays in one position for a long period of time, such as lying in bed. The bony areas of the body are the most frequently affected sites which become ischemic (ISCHEMIA) under sustained and constant pressure.	1.98	1	0
Impetigo A common superficial bacterial infection caused by STAPHYLOCOCCUS AUREUS or group A beta-hemolytic streptococci. Characteristics include pustular lesions that rupture and discharge a thin, amber-colored fluid that dries and forms a crust. This condition is commonly located on the face, especially about the mouth and nose.	1.98	1	0
AIDS Seroconversion [description not available]	2.9	4	0
P carinii Pneumonia [description not available]	3.3	2	0
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	3.3	2	0
Peritoneal Diseases Pathological processes involving the PERITONEUM.	4.63	3	2
IgA Vasculitis A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.	1.98	1	0
Familial Waldenstrom's Macroglobulinaemia [description not available]	1.98	1	0
Cancer of Stomach [description not available]	2.67	3	0
Empyema Presence of pus in a hollow organ or body cavity.	2.38	2	0
Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.	1.98	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.67	3	0
Central European Encephalitis [description not available]	1.98	1	0
Encephalomyelitis, Inflammatory [description not available]	1.98	1	0
B. burgdorferi Infection [description not available]	1.98	1	0
Encephalomyelitis A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.	1.98	1	0
Lyme Disease An infectious disease caused by a spirochete, BORRELIA BURGDORFERI, which is transmitted chiefly by Ixodes dammini (see IXODES) and pacificus ticks in the United States and Ixodes ricinis (see IXODES) in Europe. It is a disease with early and late cutaneous manifestations plus involvement of the nervous system, heart, eye, and joints in variable combinations. The disease was formerly known as Lyme arthritis and first discovered at Old Lyme, Connecticut.	1.98	1	0
Cyst [description not available]	1.99	1	0
Obstructive Lung Diseases [description not available]	5.54	3	2
Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.	5.54	3	2
Dental Plaque A film that attaches to teeth, often causing DENTAL CARIES and GINGIVITIS. It is composed of MUCINS, secreted from salivary glands, and microorganisms.	1.98	1	0
Eye Disorders [description not available]	1.99	1	0
Neuroretinitis [description not available]	2.4	2	0
Eye Injuries, Penetrating Deeply perforating or puncturing type intraocular injuries.	2.68	3	0
Eye Diseases Diseases affecting the eye.	1.99	1	0
Retinitis Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).	2.4	2	0
Absence Status [description not available]	2.39	2	0
Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)	2.39	2	0
Dental Focal Infection [description not available]	2.39	2	0
Craniocerebral Injuries [description not available]	2.9	1	0
Sinus Infections [description not available]	2.9	1	0
Craniocerebral Trauma Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.	2.9	1	0
Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.	2.9	1	0
Carcinoma, Large Cell A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)	3.38	1	1
Anemia, Hypoplastic [description not available]	2.68	3	0
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	2.68	3	0
Tooth Discoloration Any change in the hue, color, or translucency of a tooth due to any cause. Restorative filling materials, drugs (both topical and systemic), pulpal necrosis, or hemorrhage may be responsible. (Jablonski, Dictionary of Dentistry, 1992, p253)	1.99	1	0
Allergic Cutaneous Angiitis [description not available]	1.99	1	0
Hallux Abductovalgus [description not available]	1.99	1	0
Hallux Valgus Lateral displacement of the great toe (HALLUX), producing deformity of the first METATARSOPHALANGEAL JOINT with callous, bursa, or BUNION formation over the bony prominence.	1.99	1	0
Cancer of Ovary [description not available]	2.38	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.38	2	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	5.38	5	0
Nutritional Disorders [description not available]	1.99	1	0
Nutrition Disorders Disorders caused by nutritional imbalance, either overnutrition or undernutrition.	1.99	1	0
Aortitis Syndrome [description not available]	1.99	1	0
Splenic Diseases Diseases involving the SPLEEN.	2.4	2	0
Takayasu Arteritis A chronic inflammatory process that affects the AORTA and its primary branches, such as the brachiocephalic artery (BRACHIOCEPHALIC TRUNK) and CAROTID ARTERIES. It results in progressive arterial stenosis, occlusion, and aneurysm formation. The pulse in the arm is hard to detect. Patients with aortitis syndrome often exhibit retinopathy.	1.99	1	0
Eperythrozoonosis [description not available]	3.38	1	1
Infections, Helicobacter [description not available]	1.99	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	1.99	1	0
Corneal Diseases Diseases of the cornea.	1.99	1	0
Dyskinesia Syndromes [description not available]	1.99	1	0
Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.	1.99	1	0
Mitral Incompetence [description not available]	1.99	1	0
Mitral Valve Insufficiency Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.	1.99	1	0
Paratyphoid Fever A prolonged febrile illness commonly caused by several Paratyphi serotypes of SALMONELLA ENTERICA. It is similar to TYPHOID FEVER but less severe.	1.99	1	0
Tracheal Diseases Diseases involving the TRACHEA.	1.98	1	0
Aneurysm, Thoracic Aortic [description not available]	1.99	1	0
Aortic Aneurysm, Thoracic An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm.	1.99	1	0
Dementia Praecox [description not available]	1.99	1	0
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	1.99	1	0
Varices [description not available]	1.99	1	0
Varicose Veins Enlarged and tortuous VEINS.	1.99	1	0
Gastric Ulcer [description not available]	1.99	1	0
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	1.99	1	0
Anguilluliasis [description not available]	1.99	1	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	1.99	1	0
Strongyloidiasis Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea.	1.99	1	0
Bewilderment [description not available]	1.99	1	0
Action Tremor [description not available]	2.39	2	0
Tremor Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.	2.39	2	0
Cardiomyopathy, Congestive [description not available]	1.99	1	0
Cytomegaloviral Retinitis [description not available]	1.99	1	0
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	1.99	1	0
Cytomegalovirus Retinitis Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.	1.99	1	0
Bronchial Cyst [description not available]	1.99	1	0
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	3.38	1	1
Agricultural Worker Disease [description not available]	1.99	1	0
Cruveilhier-Baumgarten Syndrome Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.	2	1	0
Cirrhoses, Experimental Liver [description not available]	2	1	0
Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.	2	1	0
Bullous Dermatoses [description not available]	2.39	2	0
Autoimmune Disease [description not available]	2	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	2	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	2	1	0
Cirrhosis [description not available]	2	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2	1	0
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	2	1	0
Anus Diseases Diseases involving the ANUS.	3.31	2	0
Thrombocythemia [description not available]	3.83	1	0
Spinal Stenosis Narrowing of the spinal canal.	2	1	0
B-Cell Lymphoma [description not available]	2	1	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2	1	0
Thyroid Diseases Pathological processes involving the THYROID GLAND.	2	1	0
Necrotizing Enterocolitis [description not available]	2	1	0
Alcoholic Cirrhosis [description not available]	2	1	0
Liver Cirrhosis, Alcoholic FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.	2	1	0
Enterocolitis, Necrotizing ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.	2	1	0
Fournier Disease [description not available]	3.32	2	0
Hemorrhoids Swollen veins in the lower part of the RECTUM or ANUS. Hemorrhoids can be inside the anus (internal), under the skin around the anus (external), or protruding from inside to outside of the anus. People with hemorrhoids may or may not exhibit symptoms which include bleeding, itching, and pain.	2	1	0
Adhesions, Tissue [description not available]	2	1	0
Cardiac Output, Low A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.	2	1	0
Constrictive Pericarditis [description not available]	2	1	0
Anaphylactic Reaction [description not available]	2.38	2	0
Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.	2.38	2	0
Hepatitis B Virus Infection [description not available]	2	1	0
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	2	1	0
Autoimmune Chronic Hepatitis [description not available]	2	1	0
Boutonneuse Fever A febrile disease of the Mediterranean area, the Crimea, Africa, and India, caused by infection with RICKETTSIA CONORII.	2	1	0
Hepatitis, Autoimmune A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.	2	1	0
Coronary Heart Disease [description not available]	2	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2	1	0
Altidudinal Hemianopia [description not available]	2	1	0
Tooth Diseases Diseases involving the TEETH.	3.33	2	0
Ureteral Calculi Stones in the URETER that are formed in the KIDNEY. They are rarely more than 5 mm in diameter for larger renal stones cannot enter ureters. They are often lodged at the ureteral narrowing and can cause excruciating renal colic.	2	1	0
Fistula Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.	2	1	0
Injuries, Spinal Cord [description not available]	2	1	0
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.39	2	0
Hepatoerythropoietic Porphyria [description not available]	2	1	0
Autoimmune Thrombocytopenia [description not available]	2	1	0
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	2	1	0
Aneurysm, Anterior Cerebral Artery [description not available]	2	1	0
Adenohypophyseal Hyposecretion [description not available]	2	1	0
Intracranial Aneurysm Abnormal outpouching in the wall of intracranial blood vessels. Most common are the saccular (berry) aneurysms located at branch points in CIRCLE OF WILLIS at the base of the brain. Vessel rupture results in SUBARACHNOID HEMORRHAGE or INTRACRANIAL HEMORRHAGES. Giant aneurysms (	2	1	0
Hypopituitarism Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.	2	1	0
Arthritis, Juvenile Chronic [description not available]	2	1	0
Arthritis, Juvenile Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.	2	1	0
Prostatic Diseases Pathological processes involving the PROSTATE or its component tissues.	2.01	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2	1	0
Leukemia, Myeloid, Acute, M4 [description not available]	2.01	1	0
Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.	2.01	1	0
Immunoblastic Large-Cell Lymphoma [description not available]	2.01	1	0
Anti-GBM Disease [description not available]	2	1	0
Anti-Glomerular Basement Membrane Disease An autoimmune disease of the KIDNEY and the LUNG. It is characterized by the presence of circulating autoantibodies targeting the epitopes in the non-collagenous domains of COLLAGEN TYPE IV in the basement membranes of kidney glomeruli (KIDNEY GLOMERULUS) and lung alveoli (PULMONARY ALVEOLI), and the subsequent destruction of these basement membranes. Clinical features include pulmonary alveolar hemorrhage and glomerulonephritis.	2	1	0
Antibody Deficiency Syndrome [description not available]	2.39	2	0
Lymphocytopenia [description not available]	2.01	1	0
Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.	2.39	2	0
Lymphopenia Reduction in the number of lymphocytes.	2.01	1	0
Rheumatoid Arthritis [description not available]	2.01	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.01	1	0
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	2.01	1	0
Facial Dermatoses Skin diseases involving the FACE.	2.01	1	0
Adrenal Gland Diseases Pathological processes of the ADRENAL GLANDS.	2.01	1	0
Granulomas [description not available]	2.89	4	0
Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN.	1.98	1	0
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	2.89	4	0
Mediastinal Diseases Disorders of the mediastinum, general or unspecified.	1.98	1	0
Abscess, Periapical [description not available]	1.98	1	0
Fasciitis Inflammation of the fascia. There are three major types: 1, Eosinophilic fasciitis, an inflammatory reaction with eosinophilia, producing hard thickened skin with an orange-peel configuration suggestive of scleroderma and considered by some a variant of scleroderma; 2, Necrotizing fasciitis (FASCIITIS, NECROTIZING), a serious fulminating infection (usually by a beta hemolytic streptococcus) causing extensive necrosis of superficial fascia; 3, Nodular/Pseudosarcomatous /Proliferative fasciitis, characterized by a rapid growth of fibroblasts with mononuclear inflammatory cells and proliferating capillaries in soft tissue, often the forearm; it is not malignant but is sometimes mistaken for fibrosarcoma.	2.89	1	0
Shingles [description not available]	1.98	1	0
Nerve Pain [description not available]	1.98	1	0
Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)	1.98	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	1.98	1	0
Collagen Diseases Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that collagen was equivalent to connective tissue, but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term collagen diseases now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)	1.98	1	0
Abortion, Threatened UTERINE BLEEDING from a GESTATION of less than 20 weeks without any CERVICAL DILATATION. It is characterized by vaginal bleeding, lower back discomfort, or midline pelvic cramping and a risk factor for MISCARRIAGE.	1.98	1	0
Hiccough [description not available]	1.98	1	0
Salpingitis Inflammation of the uterine salpinx, the trumpet-shaped FALLOPIAN TUBES, usually caused by ascending infections of organisms from the lower reproductive tract. Salpingitis can lead to tubal scarring, hydrosalpinx, tubal occlusion, INFERTILITY, and ectopic pregnancy (PREGNANCY, ECTOPIC)	3.76	2	1
Scarlet Fever Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present.	1.98	1	0
P carinii Infection [description not available]	3.36	1	1
Pneumocystis Infections Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally.	3.36	1	1
Cranial Nerve Diseases Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.	1.97	1	0
Facial Palsy [description not available]	1.97	1	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	1.97	1	0
Endometrial Diseases [description not available]	2.38	2	0
Uterine Diseases Pathological processes involving any part of the UTERUS.	2.38	2	0
Convulsive Generalized Seizure Disorder [description not available]	1.97	1	0
Linear Skull Fracture [description not available]	2.89	1	0
Adnexitis Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS).	4.97	3	3
Pelvic Inflammatory Disease A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES; (SALPINGITIS); the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility.	4.97	3	3
Injuries, Knee [description not available]	1.97	1	0
Meniscitis [description not available]	1.97	1	0
Knee Injuries Injuries to the knee or the knee joint.	1.97	1	0
Leukemia, Acute Monocytic [description not available]	1.97	1	0
Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.	1.97	1	0
Central Nervous System Disease [description not available]	4.45	5	1
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	4.45	5	1
Abdominal Epilepsy [description not available]	1.97	1	0
Epilepsies, Partial Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)	1.97	1	0
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	3.36	1	1
Francisella tularensis Infection [description not available]	1.97	1	0
Tularemia A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.	1.97	1	0
Central Nervous System Origin Vertigo [description not available]	1.97	1	0
Vertigo An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)	1.97	1	0
Meningitis, Meningococcal, Serogroup A [description not available]	3.36	1	1
Meningitis, Meningococcal A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)	3.36	1	1
Delirium of Mixed Origin [description not available]	1.97	1	0
Coagulation, Disseminated Intravascular [description not available]	1.97	1	0
Delirium A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)	1.97	1	0
Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.	1.97	1	0
Cancer of Skin [description not available]	1.97	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	1.97	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	1.97	1	0
ARC [description not available]	3.36	1	1
AIDS-Related Complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS.	3.36	1	1
Autolysis The spontaneous disintegration of tissues or cells by the action of their own autogenous enzymes.	2.37	2	0
Infection, Mycobacterium avium-intracellulare [description not available]	1.97	1	0
Mycobacterium avium-intracellulare Infection A nontuberculous infection when occurring in humans. It is characterized by pulmonary disease, lymphadenitis in children, and systemic disease in AIDS patients. Mycobacterium avium-intracellulare infection of birds and swine results in tuberculosis.	1.97	1	0
Atresia, Biliary [description not available]	2.37	2	0
Biliary Atresia Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.	2.37	2	0
Bronchial Diseases Diseases involving the BRONCHI.	1.97	1	0
Infections, Listeria [description not available]	1.96	1	0
Listeria Cerebritis [description not available]	1.96	1	0
Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).	2.37	2	0
Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.	1.97	1	0
Mastitis INFLAMMATION of the BREAST, or MAMMARY GLAND.	1.97	1	0
Infections, Chlamydia [description not available]	1.97	1	0
Neisseria gonorrhoeae Infection [description not available]	1.97	1	0
Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA.	1.97	1	0
Gonorrhea Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.	1.97	1	0
Vulvar Diseases Pathological processes of the VULVA.	1.96	1	0
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	1.96	1	0
Thyroiditis Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.	1.96	1	0
Pyelitis Inflammation of the KIDNEY PELVIS and KIDNEY CALICES where urine is collected before discharge, but does not involve the renal parenchyma (the NEPHRONS) where urine is processed.	1.96	1	0
Tonsillitis Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.	1.96	1	0
Adenitis [description not available]	2.37	2	0
Femur Neck Fractures [description not available]	1.96	1	0
Femoral Neck Fractures Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.	1.96	1	0
Adhesive Capsulitis [description not available]	1.96	1	0
Bursitis Inflammation or irritation of a SYNOVIAL BURSA, the fibrous sac that acts as a cushion between moving structures of bones, muscles, tendons or skin.	1.96	1	0
Arm Injuries General or unspecified injuries involving the UPPER ARM and the FOREARM.	1.97	1	0
Bone Inflammation [description not available]	2.37	2	0
Injuries, Leg [description not available]	1.97	1	0
Chylopericardium [description not available]	1.97	1	0
Pericardial Effusion Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.	1.97	1	0
Carbuncle An infection of cutaneous and subcutaneous tissue that consists of a cluster of boils. Commonly, the causative agent is STAPHYLOCOCCUS AUREUS. Carbuncles produce fever, leukocytosis, extreme pain, and prostration.	3.35	1	1
Boils [description not available]	3.35	1	1
Skin Ulcer An ULCER of the skin and underlying tissues.	3.35	1	1

imipenem, anhydrous

Description

Cross-References

Synonyms (103)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Pathways (2)

Protein Targets (53)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (22)

Molecular Functions (8)

Ceullar Components (12)

Bioassays (5307)

Research

Studies (4,509)

Market Indicators

Research Demand Index: 6.12

Study Types

imipenem, anhydrous

Description

Cross-References

Synonyms (103)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Pathways (2)

Protein Targets (53)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (22)

Molecular Functions (8)

Ceullar Components (12)

Bioassays (5307)

Research

Studies (4,509)

Market Indicators

Research Demand Index: 6.12

Study Types

Related Drugs (1,512)

Related Conditions (1,004)